<SEC-DOCUMENT>0001801198-25-000021.txt : 20250513
<SEC-HEADER>0001801198-25-000021.hdr.sgml : 20250513
<ACCEPTANCE-DATETIME>20250513070043
ACCESSION NUMBER:		0001801198-25-000021
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250513
DATE AS OF CHANGE:		20250513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Legend Biotech Corp
		CENTRAL INDEX KEY:			0001801198
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39307
		FILM NUMBER:		25937082

	BUSINESS ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
		BUSINESS PHONE:		732-850-5598

	MAIL ADDRESS:	
		STREET 1:		2101 COTTONTAIL LANE
		CITY:			SOMERSET
		STATE:			NJ
		ZIP:			08873
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>legn-20250331.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9fafd2bc-3cfd-4d2f-adf8-3916722ba5cf,g:99013260-2431-4a14-8f08-d911c15b56e6,d:ba26d8df43d84b70a09c18a7f8360796-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:legn="http://legendbiotech.com/20250331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>legn-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-3">0001801198</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="f-4">3/31/2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-5">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-6">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-7">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-8">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="legn-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="batch"><xbrli:measure>legn:batch</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">legn:A110InterestBearingLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2022-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001801198</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-31 f-32 f-33 f-34" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-124 f-125 f-126 f-127 f-129 f-131 f-133 f-134 f-136 f-137 f-139 f-140 f-142 f-145 f-146 f-147 f-148 f-151 f-152 f-153 f-154 f-156 f-158 f-160 f-161 f-163 f-164 f-166 f-167 f-169 f-172 f-173 f-174 f-175" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-215 f-216 f-217 f-218" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/></ix:resources></ix:header></div><div id="iba26d8df43d84b70a09c18a7f8360796_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt;text-align:right"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">6-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Rule 13a-16 or 15d-16</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report: May&#160;13, 2025</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commission File Number: 001-39307</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:21pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-2">Legend Biotech Corporation</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2101 Cottontail Lane</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Somerset, New Jersey 08873</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive office)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form 20-F </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Form 40-F </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt;text-align:right"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Legend Biotech Reports Financial Results for the Three Months Ended March&#160;31, 2025</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Legend Biotech Corporation (&#8220;Legend Biotech&#8221;) is furnishing this report on Form 6-K to provide its unaudited interim condensed consolidated financial statements as of March&#160;31, 2025 and for the three months ended March&#160;31, 2025 and 2024 and to provide Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with respect to such financial statements. In addition, Legend Biotech is updating its pipeline of product candidates, as set forth in Exhibit 99.4 to this Form 6-K, as well as providing a supplemental risk factor, as set forth in Exhibit 99.5 to this Form 6-K. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On May&#160;13, 2025, Legend Biotech issued a press release regarding its unaudited financial results for the three months ended March&#160;31, 2025 and recent business highlights, which is attached to this Form 6-K as Exhibit 99.1. The unaudited interim condensed consolidated financial statements as of March&#160;31, 2025 and for the three months ended March&#160;31, 2025 and 2024 are attached to this Form 6-K as Exhibit 99.2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is attached to this Form 6-K as Exhibit 99.3.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This report on Form 6-K, including Exhibits 99.1 (other than the information included under &#8220;Webcast/Conference Call Details&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and &#8220;About Legend Biotech&#8221;), 99.2, 99.3 and 99.4,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">hereby incorporated by reference into Legend Biotech&#8217;s Registration Statements on Form F-3 (Registration Nos. 333-278050, 333-257625 and 333-272222) and Legend Biotech&#8217;s Registration Statement on Form S-8 (Registration Nos. 333-239478 and 333-283217).</span></div><div id="iba26d8df43d84b70a09c18a7f8360796_10"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT INDEX </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Title</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="a991earningsreleaseq12025.htm">99.1</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Press Release, dated May&#160;13, 2025.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#iba26d8df43d84b70a09c18a7f8360796_16">99.2</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements as of March&#160;31, 2025, and for the three months ended March&#160;31, 2025, and 2024.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="#iba26d8df43d84b70a09c18a7f8360796_79">99.3</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="q125-pipeline51225.htm">99.4</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pipeline</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:none" href="exhibit995tariffriskfactor.htm">99.5</a></span></div></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supplemental Company Risk Factor</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following materials from Legend Biotech&#8217;s Report on Form 6-K for the three months ended March&#160;31, 2025 formatted in XBRL (eXtensible Business Reporting Language): (i) the Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income, (ii) the Unaudited Interim Condensed Consolidated Statement of Financial Position, (iii) the Unaudited Interim Condensed Consolidated Statements of Changes in Equity, (iv) the Unaudited Interim Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Unaudited Interim Condensed Consolidated Financial Statements. </span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt;text-align:right"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">May 13, 2025</span></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">/s/ Ying Huang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ying Huang, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Executive Officer </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_16"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.2</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE THREE MONTHS ENDED MARCH&#160;31, 2025 AND 2024</span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"/><td style="width:59.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000, <br/>except <br/>per share data</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000, <br/>except <br/>per share data</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REVENUE</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:RevenueFromLicensingOfIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="f-9">9,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:RevenueFromLicensingOfIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="f-10">12,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-11">185,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-12">78,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherRevenue" scale="3" id="f-13">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="3" id="f-14">3,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-15">195,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-16">93,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="f-17">69,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:CostOfSales" format="ixt:num-dot-decimal" scale="3" id="f-18">49,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:CostOfLicenseAndOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="f-19">1,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:CostOfLicenseAndOtherRevenue" format="ixt:num-dot-decimal" scale="3" id="f-20">5,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-21">101,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-22">100,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-23">31,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-24">31,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and distribution expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:SellingAndDistributionExpenses" format="ixt:num-dot-decimal" scale="3" id="f-25">40,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:SellingAndDistributionExpenses" format="ixt:num-dot-decimal" scale="3" id="f-26">24,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on asset impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" scale="3" id="f-27">970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-29">5,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-30">5,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance income*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-31">12,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:FinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-32">13,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense)/income, net*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-33">54,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:OtherGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-34">49,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LOSS BEFORE TAX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-35">99,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-36">59,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-37">1,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-38">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LOSS FOR THE PERIOD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-39">100,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-40">59,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attributable to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary equity holders of the parent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-41">100,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-42">59,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-43">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-44">0.16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-45">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-46">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER COMPREHENSIVE INCOME/(LOSS)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-47">60,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-48">47,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net other comprehensive income/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-49">60,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-50">47,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-51">60,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-52">47,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL COMPREHENSIVE LOSS FOR THE PERIOD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-53">40,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-54">107,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attributable to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary equity holders of the parent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-55">40,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-56">107,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*<ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts have been reclassified to present finance income as a separate line item and to combine other income/(expense), net for comparative purposes</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_19"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT MARCH&#160;31, 2025 AND UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT DECEMBER&#160;31, 2024 </span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.030%"><tr><td style="width:1.0%"/><td style="width:62.743%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.414%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NON-CURRENT ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-57">98,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-58">99,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advance payments for property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:AdvancePaymentsForPropertyPlantAndEquipment" scale="3" id="f-59">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:AdvancePaymentsForPropertyPlantAndEquipment" scale="3" id="f-60">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-61">107,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-62">101,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:TimesDepositsNonCurrent" format="ixt:fixed-zero" scale="3" id="f-63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:TimesDepositsNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-65">2,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-66">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration prepaid leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:CollaborationPrepaidLeases" format="ixt:num-dot-decimal" scale="3" id="f-67">182,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:CollaborationPrepaidLeases" format="ixt:num-dot-decimal" scale="3" id="f-68">172,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-69">5,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:OtherNoncurrentNonfinancialAssets" format="ixt:num-dot-decimal" scale="3" id="f-70">6,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-71">396,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-72">386,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CURRENT ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-73">30,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-74">23,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentTradeReceivables" scale="3" id="f-75">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentTradeReceivables" format="ixt:num-dot-decimal" scale="3" id="f-76">6,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayments, other receivables and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-77">182,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-78">130,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pledged deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:PledgedDeposits" scale="3" id="f-79">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:PledgedDeposits" scale="3" id="f-80">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:TimesDeposits" format="ixt:num-dot-decimal" scale="3" id="f-81">563,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:TimesDeposits" format="ixt:num-dot-decimal" scale="3" id="f-82">835,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-83">441,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-84">286,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-85">1,218,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-86">1,283,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-87">1,615,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-88">1,670,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CURRENT LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Trade payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-89">58,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-90">38,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables and accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:OtherPayablesAndAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">116,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:OtherPayablesAndAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">166,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government grants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentGovernmentGrants" scale="3" id="f-93">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentGovernmentGrants" scale="3" id="f-94">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-95">5,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-96">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-97">14,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-98">20,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-99">39,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-100">46,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-101">234,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-102">277,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NON-CURRENT LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration interest-bearing advanced funding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-103">305,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:LongtermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-104">301,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities long term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-105">51,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-106">44,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Government grants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-107">6,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentGovernmentGrants" format="ixt:num-dot-decimal" scale="3" id="f-108">6,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-109">363,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-110">351,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-111">597,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-112">629,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-113">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-114">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-115">1,017,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="3" id="f-116">1,040,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total ordinary shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-117">1,017,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:EquityAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-118">1,040,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-119">1,017,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-120">1,040,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-121">1,615,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-122">1,670,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2025 AND 2024 </span></div></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.573%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Attributable to equity holders of the parent</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share <br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share <br/>premium*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Share-based <br/>compensation <br/>reserves*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Foreign <br/>currency <br/>translation <br/>reserve*</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Retained <br/>accumulated <br/>losses*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total <br/>equity</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8216;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8216;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8216;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8216;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8216;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8216;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As at January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-123">36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-124">2,637,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-125">54,621</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-126">44,304</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-127">1,484,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-128">1,251,371</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-129">59,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">59,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-131">47,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-132">47,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive loss for the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-133">47,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-134">59,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-135">107,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-136">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-137">897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-138">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification of vested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">6,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:num-dot-decimal" scale="3" id="f-140">6,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:fixed-zero" scale="3" id="f-141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity-settled share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-142">18,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-143">18,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-144">36</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-145">2,645,869</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-146">66,346</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-147">3,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-148">1,544,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-149">1,164,059</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As at January 1, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-150">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-151">2,695,976</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-152">74,427</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-153">68,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-154">1,661,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-155">1,040,546</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss for the period </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">100,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">100,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-158">60,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-159">60,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive income/(loss) for the period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-160">60,729</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-161">100,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-162">40,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-163">2,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-164">929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-165">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reclassification of vested restricted share units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:num-dot-decimal" scale="3" id="f-166">14,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">14,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" format="ixt:fixed-zero" scale="3" id="f-168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity-settled share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-169">15,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-170">15,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As at March 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-171">37</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-172">2,712,844</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-173">74,949</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-174">7,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-175">1,762,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-176">1,017,749</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:13pt"><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote">These reserve accounts comprise the consolidated reserves of $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="6" id="f-177">1,017.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="ifrs-full:OtherReserves" format="ixt:num-dot-decimal" scale="6" id="f-178">1,164.0</ix:nonFraction> million in the consolidated statements of financial position as at March&#160;31, 2025 and, 2024, respectively</ix:footnote>.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_25"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2025 AND 2024</span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"/><td style="width:59.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASH FLOWS (USED IN)/PROVIDED BY OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-179">99,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-180">59,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-181">12,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForFinanceIncome" format="ixt:num-dot-decimal" scale="3" id="f-182">13,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-183">5,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForFinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-184">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for inventory reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="legn:AdjustmentsForInventoryReserveProvision" format="ixt:num-dot-decimal" scale="3" id="f-185">3,798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:AdjustmentsForInventoryReserveProvision" format="ixt:num-dot-decimal" scale="3" id="f-186">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on asset impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="3" id="f-187">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="f-189">2,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationExpense" format="ixt:num-dot-decimal" scale="3" id="f-190">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" scale="3" id="f-191">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" scale="3" id="f-192">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForAmortisationExpense" scale="3" id="f-193">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForAmortisationExpense" scale="3" id="f-194">885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:AdjustmentsForDepreciationOfRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-195">2,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:AdjustmentsForDepreciationOfRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-196">2,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value gains on financial assets measured at fair value through profit or loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForFairValueGainsLosses" format="ixt:fixed-zero" scale="3" id="f-197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForFairValueGainsLosses" scale="3" id="f-198">449</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange loss/(gain), net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-199">55,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-200">49,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity-settled share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-201">15,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-202">18,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred government grant</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="legn:DeferredGovernmentGrant" scale="3" id="f-203">134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="legn:DeferredGovernmentGrant" scale="3" id="f-204">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-205">32,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-206">91,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-207">5,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-208">96,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in prepayments, other receivables and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-209">48,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-210">16,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" scale="3" id="f-211">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" scale="3" id="f-212">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in collaboration inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-213">3,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-214">4,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in trade payables*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-215">19,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-216">22,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Decrease)/increase in other payables and accruals*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" format="ixt:num-dot-decimal" scale="3" id="f-217">38,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" format="ixt:num-dot-decimal" scale="3" id="f-218">7,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase/(decrease) in other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="f-219">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="legn:AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" scale="3" id="f-220">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decrease in contract liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="legn:AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-221">9,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="legn:AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-222">12,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in)/provided by operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-223">106,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-224">2,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-225">14,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-226">13,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (paid)/received</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-227">11,926</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" scale="3" id="f-228">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="legn:InterestOnLeasePaymentsClassifiedAsOperatingActivities" scale="3" id="f-229">499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="legn:InterestOnLeasePaymentsClassifiedAsOperatingActivities" scale="3" id="f-230">416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in)/provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-231">103,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-232">15,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*<ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain prior year amounts have been reclassified between increase in trade payables and (decrease)/increase in other payables and accruals for comparative purposes</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2025 AND 2024</span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.818%"><tr><td style="width:1.0%"/><td style="width:59.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CASH FLOWS PROVIDED BY/(USED IN) INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-233">2,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-234">6,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepayment to collaborator for collaboration assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-235">15,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-236">16,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase of financial assets measured at fair value through profit or loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-238">150,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash receipts of investment income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" scale="3" id="f-240">663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from disposal of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" format="ixt:fixed-zero" scale="3" id="f-241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="legn:ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" scale="3" id="f-242">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Addition in time deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:AdditionInTimeDeposits" format="ixt:num-dot-decimal" scale="3" id="f-243">100,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:AdditionInTimeDeposits" format="ixt:num-dot-decimal" scale="3" id="f-244">721,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decrease in time deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:DecreaseInTimeDeposits" format="ixt:num-dot-decimal" scale="3" id="f-245">374,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:DecreaseInTimeDeposits" format="ixt:num-dot-decimal" scale="3" id="f-246">498,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by/(used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-247">256,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-248">396,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-249">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-250">1,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal portion of lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-251">777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-252">758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-253">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="f-254">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-255">153,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" format="ixt:num-dot-decimal" scale="3" id="f-256">379,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange rate changes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-257">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-258">343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-259">286,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-260">1,277,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CASH AND CASH EQUIVALENTS AT END OF PERIOD</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-261">441,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-262">897,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and bank balances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-263">1,005,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-264">1,156,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Pledged deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" id="f-265">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" id="f-266">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:TimesDepositsCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-267">563,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="legn:TimesDepositsCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-268">258,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents as stated in the statement of financial position</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" format="ixt:num-dot-decimal" scale="3" id="f-269">441,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" format="ixt:num-dot-decimal" scale="3" id="f-270">897,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents as stated in the statement of cash flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:CashAndCashEquivalentsAsStatedInStatementOfCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-271">441,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="legn:CashAndCashEquivalentsAsStatedInStatementOfCashFlows" format="ixt:num-dot-decimal" scale="3" id="f-272">897,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:31.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE UNAUDITED INTERIM CONDENSED </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL STATEMENTS </span></div><div id="iba26d8df43d84b70a09c18a7f8360796_31"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" id="f-273" continuedAt="f-273-1" escape="true">CORPORATE INFORMATION </ix:nonNumeric></span></div><ix:continuation id="f-273-1"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legend Biotech Corporation, ("Legend"), was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Act (As Revised) of the Cayman Islands. The registered office address of Legend is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1002, Cayman Islands.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legend is an investment holding company. Legend's subsidiaries are principally engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications.</span></div></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.1. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-274" continuedAt="f-274-1" escape="true">BASIS OF PREPARATION </ix:nonNumeric></span></div><ix:continuation id="f-274-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The unaudited interim condensed consolidated financial statements of Legend and its subsidiaries (collectively referred to as the &#8220;Company&#8221;) for the three months ended March&#160;31, 2025 have been prepared in accordance with International Accounting Standard (&#8220;IAS&#8221;) 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interim Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IAS34&#8221;) issued by the International Accounting Standards Board (the &#8220;IASB&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies and basis of preparation adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's financial statements for the year ended December&#160;31, 2024. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company&#8217;s annual consolidated financial statements as at December&#160;31, 2024.</span></div></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_37"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.2. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-275" continuedAt="f-275-1" escape="true">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</ix:nonNumeric></span></div><ix:continuation id="f-275-1" continuedAt="f-275-2"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new International Financial Reporting Standards (&#8220;IFRS&#8221;), amendments or interpretations issued by the IASB that became effective in the three months ended March&#160;31, 2025 that had a material impact on the Company's unaudited interim condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-275-2">The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_40"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueExplanatory" id="f-276" continuedAt="f-276-1" escape="true">REVENUE</ix:nonNumeric></span></div><ix:continuation id="f-276-1" continuedAt="f-276-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="f-277" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Novartis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="legn:RevenueFromLicensingOfIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="f-278">9,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="legn:RevenueFromLicensingOfIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="f-279">12,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue - total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:RevenueFromLicensingOfIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="f-280">9,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:RevenueFromLicensingOfIntellectualProperty" format="ixt:num-dot-decimal" scale="3" id="f-281">12,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-282">185,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-283">78,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:OtherRevenue" scale="3" id="f-284">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:OtherRevenue" format="ixt:num-dot-decimal" scale="3" id="f-285">3,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-286">195,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-287">93,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" id="f-288" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-289">9,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-290">15,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="f-291">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="f-292">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue and other revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-293">9,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:RevenueFromContractsWithCustomers" format="ixt:num-dot-decimal" scale="3" id="f-294">15,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-295">158,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-296">70,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-297">26,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-298">8,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-299">185,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:CollaborationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-300">78,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-301">195,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-302">93,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" id="f-303" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the timing of transfer of goods or services is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue at a point in time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-304">185,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-305">81,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue over time*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-306">9,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-307">12,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-308">195,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:Revenue" format="ixt:num-dot-decimal" scale="3" id="f-309">93,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" id="f-310" escape="true"><ix:continuation id="f-276-2"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the deferred revenue which is included in contract liabilities for the periods presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities (Current)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-311">39,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-312">46,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-313">39,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-314">46,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt"><span><br/></span></div><div id="iba26d8df43d84b70a09c18a7f8360796_332"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory" id="f-315" continuedAt="f-315-1" escape="true">OTHER (EXPENSE)/INCOME, NET </ix:nonNumeric></span></div><ix:continuation id="f-315-1"><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" id="f-316" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total other (expense)/income, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange (loss)/gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-317">55,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-318">49,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value gains on financial assets measured at fair value change through profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="3" id="f-320">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:OtherMiscellaneousIncomeExpense" scale="3" id="f-321">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="legn:OtherMiscellaneousIncomeExpense" scale="3" id="f-322">176</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense)/income, net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-323">54,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:OtherGainsLosses" format="ixt:num-dot-decimal" scale="3" id="f-324">49,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign currency exchange (loss)/gain, net is comprised mainly of the unrealized foreign exchange (loss)/gain that was primarily related to changes in the intercompany loan balances and cash balances as a result of exchange rate changes between USD and EUR.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="legn:EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" id="f-325" continuedAt="f-325-1" escape="true">FINANCE INCOME AND FINANCE COSTS</ix:nonNumeric></span></div><ix:continuation id="f-325-1"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Income</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-326">12.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="ifrs-full:FinanceIncome" scale="6" id="f-327">13.9</ix:nonFraction> million for the three months ended March&#160;31, 2025 and 2024, respectively, is comprised mainly of interest income earned on various bank accounts and time deposits. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Costs </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinanceCostExplanatory" id="f-328" escape="true"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-329">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-330">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration interest-bearing advanced funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-331">4,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:InterestExpenseOnBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-332">5,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-333">5,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="ifrs-full:FinanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-334">5,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_46"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-335" continuedAt="f-335-1" escape="true">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT </ix:nonNumeric></span></div><ix:continuation id="f-335-1"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basic income or loss per share is calculated by dividing net income or loss attributable to ordinary equity holders of the parent by the weighted average ordinary shares outstanding. The diluted loss per share equals the basic loss per share amounts presented for the three months ended March&#160;31, 2025 and 2024, as the impact of the outstanding share options and RSUs had an anti-dilutive effect on the basic loss per share amounts presented.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:EarningsPerShareExplanatory" id="f-336" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted loss per share are based on: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-337">100,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" format="ixt:num-dot-decimal" scale="3" id="f-338">59,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of shares<br/>Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-339">367,525,855</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-340">364,010,429</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_52"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfLeasesExplanatory" id="f-341" continuedAt="f-341-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-341-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company as a lessee</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has leases for office, research laboratory and manufacturing facilities, equipment, vehicles, and land. The terms of the leases vary, although most generally have lease terms between <ix:nonNumeric contextRef="c-47" name="legn:LesseeLeasingArrangementsLeasesTerm" format="ixt-sec:duryear" id="f-342">3</ix:nonNumeric> and <ix:nonNumeric contextRef="c-48" name="legn:LesseeLeasingArrangementsLeasesTerm" format="ixt-sec:duryear" id="f-343">29</ix:nonNumeric> years. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of <ix:nonNumeric contextRef="c-49" name="legn:LesseeLeasingArrangementsLeasesTerm" format="ixt-sec:duryear" id="f-344">50</ix:nonNumeric> years, and <ix:nonFraction unitRef="usd" contextRef="c-49" decimals="INF" name="legn:OngoingLeasePaymentsUnderTheLandLease" format="ixt:fixed-zero" scale="0" id="f-345">no</ix:nonFraction> ongoing payments will be made under the terms of these leasehold land. Leases with terms of 12 months or less are expensed as incurred. Collaboration assets represent the Company&#8217;s share of assets leased to the collaboration from Janssen Biotech, Inc., a Johnson &amp; Johnson company ("Janssen"), which purchased the assets on behalf of the collaboration, in connection with our collaboration and license agreement (the "Janssen Agreement"). Collaboration assets under construction that will be leased to the collaboration from Janssen when placed into service are classified as collaboration prepaid leases on the consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Right-of-use assets</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-346" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s right-of-use assets and the movements for the three months ended March&#160;31, 2025 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000 </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at January 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-347">101,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-348">6,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossRightofuseAssets" scale="3" id="f-349">970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" format="ixt:num-dot-decimal" scale="3" id="f-350">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-351">2,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:num-dot-decimal" scale="3" id="f-352">107,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Lease liabilities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. <ix:nonNumeric contextRef="c-1" name="legn:LesseeLeaseLiabilitiesTextBlock" id="f-353" continuedAt="f-353-1" escape="true">The balance of the Company&#8217;s lease liabilities and the movements for the three months ended March&#160;31, 2025 are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-353-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at January 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-354">49,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="legn:IncreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-355">6,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accretion of interest recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="legn:IncreaseOfLeaseLiabilitiesBalance" scale="3" id="f-356">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="ifrs-full:CashOutflowForLeases" format="ixt:num-dot-decimal" scale="3" id="f-357">1,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-358">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-359">57,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analyzed into:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-360">5,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-361">51,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-362">57,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="f-363" continuedAt="f-363-1" escape="true">COLLABORATION INVENTORIES, NET</ix:nonNumeric></span></div><ix:continuation id="f-363-1"><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" id="f-364" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-365">23,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:RawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-366">17,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="3" id="f-367">4,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:WorkInProgress" format="ixt:num-dot-decimal" scale="3" id="f-368">4,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-369">2,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:FinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-370">2,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration inventories, net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-371">30,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:Inventories" format="ixt:num-dot-decimal" scale="3" id="f-372">23,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reserve for inventory was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="legn:InventoryReserve" format="ixt:num-dot-decimal" scale="6" id="f-373">17.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="legn:InventoryReserve" scale="6" id="f-374">21.7</ix:nonFraction> million as of March&#160;31, 2025 and December&#160;31, 2024, respectively. The Company&#8217;s reserve for inventory was primarily related to certain batches or units of product that did not meet quality specifications, and expired materials. The inventory reserve was included in the collaboration cost of sales.</span></div></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" id="f-375" continuedAt="f-375-1" escape="true">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-375-1"><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" id="f-376" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="legn:OtherCollaborationReceivables" format="ixt:num-dot-decimal" scale="3" id="f-377">159,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="legn:OtherCollaborationReceivables" format="ixt:num-dot-decimal" scale="3" id="f-378">112,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="f-379">954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="f-380">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="ifrs-full:FinanceLeaseReceivables" scale="3" id="f-381">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="ifrs-full:FinanceLeaseReceivables" scale="3" id="f-382">568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VAT recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="ifrs-full:ValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-383">5,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="ifrs-full:ValueAddedTaxReceivables" format="ixt:num-dot-decimal" scale="3" id="f-384">4,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="ifrs-full:Prepayments" format="ixt:num-dot-decimal" scale="3" id="f-385">15,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="ifrs-full:Prepayments" format="ixt:num-dot-decimal" scale="3" id="f-386">12,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="legn:PrepaymentsOtherReceivablesAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-387">182,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="legn:PrepaymentsOtherReceivablesAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-388">130,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default. The Company estimated that the expected credit loss for the above receivables as at March&#160;31, 2025 and December&#160;31, 2024 is insignificant.</span></div></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_61"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="f-389" continuedAt="f-389-1" escape="true">CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" id="f-390" escape="true"><ix:continuation id="f-389-1" continuedAt="f-389-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and bank balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndBankBalancesAtCentralBanks" format="ixt:num-dot-decimal" scale="3" id="f-391">1,005,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndBankBalancesAtCentralBanks" format="ixt:num-dot-decimal" scale="3" id="f-392">1,127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pledged deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="legn:PledgedShortTermDeposits" scale="3" id="f-393">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="legn:PledgedShortTermDeposits" scale="3" id="f-394">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="legn:DepositsFromBank" format="ixt:num-dot-decimal" scale="3" id="f-395">563,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="legn:DepositsFromBank" format="ixt:num-dot-decimal" scale="3" id="f-396">840,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-397">441,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-398">286,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-399">401,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-400">230,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in RMB</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-401">15,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-402">19,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-403">24,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-404">36,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-405">441,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-406">286,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-389-2" continuedAt="f-389-3"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and cash equivalents of the Company denominated in Renminbi (&#8220;RMB&#8221;) amounted to $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-407">15.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="ifrs-full:CashAndCashEquivalents" scale="6" id="f-408">19.3</ix:nonFraction> million in the consolidated statements of financial position as at March&#160;31, 2025 and December&#160;31, 2024, respectively. The RMB is not freely convertible into other currencies, however, under Greater China Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Company is permitted to exchange RMB for other currencies through banks authorized to conduct foreign exchange business. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-389-3">Cash and cash equivalents earn interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default. The carrying amounts of the cash and cash equivalents approximate to their fair values.</ix:continuation> </span></div><div id="iba26d8df43d84b70a09c18a7f8360796_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" id="f-409" continuedAt="f-409-1" escape="true">OTHER PAYABLES AND ACCRUALS</ix:nonNumeric></span></div><ix:continuation id="f-409-1"><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" id="f-410" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:AccruedPayroll" format="ixt:num-dot-decimal" scale="3" id="f-411">27,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:AccruedPayroll" format="ixt:num-dot-decimal" scale="3" id="f-412">43,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:AccruedExpense" format="ixt:num-dot-decimal" scale="3" id="f-413">24,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:AccruedExpense" format="ixt:num-dot-decimal" scale="3" id="f-414">16,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:CollaborationPayable" format="ixt:num-dot-decimal" scale="3" id="f-415">49,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:CollaborationPayable" format="ixt:num-dot-decimal" scale="3" id="f-416">82,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:OtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-417">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:OtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-418">6,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payable for collaboration assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:PayableForCollaborationAssets" format="ixt:num-dot-decimal" scale="3" id="f-419">6,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:PayableForCollaborationAssets" format="ixt:num-dot-decimal" scale="3" id="f-420">14,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other tax payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:OtherTaxPayables" format="ixt:num-dot-decimal" scale="3" id="f-421">6,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:OtherTaxPayables" format="ixt:num-dot-decimal" scale="3" id="f-422">3,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:OtherPayablesAndAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-423">116,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:OtherPayablesAndAccrualsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-424">166,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other payables are non-interest-bearing and repayable on demand.</span></div></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_67"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBorrowingsExplanatory" id="f-425" continuedAt="f-425-1" escape="true">COLLABORATION INTEREST-BEARING ADVANCED FUNDING </ix:nonNumeric></span></div><ix:continuation id="f-425-1" continuedAt="f-425-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="f-426" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective interest rate (%)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Interest-bearing Advanced Funding</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-61" decimals="4" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="f-427">7.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No specific maturity date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived" format="ixt:num-dot-decimal" scale="3" id="f-428">305,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the Janssen Agreement, the Company is entitled to receive funding advances from the collaborator when certain operational conditions are met. As a result, the Company took an initial funding advance with principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-429">17.3</ix:nonFraction>&#160;million on June 18, 2021, a second funding advance with principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-430">53.1</ix:nonFraction>&#160;million on September 17, 2021, a third funding advance with principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-431">49.3</ix:nonFraction>&#160;million on December 17, 2021, a forth funding advance with principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-432">5.3</ix:nonFraction>&#160;million on March 18, 2022, a fifth funding advance with principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-433">60.9</ix:nonFraction>&#160;million on June 17, 2022, a sixth funding advance with principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-434">60.5</ix:nonFraction>&#160;million on September 16, 2022, and a seventh funding advance with principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-435">3.6</ix:nonFraction>&#160;million on December 16, 2022, by reducing the same amount of other payables due to the collaborator, respectively (collectively, the &#8220;Funding Advances&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These Funding Advances are accounted for as interest-bearing borrowings funded by the collaborator, constituted by a principal amounting to $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="ifrs-full:Borrowings" format="ixt:num-dot-decimal" scale="6" id="f-436">250.0</ix:nonFraction>&#160;million and applicable interests accrued amounting to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="legn:InterestBearingBorrowingsFundedInterestsAccrued" format="ixt:num-dot-decimal" scale="6" id="f-437">55.7</ix:nonFraction>&#160;million upon such principal. The respective interest rate of each borrowing has transitioned from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR) in accordance with the LIBOR ACT. Thus, outstanding advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="ifrs-full:BorrowingsAdjustmentToInterestRateBasis" scale="-2" id="f-438">2.5</ix:nonFraction>%.  For each of the <ix:nonFraction unitRef="batch" contextRef="c-69" decimals="INF" name="legn:NumberOfBorrowingBatches" format="ixt-sec:numwordsen" scale="0" id="f-439">seven</ix:nonFraction> batches of funding advances, interest started to accrue from June 18, 2021, September 17, 2021, December 17, 2021, March 18, 2022, June 17, 2022, September 16, 2022, and December 16, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the terms of the Janssen Agreement, the collaborator may recoup the aggregate amount of Funding Advances, together with interest thereon, from Company&#8217;s share of pre-tax profits starting from the first calendar quarter </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><ix:continuation id="f-425-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">following the first profitable year of the collaboration program and, subject to some limitations, from milestone payments due to the Company under the Janssen Agreement. The Company&#8217;s management estimated the loan will not be recouped by the collaborator within one year, nor does the Company expect to repay the funding advances within one year, and thus the loan was classified as a long-term liability.</span></div></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_70"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-440" continuedAt="f-440-1" escape="true">SHARE CAPITAL AND SHARE PREMIUM </ix:nonNumeric></span></div><ix:continuation id="f-440-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-441" escape="true"><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shares</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="ifrs-full:NumberOfSharesAuthorised" format="ixt:num-dot-decimal" scale="0" id="f-442"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="ifrs-full:NumberOfSharesAuthorised" format="ixt:num-dot-decimal" scale="0" id="f-443">2,000,000,000</ix:nonFraction></ix:nonFraction> ordinary shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-71" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-444"><ix:nonFraction unitRef="usdPerShare" contextRef="c-70" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-445">0.0001</ix:nonFraction></ix:nonFraction> each</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="legn:AuthorizedShareCapital" scale="3" id="f-446">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="legn:AuthorizedShareCapital" scale="3" id="f-447">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued and fully paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-448">368,058,079</ix:nonFraction> and (2024: <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="ifrs-full:NumberOfSharesIssuedAndFullyPaid" format="ixt:num-dot-decimal" scale="0" id="f-449">367,298,315</ix:nonFraction>) ordinary shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-70" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-450"><ix:nonFraction unitRef="usdPerShare" contextRef="c-71" decimals="INF" name="ifrs-full:ParValuePerShare" scale="0" id="f-451">0.0001</ix:nonFraction></ix:nonFraction> each</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-452">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="ifrs-full:IssuedCapital" scale="3" id="f-453">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" id="f-454" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of movements in the Company&#8217;s share capital and share premium is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares in issue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>premium</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024 and January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-455">367,298,315</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="legn:ShareCapitalAndSharePremium" scale="3" id="f-456">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-457">2,695,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-458">2,696,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="legn:ExerciseOfShareOptionNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-459">286,658</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="legn:ExerciseOfShareOption" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="legn:ExerciseOfShareOption" format="ixt:num-dot-decimal" scale="3" id="f-461">2,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:ExerciseOfShareOption" format="ixt:num-dot-decimal" scale="3" id="f-462">2,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification of vesting of restricted share units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="legn:ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-463">473,106</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-465">14,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-466">14,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue" format="ixt:num-dot-decimal" scale="0" id="f-467">368,058,079</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="legn:ShareCapitalAndSharePremium" scale="3" id="f-468">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-469">2,712,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="legn:ShareCapitalAndSharePremium" format="ixt:num-dot-decimal" scale="3" id="f-470">2,712,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iba26d8df43d84b70a09c18a7f8360796_76"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory" id="f-471" continuedAt="f-471-1" escape="true">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-471-1">The interim condensed consolidated financial statements were approved and authorized for issue by the Audit Committee of the Board of Directors on  May&#160;6, 2025.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.3</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), unless otherwise indicated or the context otherwise requires, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;Legend Biotech&#8221; refer to Legend Biotech Corporation and its consolidated subsidiaries. &#8220;Legend Biotech,&#8221; the Legend logo and other trademarks or service marks of the Company appearing in this MD&amp;A are the property of the Company. Solely for convenience, the trademarks, service marks and trade names referred to in this MD&amp;A are without the &#174;, &#8482; and other similar symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. CARVYKTI is a registered trademark in the United States of Johnson &amp; Johnson. Other trade names, trademarks and service marks of other companies appearing in this MD&amp;A are the property of their respective holders. We do not intend our use or display of other companies&#8217; trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other person.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our interim condensed consolidated financial statements and the accompanying notes. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This MD&amp;A contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of present and historical facts and conditions are forward-looking statements. Forward-looking statements can often be identified by words or phrases, such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;is/are likely to,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or other similar expressions. Such forward-looking statements reflect our current expectations and views of future events, but are not assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our financial needs, our operational results and other future conditions. These forward-looking statements involve various risks and uncertainties. Many important factors may adversely affect such forward-looking statements and cause actual results to differ from those in any forward-looking statement, including, without limitation,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> our strategies and o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">bjectives; statements relating to CARVYKTI, including our expectations for CARVYKTI, such as our manufacturing and commercialization expectations for CARVYKTI and the potential effect of treatment with CARVYKTI; statements related to Legend Biotech&#8217;s ability to fund its operations and achieve operating profit; uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech&#8217;s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; the impact of U.S. or foreign laws and regulations on our operations, including the impact of tariffs; the impact of U.S. or foreign laws and regulations on our operations, including the impact of tariffs; competition in general; government, industry, and general product pricing and other political pressures; commercialization factors, including regulatory approval and pricing determinations; disruptions to access to raw materials; delays or disruptions at manufacturing facilities; proliferation and continuous evolution of new technologies; dislocations in the capital markets; and other important factors described under &#8220;Risk Factors&#8221; in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 11, 2025 (the &#8220;Annual Report&#8221;) and under &#8220;Risk Factors&#8221; in any other reports that we file with the Securities and Exchange Commission. As a result of these factors, we cannot assure you that the forward-looking statements in this interim report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, even if our results of operations, financial condition and liquidity are consistent with the forward-looking statements contained in this report, those results or developments may not be indicative of results or developments in subsequent periods.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:18pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a global biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications. Our team of approximately 2,700 employees in the United States, China and Europe, our differentiated technology, as well as our global development and manufacturing expertise provide us with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs. Our lead product candidate, ciltacabtagene autoleucel, ("cilta-cel") (referred to as LCAR- B38M for purposes of our LEGEND-2 trial), is a CAR-T cell therapy we are jointly developing with our strategic partner, Janssen Biotech, Inc., a Johnson &amp; Johnson company ("Janssen"), for the treatment of multiple myeloma (&#8220;MM&#8221;). Clinical trial results achieved to date demonstrate that cilta-cel is the first CAR-T cell therapy to demonstrate overall survival benefit when compared to standard therapies in patients with relapsed and refractory multiple myeloma ("RRMM") with a manageable safety profile.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 28, 2022, cilta-cel was approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) under the trademark CARVYKTI for the treatment of adults with RRMM who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024, the FDA approved CARVYKTI for the treatment of patients with RRMM who have received at least one prior line of therapy, including proteasome inhibitor, and an immunomodulatory agent, and are refractory to lenalidomide. CARVYKTI is our first and only product approved by a health authority.</span></div><div style="text-align:justify"><span><br/></span></div><div id="iba26d8df43d84b70a09c18a7f8360796_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Business Developments</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Over 6,000 patients treated to date</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Initiated CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> clinical production at the Tech Lane facility</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Received positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> label</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Australia&#8217;s TGA approved CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in second-line plus settings for multiple myeloma patients</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Cash and cash equivalents, and time deposits of $1.0&#160;billion, as of March&#160;31, 2025, which Legend Biotech believes will provide financial runway into the second quarter of 2026</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="iba26d8df43d84b70a09c18a7f8360796_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Global Economic Conditions</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Worldwide economic conditions remain uncertain and we continue to monitor the impact of macroeconomic conditions, including those related to the public health crises, international tension and conflicts, the failure and instability of financial institutions and rising inflation rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Changes in tariffs, supply chain constraints, logistics challenges, labor shortages, international tension and conflicts and steps taken by governments and central banks, have led to fluctuating inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including fluctuating interest rates. Our manufacturing activities in the US, Europe and China have continued. Currently, we have not experienced any material impact to our supply chain as a result of inflation and fluctuating interest rates. Increased quantities of certain raw materials and consumables have been stocked as an appropriate safety measure. We believe we have established robust sourcing strategies for all necessary materials and do not expect any significant impact.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically with respect to the current tariffs imposed by the Trump administration, we do not currently believe such tariffs will have a material impact on our financial condition, as pharmaceuticals were exempted from these tariffs. However, the Trump administration has announced an intention to implement tariffs for pharmaceuticals at a future date. While the impact of any such pharmaceutical tariffs on Legend may be mitigated by the fact that the US Carvykti supply is domestically produced at the Raritan site in New Jersey and at the Novartis CMO facility in Morris Plains, New Jersey, we may face tariff exposure from certain pharmaceutical ingredients and processing materials that are imported from outside the US.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these changes in economic conditions continue or if they increase in severity, it could result in further economic uncertainty and volatility in the capital markets in the near term and could negatively affect our operations. Although we do not believe that these macroeconomic conditions have had a material impact on our financial position or results of operations to date, we may experience impacts in the near future (especially if inflation rates begin to rise again or significant tariffs are imposed on pharmaceutical ingredients) on our operating costs, including our cost of goods sold, labor costs and research and development costs, due to tariffs, supply chain constraints, consequences associated with public health crises, international tension and conflicts, and employee availability and wage increases, which may result in additional stress on our working capital resources. </span></div><div id="iba26d8df43d84b70a09c18a7f8360796_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Three Months Ended March&#160;31, 2025 and 2024 </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended March&#160;31, 2025 and 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variance</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185,615&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,053&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,991&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,062&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of collaboration revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(101,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100,964)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,929)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and distribution expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(40,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,223)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment asset</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,061)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,475)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense)/income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(54,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(104,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(99,130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,342)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,786)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,781)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss for the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100,916)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,793)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue was $9.3 million for the three months ended March&#160;31, 2025, compared to $12.2 million for the three months ended March&#160;31, 2024. The decrease of $2.9 million was solely attributed to revenue recognized pursuant to Legend Biotech&#8217;s license agreement with Novartis for the development, manufacture, and commercialization of LB2102 and other potential CAR-T therapies selectively targeting DLL-3 (the &#8220;Novartis License Agreement&#8221;). This revenue is recognized over time as Legend Biotech conducts a Phase 1 clinical trial for LB2102. The decrease resulted from the timing of the underlying activities performed in connection with such trial.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $185.6 million for the three months ended March&#160;31, 2025, compared to $78.5 million for the three months ended March&#160;31, 2024. The increase was due to an increase in revenue generated from sales of CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in connection with our collaboration and license agreement with Janssen (the "Janssen Agreement").</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue was $0.1 million for the three months ended March&#160;31, 2025, compared to $3.3 million for the three months ended March&#160;31, 2024. This decrease of $3.2 million was driven by a decrease in other revenue recognized from the supply of materials to Novartis in connection with the Novartis License Agreement for the three months ended March&#160;31, 2024, which did not recur for the three months ended March&#160;31, 2025 since the material supply was substantially completed in 2024.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Collaboration Revenue </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of collaboration revenue was $69.5 million for the three months ended March&#160;31, 2025, compared to $49.1 million for the three months ended March&#160;31, 2024. The increase was primarily due to Legend Biotech&#8217;s share of the cost of sales in connection with CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> sales under the Janssen Agreement and expenditures to support expansion in manufacturing capacity.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cost of License and Other Revenue </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license and other revenue was $1.8 million for the three months ended March&#160;31, 2025, compared to $5.6 million for the three months ended March&#160;31, 2024 and consisted of costs recognized in connection with the Novartis License Agreement. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $101.9 million for the three months ended March&#160;31, 2025 compared to $101.0 million for the three months ended March&#160;31, 2024. The increase was due to research and development activities in cilta-cel with two frontline clinical trials ongoing during 2025, offset by a decrease in other cilta-cel research and development activities. </span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Administrative Expenses </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative expenses were $31.5 million for the three months ended March 31, 2025, compared to $31.9 million for thethree months ended March&#160;31, 2024. Administrative expenses remained relatively flat, with an increase in staffing-related expenses due to higher headcount, offset by lower IT expenses due to the timing of completion of existing projects or the initiation of new projects compared to same period in the prior year.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Distribution Expenses </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and distribution expenses were $41.0 million for the three months ended March&#160;31, 2025, compared to $24.2&#160;million for the three months ended March&#160;31, 2024. The increase was due to increased costs associated with commercial activities including expansion of the sales force due to growing sales of CARVYKTI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Income</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance income for the three months ended March&#160;31, 2025 was $12.1&#160;million, compared to $13.9&#160;million for the three months ended March&#160;31, 2024. The decrease of $1.8&#160;million was primarily driven by less interest income earned from various bank accounts and time deposits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance Costs</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance costs for the three months ended March&#160;31, 2025, were $5.1 million, compared to $5.5&#160;million for the three months ended March&#160;31, 2024. Finance costs for the three months ended March&#160;31, 2025 and 2024 were primarily </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to interest on advance funding, which is interest-bearing borrowings funded by Janssen under the Janssen Agreement and constituted by principal and applicable interests upon such principal. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income/(Expense), net</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Income/(Expense), net for the three months ended March&#160;31, 2025, was $(54.5) million, compared to Other Income/(Expense), net of $49.7 million for the three months ended March&#160;31, 2024. The decrease in Other income of $104.2 million was primarily driven by the unrealized foreign exchange loss, which resulted from changes in the intercompany loan balances and cash balances due to exchange rate changes between USD and EUR.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Loss for the Period</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2025, net loss was $100.9 million, or $0.27 per share, compared to a net loss of $59.8 million, or $0.16 per share, for the three months ended March&#160;31, 2024.</span></div><div id="iba26d8df43d84b70a09c18a7f8360796_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sources of Liquidity<br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since our inception, we have incurred significant operating losses. We expect to incur operating losses in the near term as we advance the preclinical and clinical development of our research programs and product candidates. We believe our cash and cash equivalent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">s, and time deposits of $1.0&#160;billion, as of March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, will be able to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provide financial runway for at least the next 12 months.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With the exception of our first product, CARVYKTI, which was initially approved by the FDA on February 28, 2022, we do not currently have any approved products and we have not generated any revenue from product sales for other products. From inception through March&#160;31, 2025, we have funded our operations primarily with approximately:</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.9 million in capital contributions from Genscript Biotech Corporation ("Genscript");</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$160.5 million in gross proceeds from the sale of our Series A preference shares;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$760.0 mi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llion in upfront and milestone payments from Janssen under our collaboration and license agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$450.1 million in net proceeds from our U.S. initial public offering and an additional $12 million from a concurrent private placement with Genscript;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$300.0 million in net proceeds from our private placement to an investor and related warrant issuance in May 2021;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$323.4 million in net proceeds from our public offering of ADSs that closed in December 2021;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$250.0 million in advances from Janssen under the Janssen Agreement; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$377.6 million in net proceeds from our public offering of ADSs that closed in July 2022; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$234.4 million in net proceeds from private placements to certain investors in May and June 2023; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$349.3 million in net proceeds from our public offering of ADS that closed in May 2023;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$199.7 million in net proceeds from the exercise in full of a warrant held by one of our investors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$100.0 million upfront payment from Novartis under the Novartis License Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2025, we had approximately $441.7 million in cash and cash equivalents, approximately $563.7 million of time deposits, and accumulated losses of $1.8 billion. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Certain of our subsidiaries, including those registered as wholly foreign-owned enterprises in the People's Republic of China (the "PRC"), are required to set aside at least 10.0% of their after-tax profits to their general reserves until such reserves reach 50.0% of their registered capital. Under PRC regulations, foreign-invested enterprises may pay dividends only out of their accumulated profit, if any, as determined in accordance with PRC accounting standards and regulations. A PRC company is not permitted to distribute any profits until any losses from prior fiscal years have been offset. Profits retained from prior fiscal years may be distributed together with distributable profits from the current fiscal year. Although we do not currently require any such dividends from our PRC subsidiaries to fund our operations, should we require additional sources of liquidity in the future, such restrictions may have a material adverse effect on our liquidity and capital resources. For more information, see &#8220;Item 4.B-Business Overview - Government Regulation - PRC Regulation - Other PRC National- and Provincial-Level Laws and Regulations - Regulations Relating to Dividend Distributions&#8221; in our Annual Report on Form 20-F for the year ended December 31, 2024.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flow:</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000 </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in)/provided by operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(103,754)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by/(used in) by investing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(396,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase/(decrease) in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,553&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(379,799)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="iba26d8df43d84b70a09c18a7f8360796_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2025 was $103.8 million, primarily as a result of net loss before tax of $99.1 million after adjusting for non-cash items, and changes in operating assets and liabilities. Adjustments mainly included $12.1 million of finance income, offset by $55.2 million of foreign exchange loss and $15.9 million of equity-settled share-based compensation expenses. Changes in operating assets and liabilities mainly include an increase in prepayment, other receivable and other assets of $48.6 million, a decrease in other payables and accruals of $38.6 million, and a decrease in contract liabilities, net of $9.0 million. This was partially offset by an increase in trade payables of $19.5 million. Cash items primarily include interest income received of $15.0 million. This was partially offset by income tax payment of $11.9 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities for the three months ended March&#160;31, 2024 was $15.5 million, primarily as a result of net loss before tax of approximately $59.8 million after adjusting for non-cash items, and changes in operating assets and liabilities. Adjustments mainly included $18.7 million of equity-settled share-based compensation expense offset by $13.9 million of finance income and a net decrease in contract liabilities of $12.2 million. Changes in operating assets and liabilities mainly include a decrease in trade receivables of $96.7 million, an increase in trade payables of $22.8 million, an increase in other payables and accruals of $7.4 million, and $13.5 million of interest income received.</span></div><div id="iba26d8df43d84b70a09c18a7f8360796_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2025 was $256.6 million, consisting primarily of a redemption of time deposits of $374.0 million.  This was partially offset by a $100.0 million addition of time deposits, and a $15.4 million prepayment to our collaborator for collaboration assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the three months ended March&#160;31, 2024 was $396.1 million, consisting primarily of the prepayment to Janssen for collaboration assets of $16.5 million and an addition of time deposits of $722.0 million, and the purchase of financial assets measured at fair value through profit or loss of $150.3 million, which was partially offset by a redemption of time deposits of $498.3 million. </span></div><div id="iba26d8df43d84b70a09c18a7f8360796_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2025 was $0.7 million, consisting primarily of proceeds from exercise of share options of $1.4 million, partially offset by the principal portion of lease payments of $0.8 million.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2024 was $0.8 million, consisting primarily of the increase in proceeds from exercise of share options of $1.6 million, partially offset by the principal portion of lease payments of $0.8 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><div id="iba26d8df43d84b70a09c18a7f8360796_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur expenses in connection with our ongoing activities, particularly as we continue the research and development of, continue or initiate clinical trials of, and seek marketing approval for, our product candidates. In addition, following the FDA&#8217;s approval of CARVYKTI, we continue to incur significant commercialization expenses related to program sales, marketing, manufacturing and distribution. For example, in addition to investing in our own facilities, we have supplemented our manufacturing capabilities and infrastructure by entering into agreements with a CMO and may enter into additional CMO agreements in the future. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we may need to obtain additional funding in connection with our continuing operations. If we are unable to raise capital if and when needed or on attractive terms, or if we are unable to achieve an operating profit, excluding unrealized foreign exchange gains or losses, which we potentially anticipate in the second quarter of 2026, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although consequences of the macroeconomic conditions, including global conflicts and inflation, and resulting economic uncertainty could adversely affect our liquidity and capital resources in the future, and cash requirements may fluctuate based on the timing and extent of many factors such as those discussed below, we currently expect our existing cash and cash equivalents, and time deposits of $1.0&#160;billion, which we believe will provide financial runway into the second quarter of 2026, when we anticipate potentially achieving an operating profit excluding unrealized foreign exchange gains or losses. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of revenue we receive from commercial sales of CARVYKTI under the Janssen Agreement;</span></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of product discovery, preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, prioritization and number of our research and development programs;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under the Janssen Agreement and any other collaboration agreements we enter into;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under collaboration agreements, if any;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of securing manufacturing arrangements for commercial production; and</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our commercial product CARVYKTI, we have a broad portfolio of earlier-stage product candidates. Identifying potential product candidates and conducting preclinical studies and clinical trials is a time consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for such product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues from earlier-stage product candidates, if any, will be derived from sales of product candidates that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our cash proceeds from the product revenue, we might need to finance our cash through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, holders of our ADSs will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market that we would otherwise prefer to develop and market ourselves.<br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Janssen Agreement, we are entitled to receive advances from Janssen if the collaboration&#8217;s estimated working capital for any year falls below $50 million. In such event, Janssen provides advances to us in an amount equal to the excess of $50 million over the collaboration&#8217;s working capital for the year. The total amount of such advances in any calendar year may not exceed $125 million and the total amount of such advances outstanding at any time may not exceed $250 million. The interest rate pursuant to the Janssen Agreement has transitioned in accordance with the LIBOR Act. Thus, outstanding advances accrue interest at 12 month CME term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) plus LIBOR/SOFR adjustment (12 month) plus a margin of 2.5%. Janssen has the right to recoup such advances and interest from our share of the collaboration&#8217;s pre-tax profits starting from the first calendar quarter following the first profitable year of the collaboration program and, subject to some limitations, from milestone payments due to us under the Janssen Agreement. We are not otherwise obligated to repay the advances or interest, except in connection with our change in control or a termination of the Janssen Agreement by Janssen due to our material breach of the agreement. We may at any time in our discretion voluntarily pre-pay any portion of the then outstanding advances or associated interest. As of March&#160;31, 2025, the aggregate outstanding principal amount of such advances and interest were approximately $250.0&#160;million and $55.7&#160;million, respectively. </span></div><div id="iba26d8df43d84b70a09c18a7f8360796_356"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certain Supplemental Non-IFRS Metrics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">             Our management uses various financial metrics, including certain metrics that are not prepared in accordance with IFRS, to measure and assess the performance of our business, to make critical business decisions, and to assess our compliance with certain financial obligations. We therefore believe that presentation of certain of these non-IFRS metrics alongside the IFRS measures will aid investors in understanding our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">            The non-IFRS metrics should be considered in addition to, and not as a substitute for, or as superior to, measures of financial performance, financial position or cash flows reported in accordance with IFRS. We strongly encourage investors to review our historical financial statements in their entirety and to use the measures presented in accordance with IFRS as the primary means of evaluating our performance. Moreover, we encourage investors to review the definitions and reconciliations of non-IFRS financial measures to their most directly comparable IFRS measures. In addition, non-IFRS metrics are not uniformly defined by all companies, including those in our industry. Accordingly, non-IFRS metrics may not be comparable with similarly titled measures and disclosures by other companies, and we therefore encourage investors to review the discussions of these non-IFRS financial measures particularly the limitations on their usefulness and to understand how such measures differ from similarly titled measures that may be presented by other companies in the pharmaceutical industry or in general.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Adjusted Net Loss and Adjusted Net Loss per Share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as &#8220;Adjusted EPS&#8221; or &#8220;ANL per Share&#8221;, respectively) as performance metrics. Adjusted Net Loss and ANL per share are not defined under IFRS, are not a measure of operating income, operating performance, or liquidity presented in accordance with IFRS, and are subject to important limitations. Our use of Adjusted Net Loss has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. For example:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted Net Loss does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted Net Loss excludes unrealized foreign exchange gain or loss which resulted primarily from changes in the intercompany loan balances and cash balances as a result of exchange rate changes between USD and EUR.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted Net Loss does not reflect changes in, or cash requirements for, our working capital needs.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, Adjusted Net Loss excludes such as share based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">             Also, our definition of Adjusted Net Loss and ANL per Share may not be the same as similarly titled measures used by other companies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">            However, we believe that providing information concerning Adjusted Net Loss and ANL per Share enhances an investor&#8217;s understanding of our financial performance. We use Adjusted Net Loss as a performance metric that guides management in its operation of and planning for the future of the business. We believe that Adjusted Net Loss provides a useful measure of our operating performance from period to period by excluding certain items that we believe are not representative of our core business. We define Adjusted Net Loss as net loss adjusted for (1) non-cash items such as depreciation and amortization, share based compensation, and loss on impairment asset, and (2) unrealized foreign exchange gain or loss mainly related to intercompany loan balances and cash deposit balances as a result of exchange rate changes between USD and EUR.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">           ANL per Share is computed by dividing Adjusted Net Loss by the weighted average shares outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">            A reconciliation between Adjusted Net Loss and Net Loss, the most directly comparable measure under IFRS, has been provided in the table below.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000 except per share data</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized foreign exchange loss/(gain) (included in Other income/(expense), net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted net loss (ANL)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,999)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(85,257)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANL per share:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANL per share - basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.23)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANL per share - diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.07)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.23)</span></td></tr></table></div><div id="iba26d8df43d84b70a09c18a7f8360796_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash is held in readily available operating accounts and short to medium term deposits and securities. These securities are principal secured and not adversely impacted by interest rate fluctuations. As a result, a change in market interest rates would not have any significant impact on our cash balance.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The interest rate pursuant to our collaboration and license agreement with Janssen, has transitioned in accordance with the LIBOR Act. Thus, outstanding advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of 2.5%. Accordingly, changes in SOFR could result in fluctuations in our cash flow. For example, based on the $250.0 million aggregate principal amount of advances outstanding from Janssen as of March&#160;31, 2025, a 0.5% (fifty basis point) per annum increase in SOFR would result in an additional $1.3 million per year in interest payable by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the three months ended March&#160;31, 2025 and 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our financial results are subject to fluctuations due to foreign exchange rate movements. We conduct business in multiple currencies, and as a result, we are exposed to exchange rate fluctuations that may impact our financial statements. Unrealized foreign exchange gains and losses arise from the revaluation of monetary assets and liabilities denominated in foreign currencies, as well as from translation adjustments related to our international operations. These unrealized gains and losses can significantly impact our net income and financial position, even when there is no underlying economic impact on our cash flows. If exchange rates move unfavorably, we may experience substantial unrealized losses, which could negatively affect our reported earnings and create volatility in our financial performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In addition, the value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions in China and by China&#8217;s foreign exchange policies. In recent years, the RMB has fluctuated against the U.S. dollar, at times significantly and unpredictably. Significant revaluation of the RMB may have a negative effect on our business.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of the date thereof, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a991earningsreleaseq12025.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i55afb8ed4a4e409f81f4b8c915b4d96d_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><img alt="legendlogo.jpg" src="legendlogo.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Legend Biotech Reports First Quarter 2025 Results and Recent Highlights</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> (ciltacabtagene autoleucel&#59; cilta-cel) net trade sales of approximately $369 million</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Over 6,000 patients treated to date</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Initiated CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> clinical production at the Tech Lane facility</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Received positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> label</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Australia&#8217;s TGA approved CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in second-line plus settings for multiple myeloma patients</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">Cash and cash equivalents, and time deposits of $1.0&#160;billion, as of March&#160;31, 2025, which Legend Biotech believes will provide financial runway into the second quarter of 2026</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SOMERSET, N.J.&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May&#160;13, 2025&#8212; Legend Biotech Corporation (NASDAQ&#58; LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key corporate highlights. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;CARVYKTI, underpinned by its continued strong commercial performance, continues to set the standard for CAR-T therapies in multiple myeloma,&#8221; said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. &#8220;We believe our achievements from this past quarter, including capacity expansion and additional global approvals, are setting the stage for Legend Biotech to achieve company-wide profitability by next year. As we unlock new markets and meet growing global demand, we believe our manufacturing expansion and commercial execution will maintain CARVYKTI&#8217;s market leadership position and enable us to deliver our differentiated cell therapy to more patients around the world.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Regulatory Updates</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Committee for Medicinal Products for Human Use</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (CHMP) of the European Medicines Agency (EMA) provided a positive opinion for CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">on its CARTITUDE-4 overall survival (OS) update where a statistically significant and clinically meaningful improvement was achieved. The Summary of Product Characteristics will contain progression-free survival (PFS), OS, and safety information based on second interim analysis.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Australia&#8217;s </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Therapeutic Goods Administration</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (TGA) approved the registration of CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI), and are refractory to lenalidomide or who have received at least three prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Key Business Developments</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Treated over 6,000 clinical and commercial patients to date.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">In the first quarter of 2025, initiated clinical production of CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">at the Tech Lane facility in Ghent, Belgium. The company expects to initiate commercial production at the Tech Lane facility by the end of 2025, providing expanded capacity to meet global demand.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Published Legend Biotech&#8217;s second annual Environmental, Social &#38; Governance (ESG) report, covering fiscal year 2024 data, which aligns with the Sustainable Accounting Standards Board (SASB) Biotechnology and Pharmaceutical sector standards, the Greenhouse Gas (GHG) Protocol, and references the Global Reporting Initiative (GRI) standards&#59; the report underscores Legend Biotech&#8217;s dedication to the long-term wellbeing and success of its company, its employees, and the patients it serves.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Cash and cash equivalents, and time deposits of $1.0&#160;billion, which Legend Biotech believes will provide financial runway into the second quarter of 2026, when Legend Biotech anticipates potentially achieving an operating profit excluding unrealized foreign exchange gains or losses.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">First Quarter 2025 Financial Results</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;padding-left:14.5pt">Cash Position</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58; Cash and cash equivalents, and time deposits were $1.0&#160;billion as of March&#160;31, 2025.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">License Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; License revenue was $9.3 million for the three months ended March&#160;31, 2025, compared to $12.2 million for the three months ended March&#160;31, 2024. The decrease of $2.9 million was solely attributed to revenue recognized pursuant to Legend Biotech&#8217;s license agreement with Novartis for the development, manufacture, and commercialization of LB2102 and other potential CAR-T therapies selectively targeting DLL-3 </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#8220;Novartis License Agreement&#8221;). This revenue is recognized over time as Legend Biotech conducts a Phase 1 clinical trial for LB2102. The decrease resulted from the timing of the underlying activities performed in connection with such trial.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Collaboration Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Collaboration revenue was $185.6 million for the three months ended March&#160;31, 2025, compared to $78.5 million for the three months ended March&#160;31, 2024. The increase was due to an increase in revenue generated from sales of CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in connection with our collaboration and license agreement with Janssen (the &#34;Janssen Agreement&#34;).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Cost of Collaboration Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Cost of collaboration revenue was $69.5 million for the three months ended March&#160;31, 2025, compared to $49.1 million for the three months ended March&#160;31, 2024. The increase was primarily due to Legend Biotech&#8217;s share of the cost of sales in connection with CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> sales under the Janssen Agreement and expenditures to support expansion in manufacturing capacity.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Cost of License and Other Revenue</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Cost of license and other revenue was $1.8 million for the three months ended March&#160;31, 2025, compared to $5.6 million for the three months ended March&#160;31, 2024, and consisted of costs recognized in connection with the Novartis License Agreement. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:13.31pt">Research and Development Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Research and development expenses were $101.9 million for the three months ended March&#160;31, 2025, compared to $101.0 million for the three months ended March&#160;31, 2024. The increase was due to research and development activities in cilta-cel with two frontline clinical trials ongoing during 2025, offset by a decrease in other cilta-cel research and development activities. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Administrative Expenses&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Administrative expenses were $31.5 million for the three months ended March 31, 2025, compared to $31.9 million for the three months ended March&#160;31, 2024. Administrative expenses remained relatively flat, with an increase in staffing-related expenses due to higher headcount, offset by lower IT expenses due to the timing of completion of existing projects or the initiation of new projects compared to same period in the prior year.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Selling and Distribution Expe</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">nses&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Selling and distribution expenses were $41.0 million for the three months ended March&#160;31, 2025, compared to $24.2&#160;million for the three months ended March&#160;31, 2024. The increase was due to increased costs associated with commercial activities including expansion of the sales force due to growing sales of CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Net Loss</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; Net loss was $100.9 million for the three months ended March 31, 2025, compared to a net loss of $59.8 million for the three months ended March&#160;31, 2024.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%;padding-left:14.5pt">Adjusted Net Loss&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Adjusted net loss was $27.0 million for the three months ended March 31, 2025, compared to an adjusted net loss of $85.3 million for the three months ended March&#160;31, 2024.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#47;Conference Call Details&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legend Biotech will host its quarterly earnings call and webcast today at 8&#58;00am ET. To access the webcast, please visit this weblink. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A replay of the webcast will be available on Legend Biotech&#8217;s website at https&#58;&#47;&#47;investors.legendbiotech.com&#47;events-and-presentations.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">About Legend Biotech </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With over 2,600 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson &#38; Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI&#8217;s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Learn more at https&#58;&#47;&#47;legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute &#8220;forward-looking statements&#8221; within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech&#8217;s strategies and objectives&#59; statements relating to CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">, including Legend Biotech&#8217;s expectations for </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> and its therapeutic potential&#59; statements related to Legend Biotech manufacturing expectations for CARVYKTI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> and the ability of Legend Biotech&#8217;s manufacturing expansion and commercial execution to maintain CARVYKTI&#8217;s market leadership position&#59; statements related to Legend Biotech&#8217;s ability to fund its operations into the second quarter of 2026 and to achieve profitability in 2026&#59; and the potential benefits of Legend Biotech&#8217;s product candidates. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech&#8217;s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products&#59; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data&#59; unexpected regulatory actions or delays, including requests for additional safety and&#47;or efficacy data or analysis of data, or government regulation generally&#59; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners&#59; uncertainties arising from challenges to Legend Biotech&#8217;s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process&#59; government, industry, and general product pricing and other political pressures&#59; as well as the other factors discussed in the &#8220;Risk Factors&#8221; section of Legend Biotech&#8217;s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 11, 2025 and Legend Biotech&#8217;s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INVESTOR CONTACT&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jessie Yeung</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tel&#58; (732) 956-8271</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jessie.yeung&#64;legendbiotech.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PRESS CONTACT&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mary Ann Ondish</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tel&#58; (914) 552-4625</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">media&#64;legendbiotech.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i55afb8ed4a4e409f81f4b8c915b4d96d_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.575%"><tr><td style="width:1.0%"></td><td style="width:57.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.637%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$&#8217;000, except share and per share data</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVENUE</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,348&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,181&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,615&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,481&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,053&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,991&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of collaboration revenue</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,497)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,101)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of license and other revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,847)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,638)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,924)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,964)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrative expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,463)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,929)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and distribution expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,969)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,223)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on asset impairment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(970)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance costs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,061)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,475)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance income*</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,056&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,870&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense)&#47;income, net*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,508)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,681&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOSS BEFORE TAX</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,130)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,788)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,786)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOSS FOR THE PERIOD</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,916)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,793)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attributable to&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary equity holders of the parent</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,916)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,793)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.27)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORDINARY SHARES USED IN LOSS PER SHARE COMPUTATION</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,525,855&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,010,429&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,525,855&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,010,429&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to present finance income as a separate line item and to combine other income&#47;(expense),net for comparative purposes</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i55afb8ed4a4e409f81f4b8c915b4d96d_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.415%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">US$&#8217;000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">US$&#8217;000</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-CURRENT ASSETS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,810&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advance payments for property, plant and equipment</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,224&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,932&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Time deposits</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,082&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration prepaid leases</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,613&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,064&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,583&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,056&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,857&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,236&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CURRENT ASSETS</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration inventories, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,933&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,903&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,287&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepayments, other receivables and other assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,040&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,975&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pledged deposits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Time deposits</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563,678&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">835,934&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">441,702&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,749&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,218,792&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,283,918&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,615,649&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,670,154&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CURRENT LIABILITIES</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade payables</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,143&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payables and accruals</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,810&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,180&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government grants</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">532&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,341&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,794&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax payable</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,009&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,671&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,535&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,874&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234,373&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277,645&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NON-CURRENT LIABILITIES</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration interest-bearing advanced funding</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305,745&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,196&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities long term</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,724&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,613&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government grants</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,058&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,154&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363,527&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351,963&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597,900&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,608&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EQUITY</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share capital</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,017,712&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040,509&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total ordinary shareholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,017,749&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040,546&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,017,749&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040,546&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,615,649&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,670,154&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i55afb8ed4a4e409f81f4b8c915b4d96d_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"></td><td style="width:64.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">US$&#8217;000</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LOSS BEFORE TAX</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,130)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,788)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS (USED IN)&#47;PROVIDED BY, OPERATING ACTIVITIES</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,754)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,518&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS PROVIDED BY&#47;(USED IN) INVESTING ACTIVITIES</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,640&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396,148)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET INCREASE&#47;(DECREASE) IN CASH AND CASH EQUIVALENTS</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,553&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379,799)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(343)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of the period</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,749&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277,713&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH AND CASH EQUIVALENTS AT END OF THE YEAR</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,702&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897,571&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and bank balances</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005,450&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156,674&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58; Pledged deposits</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563,678&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,744&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents as stated in the statement of financial position</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,702&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897,571&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents as stated in the statement of cash flows</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,702&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897,571&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i55afb8ed4a4e409f81f4b8c915b4d96d_81"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF IFRS TO NON-IFRS MEASURES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as &#8220;Adjusted EPS&#8221; &#8220;ANL per Share&#8221;) as performance metrics. Adjusted Net Loss and ANL per share are not defined under IFRS, are not a measure of operating income, operating performance, or liquidity presented in accordance with IFRS, and are subject to important limitations. Our use of Adjusted Net Loss has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. For example&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted Net Loss does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">Adjusted Net Loss excludes unrealized foreign exchange gain or loss which resulted primarily from changes in the intercompany loan balances and cash balances as a result of exchange rate changes between USD and EUR.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">Adjusted Net Loss does not reflect changes in, or cash requirements for, our working capital needs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">In addition, Adjusted Net Loss excludes such as share based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, our definition of Adjusted Net Loss and ANL per Share may not be the same as similarly titled measures used by other companies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, we believe that providing information concerning Adjusted Net Loss and ANL per Share enhances an investor&#8217;s understanding of our financial performance. We use Adjusted Net Loss as a performance metric that guides management in its operation of and planning for the future of the business. We believe that Adjusted Net Loss provides a useful measure of our operating performance from period to period by excluding certain items that we believe are not representative of our core business. We define Adjusted Net Loss as net loss adjusted for (1) non-cash items such as depreciation and amortization, share based compensation, impairment loss, and (2) unrealized foreign exchange gain or loss mainly related to intercompany loan balances and cash deposit balances as a result of exchange rate changes between USD and EUR.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ANL per Share is computed by dividing Adjusted Net Loss by the weighted average shares outstanding.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation between Adjusted Net Loss and Net Loss, the most directly comparable measure under IFRS, has been provided in the table below.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGEND BIOTECH CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECONCILIATION OF IFRS TO NON-IFRS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months ended March 31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">US$&#8217;000 except per share data</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,916)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,793)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,722&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,946&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,703&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss&#47;(gain) (included in Other income&#47;(expense), net)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,802&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,889)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted net loss (ANL)</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,999)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,257)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANL per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANL per share - basic</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANL per share - diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.07)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>3
<FILENAME>q125-pipeline51225.htm
<DESCRIPTION>EX-99.4
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>q125-pipeline51225</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1365;"><!-- q125-pipeline51225001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="q125-pipeline51225001.jpg" title="slide1" width="1365" height="768">
<DIV><FONT size="1" style="font-size:1pt;color:white">1 *In collaboration with Janssen, Pharmaceutical Companies of Johnson &amp; Johnson. &#8224;Phase 1 investigator-initiated trial. &#8225;IND applications have been cleared by the U.S. FDA. #Subject to an exclusive license agreement with Novartis Pharma AG. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still  confidential, certain candidates may not be included in this list.  INDICATIONS: ALL: acute lymphoblastic leukemia; LCNEC: large cell neuroendocrine carcinoma; MM: multiple myeloma; NDMM: newly diagnosed multiple myeloma; NHL: non-Hodgkin lymphoma; RRMM: relapsed or refractory multiple myeloma; SCLC: small cell lung cancer TARGETS: BCMA: B-cell maturation antigen; DLL3: delta-like ligand 3; GCC: guanylyl cyclase C; GPRC5D: G-protein coupled receptor, family C, group 5, member D Autologous  Therapies BCMA-directed  Autologous  Therapy P H A S E  2 P H A S E  3 LEGEND-2&#8224; RRMM NCT03090659 CARTIFAN-1* RRMM  NCT03758417  CARTITUDE-1* RRMM  NCT03548207 CARTITUDE-2* MM NCT04133636 CARTITUDE-4* RRMM 1-3 Prior Lines  NCT04181827 CARTITUDE-5* NDMM Transplant Not  Intended  NCT04923893 CARTITUDE-6* NDMM  Transplant Eligible NCT05257083 Ciltacabtagene Autoleucel Clinical Studies  P H A S E  1 P R E C L I N I C A L P H A S E  1 NHL &#8224; /ALL&#8224;  (CD19 X CD20 X  CD22) GASTRIC &amp;  PANCREATIC&#8225; (CLAUDIN 18.2)  SCLC &amp; LCNEC&#8225;# (DLL3) COLORECTAL&#8224; (GCC) Additional Pipeline Assets Allogeneic  Therapies MM&#8224; (BCMA) CAR-&#947;&#948; T NHL&#8224;  (CD19 X CD20) CAR-&#947;&#948; T NHL&#8224; (CD20) CAR-&#945;&#946; T MM&#8224;  (BCMA)  CAR-NK MM &#8224; (CD19 X GPRC5D),  (GPRC5D) AUTOIMMUNE &#8224; (CD19 X CD20 X  CD22) AUTOIMMUNE (CD19 X BCMA) Our Pipeline </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>4
<FILENAME>exhibit995tariffriskfactor.htm
<DESCRIPTION>EX-99.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia0244a8ef7ac4804a1d81344bff63f07_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.5</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">International trade policies, including tariffs, sanctions and trade barriers may adversely affect our</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">business, financial condition, results of operations and prospects.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a global economy, and our business depends on a global supply chain for the development, manufacturing, and distribution of our pharmaceutical products, and for the advancement of our preclinical and clinical development programs. There is inherent risk, based on the complex relationships among the U.S. and the countries in which we conduct our business, that political, diplomatic, and national security factors can lead to global trade restrictions and changes in trade policies and export regulations that may adversely affect our business and operations. The current international trade and regulatory environment is subject to significant ongoing uncertainty. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source certain ingredients, precursor chemicals, and specialized equipment from international suppliers, with reliance on foreign manufacturers, including China and Europe. Tariff policies, particularly those affecting China, Europe and&#47;or pharmaceutical products or ingredients and related materials, could materially increase our costs and reduce our profitability, including as a result of our inability to adjust pricing in formulary-based markets. Recent and potential future changes in international trade policies, including U.S.-China trade relations and pharmaceutical-specific tariffs, present material risks to our operations and financial performance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent policy discussions have included potential targeted tariffs or other trade measures specifically aimed at pharmaceutical products and ingredients as part of broader healthcare cost control or national security initiatives. Unlike consumer goods, pharmaceuticals face unique regulatory constraints that make rapid supply chain adjustments particularly difficult and costly. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike many industries, our ability to pass increased costs to customers is limited by the structure of pharmaceutical pricing and reimbursement systems. In certain markets, including the United States and the European Union, drug pricing is subject to government regulation, insurance reimbursement limits or long-term contractual pricing agreements with payers and distributors. In addition, price increases can adversely impact commercial payer formulary decisions.  These constraints may prevent us from passing increased costs from tariffs to customers.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current or future tariffs may also result in increased research and development expenses, including with respect to increased costs associated with ingredients, raw materials, laboratory equipment and research materials and components. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence and negatively impact our business, results of operations, financial condition and growth prospects. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexity of announced or future tariffs may also increase the risk that we or our customers or suppliers may be subject to civil or criminal enforcement actions in the United States or foreign jurisdictions related to compliance with trade regulations. Foreign governments may also adopt non-tariff measures, such as procurement preferences or informal disincentives to engage with, purchase from or invest in U.S. entities, which may limit our ability to compete internationally and attract non-U.S. investment, employees, customers and suppliers. Foreign governments may also take other retaliatory actions against U.S. entities, such as decreased intellectual property protection, increased enforcement actions, or delays in regulatory approvals, which may result in heightened international legal and operational risks. In addition, the United States and other governments have imposed and may continue to impose additional sanctions, such as trade restrictions or trade barriers, which could restrict us from doing business directly or indirectly in or with certain countries or parties and may impose additional costs and complexity to our business.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade disputes, tariffs, restrictions and other political tensions between the United States and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns. The ultimate impact of current or future tariffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economic downturn, escalation in trade </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, ability to access the capital markets or other financing sources, results of operations, financial condition and prospects. In addition, tariffs and other trade developments have and may continue to heighten the risks related to the other risk factors described in our Annual Report for the fiscal year ended December 31, 2024.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>legn-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9fafd2bc-3cfd-4d2f-adf8-3916722ba5cf,g:99013260-2431-4a14-8f08-d911c15b56e6-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:legn="http://legendbiotech.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://legendbiotech.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="legn-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://legendbiotech.com/role/COVER">
        <link:definition>0000001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME">
        <link:definition>9952151 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>9952152 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>9952153 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952154 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATEINFORMATION" roleURI="http://legendbiotech.com/role/CORPORATEINFORMATION">
        <link:definition>9952155 - Disclosure - CORPORATE INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPREPARATION" roleURI="http://legendbiotech.com/role/BASISOFPREPARATION">
        <link:definition>9952156 - Disclosure - BASIS OF PREPARATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY" roleURI="http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY">
        <link:definition>9952157 - Disclosure - NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://legendbiotech.com/role/REVENUE">
        <link:definition>9952158 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENET" roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENET">
        <link:definition>9952159 - Disclosure - OTHER (EXPENSE)/INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCEINCOMEANDFINANCECOSTS" roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTS">
        <link:definition>9952160 - Disclosure - FINANCE INCOME AND FINANCE COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT" roleURI="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT">
        <link:definition>9952161 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://legendbiotech.com/role/LEASES">
        <link:definition>9952162 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNET" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET">
        <link:definition>9952163 - Disclosure - COLLABORATION INVENTORIES, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS">
        <link:definition>9952164 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS" roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS">
        <link:definition>9952165 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERPAYABLESANDACCRUALS" roleURI="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS">
        <link:definition>9952166 - Disclosure - OTHER PAYABLES AND ACCRUALS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING">
        <link:definition>9952167 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUM" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM">
        <link:definition>9952168 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS" roleURI="http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS">
        <link:definition>9952169 - Disclosure - APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://legendbiotech.com/role/REVENUETables">
        <link:definition>9955511 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETTables" roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables">
        <link:definition>9955512 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCEINCOMEANDFINANCECOSTSTables" roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSTables">
        <link:definition>9955513 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables" roleURI="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables">
        <link:definition>9955514 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://legendbiotech.com/role/LEASESTables">
        <link:definition>9955515 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNETTables" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables">
        <link:definition>9955516 - Disclosure - COLLABORATION INVENTORIES, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables">
        <link:definition>9955517 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables" roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables">
        <link:definition>9955518 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERPAYABLESANDACCRUALSTables" roleURI="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables">
        <link:definition>9955519 - Disclosure - OTHER PAYABLES AND ACCRUALS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables">
        <link:definition>9955520 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUMTables" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables">
        <link:definition>9955521 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESummaryofAnalysisofRevenueDetails" roleURI="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails">
        <link:definition>9955522 - Disclosure - REVENUE - Summary of Analysis of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESummaryofRevenueDetails" roleURI="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails">
        <link:definition>9955523 - Disclosure - REVENUE - Summary of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" roleURI="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails">
        <link:definition>9955524 - Disclosure - REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUESummaryofDeferredRevenueDetails" roleURI="http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails">
        <link:definition>9955525 - Disclosure - REVENUE - Summary of Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSEINCOMENETDetails" roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails">
        <link:definition>9955526 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCEINCOMEANDFINANCECOSTSNarrativeDetails" roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSNarrativeDetails">
        <link:definition>9955527 - Disclosure - FINANCE INCOME AND FINANCE COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails" roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails">
        <link:definition>9955528 - Disclosure - FINANCE INCOME AND FINANCE COSTS - Summary of Finance Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails" roleURI="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails">
        <link:definition>9955529 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAdditionalInformationDetails" roleURI="http://legendbiotech.com/role/LEASESAdditionalInformationDetails">
        <link:definition>9955530 - Disclosure - LEASES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" roleURI="http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails">
        <link:definition>9955531 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails">
        <link:definition>9955532 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails">
        <link:definition>9955533 - Disclosure - COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINVENTORIESNETAdditionalInformationDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails">
        <link:definition>9955534 - Disclosure - COLLABORATION INVENTORIES, NET - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails">
        <link:definition>9955535 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails">
        <link:definition>9955536 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails" roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails">
        <link:definition>9955537 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERPAYABLESANDACCRUALSDetails" roleURI="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails">
        <link:definition>9955538 - Disclosure - OTHER PAYABLES AND ACCRUALS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails">
        <link:definition>9955539 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails">
        <link:definition>9955540 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails">
        <link:definition>9955541 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails">
        <link:definition>9955542 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="legn_RevenueFromLicensingOfIntellectualProperty" abstract="false" name="RevenueFromLicensingOfIntellectualProperty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CollaborationRevenue" abstract="false" name="CollaborationRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CostOfLicenseAndOtherRevenue" abstract="false" name="CostOfLicenseAndOtherRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_SellingAndDistributionExpenses" abstract="false" name="SellingAndDistributionExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdvancePaymentsForPropertyPlantAndEquipment" abstract="false" name="AdvancePaymentsForPropertyPlantAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_TimesDepositsNonCurrent" abstract="false" name="TimesDepositsNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CollaborationPrepaidLeases" abstract="false" name="CollaborationPrepaidLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_PledgedDeposits" abstract="false" name="PledgedDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_TimesDeposits" abstract="false" name="TimesDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_OtherPayablesAndAccrualsCurrent" abstract="false" name="OtherPayablesAndAccrualsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_StatementOfChangesInEquityRollForward" abstract="true" name="StatementOfChangesInEquityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" abstract="false" name="IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForInventoryReserveProvision" abstract="false" name="AdjustmentsForInventoryReserveProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForDepreciationOfRightOfUseAssets" abstract="false" name="AdjustmentsForDepreciationOfRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DeferredGovernmentGrant" abstract="false" name="DeferredGovernmentGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" abstract="false" name="AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" abstract="false" name="AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" abstract="false" name="AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" abstract="false" name="AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities" abstract="false" name="InterestOnLeasePaymentsClassifiedAsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" abstract="false" name="PrepaymentToCollaboratorForCollaborationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" abstract="false" name="CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" abstract="false" name="ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AdditionInTimeDeposits" abstract="false" name="AdditionInTimeDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DecreaseInTimeDeposits" abstract="false" name="DecreaseInTimeDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_TimesDepositsCurrentAndNoncurrent" abstract="false" name="TimesDepositsCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" abstract="false" name="CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows" abstract="false" name="CashAndCashEquivalentsAsStatedInStatementOfCashFlows" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ProceedsFromPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" abstract="false" name="ProceedsFromPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_IncreaseDecreaseInPledgedDepositsNet" abstract="false" name="IncreaseDecreaseInPledgedDepositsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" abstract="false" name="DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_BasisOfPreparationAbstract" abstract="true" name="BasisOfPreparationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfOtherIncomeAndExpenseAbstract" abstract="true" name="DisclosureOfOtherIncomeAndExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_FinanceIncomeAndFinanceCostsAbstract" abstract="true" name="FinanceIncomeAndFinanceCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" abstract="false" name="EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_LeaseAbstract" abstract="true" name="LeaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" abstract="true" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" abstract="false" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract" abstract="true" name="DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfOtherPayablesAndAccrualsAbstract" abstract="true" name="DisclosureOfOtherPayablesAndAccrualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" abstract="false" name="DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" abstract="false" name="DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" abstract="false" name="DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="legn_LesseeLeaseLiabilitiesTextBlock" abstract="false" name="LesseeLeaseLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" abstract="false" name="DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" abstract="false" name="DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="legn_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_OtherMiscellaneousIncomeExpense" abstract="false" name="OtherMiscellaneousIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_LeasesTable" abstract="true" name="LeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="legn_LeasesLineItems" abstract="true" name="LeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_LesseeLeasingArrangementsLeasesTerm" abstract="false" name="LesseeLeasingArrangementsLeasesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="legn_OngoingLeasePaymentsUnderTheLandLease" abstract="false" name="OngoingLeasePaymentsUnderTheLandLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_RightOfUseAssetsRollForward" abstract="true" name="RightOfUseAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" abstract="false" name="IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" abstract="true" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" abstract="true" name="DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_LeasesRollForward" abstract="true" name="LeasesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_IncreaseInLeaseLiabilities" abstract="false" name="IncreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_IncreaseOfLeaseLiabilitiesBalance" abstract="false" name="IncreaseOfLeaseLiabilitiesBalance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_InventoryReserve" abstract="false" name="InventoryReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" abstract="true" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" abstract="true" name="PrepaymentsOtherReceivablesAndOtherAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" abstract="true" name="DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_OtherCollaborationReceivables" abstract="false" name="OtherCollaborationReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_PrepaymentsOtherReceivablesAndOtherAssets" abstract="false" name="PrepaymentsOtherReceivablesAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" abstract="true" name="DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" abstract="true" name="DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_PledgedShortTermDeposits" abstract="false" name="PledgedShortTermDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_DepositsFromBank" abstract="false" name="DepositsFromBank" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AccruedPayroll" abstract="false" name="AccruedPayroll" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_AccruedExpense" abstract="false" name="AccruedExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_CollaborationPayable" abstract="false" name="CollaborationPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_PayableForCollaborationAssets" abstract="false" name="PayableForCollaborationAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_OtherTaxPayables" abstract="false" name="OtherTaxPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_A110InterestBearingLoansMember" abstract="true" name="A110InterestBearingLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_InterestBearingBorrowingsFundedInterestsAccrued" abstract="false" name="InterestBearingBorrowingsFundedInterestsAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_NumberOfBorrowingBatches" abstract="false" name="NumberOfBorrowingBatches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="legn_AuthorisedAbstract" abstract="true" name="AuthorisedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_AuthorizedShareCapital" abstract="false" name="AuthorizedShareCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ShareCapitalMember" abstract="true" name="ShareCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="legn_ShareCapitalRollForward" abstract="true" name="ShareCapitalRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" abstract="false" name="ShareCapitalAndSharePremiumNumberOfSharesInIssue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="legn_ShareCapitalAndSharePremium" abstract="false" name="ShareCapitalAndSharePremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ExerciseOfShareOptionNumberOfSharesInIssue" abstract="false" name="ExerciseOfShareOptionNumberOfSharesInIssue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="legn_ExerciseOfShareOption" abstract="false" name="ExerciseOfShareOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" abstract="false" name="ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" abstract="false" name="ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>legn-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9fafd2bc-3cfd-4d2f-adf8-3916722ba5cf,g:99013260-2431-4a14-8f08-d911c15b56e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_18190503-129b-48f5-b15e-30d8f47f407d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_14ee6ec7-d4a7-41ed-9c4a-ee7de2450a44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_18190503-129b-48f5-b15e-30d8f47f407d" xlink:to="loc_ifrs-full_ProfitLoss_14ee6ec7-d4a7-41ed-9c4a-ee7de2450a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_3c2af874-277e-42dc-85ec-df65239762cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_18190503-129b-48f5-b15e-30d8f47f407d" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_3c2af874-277e-42dc-85ec-df65239762cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_f77c9cde-397c-4c80-9684-a7a288d3f76d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_ffac469f-0ec8-4c03-b475-789f9b8f6a46" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_f77c9cde-397c-4c80-9684-a7a288d3f76d" xlink:to="loc_ifrs-full_ComprehensiveIncome_ffac469f-0ec8-4c03-b475-789f9b8f6a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_d3093015-38f7-4f2a-bfeb-08bc432c0ce7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_FinanceCosts_d3093015-38f7-4f2a-bfeb-08bc432c0ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_67fdc7ce-35ee-4533-a431-ec36744aabdb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_FinanceIncome_67fdc7ce-35ee-4533-a431-ec36744aabdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_b081a3a2-fb6e-41e3-a523-6b7a2afee709" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_CostOfSales_b081a3a2-fb6e-41e3-a523-6b7a2afee709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CostOfLicenseAndOtherRevenue_60887107-fb95-43bb-a5d8-de9ee86f31e1" xlink:href="legn-20250331.xsd#legn_CostOfLicenseAndOtherRevenue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_legn_CostOfLicenseAndOtherRevenue_60887107-fb95-43bb-a5d8-de9ee86f31e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_be55fcf8-f141-4e92-b013-2576d6309f0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_be55fcf8-f141-4e92-b013-2576d6309f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_53c2a4b0-6060-4b2e-a5be-ff98b4d9e287" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_53c2a4b0-6060-4b2e-a5be-ff98b4d9e287" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_8066ec84-8019-4fc3-be0d-75d33710f4cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_Revenue_8066ec84-8019-4fc3-be0d-75d33710f4cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense_2ce30fe3-e09d-413e-8879-8a05a187769c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_AdministrativeExpense_2ce30fe3-e09d-413e-8879-8a05a187769c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_77ebb9dd-70ef-4178-a5b2-379910a3689f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_ifrs-full_OtherGainsLosses_77ebb9dd-70ef-4178-a5b2-379910a3689f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SellingAndDistributionExpenses_1605ae56-b022-459c-b64e-2d057d5c9c49" xlink:href="legn-20250331.xsd#legn_SellingAndDistributionExpenses"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_b0ce8d53-f678-4819-8671-5e7dc29b8d25" xlink:to="loc_legn_SellingAndDistributionExpenses_1605ae56-b022-459c-b64e-2d057d5c9c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_86829688-2fc9-4943-9724-84c7112d3d1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4a806fa6-fe43-45a7-b57d-4a2c19b9899e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_86829688-2fc9-4943-9724-84c7112d3d1a" xlink:to="loc_ifrs-full_ProfitLoss_4a806fa6-fe43-45a7-b57d-4a2c19b9899e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_9233414a-9596-4102-98c5-df0d89192f16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_034b6ef3-0976-4ace-aa9b-244856877694" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_9233414a-9596-4102-98c5-df0d89192f16" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_034b6ef3-0976-4ace-aa9b-244856877694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_5eab2cf4-ecee-4382-8d14-fe7fb7f391a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_1c03e36a-8318-4cad-840d-d9c841e44dd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_5eab2cf4-ecee-4382-8d14-fe7fb7f391a4" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_1c03e36a-8318-4cad-840d-d9c841e44dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_4908944c-537e-46c6-847e-ab13ca9831e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_5eab2cf4-ecee-4382-8d14-fe7fb7f391a4" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_4908944c-537e-46c6-847e-ab13ca9831e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_3fb7ac66-3901-440b-b944-517db4cd65d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_be4e38d6-c886-4397-93c5-837fd0a1bbdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_3fb7ac66-3901-440b-b944-517db4cd65d2" xlink:to="loc_ifrs-full_OtherRevenue_be4e38d6-c886-4397-93c5-837fd0a1bbdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_f4bd1d4f-c663-492a-b300-3542c819a0d4" xlink:href="legn-20250331.xsd#legn_CollaborationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_3fb7ac66-3901-440b-b944-517db4cd65d2" xlink:to="loc_legn_CollaborationRevenue_f4bd1d4f-c663-492a-b300-3542c819a0d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty_192641ce-51bb-4dfc-868f-c2490fc46c77" xlink:href="legn-20250331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Revenue_3fb7ac66-3901-440b-b944-517db4cd65d2" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualProperty_192641ce-51bb-4dfc-868f-c2490fc46c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_c261f495-96fc-44f6-aca3-367a5246c379" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_789e414c-1852-4c8c-a4d9-d7b949db5f6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherComprehensiveIncome_c261f495-96fc-44f6-aca3-367a5246c379" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_789e414c-1852-4c8c-a4d9-d7b949db5f6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_9ee6d582-320d-4f1c-9c1c-4bc4b13187b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_39b75113-47df-468a-8577-5c6b982e1e80" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_9ee6d582-320d-4f1c-9c1c-4bc4b13187b8" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_39b75113-47df-468a-8577-5c6b982e1e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentGovernmentGrants_8ff698b0-75d3-4393-a269-1e0b61ac7de3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentGovernmentGrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_9ee6d582-320d-4f1c-9c1c-4bc4b13187b8" xlink:to="loc_ifrs-full_NoncurrentGovernmentGrants_8ff698b0-75d3-4393-a269-1e0b61ac7de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_43a9b47a-3c9d-41a6-9685-1f82c91c8572" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_9ee6d582-320d-4f1c-9c1c-4bc4b13187b8" xlink:to="loc_ifrs-full_LongtermBorrowings_43a9b47a-3c9d-41a6-9685-1f82c91c8572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentLiabilities_a3277c44-c021-440d-a428-1d36bbb3dfde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentLiabilities_9ee6d582-320d-4f1c-9c1c-4bc4b13187b8" xlink:to="loc_ifrs-full_OtherNoncurrentLiabilities_a3277c44-c021-440d-a428-1d36bbb3dfde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_417e40e6-d922-4eb2-8bac-367a2ad98f88" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_545819e3-72ff-4c6b-9374-a3722de79d3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_417e40e6-d922-4eb2-8bac-367a2ad98f88" xlink:to="loc_ifrs-full_CurrentLiabilities_545819e3-72ff-4c6b-9374-a3722de79d3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_ee3453da-41d6-44af-9ccd-17d78f9f822f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_417e40e6-d922-4eb2-8bac-367a2ad98f88" xlink:to="loc_ifrs-full_NoncurrentLiabilities_ee3453da-41d6-44af-9ccd-17d78f9f822f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_37d4370c-d942-4f9b-8141-85dbb67f5567" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_f45bfb7b-babb-470f-928c-88f3e26c2f9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_37d4370c-d942-4f9b-8141-85dbb67f5567" xlink:to="loc_ifrs-full_NoncurrentAssets_f45bfb7b-babb-470f-928c-88f3e26c2f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_b017faa9-6515-4b87-8af9-17c6de42ddf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_37d4370c-d942-4f9b-8141-85dbb67f5567" xlink:to="loc_ifrs-full_CurrentAssets_b017faa9-6515-4b87-8af9-17c6de42ddf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_0e325dab-f9e8-449c-99d8-1f6b13ab9ba6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:to="loc_ifrs-full_Inventories_0e325dab-f9e8-449c-99d8-1f6b13ab9ba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_9fa44555-29f8-474a-b4a9-d1929f2a5c12" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:to="loc_ifrs-full_CurrentTradeReceivables_9fa44555-29f8-474a-b4a9-d1929f2a5c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_acf2ce5b-816e-4611-b3db-a66ccc8b2092" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_acf2ce5b-816e-4611-b3db-a66ccc8b2092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss_82912dc9-bd40-4091-ae6e-cf4c2a6d9030" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss_82912dc9-bd40-4091-ae6e-cf4c2a6d9030" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PledgedDeposits_07b6c85b-6396-4517-8ff6-f42aefdfaad1" xlink:href="legn-20250331.xsd#legn_PledgedDeposits"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:to="loc_legn_PledgedDeposits_07b6c85b-6396-4517-8ff6-f42aefdfaad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDeposits_4a0f6c5b-8394-405c-9dc7-32a11857e709" xlink:href="legn-20250331.xsd#legn_TimesDeposits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:to="loc_legn_TimesDeposits_4a0f6c5b-8394-405c-9dc7-32a11857e709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_fb2d8844-f977-433b-b3c5-9766ecd072be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_63199a3c-a997-4864-bd95-229869f975e0" xlink:to="loc_ifrs-full_CashAndCashEquivalents_fb2d8844-f977-433b-b3c5-9766ecd072be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_0279d95d-1168-4209-ae3a-b0060c43e58b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_388188e2-554a-42a0-b854-3b02dabbcecf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_0279d95d-1168-4209-ae3a-b0060c43e58b" xlink:to="loc_ifrs-full_Equity_388188e2-554a-42a0-b854-3b02dabbcecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_31beb65f-9ad8-4996-9a94-2a81b9e42be0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_0279d95d-1168-4209-ae3a-b0060c43e58b" xlink:to="loc_ifrs-full_Liabilities_31beb65f-9ad8-4996-9a94-2a81b9e42be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_04cfd080-6554-4708-85b5-579753082376" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_5be7dcaa-9a39-4075-b210-7129b44ea00f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_04cfd080-6554-4708-85b5-579753082376" xlink:to="loc_ifrs-full_CurrentContractLiabilities_5be7dcaa-9a39-4075-b210-7129b44ea00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_86add632-41ab-46d1-9fae-037dfd8e0177" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_04cfd080-6554-4708-85b5-579753082376" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_86add632-41ab-46d1-9fae-037dfd8e0177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_6e62315e-19ab-49ac-9f52-c334a263c5b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_04cfd080-6554-4708-85b5-579753082376" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_6e62315e-19ab-49ac-9f52-c334a263c5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentGovernmentGrants_4efcaf32-17cc-4757-8881-e42c1d8d0e8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_04cfd080-6554-4708-85b5-579753082376" xlink:to="loc_ifrs-full_CurrentGovernmentGrants_4efcaf32-17cc-4757-8881-e42c1d8d0e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_c6697bb0-1a5b-4627-bb29-779c8bc61170" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_04cfd080-6554-4708-85b5-579753082376" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_c6697bb0-1a5b-4627-bb29-779c8bc61170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent_e1c78636-a69f-4735-909d-6835404cc4c5" xlink:href="legn-20250331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_04cfd080-6554-4708-85b5-579753082376" xlink:to="loc_legn_OtherPayablesAndAccrualsCurrent_e1c78636-a69f-4735-909d-6835404cc4c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_b92ddf81-6a99-4bf7-8c4d-c592b2656857" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_b92ddf81-6a99-4bf7-8c4d-c592b2656857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdvancePaymentsForPropertyPlantAndEquipment_18ed871b-e3ce-47e3-8f22-ed4bb9e8b59d" xlink:href="legn-20250331.xsd#legn_AdvancePaymentsForPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:to="loc_legn_AdvancePaymentsForPropertyPlantAndEquipment_18ed871b-e3ce-47e3-8f22-ed4bb9e8b59d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_5a2bbe13-f8d9-4f83-ad27-649b854c725e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:to="loc_ifrs-full_RightofuseAssets_5a2bbe13-f8d9-4f83-ad27-649b854c725e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsNonCurrent_c3880fe0-0686-4481-81bb-a7a249d7c758" xlink:href="legn-20250331.xsd#legn_TimesDepositsNonCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:to="loc_legn_TimesDepositsNonCurrent_c3880fe0-0686-4481-81bb-a7a249d7c758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_308e9293-38fd-438f-94cd-7f0bc4a37bba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_308e9293-38fd-438f-94cd-7f0bc4a37bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPrepaidLeases_1120480d-2e18-4d96-b9be-520ac5f6cbaa" xlink:href="legn-20250331.xsd#legn_CollaborationPrepaidLeases"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:to="loc_legn_CollaborationPrepaidLeases_1120480d-2e18-4d96-b9be-520ac5f6cbaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_16a72471-f7cd-4ba3-83b5-7d115c3d7b91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_3ea8ef98-be9b-4eca-818e-b6377128da0d" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_16a72471-f7cd-4ba3-83b5-7d115c3d7b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_2ca4a211-63fe-4f42-b3e3-c17b363d8bf0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_6afbfa92-b585-4c0f-9083-c9c43c5c3e7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_2ca4a211-63fe-4f42-b3e3-c17b363d8bf0" xlink:to="loc_ifrs-full_IssuedCapital_6afbfa92-b585-4c0f-9083-c9c43c5c3e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_4fc86be4-6e33-4bcb-9222-8861917d9d13" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent_2ca4a211-63fe-4f42-b3e3-c17b363d8bf0" xlink:to="loc_ifrs-full_OtherReserves_4fc86be4-6e33-4bcb-9222-8861917d9d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_14a76618-cbbb-48a8-b83e-01fa1cbbe4bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_0b5c525b-01ee-4050-8efa-dd61fa85e75f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_14a76618-cbbb-48a8-b83e-01fa1cbbe4bb" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_0b5c525b-01ee-4050-8efa-dd61fa85e75f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_b1eb59d4-f9c9-491f-a4fc-629303625faa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_1929aeae-9407-4963-b360-bac48cfa83ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_b1eb59d4-f9c9-491f-a4fc-629303625faa" xlink:to="loc_ifrs-full_ProfitLoss_1929aeae-9407-4963-b360-bac48cfa83ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_26eb4cd4-97a6-4d09-906c-c80ca980aebc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_b1eb59d4-f9c9-491f-a4fc-629303625faa" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_26eb4cd4-97a6-4d09-906c-c80ca980aebc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_93e6dba3-6da6-4c8b-9cad-f82d5b7084ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_ca0eaaf9-39a2-41f6-b0a0-8dac7ce8e7dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_93e6dba3-6da6-4c8b-9cad-f82d5b7084ec" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_ca0eaaf9-39a2-41f6-b0a0-8dac7ce8e7dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_9b0012cb-a655-4ca3-8a59-7c0e2165c3fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_93e6dba3-6da6-4c8b-9cad-f82d5b7084ec" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_9b0012cb-a655-4ca3-8a59-7c0e2165c3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1797eb13-e65f-41dd-b97f-c7e0ce630cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_aaabe5f0-817b-454f-8ba6-20ada5863c58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1797eb13-e65f-41dd-b97f-c7e0ce630cd9" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_aaabe5f0-817b-454f-8ba6-20ada5863c58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_cc86ea89-54d5-43cd-b339-6d45ef879648" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1797eb13-e65f-41dd-b97f-c7e0ce630cd9" xlink:to="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_cc86ea89-54d5-43cd-b339-6d45ef879648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_586b9940-f640-4738-90af-0dacbd577818" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1797eb13-e65f-41dd-b97f-c7e0ce630cd9" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_586b9940-f640-4738-90af-0dacbd577818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities_bb35c297-8303-44e6-8d1b-3cc951ff2c3d" xlink:href="legn-20250331.xsd#legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_1797eb13-e65f-41dd-b97f-c7e0ce630cd9" xlink:to="loc_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities_bb35c297-8303-44e6-8d1b-3cc951ff2c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_d3a1efc5-1dbb-454c-b6c3-53237499a783" xlink:href="legn-20250331.xsd#legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_d3a1efc5-1dbb-454c-b6c3-53237499a783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DecreaseInTimeDeposits_b7d6e22a-a8c1-42a1-bb3e-f1593600b922" xlink:href="legn-20250331.xsd#legn_DecreaseInTimeDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_legn_DecreaseInTimeDeposits_b7d6e22a-a8c1-42a1-bb3e-f1593600b922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdditionInTimeDeposits_f2e0d69a-ce53-4f2e-bd68-4b8e8d882c69" xlink:href="legn-20250331.xsd#legn_AdditionInTimeDeposits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_legn_AdditionInTimeDeposits_f2e0d69a-ce53-4f2e-bd68-4b8e8d882c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets_93d61f10-466e-43a4-bc7c-fc16933d1e9b" xlink:href="legn-20250331.xsd#legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets_93d61f10-466e-43a4-bc7c-fc16933d1e9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities_fb47614f-3ebd-4928-9644-d87dd2b25e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities_fb47614f-3ebd-4928-9644-d87dd2b25e6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ProceedsFromPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_6f416a80-1bcb-43ff-9886-a6d18112367c" xlink:href="legn-20250331.xsd#legn_ProceedsFromPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_legn_ProceedsFromPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_6f416a80-1bcb-43ff-9886-a6d18112367c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_31993426-5882-4688-8103-3f2ec2ce9f18" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_31993426-5882-4688-8103-3f2ec2ce9f18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities_6fb2ffa4-8d1e-4743-b542-070e005a7325" xlink:href="legn-20250331.xsd#legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d7ffbdef-250d-4044-97eb-3afd2bc149b5" xlink:to="loc_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities_6fb2ffa4-8d1e-4743-b542-070e005a7325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_64aef89b-093a-41f1-a7a3-bb02f8b95636" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_64aef89b-093a-41f1-a7a3-bb02f8b95636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_38139425-3c87-49bc-8c7b-589845313690" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_38139425-3c87-49bc-8c7b-589845313690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_f95eb31a-fac1-48c6-b898-58d74a0a5cbf" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_f95eb31a-fac1-48c6-b898-58d74a0a5cbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets_571493cc-96a1-4c6e-8128-9202352a6ff7" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets_571493cc-96a1-4c6e-8128-9202352a6ff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_ff2b55b3-c0cb-4f16-93da-6d157fffc03e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_ff2b55b3-c0cb-4f16-93da-6d157fffc03e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_f34cb049-09cd-4f47-aaf1-92aad5ff5827" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_f34cb049-09cd-4f47-aaf1-92aad5ff5827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_4bc9a4af-88d4-43d5-97d0-cee1be8fcde7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_4bc9a4af-88d4-43d5-97d0-cee1be8fcde7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities_c196d9a3-6149-45dc-bbce-56c25099a639" xlink:href="legn-20250331.xsd#legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities_c196d9a3-6149-45dc-bbce-56c25099a639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseInPledgedDepositsNet_59c86cde-fdd2-484d-8bd3-2bc3fbe65c1c" xlink:href="legn-20250331.xsd#legn_IncreaseDecreaseInPledgedDepositsNet"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_legn_IncreaseDecreaseInPledgedDepositsNet_59c86cde-fdd2-484d-8bd3-2bc3fbe65c1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent_d2b567b5-2b46-42f6-afa0-0226ed127aa0" xlink:href="legn-20250331.xsd#legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_e1771111-296d-48c4-8a9f-f9cb61e86b91" xlink:to="loc_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent_d2b567b5-2b46-42f6-afa0-0226ed127aa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_1ec8ed7b-5595-4040-b3d3-76459596b529" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_1ec8ed7b-5595-4040-b3d3-76459596b529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DeferredGovernmentGrant_0beec982-2b18-42bc-8320-8ffface0ddd8" xlink:href="legn-20250331.xsd#legn_DeferredGovernmentGrant"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_legn_DeferredGovernmentGrant_0beec982-2b18-42bc-8320-8ffface0ddd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_be38a581-bbc7-4976-b791-1bdebd30e283" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_be38a581-bbc7-4976-b791-1bdebd30e283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense_29923f05-3592-4fb1-a80c-8680f83390af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_AdjustmentsForAmortisationExpense_29923f05-3592-4fb1-a80c-8680f83390af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_834a3352-1be5-40d5-85ab-ac16b0f4e231" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_834a3352-1be5-40d5-85ab-ac16b0f4e231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_a59a5538-5c38-4cd8-9268-3f971ec65986" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_a59a5538-5c38-4cd8-9268-3f971ec65986" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_673798a9-b8b6-4058-b169-58680b6e65de" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_673798a9-b8b6-4058-b169-58680b6e65de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense_79ec08f8-a34b-4d82-a724-5dba376f87b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationExpense_79ec08f8-a34b-4d82-a724-5dba376f87b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_a6880d3d-6f4c-4356-b64b-0734d8ff039d" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDepreciationOfRightOfUseAssets"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_a6880d3d-6f4c-4356-b64b-0734d8ff039d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_6139efc1-ec0d-4036-b568-02a5749510f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_6139efc1-ec0d-4036-b568-02a5749510f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_25064650-cbdb-40f2-a72c-4b22b94bd7af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_25064650-cbdb-40f2-a72c-4b22b94bd7af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_2a28c6da-0041-4bf5-8b1a-a2425d08475c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_2a28c6da-0041-4bf5-8b1a-a2425d08475c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForInventoryReserveProvision_424087fc-91f8-4193-b68f-12d163602c58" xlink:href="legn-20250331.xsd#legn_AdjustmentsForInventoryReserveProvision"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_96e6ee26-8003-4097-b77b-aa143a55ec0c" xlink:to="loc_legn_AdjustmentsForInventoryReserveProvision_424087fc-91f8-4193-b68f-12d163602c58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_b3ba3a85-aa61-4202-a571-24eb0e52eb30" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_c34efb84-2808-44ba-9b60-c3835d4a65ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_b3ba3a85-aa61-4202-a571-24eb0e52eb30" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_c34efb84-2808-44ba-9b60-c3835d4a65ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_165f45c5-8ab2-41b9-82e2-29b5999600a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_b3ba3a85-aa61-4202-a571-24eb0e52eb30" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_165f45c5-8ab2-41b9-82e2-29b5999600a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4c1a0973-ff0a-430a-97f8-09f3dbe1bfb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_b3ba3a85-aa61-4202-a571-24eb0e52eb30" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_4c1a0973-ff0a-430a-97f8-09f3dbe1bfb1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUESummaryofDeferredRevenueDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_c9869890-bd39-4d85-ac16-1e1964e7ef38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_8df988e8-4ea5-4ce9-9866-48c5e6890749" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ContractLiabilities_c9869890-bd39-4d85-ac16-1e1964e7ef38" xlink:to="loc_ifrs-full_CurrentContractLiabilities_8df988e8-4ea5-4ce9-9866-48c5e6890749" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHEREXPENSEINCOMENETDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_7b5608a5-a06c-40f7-b365-80983343555f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_80ca1481-e220-4b49-8dd7-7a3fa9dd5620" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_7b5608a5-a06c-40f7-b365-80983343555f" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_80ca1481-e220-4b49-8dd7-7a3fa9dd5620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_ac7736a2-dfd1-4398-8772-22169ac542bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_7b5608a5-a06c-40f7-b365-80983343555f" xlink:to="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_ac7736a2-dfd1-4398-8772-22169ac542bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherMiscellaneousIncomeExpense_2777619b-f896-4ef6-8031-1d967cb37f8b" xlink:href="legn-20250331.xsd#legn_OtherMiscellaneousIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherGainsLosses_7b5608a5-a06c-40f7-b365-80983343555f" xlink:to="loc_legn_OtherMiscellaneousIncomeExpense_2777619b-f896-4ef6-8031-1d967cb37f8b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_1e99d640-3e3b-4a33-acb8-f895dab4a15e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_f37a71d6-349e-4358-89e5-2dc9afe8745e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_1e99d640-3e3b-4a33-acb8-f895dab4a15e" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_f37a71d6-349e-4358-89e5-2dc9afe8745e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_886b2daa-0703-4212-89e7-fe218da23548" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_FinanceCosts_1e99d640-3e3b-4a33-acb8-f895dab4a15e" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_886b2daa-0703-4212-89e7-fe218da23548" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_3129cbca-8fe8-4e11-8e9d-a316ae65bc2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_78110054-eb31-4efa-93dd-e6f6ebeeae50" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_3129cbca-8fe8-4e11-8e9d-a316ae65bc2c" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_78110054-eb31-4efa-93dd-e6f6ebeeae50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_dfe605b6-b383-4979-96ba-0a45cdd9eff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_LeaseLiabilities_3129cbca-8fe8-4e11-8e9d-a316ae65bc2c" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_dfe605b6-b383-4979-96ba-0a45cdd9eff2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_1e9126b8-007b-4c78-8cfe-3c6155a25abd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_be895bb5-e145-41ed-be43-23636c45148c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WorkInProgress"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_1e9126b8-007b-4c78-8cfe-3c6155a25abd" xlink:to="loc_ifrs-full_WorkInProgress_be895bb5-e145-41ed-be43-23636c45148c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_5f0942bd-b04e-4283-8bee-4522775091e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_1e9126b8-007b-4c78-8cfe-3c6155a25abd" xlink:to="loc_ifrs-full_RawMaterials_5f0942bd-b04e-4283-8bee-4522775091e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_bdebbbc9-ace0-42fe-af59-f34b6f94cce6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Inventories_1e9126b8-007b-4c78-8cfe-3c6155a25abd" xlink:to="loc_ifrs-full_FinishedGoods_bdebbbc9-ace0-42fe-af59-f34b6f94cce6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_3db83927-e220-4a21-84ae-d3269d58a773" xlink:href="legn-20250331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables_0c3b3c2f-364e-4b9f-9949-416d648f8352" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_3db83927-e220-4a21-84ae-d3269d58a773" xlink:to="loc_ifrs-full_ValueAddedTaxReceivables_0c3b3c2f-364e-4b9f-9949-416d648f8352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_e3260429-9f64-40f2-a284-f2ebec2b74d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Prepayments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_3db83927-e220-4a21-84ae-d3269d58a773" xlink:to="loc_ifrs-full_Prepayments_e3260429-9f64-40f2-a284-f2ebec2b74d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_6aa7000f-95e2-4048-873c-6d98178b4215" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_3db83927-e220-4a21-84ae-d3269d58a773" xlink:to="loc_ifrs-full_OtherReceivables_6aa7000f-95e2-4048-873c-6d98178b4215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables_7b9be7ff-eedd-427b-b634-9fad0bcff1e0" xlink:href="legn-20250331.xsd#legn_OtherCollaborationReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_3db83927-e220-4a21-84ae-d3269d58a773" xlink:to="loc_legn_OtherCollaborationReceivables_7b9be7ff-eedd-427b-b634-9fad0bcff1e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceLeaseReceivables_830ae41c-fd8b-4010-937f-d613f8f2ae59" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceLeaseReceivables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_3db83927-e220-4a21-84ae-d3269d58a773" xlink:to="loc_ifrs-full_FinanceLeaseReceivables_830ae41c-fd8b-4010-937f-d613f8f2ae59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_27a51fed-ef90-45fb-b463-2842d979241c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndBankBalancesAtCentralBanks_097ddcae-a708-4940-9ad9-7c272ad99f81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndBankBalancesAtCentralBanks"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_27a51fed-ef90-45fb-b463-2842d979241c" xlink:to="loc_ifrs-full_CashAndBankBalancesAtCentralBanks_097ddcae-a708-4940-9ad9-7c272ad99f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PledgedShortTermDeposits_3dd6bf72-3f50-4b1f-a642-928af0aaf23a" xlink:href="legn-20250331.xsd#legn_PledgedShortTermDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_27a51fed-ef90-45fb-b463-2842d979241c" xlink:to="loc_legn_PledgedShortTermDeposits_3dd6bf72-3f50-4b1f-a642-928af0aaf23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DepositsFromBank_11b66df7-d715-479a-860f-92b9381ec66d" xlink:href="legn-20250331.xsd#legn_DepositsFromBank"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashAndCashEquivalents_27a51fed-ef90-45fb-b463-2842d979241c" xlink:to="loc_legn_DepositsFromBank_11b66df7-d715-479a-860f-92b9381ec66d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHERPAYABLESANDACCRUALSDetails"/>
  <link:calculationLink xlink:role="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent_82076dbb-0c48-48a6-aa0c-dbac3ffb026c" xlink:href="legn-20250331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AccruedPayroll_264f1ded-86b5-4ca4-80ce-033b3add480d" xlink:href="legn-20250331.xsd#legn_AccruedPayroll"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent_82076dbb-0c48-48a6-aa0c-dbac3ffb026c" xlink:to="loc_legn_AccruedPayroll_264f1ded-86b5-4ca4-80ce-033b3add480d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AccruedExpense_42e2e8c8-6fa9-40dd-873e-1aae9523f087" xlink:href="legn-20250331.xsd#legn_AccruedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent_82076dbb-0c48-48a6-aa0c-dbac3ffb026c" xlink:to="loc_legn_AccruedExpense_42e2e8c8-6fa9-40dd-873e-1aae9523f087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPayables_c4ab0d5c-875a-4ca7-a6bb-5ad48f8f8b5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent_82076dbb-0c48-48a6-aa0c-dbac3ffb026c" xlink:to="loc_ifrs-full_OtherPayables_c4ab0d5c-875a-4ca7-a6bb-5ad48f8f8b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PayableForCollaborationAssets_4068ee22-4ec5-47cc-9b82-b26cd4928467" xlink:href="legn-20250331.xsd#legn_PayableForCollaborationAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent_82076dbb-0c48-48a6-aa0c-dbac3ffb026c" xlink:to="loc_legn_PayableForCollaborationAssets_4068ee22-4ec5-47cc-9b82-b26cd4928467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherTaxPayables_36495c50-55e7-4c62-bc0b-37f99df24003" xlink:href="legn-20250331.xsd#legn_OtherTaxPayables"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent_82076dbb-0c48-48a6-aa0c-dbac3ffb026c" xlink:to="loc_legn_OtherTaxPayables_36495c50-55e7-4c62-bc0b-37f99df24003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPayable_a486100b-db00-4745-9129-c035b102a0fd" xlink:href="legn-20250331.xsd#legn_CollaborationPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent_82076dbb-0c48-48a6-aa0c-dbac3ffb026c" xlink:to="loc_legn_CollaborationPayable_a486100b-db00-4745-9129-c035b102a0fd" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>legn-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9fafd2bc-3cfd-4d2f-adf8-3916722ba5cf,g:99013260-2431-4a14-8f08-d911c15b56e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_4178f3b7-e78f-4342-b8a1-63fab64eb145" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_4178f3b7-e78f-4342-b8a1-63fab64eb145" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_4178f3b7-e78f-4342-b8a1-63fab64eb145" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f8853bbc-7068-48ac-828c-991a315f64b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_IssuedCapitalMember_f8853bbc-7068-48ac-828c-991a315f64b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_74a91f07-9dbf-434c-861b-c85f5097aa81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_SharePremiumMember_74a91f07-9dbf-434c-861b-c85f5097aa81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_acd5cab6-6702-409e-ad51-cd83a204639b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_acd5cab6-6702-409e-ad51-cd83a204639b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_da0c8e82-72bf-4c8a-af14-9f1400ed2335" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_da0c8e82-72bf-4c8a-af14-9f1400ed2335" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_646d4580-fecb-4f37-91a3-e974d22e1f60" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_RetainedEarningsMember_646d4580-fecb-4f37-91a3-e974d22e1f60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:href="legn-20250331.xsd#legn_StatementOfChangesInEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:to="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_8b7ed571-a266-49a5-9346-bf9cba98720f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_Equity_8b7ed571-a266-49a5-9346-bf9cba98720f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_95cc5149-3098-445f-8480-1a1e5a2a6fb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_ProfitLoss_95cc5149-3098-445f-8480-1a1e5a2a6fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_d1bf4aec-edc1-45a9-a180-9e481f332adf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_d1bf4aec-edc1-45a9-a180-9e481f332adf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a9addd79-1838-4224-a711-035313baf001" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_d1bf4aec-edc1-45a9-a180-9e481f332adf" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a9addd79-1838-4224-a711-035313baf001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1ee17380-5f89-4508-98f3-b11058532902" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_ComprehensiveIncome_1ee17380-5f89-4508-98f3-b11058532902" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7190825a-ac1a-40cf-9b1b-5f6f27221001" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7190825a-ac1a-40cf-9b1b-5f6f27221001" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_23719f19-186c-4be2-9ad5-514076498a2f" xlink:href="legn-20250331.xsd#legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_23719f19-186c-4be2-9ad5-514076498a2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cb5acddd-8c62-437e-b7de-d53b72e92648" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cb5acddd-8c62-437e-b7de-d53b72e92648" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_c838341a-f44a-4177-8f15-ebae8f4cd5ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_ddee2aca-b88d-4f77-9cb0-04dec636de06" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:to="loc_ifrs-full_OtherReserves_ddee2aca-b88d-4f77-9cb0-04dec636de06" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUESummaryofAnalysisofRevenueDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8116d3b9-b174-467e-904a-ab903855b3a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8116d3b9-b174-467e-904a-ab903855b3a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_258d68e0-1d3f-4d63-9845-75f42a10c0cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8116d3b9-b174-467e-904a-ab903855b3a4" xlink:to="loc_ifrs-full_CounterpartiesAxis_258d68e0-1d3f-4d63-9845-75f42a10c0cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_258d68e0-1d3f-4d63-9845-75f42a10c0cc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CounterpartiesAxis_258d68e0-1d3f-4d63-9845-75f42a10c0cc" xlink:to="loc_ifrs-full_CounterpartiesDomain_258d68e0-1d3f-4d63-9845-75f42a10c0cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_0868a254-af1d-4e11-b535-5b1f1571cd22" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CounterpartiesAxis_258d68e0-1d3f-4d63-9845-75f42a10c0cc" xlink:to="loc_ifrs-full_CounterpartiesDomain_0868a254-af1d-4e11-b535-5b1f1571cd22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NovartisMember_9cf6d32c-2ca4-4007-a9fd-0a1f6ec5be30" xlink:href="legn-20250331.xsd#legn_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CounterpartiesDomain_0868a254-af1d-4e11-b535-5b1f1571cd22" xlink:to="loc_legn_NovartisMember_9cf6d32c-2ca4-4007-a9fd-0a1f6ec5be30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty_574d9127-5196-406e-a574-75b6cb4ad9d1" xlink:href="legn-20250331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualProperty_574d9127-5196-406e-a574-75b6cb4ad9d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_081c31c6-5107-4d86-aad8-bab80c34cd41" xlink:href="legn-20250331.xsd#legn_CollaborationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_legn_CollaborationRevenue_081c31c6-5107-4d86-aad8-bab80c34cd41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_0fd35871-21b3-42d3-80dd-30743b14dffe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_ifrs-full_OtherRevenue_0fd35871-21b3-42d3-80dd-30743b14dffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_1d790266-901b-4d0b-a64c-cdc90d6b88f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_ifrs-full_Revenue_1d790266-901b-4d0b-a64c-cdc90d6b88f9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUESummaryofRevenueDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_91046eed-12e6-44ac-aa63-83eae0fba146" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_91046eed-12e6-44ac-aa63-83eae0fba146" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_91046eed-12e6-44ac-aa63-83eae0fba146" xlink:to="loc_srt_StatementGeographicalAxis_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c" xlink:to="loc_srt_SegmentGeographicalDomain_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c" xlink:to="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2e2e3a1b-14e6-49cb-bb6a-958bcd7d3a42" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:to="loc_country_US_2e2e3a1b-14e6-49cb-bb6a-958bcd7d3a42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_647e1c53-489f-4327-99b5-ba7612901ac8" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:to="loc_country_CN_647e1c53-489f-4327-99b5-ba7612901ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_59c68b80-81a2-43a2-80f7-481c5728e70d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:to="loc_srt_EuropeMember_59c68b80-81a2-43a2-80f7-481c5728e70d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_460e0e63-e411-4752-bb95-b327639ac149" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_460e0e63-e411-4752-bb95-b327639ac149" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_38af8017-a6a5-4323-835d-3dc4dd92a657" xlink:href="legn-20250331.xsd#legn_CollaborationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:to="loc_legn_CollaborationRevenue_38af8017-a6a5-4323-835d-3dc4dd92a657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_8e97f8d2-4f5a-47c4-ba7e-886c1b714257" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:to="loc_ifrs-full_Revenue_8e97f8d2-4f5a-47c4-ba7e-886c1b714257" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_9d50d33c-c06d-4fef-b3b1-334a31c6a276" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_78a1f072-90d7-401c-be58-d5f8e5b6114d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_9d50d33c-c06d-4fef-b3b1-334a31c6a276" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_78a1f072-90d7-401c-be58-d5f8e5b6114d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_8ee5edc4-ee03-4548-8955-4692fdad97fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_78a1f072-90d7-401c-be58-d5f8e5b6114d" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_8ee5edc4-ee03-4548-8955-4692fdad97fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_8ee5edc4-ee03-4548-8955-4692fdad97fc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_8ee5edc4-ee03-4548-8955-4692fdad97fc" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_8ee5edc4-ee03-4548-8955-4692fdad97fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_8ee5edc4-ee03-4548-8955-4692fdad97fc" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1502ea79-d24a-4efd-ac83-e891d80499ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1502ea79-d24a-4efd-ac83-e891d80499ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_b744e4e7-1f63-4758-b254-10d18d0b649e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_b744e4e7-1f63-4758-b254-10d18d0b649e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_95332b2d-7633-4fb2-978f-8498155eeb11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_9d50d33c-c06d-4fef-b3b1-334a31c6a276" xlink:to="loc_ifrs-full_Revenue_95332b2d-7633-4fb2-978f-8498155eeb11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:href="legn-20250331.xsd#legn_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:href="legn-20250331.xsd#legn_LeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:to="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_8f2b88ff-9c18-494e-974b-ae668904ab91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:to="loc_ifrs-full_RangeAxis_8f2b88ff-9c18-494e-974b-ae668904ab91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_8f2b88ff-9c18-494e-974b-ae668904ab91_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_8f2b88ff-9c18-494e-974b-ae668904ab91" xlink:to="loc_ifrs-full_RangeDomain_8f2b88ff-9c18-494e-974b-ae668904ab91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_8f2b88ff-9c18-494e-974b-ae668904ab91" xlink:to="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_e7d572b9-a02b-46c2-9211-5f7eff76c63d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:to="loc_ifrs-full_BottomOfRangeMember_e7d572b9-a02b-46c2-9211-5f7eff76c63d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_9ca5e180-e6da-4ac7-ba94-a48a017f83c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:to="loc_ifrs-full_TopOfRangeMember_9ca5e180-e6da-4ac7-ba94-a48a017f83c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_df6bf260-073e-4672-affb-e5831c9e8017" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_df6bf260-073e-4672-affb-e5831c9e8017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_df6bf260-073e-4672-affb-e5831c9e8017_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_df6bf260-073e-4672-affb-e5831c9e8017" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_df6bf260-073e-4672-affb-e5831c9e8017_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_29dacd10-aa80-4815-a63c-373f3ae76bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_df6bf260-073e-4672-affb-e5831c9e8017" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_29dacd10-aa80-4815-a63c-373f3ae76bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_8cbea270-ceae-455f-9001-d135583cd1a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_29dacd10-aa80-4815-a63c-373f3ae76bff" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_8cbea270-ceae-455f-9001-d135583cd1a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember_684af50e-1b99-42cd-b3c3-c4f958173efa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8cbea270-ceae-455f-9001-d135583cd1a1" xlink:to="loc_ifrs-full_LandMember_684af50e-1b99-42cd-b3c3-c4f958173efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeasingArrangementsLeasesTerm_1c005ad6-8b7b-4856-b12f-bfd6afc7a9b7" xlink:href="legn-20250331.xsd#legn_LesseeLeasingArrangementsLeasesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:to="loc_legn_LesseeLeasingArrangementsLeasesTerm_1c005ad6-8b7b-4856-b12f-bfd6afc7a9b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OngoingLeasePaymentsUnderTheLandLease_37749a00-df9a-413d-a0a4-d6e3dd754da1" xlink:href="legn-20250331.xsd#legn_OngoingLeasePaymentsUnderTheLandLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:to="loc_legn_OngoingLeasePaymentsUnderTheLandLease_37749a00-df9a-413d-a0a4-d6e3dd754da1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0382a269-2ef8-40e8-834a-03c21b9d7178" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0382a269-2ef8-40e8-834a-03c21b9d7178" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d1003650-f876-4e01-8a4f-09999ba370e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0382a269-2ef8-40e8-834a-03c21b9d7178" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d1003650-f876-4e01-8a4f-09999ba370e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_d1003650-f876-4e01-8a4f-09999ba370e1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d1003650-f876-4e01-8a4f-09999ba370e1" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_d1003650-f876-4e01-8a4f-09999ba370e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_03d45b57-6335-4baa-870a-a1fc38bde289" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d1003650-f876-4e01-8a4f-09999ba370e1" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_03d45b57-6335-4baa-870a-a1fc38bde289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_5beb6ddb-0ea2-4672-befa-42657587ff6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_03d45b57-6335-4baa-870a-a1fc38bde289" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_5beb6ddb-0ea2-4672-befa-42657587ff6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:href="legn-20250331.xsd#legn_LeasesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:to="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_afb99b53-f1cb-4706-a37e-15b7b23219e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_ifrs-full_LeaseLiabilities_afb99b53-f1cb-4706-a37e-15b7b23219e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseInLeaseLiabilities_7ef11c3f-dafc-4b26-8110-651d5fa73f78" xlink:href="legn-20250331.xsd#legn_IncreaseInLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_legn_IncreaseInLeaseLiabilities_7ef11c3f-dafc-4b26-8110-651d5fa73f78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseOfLeaseLiabilitiesBalance_c8a5f1ad-0caa-450a-8041-85888c3f0431" xlink:href="legn-20250331.xsd#legn_IncreaseOfLeaseLiabilitiesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_legn_IncreaseOfLeaseLiabilitiesBalance_c8a5f1ad-0caa-450a-8041-85888c3f0431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_c9fcaec4-4bdf-4af6-82b7-6ac73dab796f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_ifrs-full_CashOutflowForLeases_c9fcaec4-4bdf-4af6-82b7-6ac73dab796f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_c265f07d-164e-4797-9f6f-978671f633cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_c265f07d-164e-4797-9f6f-978671f633cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_9503031f-d9fc-484c-b7cb-2e5e91032321" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_a40c9da7-f60c-4304-a7cf-02433e523a3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_a40c9da7-f60c-4304-a7cf-02433e523a3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_a03fd150-4311-4c5f-9e9e-ac2857a9fe0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_a03fd150-4311-4c5f-9e9e-ac2857a9fe0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_cbf11be1-35e9-416f-88f1-14818d8a56f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_a5027040-46f2-4974-a0c0-1b59a89a13ff" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_a5027040-46f2-4974-a0c0-1b59a89a13ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_725a6149-cac6-49eb-ab1c-a46e1751b003" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_a5027040-46f2-4974-a0c0-1b59a89a13ff" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_725a6149-cac6-49eb-ab1c-a46e1751b003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_725a6149-cac6-49eb-ab1c-a46e1751b003_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_725a6149-cac6-49eb-ab1c-a46e1751b003" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_725a6149-cac6-49eb-ab1c-a46e1751b003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_e0088953-e404-4a0d-b84e-5f7232c1577f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_725a6149-cac6-49eb-ab1c-a46e1751b003" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_e0088953-e404-4a0d-b84e-5f7232c1577f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_e6172894-1c76-4aa3-a207-9d3787cdcf63" xlink:href="legn-20250331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_e0088953-e404-4a0d-b84e-5f7232c1577f" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_e6172894-1c76-4aa3-a207-9d3787cdcf63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables_b3ae2fea-accf-45f4-82c4-626416c9bbf0" xlink:href="legn-20250331.xsd#legn_OtherCollaborationReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_legn_OtherCollaborationReceivables_b3ae2fea-accf-45f4-82c4-626416c9bbf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_d8e97c2e-b47d-4649-a2d4-fc05f2041c2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_OtherReceivables_d8e97c2e-b47d-4649-a2d4-fc05f2041c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceLeaseReceivables_2501e2d4-4754-40ca-a1ae-1e3cee231641" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceLeaseReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_FinanceLeaseReceivables_2501e2d4-4754-40ca-a1ae-1e3cee231641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables_63edaba4-9c5b-4661-804f-8ec759873a35" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_ValueAddedTaxReceivables_63edaba4-9c5b-4661-804f-8ec759873a35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_1261f931-65d2-46da-93fb-630c69825564" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Prepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_Prepayments_1261f931-65d2-46da-93fb-630c69825564" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_0a20d883-04b8-4e18-9474-84e04a784220" xlink:href="legn-20250331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_0a20d883-04b8-4e18-9474-84e04a784220" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_ab6be098-feba-41ce-9459-2a131a839b64" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_ab6be098-feba-41ce-9459-2a131a839b64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_1bdef293-0f1f-44f6-a7a2-4127b700f3b7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_ab6be098-feba-41ce-9459-2a131a839b64" xlink:to="loc_srt_CurrencyAxis_1bdef293-0f1f-44f6-a7a2-4127b700f3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_1bdef293-0f1f-44f6-a7a2-4127b700f3b7_default" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1bdef293-0f1f-44f6-a7a2-4127b700f3b7" xlink:to="loc_currency_AllCurrenciesDomain_1bdef293-0f1f-44f6-a7a2-4127b700f3b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1bdef293-0f1f-44f6-a7a2-4127b700f3b7" xlink:to="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_443fcf01-3c99-45fe-b660-b7a23be2374d" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:to="loc_currency_USD_443fcf01-3c99-45fe-b660-b7a23be2374d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_8b5ecb8b-a655-499a-9dfb-75583aea2ffe" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:to="loc_currency_CNY_8b5ecb8b-a655-499a-9dfb-75583aea2ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_f2554ceb-2104-4ec7-94ef-314419840879" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:to="loc_currency_EUR_f2554ceb-2104-4ec7-94ef-314419840879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndBankBalancesAtCentralBanks_9b73e1ba-f12d-4cab-a5aa-32f130a40174" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndBankBalancesAtCentralBanks"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_ifrs-full_CashAndBankBalancesAtCentralBanks_9b73e1ba-f12d-4cab-a5aa-32f130a40174" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PledgedShortTermDeposits_6f06af66-c9a7-404e-bc5b-2576350d90a7" xlink:href="legn-20250331.xsd#legn_PledgedShortTermDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_legn_PledgedShortTermDeposits_6f06af66-c9a7-404e-bc5b-2576350d90a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DepositsFromBank_45c64ea1-2292-4b4b-a145-2df8db43fc0e" xlink:href="legn-20250331.xsd#legn_DepositsFromBank"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_legn_DepositsFromBank_45c64ea1-2292-4b4b-a145-2df8db43fc0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_5cbbbc97-926d-429a-a8e1-f194f9568017" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_ifrs-full_CashAndCashEquivalents_5cbbbc97-926d-429a-a8e1-f194f9568017" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_1acd1210-e3f5-40d0-aedf-704c42e207d6" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_1bbdc588-ed2b-4b72-bb55-85eec56dd163" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_1acd1210-e3f5-40d0-aedf-704c42e207d6" xlink:to="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_1bbdc588-ed2b-4b72-bb55-85eec56dd163" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_11984e26-b9cd-4bad-bf56-f8fd21fe50c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_1bbdc588-ed2b-4b72-bb55-85eec56dd163" xlink:to="loc_srt_CurrencyAxis_11984e26-b9cd-4bad-bf56-f8fd21fe50c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_11984e26-b9cd-4bad-bf56-f8fd21fe50c1_default" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_11984e26-b9cd-4bad-bf56-f8fd21fe50c1" xlink:to="loc_currency_AllCurrenciesDomain_11984e26-b9cd-4bad-bf56-f8fd21fe50c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_2cf88e0c-dbc2-4301-8234-7ab962477f1e" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_11984e26-b9cd-4bad-bf56-f8fd21fe50c1" xlink:to="loc_currency_AllCurrenciesDomain_2cf88e0c-dbc2-4301-8234-7ab962477f1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_c1872c32-b7e6-44dd-90f2-0284e9442328" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_2cf88e0c-dbc2-4301-8234-7ab962477f1e" xlink:to="loc_currency_CNY_c1872c32-b7e6-44dd-90f2-0284e9442328" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a09869c2-5ae6-4a0b-92b7-b563212eadae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_1acd1210-e3f5-40d0-aedf-704c42e207d6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a09869c2-5ae6-4a0b-92b7-b563212eadae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2b52248f-823b-4641-ad52-f4ed8f815d58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2b52248f-823b-4641-ad52-f4ed8f815d58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_ab6a2201-ee75-44af-8acf-a8ce69228ae8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2b52248f-823b-4641-ad52-f4ed8f815d58" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_ab6a2201-ee75-44af-8acf-a8ce69228ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_ab6a2201-ee75-44af-8acf-a8ce69228ae8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_ab6a2201-ee75-44af-8acf-a8ce69228ae8" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_ab6a2201-ee75-44af-8acf-a8ce69228ae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_b969ac43-7c3e-4b2c-ba1f-121ca0d0a671" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_ab6a2201-ee75-44af-8acf-a8ce69228ae8" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_b969ac43-7c3e-4b2c-ba1f-121ca0d0a671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_A110InterestBearingLoansMember_0aacc4a9-d4b4-4267-8830-d3045e5c4d25" xlink:href="legn-20250331.xsd#legn_A110InterestBearingLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_b969ac43-7c3e-4b2c-ba1f-121ca0d0a671" xlink:to="loc_legn_A110InterestBearingLoansMember_0aacc4a9-d4b4-4267-8830-d3045e5c4d25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_70fc7d08-acd0-47e0-a568-aa549942026b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:to="loc_ifrs-full_BorrowingsInterestRate_70fc7d08-acd0-47e0-a568-aa549942026b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_76ecba35-01e8-41e7-8f05-bda42a7ae83c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_76ecba35-01e8-41e7-8f05-bda42a7ae83c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8047d952-5ff4-40a1-a15e-7ffaf054d9f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8047d952-5ff4-40a1-a15e-7ffaf054d9f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_b0e75003-0a83-4709-a2a6-b19658ce0951" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8047d952-5ff4-40a1-a15e-7ffaf054d9f4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_b0e75003-0a83-4709-a2a6-b19658ce0951" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_b0e75003-0a83-4709-a2a6-b19658ce0951_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b0e75003-0a83-4709-a2a6-b19658ce0951" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_b0e75003-0a83-4709-a2a6-b19658ce0951_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_0a67390b-4c58-43dc-b533-9de683fe72da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b0e75003-0a83-4709-a2a6-b19658ce0951" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_0a67390b-4c58-43dc-b533-9de683fe72da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_12c1628f-6e3b-4f2b-a842-9c648c583df7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_0a67390b-4c58-43dc-b533-9de683fe72da" xlink:to="loc_ifrs-full_OrdinarySharesMember_12c1628f-6e3b-4f2b-a842-9c648c583df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:href="legn-20250331.xsd#legn_AuthorisedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:to="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_9ed0b36c-bf19-4647-965e-c38e2e0e9049" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_9ed0b36c-bf19-4647-965e-c38e2e0e9049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_b9517afe-b10e-4739-aeec-9e41cfba5225" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:to="loc_ifrs-full_ParValuePerShare_b9517afe-b10e-4739-aeec-9e41cfba5225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorizedShareCapital_59d82cdc-5400-4197-b353-a53825ab0ef7" xlink:href="legn-20250331.xsd#legn_AuthorizedShareCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:to="loc_legn_AuthorizedShareCapital_59d82cdc-5400-4197-b353-a53825ab0ef7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_91ebc30f-e645-4fa2-aa3e-4ed7d4223052" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_91ebc30f-e645-4fa2-aa3e-4ed7d4223052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_d96b0c8c-75d6-4f80-bf67-c9951756b28e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_746146d0-c979-47b2-86f1-00d829ad7907" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:to="loc_ifrs-full_IssuedCapital_746146d0-c979-47b2-86f1-00d829ad7907" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"/>
  <link:definitionLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7a55b621-8cd5-42b3-836d-a629aaa069f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_64a947ec-0f75-4082-9d13-8c6d587f2378" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7a55b621-8cd5-42b3-836d-a629aaa069f2" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_64a947ec-0f75-4082-9d13-8c6d587f2378" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_82333bbe-b5b0-42ba-af89-89cf946d4242" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_64a947ec-0f75-4082-9d13-8c6d587f2378" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_82333bbe-b5b0-42ba-af89-89cf946d4242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_82333bbe-b5b0-42ba-af89-89cf946d4242_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_82333bbe-b5b0-42ba-af89-89cf946d4242" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_82333bbe-b5b0-42ba-af89-89cf946d4242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_82333bbe-b5b0-42ba-af89-89cf946d4242" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_5a2782e5-5a60-4395-a775-ecab0b7dabdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:to="loc_ifrs-full_IssuedCapitalMember_5a2782e5-5a60-4395-a775-ecab0b7dabdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalMember_182e6781-21b4-48df-89a8-4ba0dd015342" xlink:href="legn-20250331.xsd#legn_ShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:to="loc_legn_ShareCapitalMember_182e6781-21b4-48df-89a8-4ba0dd015342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_17169875-f42f-4509-986c-0f1e7a66917d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:to="loc_ifrs-full_SharePremiumMember_17169875-f42f-4509-986c-0f1e7a66917d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:href="legn-20250331.xsd#legn_ShareCapitalRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7a55b621-8cd5-42b3-836d-a629aaa069f2" xlink:to="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_7f6ecec6-e34d-406b-8271-61907ea888cb" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_7f6ecec6-e34d-406b-8271-61907ea888cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_1d0b0da7-4c90-4157-bf6e-48359720cf0d" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ShareCapitalAndSharePremium_1d0b0da7-4c90-4157-bf6e-48359720cf0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_1f98fe0f-5dc7-4f4e-8f91-c68257f1acda" xlink:href="legn-20250331.xsd#legn_ExerciseOfShareOptionNumberOfSharesInIssue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_1f98fe0f-5dc7-4f4e-8f91-c68257f1acda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOption_84d40e7a-ae5e-4a3f-a7b5-b0eb9681faff" xlink:href="legn-20250331.xsd#legn_ExerciseOfShareOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ExerciseOfShareOption_84d40e7a-ae5e-4a3f-a7b5-b0eb9681faff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_60b2c83c-a6c4-4e45-a17d-fe30cbc1ec11" xlink:href="legn-20250331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_60b2c83c-a6c4-4e45-a17d-fe30cbc1ec11" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_44668bba-6f67-4dc5-963f-80d337577306" xlink:href="legn-20250331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_44668bba-6f67-4dc5-963f-80d337577306" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_6ae6f8c3-98b7-4033-9682-a81d26941904" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_eb4f0077-bafe-4c06-a476-fc9729d422c1" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremium"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>legn-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9fafd2bc-3cfd-4d2f-adf8-3916722ba5cf,g:99013260-2431-4a14-8f08-d911c15b56e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_legn_OtherMiscellaneousIncomeExpense_89a7cb11-cf51-4826-b839-a8faa46af4b2_terseLabel_en-US" xlink:label="lab_legn_OtherMiscellaneousIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_legn_OtherMiscellaneousIncomeExpense_label_en-US" xlink:label="lab_legn_OtherMiscellaneousIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Income (Expense)</link:label>
    <link:label id="lab_legn_OtherMiscellaneousIncomeExpense_documentation_en-US" xlink:label="lab_legn_OtherMiscellaneousIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Miscellaneous Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherMiscellaneousIncomeExpense" xlink:href="legn-20250331.xsd#legn_OtherMiscellaneousIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OtherMiscellaneousIncomeExpense" xlink:to="lab_legn_OtherMiscellaneousIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_7bd82235-badc-4bc8-b0c7-2c4faea67a93_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OtherTaxPayables_6ff8aa94-324a-439f-b605-37c0ba1e08e1_terseLabel_en-US" xlink:label="lab_legn_OtherTaxPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other tax payables</link:label>
    <link:label id="lab_legn_OtherTaxPayables_label_en-US" xlink:label="lab_legn_OtherTaxPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Payables</link:label>
    <link:label id="lab_legn_OtherTaxPayables_documentation_en-US" xlink:label="lab_legn_OtherTaxPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other tax payables,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherTaxPayables" xlink:href="legn-20250331.xsd#legn_OtherTaxPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OtherTaxPayables" xlink:to="lab_legn_OtherTaxPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_dc39d3ae-948f-414d-9648-787163a30082_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_bc164fde-cad4-437a-b01d-d4a7ca881b5f_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">LOSS FOR THE PERIOD</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_2951d1f0-6b70-4e95-b785-c24eb6e88b47_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss for the period</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ef96e1b1-ddf3-40b7-8015-a163eba279b5_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [domain]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock_e91082b8-a153-4bc3-bae0-bd1ff961a2a4_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Cash And Cash Equivalents Time Deposits And Pledged Deposits Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about cash and cash equivalents, time deposits and pledged deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_TimesDepositsNonCurrent_3d50cbef-74cf-4f37-b2a0-065e4b199464_terseLabel_en-US" xlink:label="lab_legn_TimesDepositsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_legn_TimesDepositsNonCurrent_label_en-US" xlink:label="lab_legn_TimesDepositsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Times Deposits Non Current</link:label>
    <link:label id="lab_legn_TimesDepositsNonCurrent_documentation_en-US" xlink:label="lab_legn_TimesDepositsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Times deposits, non-current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsNonCurrent" xlink:href="legn-20250331.xsd#legn_TimesDepositsNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_TimesDepositsNonCurrent" xlink:to="lab_legn_TimesDepositsNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_1ac32fbf-999c-43a2-91a1-fba44e1a236f_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_NovartisMember_2dbbf87f-40f3-4717-ae9b-402e8c9b64f9_terseLabel_en-US" xlink:label="lab_legn_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_legn_NovartisMember_label_en-US" xlink:label="lab_legn_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_legn_NovartisMember_documentation_en-US" xlink:label="lab_legn_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NovartisMember" xlink:href="legn-20250331.xsd#legn_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_NovartisMember" xlink:to="lab_legn_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_09ce00a1-998e-440a-979b-ff7232c0ae36_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_d672c6f1-b785-4235-b8ff-3706238f091e_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_f7cdd912-2da9-4e6a-95e3-1d839e4e9eb1_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows provided by (used in) operations before changes in working capital</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DepositsFromBank_910071df-04bb-4c28-babf-624d66dc5371_terseLabel_en-US" xlink:label="lab_legn_DepositsFromBank" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_legn_DepositsFromBank_label_en-US" xlink:label="lab_legn_DepositsFromBank" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits From Bank</link:label>
    <link:label id="lab_legn_DepositsFromBank_documentation_en-US" xlink:label="lab_legn_DepositsFromBank" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deposits from bank.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DepositsFromBank" xlink:href="legn-20250331.xsd#legn_DepositsFromBank"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DepositsFromBank" xlink:to="lab_legn_DepositsFromBank" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows_c3a6e6cd-7ab4-4307-b261-893b196acfff_terseLabel_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents as stated in the statement of cash flows</link:label>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows_label_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents As Stated In Statement Of Cash Flows</link:label>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows_documentation_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents as stated in statement of cash flows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows" xlink:href="legn-20250331.xsd#legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows" xlink:to="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_9f0f080a-c751-48f3-a67a-1f3a54924f26_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="lab_ifrs-full_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForAmortisationExpense_b6ae4740-fea8-4d70-90e5-790b839415ee_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_1d261f57-1636-4d1a-b74c-1b63f4833878_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_a3f90942-d1fd-46cc-a696-2231130012e5_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:to="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_4909d9ea-b2b4-4dc7-8bd9-aec3c8e3b891_terseLabel_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:label id="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_label_en-US" xlink:label="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of transfer of goods or services [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="lab_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_a3282c90-dac5-430b-b8c2-6faa6940ca1e_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange (loss)/gain, net</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_0639bdd0-7ce1-4f7d-bade-e260a631fc2a_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock_0c9d445b-3a4b-442a-99cf-c82b630050c1_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER PAYABLES AND ACCRUALS</link:label>
    <link:label id="lab_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Payables And Accruals Explanatory [Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other payables and accruals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" xlink:to="lab_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_d2d384ec-fdff-4267-ab67-c240eb7dc728_periodStartLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_4f107682-7c57-4a7d-9d1a-b8a85176b54e_periodEndLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_label_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital And Share Premium Number Of Shares In Issue</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_documentation_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share capital and share premium, number of shares in issue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:to="lab_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_e8463ce7-f565-4efb-a508-d6811a3efaef_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange differences on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_db9d4209-78ca-4e4b-8317-c2f3f0c5c114_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exchange differences on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_ee0fb1fd-8410-4668-be68-cdc2841fe031_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Ordinary equity holders of the parent</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income, attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_48b28445-793a-40ba-b19a-f3036ebaa03e_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [domain]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeasesTable_88665d29-5e7a-4d06-9293-83069f451057_terseLabel_en-US" xlink:label="lab_legn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_legn_LeasesTable_label_en-US" xlink:label="lab_legn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_legn_LeasesTable_documentation_en-US" xlink:label="lab_legn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesTable" xlink:href="legn-20250331.xsd#legn_LeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeasesTable" xlink:to="lab_legn_LeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_StatementOfChangesInEquityRollForward_ca175a6a-6a68-4906-be8f-8398973027da_terseLabel_en-US" xlink:label="lab_legn_StatementOfChangesInEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [Roll Forward]</link:label>
    <link:label id="lab_legn_StatementOfChangesInEquityRollForward_label_en-US" xlink:label="lab_legn_StatementOfChangesInEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [Roll Forward]</link:label>
    <link:label id="lab_legn_StatementOfChangesInEquityRollForward_documentation_en-US" xlink:label="lab_legn_StatementOfChangesInEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statement of changes in equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_StatementOfChangesInEquityRollForward" xlink:href="legn-20250331.xsd#legn_StatementOfChangesInEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_StatementOfChangesInEquityRollForward" xlink:to="lab_legn_StatementOfChangesInEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_8c0b5efe-d58b-420b-8a31-8f205265f324_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value gains on financial assets measured at fair value change through profit or loss</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0707d283-efb3-47f3-a7b4-c24cbdd67500_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_5991b459-fdfd-494e-aa17-85d800741807_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_ifrs-full_OtherNoncurrentNonfinancialAssets_label_en-US" xlink:label="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:to="lab_ifrs-full_OtherNoncurrentNonfinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_FinanceIncomeAndFinanceCostsAbstract_334bb8e4-793d-4585-90c3-d8241a981432_terseLabel_en-US" xlink:label="lab_legn_FinanceIncomeAndFinanceCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Income And Finance Costs [Abstract]</link:label>
    <link:label id="lab_legn_FinanceIncomeAndFinanceCostsAbstract_label_en-US" xlink:label="lab_legn_FinanceIncomeAndFinanceCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Income And Finance Costs [Abstract]</link:label>
    <link:label id="lab_legn_FinanceIncomeAndFinanceCostsAbstract_documentation_en-US" xlink:label="lab_legn_FinanceIncomeAndFinanceCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_FinanceIncomeAndFinanceCostsAbstract" xlink:href="legn-20250331.xsd#legn_FinanceIncomeAndFinanceCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_FinanceIncomeAndFinanceCostsAbstract" xlink:to="lab_legn_FinanceIncomeAndFinanceCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RawMaterials_73b029ca-f3e8-471e-b237-062425f43819_terseLabel_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_ifrs-full_RawMaterials_label_en-US" xlink:label="lab_ifrs-full_RawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current raw materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RawMaterials" xlink:to="lab_ifrs-full_RawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_10adff5a-eb62-407d-9d1f-49bc16586270_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ParValuePerShare_3df85d39-ac2c-478e-9e70-8d2fc082131b_netLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Authorized, price per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_0d8a5ce8-9c95-44d8-bed9-50febb4f3552_verboseLabel_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ParValuePerShare_label_en-US" xlink:label="lab_ifrs-full_ParValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Par value per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ParValuePerShare" xlink:to="lab_ifrs-full_ParValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_aac26c48-bd3c-418d-9c32-a5a13a03f115_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_TimesDeposits_428aef97-31d9-474e-b905-d428bee846bb_terseLabel_en-US" xlink:label="lab_legn_TimesDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_legn_TimesDeposits_label_en-US" xlink:label="lab_legn_TimesDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Times Deposits</link:label>
    <link:label id="lab_legn_TimesDeposits_documentation_en-US" xlink:label="lab_legn_TimesDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Times deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDeposits" xlink:href="legn-20250331.xsd#legn_TimesDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_TimesDeposits" xlink:to="lab_legn_TimesDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_14924eb7-90b7-43dd-93e8-631c71da5c3c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Interest-Bearing Loans and Borrowings</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_BasisOfPreparationAbstract_label_en-US" xlink:label="lab_legn_BasisOfPreparationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Preparation [Abstract]</link:label>
    <link:label id="lab_legn_BasisOfPreparationAbstract_documentation_en-US" xlink:label="lab_legn_BasisOfPreparationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of Preparation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_BasisOfPreparationAbstract" xlink:href="legn-20250331.xsd#legn_BasisOfPreparationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_BasisOfPreparationAbstract" xlink:to="lab_legn_BasisOfPreparationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_2fb89844-4ec2-46c2-a787-86c7754a3068_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_071a2987-5bc7-4f5c-bd0f-5955d224292d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock_6f8a1615-5a67-4f9b-8f58-ca73de536591_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Other Payables and Accruals</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Payables And Accruals Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about other payables and accruals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_b0f7a484-99ab-4753-ac6b-66345dc09f6a_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilities" xlink:to="lab_ifrs-full_NoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WorkInProgress_20a1cc12-3e5a-45d4-b8fa-e76fef813ad0_terseLabel_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_ifrs-full_WorkInProgress_label_en-US" xlink:label="lab_ifrs-full_WorkInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current work in progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WorkInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WorkInProgress" xlink:to="lab_ifrs-full_WorkInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_7c7a5884-d8db-47cb-b612-351ef83e84b4_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in trade payables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_64fb15eb-4ae7-465f-8c68-bccb1f1c27d6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOperatingSegmentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of operating segments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="lab_ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_04d931d7-8019-4e2a-a172-0ad28c68358c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceCosts_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceCosts" xlink:to="lab_ifrs-full_AdjustmentsForFinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_d52a1881-db99-45b5-83d5-ec601dd3b181_terseLabel_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of vested restricted share units</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_label_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease Through Reclassification Of Vested Restricted Stock Equity</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_documentation_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through reclassification of vested restricted stock, equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:href="legn-20250331.xsd#legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:to="lab_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_d15d1c55-9ea0-4ef9-9aa9-2c0b5e9414da_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseOfLeaseLiabilitiesBalance_eb5a371f-7472-4825-8c7b-5c4f9be58b68_terseLabel_en-US" xlink:label="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of interest recognized during the period</link:label>
    <link:label id="lab_legn_IncreaseOfLeaseLiabilitiesBalance_label_en-US" xlink:label="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Of Lease Liabilities Balance</link:label>
    <link:label id="lab_legn_IncreaseOfLeaseLiabilitiesBalance_documentation_en-US" xlink:label="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase of lease liabilities balance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:href="legn-20250331.xsd#legn_IncreaseOfLeaseLiabilitiesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:to="lab_legn_IncreaseOfLeaseLiabilitiesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f62d00cc-408a-4d5c-85b7-62fab15f8d95_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_67da0a5f-a2e7-4a99-8aaa-df0007d0ed9b_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Movements in the Company's Share Capital and Share Premium</link:label>
    <link:label id="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Movements In Company Share Capital And Share Premium Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of movements in the company's share capital and share premium explanatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_d24a3f55-71e8-4a59-9de6-c907df600a5c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PREPARATION</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinishedGoods_f5ff8231-8a9a-478c-877f-971c8b91b5a4_terseLabel_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_ifrs-full_FinishedGoods_label_en-US" xlink:label="lab_ifrs-full_FinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current finished goods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinishedGoods" xlink:to="lab_ifrs-full_FinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AccruedPayroll_8be246a0-5c2f-46b8-ac48-0031c38e1e5a_terseLabel_en-US" xlink:label="lab_legn_AccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_legn_AccruedPayroll_label_en-US" xlink:label="lab_legn_AccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payroll</link:label>
    <link:label id="lab_legn_AccruedPayroll_documentation_en-US" xlink:label="lab_legn_AccruedPayroll" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued payroll.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AccruedPayroll" xlink:href="legn-20250331.xsd#legn_AccruedPayroll"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AccruedPayroll" xlink:to="lab_legn_AccruedPayroll" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OtherCollaborationReceivables_3b10e2ab-2bf8-4d9c-9a74-ee2cd2ff0beb_terseLabel_en-US" xlink:label="lab_legn_OtherCollaborationReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration receivables</link:label>
    <link:label id="lab_legn_OtherCollaborationReceivables_label_en-US" xlink:label="lab_legn_OtherCollaborationReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaboration Receivables</link:label>
    <link:label id="lab_legn_OtherCollaborationReceivables_documentation_en-US" xlink:label="lab_legn_OtherCollaborationReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables" xlink:href="legn-20250331.xsd#legn_OtherCollaborationReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OtherCollaborationReceivables" xlink:to="lab_legn_OtherCollaborationReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LesseeLeaseLiabilitiesTextBlock_8ef15437-3a3e-4692-a1b0-0212ea9d3aaa_terseLabel_en-US" xlink:label="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term</link:label>
    <link:label id="lab_legn_LesseeLeaseLiabilitiesTextBlock_label_en-US" xlink:label="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Lease Liabilities [Text Block]</link:label>
    <link:label id="lab_legn_LesseeLeaseLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee lease liabilities text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeaseLiabilitiesTextBlock" xlink:href="legn-20250331.xsd#legn_LesseeLeaseLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LesseeLeaseLiabilitiesTextBlock" xlink:to="lab_legn_LesseeLeaseLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_e222929c-1265-4219-824d-4438f6ac37bd_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfInventoriesAbstract_29b4ee69-fd21-4f6b-8184-6da6db79eb81_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of current inventories [abstract]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfInventoriesAbstract_label_en-US" xlink:label="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of current inventories [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract" xlink:to="lab_ifrs-full_ClassesOfInventoriesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherGainsLosses_3ba1f054-4b93-4661-9efb-1752ad234234_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense)/income, net</link:label>
    <link:label id="lab_ifrs-full_OtherGainsLosses_4bc7acd6-e641-4340-987e-9b9151aecbad_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other (expense)/income, net</link:label>
    <link:label id="lab_ifrs-full_OtherGainsLosses_label_en-US" xlink:label="lab_ifrs-full_OtherGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other gains (losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherGainsLosses" xlink:to="lab_ifrs-full_OtherGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_e830c8bd-7d98-4cb5-8d2c-39b0ae022eb3_terseLabel_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange realignment</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_label_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Effect Of Exchange Realignment In Foreign Exchange Rate</link:label>
    <link:label id="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_documentation_en-US" xlink:label="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of exchange realignment in foreign exchange rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:href="legn-20250331.xsd#legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:to="lab_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AccruedExpense_df472de2-7eff-4876-ba82-9766eb860a13_terseLabel_en-US" xlink:label="lab_legn_AccruedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense</link:label>
    <link:label id="lab_legn_AccruedExpense_label_en-US" xlink:label="lab_legn_AccruedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expense</link:label>
    <link:label id="lab_legn_AccruedExpense_documentation_en-US" xlink:label="lab_legn_AccruedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AccruedExpense" xlink:href="legn-20250331.xsd#legn_AccruedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AccruedExpense" xlink:to="lab_legn_AccruedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndBankBalancesAtCentralBanks_737d3e58-5303-4733-8727-9540d25e43f6_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndBankBalancesAtCentralBanks" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and bank balances</link:label>
    <link:label id="lab_ifrs-full_CashAndBankBalancesAtCentralBanks_label_en-US" xlink:label="lab_ifrs-full_CashAndBankBalancesAtCentralBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and bank balances at central banks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndBankBalancesAtCentralBanks" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndBankBalancesAtCentralBanks"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndBankBalancesAtCentralBanks" xlink:to="lab_ifrs-full_CashAndBankBalancesAtCentralBanks" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock_bbbe7ed9-c921-44c3-87f5-4b9577c394ce_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Deferred Revenue from Contract Liabilities</link:label>
    <link:label id="lab_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Deferred Revenue From Customer Contract Liabilities [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Deferred Revenue From Customer Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" xlink:to="lab_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdministrativeExpense_b54abc8b-b84f-449d-997f-3269b20cf05e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
    <link:label id="lab_ifrs-full_AdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_AdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdministrativeExpense" xlink:to="lab_ifrs-full_AdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_437c65a6-45cd-4bcf-9cd5-d48f0ff19223_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CostOfSales_93446cd6-ca4f-432f-b87d-d7def94208fb_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of collaboration revenue</link:label>
    <link:label id="lab_ifrs-full_CostOfSales_label_en-US" xlink:label="lab_ifrs-full_CostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CostOfSales" xlink:to="lab_ifrs-full_CostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_53482f74-9cb3-479c-a107-41685bbe4319_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax (paid)/received</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund), classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_be700870-1448-499e-94f3-3c629ceece6f_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_label_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_documentation_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" xlink:to="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_af8d6253-2976-4d63-b525-fc0fe509f03d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_5430a537-e92a-4d8c-98f5-15811b8a3647_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_aa2b3318-a876-4556-b03c-87280b8eeff8_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncome" xlink:to="lab_ifrs-full_OtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceCosts_04c551d5-aa44-4928-b549-fdb36f9caeb2_negatedNetLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_3feeb129-3de6-4be9-944d-b7fd27ac0039_totalLabel_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_FinanceCosts_label_en-US" xlink:label="lab_ifrs-full_FinanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceCosts" xlink:to="lab_ifrs-full_FinanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PledgedShortTermDeposits_9f02909a-95b7-49f6-8fee-9ee9a9266c3c_terseLabel_en-US" xlink:label="lab_legn_PledgedShortTermDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Pledged deposits</link:label>
    <link:label id="lab_legn_PledgedShortTermDeposits_label_en-US" xlink:label="lab_legn_PledgedShortTermDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pledged Short Term Deposits</link:label>
    <link:label id="lab_legn_PledgedShortTermDeposits_documentation_en-US" xlink:label="lab_legn_PledgedShortTermDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pledged short-term deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PledgedShortTermDeposits" xlink:href="legn-20250331.xsd#legn_PledgedShortTermDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PledgedShortTermDeposits" xlink:to="lab_legn_PledgedShortTermDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_eba136d5-8f89-40fb-8ff1-27b30b3e6236_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS PROVIDED BY/(USED IN) INVESTING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities_7f2de69f-ae29-4129-bd81-efa48fa44881_terseLabel_en-US" xlink:label="lab_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease payments</link:label>
    <link:label id="lab_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest On Lease Payments Classified As Operating Activities</link:label>
    <link:label id="lab_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities_documentation_en-US" xlink:label="lab_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest on lease payments classified as operating activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities" xlink:href="legn-20250331.xsd#legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities" xlink:to="lab_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_49c6f6b8-604f-492d-a01a-a722833bd057_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Ordinary equity holders of the parent</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_1922815d-11e4-40ac-a873-016f359ccb76_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_c4aabe47-966c-4674-bb1c-c043933a0cf2_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal portion of lease payments</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_31b7726d-2fb3-4271-bcfb-74ca478d3e23_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION INVENTORIES, NET</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfInventoriesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfInventoriesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CollaborationPrepaidLeases_34402ef6-e4ef-422d-a5fd-cdeb7579e1ab_terseLabel_en-US" xlink:label="lab_legn_CollaborationPrepaidLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration prepaid leases</link:label>
    <link:label id="lab_legn_CollaborationPrepaidLeases_label_en-US" xlink:label="lab_legn_CollaborationPrepaidLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Prepaid Leases</link:label>
    <link:label id="lab_legn_CollaborationPrepaidLeases_documentation_en-US" xlink:label="lab_legn_CollaborationPrepaidLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Prepaid Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPrepaidLeases" xlink:href="legn-20250331.xsd#legn_CollaborationPrepaidLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CollaborationPrepaidLeases" xlink:to="lab_legn_CollaborationPrepaidLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LongtermBorrowings_ed2a8bed-5d43-4ede-b3a4-841497974f19_terseLabel_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration interest-bearing advanced funding</link:label>
    <link:label id="lab_ifrs-full_LongtermBorrowings_label_en-US" xlink:label="lab_ifrs-full_LongtermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of non-current borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LongtermBorrowings" xlink:to="lab_ifrs-full_LongtermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_9ee1cc9e-52f7-4aa2-a32d-9776b96dd7b2_totalLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_c8d50be9-dce7-434e-8f14-f190b912c354_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_20b4291a-cd6e-4822-8582-c9e404752356_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities long term</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_6c2a1ab4-7dfe-4c77-b055-c1dd9bf1a9f3_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_57a4ee27-a61b-4688-be11-a3c5404b1678_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CURRENT ASSETS</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_7c40c094-89fc-4437-b67a-564429337f6d_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract" xlink:to="lab_ifrs-full_BasicEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_33e3887e-0ff7-4282-85bf-4a772b854a11_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in prepayments, other receivables and other assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_label_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_documentation_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for decrease increase in prepayments other receivable other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:to="lab_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_258bbf2f-1359-4385-b335-5650345b6bfe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Carrying Amounts of The Right-of-use Assets and Movements</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_cb390e0e-0b3a-4ff9-8cfb-f11f265f6964_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHARE CAPITAL AND SHARE PREMIUM</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a09cd1dd-9471-42a8-81dc-ee4037aacaa9_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_1e0cb78d-da35-4d2a-9faf-078a075d15ea_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_9912149a-2e41-4744-91f0-ac7e5a51c8e1_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_c95cc68e-4a08-429d-bed0-1e94d16fe6f1_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameAxis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameAxis" xlink:to="lab_ifrs-full_BorrowingsByNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_081a8a8d-e896-4412-8cbc-61faf2bb54bd_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Total Other Income And Expense</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Income (Expense) [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceCostExplanatory_a051df4f-7852-4ae7-9801-367aa74848b2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Finance Costs</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinanceCostExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance cost [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherRevenue_1b2a4a40-fea9-46e7-8b6f-c70ee2e9efc8_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_ifrs-full_OtherRevenue_label_en-US" xlink:label="lab_ifrs-full_OtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherRevenue" xlink:to="lab_ifrs-full_OtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_1b0c3705-956d-4776-be02-384f1140f533_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares authorized (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesAuthorised_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesAuthorised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares authorised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesAuthorised" xlink:to="lab_ifrs-full_NumberOfSharesAuthorised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_19aeb873-63e1-47be-8d18-093ae11b1370_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_4f82801b-0b0f-4f32-a99c-5947e50bd1b4_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange realignment</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_bdfe039c-5610-41fd-9492-b71c480029b0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_dbb0fb06-3699-4ad9-8961-dcb86b8ae5f8_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_cdab73bf-32d8-453b-8ef9-dda31fca2ec0_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominated in USD</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_7a1e9c1c-9611-4f58-92a8-8cb621793710_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation of right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherPayables_0765c543-4f04-46c7-aad3-4ca34b3f3197_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</link:label>
    <link:label id="lab_ifrs-full_OtherPayables_label_en-US" xlink:label="lab_ifrs-full_OtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherPayables" xlink:to="lab_ifrs-full_OtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_51b05155-3c67-42c7-834e-9089a9d526a3_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_4d67930f-015a-4e8d-83db-cbdf17c6270e_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate (%)</link:label>
    <link:label id="lab_ifrs-full_BorrowingsInterestRate_label_en-US" xlink:label="lab_ifrs-full_BorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsInterestRate" xlink:to="lab_ifrs-full_BorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Prepayments_8f922d3e-fd96-4c55-8bb5-33fb7665f8cf_verboseLabel_en-US" xlink:label="lab_ifrs-full_Prepayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepayments</link:label>
    <link:label id="lab_ifrs-full_Prepayments_label_en-US" xlink:label="lab_ifrs-full_Prepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Prepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Prepayments" xlink:to="lab_ifrs-full_Prepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_c96a28e5-7c77-412c-89c4-381c4a95b700_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_NumberOfBorrowingBatches_1aa507bb-2a47-4e9b-bb8d-3325f38b07c1_terseLabel_en-US" xlink:label="lab_legn_NumberOfBorrowingBatches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of batches of funding advances</link:label>
    <link:label id="lab_legn_NumberOfBorrowingBatches_label_en-US" xlink:label="lab_legn_NumberOfBorrowingBatches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Borrowing Batches</link:label>
    <link:label id="lab_legn_NumberOfBorrowingBatches_documentation_en-US" xlink:label="lab_legn_NumberOfBorrowingBatches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Borrowing Batches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NumberOfBorrowingBatches" xlink:href="legn-20250331.xsd#legn_NumberOfBorrowingBatches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_NumberOfBorrowingBatches" xlink:to="lab_legn_NumberOfBorrowingBatches" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_3afbdb70-1281-44e3-9d15-b5b3cd3a5d38_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_f298dbb6-c8a7-4437-afa4-8886d08f4a5d_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities (Current)</link:label>
    <link:label id="lab_ifrs-full_CurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentContractLiabilities" xlink:to="lab_ifrs-full_CurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_3ae18daf-4b51-4c84-9525-cdecd2279679_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAbstract_da8b3f3c-c79d-4a2b-bf25-9e34b9e89403_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued and fully paid:</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAbstract_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DeferredGovernmentGrant_3e9e3f93-2ceb-434f-aaab-a22e5abf4ddb_terseLabel_en-US" xlink:label="lab_legn_DeferredGovernmentGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred government grant</link:label>
    <link:label id="lab_legn_DeferredGovernmentGrant_label_en-US" xlink:label="lab_legn_DeferredGovernmentGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Government Grant</link:label>
    <link:label id="lab_legn_DeferredGovernmentGrant_documentation_en-US" xlink:label="lab_legn_DeferredGovernmentGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred government grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DeferredGovernmentGrant" xlink:href="legn-20250331.xsd#legn_DeferredGovernmentGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DeferredGovernmentGrant" xlink:to="lab_legn_DeferredGovernmentGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_32d04580-04cd-4ce4-b2e6-9528f10b1e8b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of authorisation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueAbstract_40b98f55-17e9-4e41-94f7-6cdb6b860fe7_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_ifrs-full_RevenueAbstract_label_en-US" xlink:label="lab_ifrs-full_RevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueAbstract" xlink:to="lab_ifrs-full_RevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PledgedDeposits_66872dfa-f78f-49e1-99ef-b28b48f142ce_terseLabel_en-US" xlink:label="lab_legn_PledgedDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pledged deposits</link:label>
    <link:label id="lab_legn_PledgedDeposits_label_en-US" xlink:label="lab_legn_PledgedDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pledged Deposits</link:label>
    <link:label id="lab_legn_PledgedDeposits_documentation_en-US" xlink:label="lab_legn_PledgedDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pledged deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PledgedDeposits" xlink:href="legn-20250331.xsd#legn_PledgedDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PledgedDeposits" xlink:to="lab_legn_PledgedDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_bd0891c5-387b-4d27-a75e-0490e1750417_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CORPORATE INFORMATION</link:label>
    <link:label id="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_label_en-US" xlink:label="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of notes and other explanatory information [text block]</link:label>
    <link:label id="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_documentation_en-US" xlink:label="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of notes and other explanatory information as part of a complete set of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:href="legn-20250331.xsd#legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="lab_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_8f9c8c99-78ac-42ad-bbe6-04776d201e03_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency exchange loss/(gain), net</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_106a22f5-f5c1-40a2-946e-8f1ca75dd5bf_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Calculations of Basic and Diluted Loss per Share</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareExplanatory" xlink:to="lab_ifrs-full_EarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualProperty_adb4226d-31a7-49dc-9595-2b0744632b0e_terseLabel_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualProperty_label_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Licensing Of Intellectual Property</link:label>
    <link:label id="lab_legn_RevenueFromLicensingOfIntellectualProperty_documentation_en-US" xlink:label="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from licensing of intellectual property.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty" xlink:href="legn-20250331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_RevenueFromLicensingOfIntellectualProperty" xlink:to="lab_legn_RevenueFromLicensingOfIntellectualProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReserves_e7a754c3-d0c0-4722-b098-f680b357c31d_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
    <link:label id="lab_ifrs-full_OtherReserves_label_en-US" xlink:label="lab_ifrs-full_OtherReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReserves" xlink:to="lab_ifrs-full_OtherReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_663986f4-f92f-49dc-8ed0-38cbc6636c8f_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_932ae34d-8de3-4dbe-9a88-2905ba11b2f2_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [domain]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesDomain_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesDomain" xlink:to="lab_ifrs-full_CounterpartiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalRollForward_77336dd7-b7c8-458f-b288-10092232b072_terseLabel_en-US" xlink:label="lab_legn_ShareCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital [Roll Forward]</link:label>
    <link:label id="lab_legn_ShareCapitalRollForward_label_en-US" xlink:label="lab_legn_ShareCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital [Roll Forward]</link:label>
    <link:label id="lab_legn_ShareCapitalRollForward_documentation_en-US" xlink:label="lab_legn_ShareCapitalRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalRollForward" xlink:href="legn-20250331.xsd#legn_ShareCapitalRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalRollForward" xlink:to="lab_legn_ShareCapitalRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_8eec5b2e-8bc3-4b3f-8fa7-517385041f7b_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, carrying amount</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_3c3d8019-388f-4e6a-935e-ea3f76c7f742_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, carrying amount</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_94c9faae-fd45-4762-8a2d-ea0d1c982196_totalLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Carrying amount at March 31, 2025</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets_2fe4f141-2da0-45ca-b6d3-06d956198ae1_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in other non-current assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets_label_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Other Non-current Assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Decrease (Increase) In Other Non-current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" xlink:to="lab_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_b1c98429-f628-46a6-997b-dd5db6a9bf68_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total ordinary shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAttributableToOwnersOfParent_label_en-US" xlink:label="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity attributable to owners of parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="lab_ifrs-full_EquityAttributableToOwnersOfParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_46251880-f31c-44ba-8b20-9dc42bbc3945_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_7ca7969c-e17d-4dec-9bdc-12c3321bf905_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate margin percentage</link:label>
    <link:label id="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_label_en-US" xlink:label="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings, adjustment to interest rate basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:to="lab_ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_c12af900-df57-4215-8c15-2eeccfd32b7a_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_7cdc84c3-dd67-43de-8c64-dbe2b2edf19b_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_d74c57e9-c2ab-4be3-ba91-28113396f997_terseLabel_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of vesting of restricted share units (in shares)</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_label_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_documentation_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of vested restricted stock units, number of shares in issue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:href="legn-20250331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:to="lab_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_f4809c4c-540b-4cad-b583-4dadde3a7e68_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_57161e2c-0d59-4960-b9d0-0f3427f396f7_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_e380c4fc-2ebb-4275-bd61-99299e6222fe_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_037e1cc8-1ea5-4e7b-984a-4e9edde41aaf_totalLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_90f1a5b7-545d-46d8-bc81-e1727fba2035_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in collaboration inventories</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue_264d25f2-4c62-4dc8-9b15-ce5ea11299bc_terseLabel_en-US" xlink:label="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share option (in shares)</link:label>
    <link:label id="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue_label_en-US" xlink:label="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Share Option Number Of Shares In Issue</link:label>
    <link:label id="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue_documentation_en-US" xlink:label="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise of share option number of shares in issue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:href="legn-20250331.xsd#legn_ExerciseOfShareOptionNumberOfSharesInIssue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:to="lab_legn_ExerciseOfShareOptionNumberOfSharesInIssue" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeasesLineItems_f51f0136-76d1-4552-81f6-a41627367d79_terseLabel_en-US" xlink:label="lab_legn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_legn_LeasesLineItems_label_en-US" xlink:label="lab_legn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_legn_LeasesLineItems_documentation_en-US" xlink:label="lab_legn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases line items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesLineItems" xlink:href="legn-20250331.xsd#legn_LeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeasesLineItems" xlink:to="lab_legn_LeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_f88f8da2-c6c8-42db-9f25-62340e7178d1_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares issued and fully paid (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued and fully paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="lab_ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OtherPayablesAndAccrualsCurrent_8a0e45f0-ae76-4def-b593-74a3d0195019_terseLabel_en-US" xlink:label="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables and accruals</link:label>
    <link:label id="lab_legn_OtherPayablesAndAccrualsCurrent_ecb8baff-179d-4508-834e-e52bafdeb8f8_totalLabel_en-US" xlink:label="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_legn_OtherPayablesAndAccrualsCurrent_label_en-US" xlink:label="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Payables And Accruals Current</link:label>
    <link:label id="lab_legn_OtherPayablesAndAccrualsCurrent_documentation_en-US" xlink:label="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other payables and accruals, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent" xlink:href="legn-20250331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OtherPayablesAndAccrualsCurrent" xlink:to="lab_legn_OtherPayablesAndAccrualsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_8749436b-610f-4c57-9e81-97ebfe68b304_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominated in EUR</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_6f90e1b9-54d8-47c5-be98-1c086e4c839b_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_c5a51513-1d71-4df9-b435-c0755c7834ab_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in)/provided by operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_a4e63fff-b0a5-4f85-90d7-f5fdfde5caf7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-settled share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_4613928e-0101-47ff-89ee-8c9811163634_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analyzed into:</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_138e0bc7-e87f-4a82-b5f8-4600562c633d_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_8b272938-65b2-4b9b-a7dc-3a7c20e4e0bd_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue at a point in time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred at point in time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_723f6cae-9f78-4e9f-90b6-bc2d01d4bd44_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Inventories_d3e9bf58-d203-48cb-9d03-554f0506b044_terseLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration inventories, net</link:label>
    <link:label id="lab_ifrs-full_Inventories_517367ee-dbed-46b9-b33d-75d2cef95103_totalLabel_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total collaboration inventories, net</link:label>
    <link:label id="lab_ifrs-full_Inventories_label_en-US" xlink:label="lab_ifrs-full_Inventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Inventories" xlink:to="lab_ifrs-full_Inventories" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_817474c6-b406-4e71-a274-c7a63d2d3c4a_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Inventories Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of detailed information about inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_629cf2fe-7e14-4481-b263-5d54480870e9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_ifrs-full_CurrentTradeReceivables_label_en-US" xlink:label="lab_ifrs-full_CurrentTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTradeReceivables" xlink:to="lab_ifrs-full_CurrentTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c503ccf7-c4e0-459d-a3dd-5e7253a40551_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Classes Of Share Capital [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_dcd19680-6897-4db1-8c91-47e00e67a781_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange rate changes, net</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d731afc3-71d2-43a8-baaa-bdaeee431596_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1c454495-b513-4f86-a9fa-46ea9cbb52f6_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS (USED IN)/PROVIDED BY OPERATING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_21e79d43-23de-45f8-b589-c14a1fe261b6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_91413be6-3cc4-427c-8aff-5b9171209670_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_f5d4bfba-03ea-42a1-9e3f-0abb1354b509_terseLabel_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:label id="lab_ifrs-full_BorrowingsByNameDomain_label_en-US" xlink:label="lab_ifrs-full_BorrowingsByNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BorrowingsByNameDomain" xlink:to="lab_ifrs-full_BorrowingsByNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_2fca650a-b83c-463f-adfc-659428521a38_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation reserves</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_2ba3b83f-92dd-4dfa-bad5-7dd8b6a4db8f_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments, other receivables and other assets</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepayments and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="lab_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PayableForCollaborationAssets_21624dea-08b8-4e1c-a7bd-8c6381cd10d5_terseLabel_en-US" xlink:label="lab_legn_PayableForCollaborationAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable for collaboration assets</link:label>
    <link:label id="lab_legn_PayableForCollaborationAssets_label_en-US" xlink:label="lab_legn_PayableForCollaborationAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payable For Collaboration Assets</link:label>
    <link:label id="lab_legn_PayableForCollaborationAssets_documentation_en-US" xlink:label="lab_legn_PayableForCollaborationAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payable For Collaboration Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PayableForCollaborationAssets" xlink:href="legn-20250331.xsd#legn_PayableForCollaborationAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PayableForCollaborationAssets" xlink:to="lab_legn_PayableForCollaborationAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_label_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]</link:label>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_documentation_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract" xlink:to="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_OngoingLeasePaymentsUnderTheLandLease_dadc6e46-e7af-471a-930d-62b6a7fdfcdb_terseLabel_en-US" xlink:label="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ongoing lease payments</link:label>
    <link:label id="lab_legn_OngoingLeasePaymentsUnderTheLandLease_label_en-US" xlink:label="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ongoing Lease Payments Under The Land Lease</link:label>
    <link:label id="lab_legn_OngoingLeasePaymentsUnderTheLandLease_documentation_en-US" xlink:label="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ongoing lease payments under the land lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:href="legn-20250331.xsd#legn_OngoingLeasePaymentsUnderTheLandLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:to="lab_legn_OngoingLeasePaymentsUnderTheLandLease" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_23a94a0b-79c3-4055-9c6c-8b176d3049e1_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_531abcde-140e-4906-9d85-f8f17e1291f4_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_5f5f4af2-ebeb-400c-bb05-9da3aea8168c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_817a0150-d4d2-4437-9245-032f60018d85_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CollaborationRevenue_559633d4-bb6f-4975-ac4a-d0ba35411076_terseLabel_en-US" xlink:label="lab_legn_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_legn_CollaborationRevenue_label_en-US" xlink:label="lab_legn_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:label id="lab_legn_CollaborationRevenue_documentation_en-US" xlink:label="lab_legn_CollaborationRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue" xlink:href="legn-20250331.xsd#legn_CollaborationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CollaborationRevenue" xlink:to="lab_legn_CollaborationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_9a524f3e-1314-4fd3-96c7-b5d78032daca_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_ab5898e7-f15a-4886-b09e-368f15af9d84_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_5fe868bf-6a6c-49a1-a6a9-15630d078a65_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_6b6eced4-ba30-4916-b6c5-cbf82b5c9c54_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Interest-bearing Advanced Funding</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_label_en-US" xlink:label="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current portion of non-current loans received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:to="lab_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7fa13765-1462-4a6c-a2a5-be218561e417_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_e6ec84ed-dcdf-49ea-bef6-48eb1cb612e9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER (EXPENSE)/INCOME, NET</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other operating income (expense) [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_0e312728-e134-43d7-b835-b82bf15a3389_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_acf7ca55-725d-46b9-9a0e-25b8376bade7_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_0b11330f-eb83-446a-b346-f8d6f639b3a6_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Lease Liabilities [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets_455f85bd-047e-4d5d-ac54-1247cb4af7e4_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of right-of-use assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets_label_en-US" xlink:label="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation Of Right Of Use Assets</link:label>
    <link:label id="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets_documentation_en-US" xlink:label="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation of right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDepreciationOfRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:to="lab_legn_AdjustmentsForDepreciationOfRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalMember_262354e5-d922-4cfa-8e09-4693237fd283_terseLabel_en-US" xlink:label="lab_legn_ShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_legn_ShareCapitalMember_label_en-US" xlink:label="lab_legn_ShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital [Member]</link:label>
    <link:label id="lab_legn_ShareCapitalMember_documentation_en-US" xlink:label="lab_legn_ShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalMember" xlink:href="legn-20250331.xsd#legn_ShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalMember" xlink:to="lab_legn_ShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_d38805ec-7593-4d52-9115-4a5ce372f432_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Shares</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1441c1c5-6a5e-433d-88c8-533863e55a69_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_5c7b5bba-f5e0-4563-bfbc-3fadbe8fb1c3_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InventoryReserve_d320d463-c90e-461d-9534-7eb839423bf6_terseLabel_en-US" xlink:label="lab_legn_InventoryReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_legn_InventoryReserve_label_en-US" xlink:label="lab_legn_InventoryReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_legn_InventoryReserve_documentation_en-US" xlink:label="lab_legn_InventoryReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InventoryReserve" xlink:href="legn-20250331.xsd#legn_InventoryReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InventoryReserve" xlink:to="lab_legn_InventoryReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities_9956ec46-f903-4fed-9906-d7da6a22cad8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of financial assets measured at fair value through profit or loss</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial assets measured at fair value through profit or loss, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CostOfLicenseAndOtherRevenue_982d9d41-cbde-4c4c-a948-7d9e1ddcd6c2_negatedTerseLabel_en-US" xlink:label="lab_legn_CostOfLicenseAndOtherRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of license and other revenue</link:label>
    <link:label id="lab_legn_CostOfLicenseAndOtherRevenue_label_en-US" xlink:label="lab_legn_CostOfLicenseAndOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost Of License And Other Revenue</link:label>
    <link:label id="lab_legn_CostOfLicenseAndOtherRevenue_documentation_en-US" xlink:label="lab_legn_CostOfLicenseAndOtherRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cost Of License And Other Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CostOfLicenseAndOtherRevenue" xlink:href="legn-20250331.xsd#legn_CostOfLicenseAndOtherRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CostOfLicenseAndOtherRevenue" xlink:to="lab_legn_CostOfLicenseAndOtherRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AuthorizedShareCapital_38684830-898a-4882-9ced-d81805f07f68_terseLabel_en-US" xlink:label="lab_legn_AuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2,000,000,000 ordinary shares of $0.0001 each</link:label>
    <link:label id="lab_legn_AuthorizedShareCapital_label_en-US" xlink:label="lab_legn_AuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Authorized Share Capital</link:label>
    <link:label id="lab_legn_AuthorizedShareCapital_documentation_en-US" xlink:label="lab_legn_AuthorizedShareCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Authorized share capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorizedShareCapital" xlink:href="legn-20250331.xsd#legn_AuthorizedShareCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AuthorizedShareCapital" xlink:to="lab_legn_AuthorizedShareCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_IncreaseInLeaseLiabilities_ffb12990-b049-4192-b6d2-079f227466c5_terseLabel_en-US" xlink:label="lab_legn_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_legn_IncreaseInLeaseLiabilities_label_en-US" xlink:label="lab_legn_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Lease Liabilities</link:label>
    <link:label id="lab_legn_IncreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_legn_IncreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseInLeaseLiabilities" xlink:href="legn-20250331.xsd#legn_IncreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_IncreaseInLeaseLiabilities" xlink:to="lab_legn_IncreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_d51cd9a4-f163-46bf-9b64-89ec3d110d0b_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets_74438643-0789-4de5-bb91-763fb5215d6a_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_fc27cdf4-cd49-4c1d-b44f-e7ad69ff879d_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-settled share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_78fb1b8c-853b-47d4-a72c-6a6edf478d63_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Analysis of Revenue</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_b1ffa156-8d15-4daa-b94a-988c949033a9_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on disposals of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_18f82d1e-03de-460b-ab6c-c94440001735_terseLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and bank balances</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CNY_74104fda-7955-4521-81a5-cbff330a0873_terseLabel_en-US" xlink:label="lab_currency_CNY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominated in RMB</link:label>
    <link:label id="lab_currency_CNY_label_en-US" xlink:label="lab_currency_CNY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China, Yuan Renminbi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CNY" xlink:to="lab_currency_CNY" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LandMember_8cadf72d-9d03-47de-8c14-1b19bae59f72_verboseLabel_en-US" xlink:label="lab_ifrs-full_LandMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leasehold land</link:label>
    <link:label id="lab_ifrs-full_LandMember_label_en-US" xlink:label="lab_ifrs-full_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LandMember" xlink:to="lab_ifrs-full_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_d095f84e-1ce3-44dc-8c1c-0dcb5868b7d4_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bottom of Range</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DecreaseInTimeDeposits_0373b943-c277-4216-86a6-5278a91819d7_terseLabel_en-US" xlink:label="lab_legn_DecreaseInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in time deposits</link:label>
    <link:label id="lab_legn_DecreaseInTimeDeposits_label_en-US" xlink:label="lab_legn_DecreaseInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease In Time Deposits</link:label>
    <link:label id="lab_legn_DecreaseInTimeDeposits_documentation_en-US" xlink:label="lab_legn_DecreaseInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Decrease in time deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DecreaseInTimeDeposits" xlink:href="legn-20250331.xsd#legn_DecreaseInTimeDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DecreaseInTimeDeposits" xlink:to="lab_legn_DecreaseInTimeDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_3dbc3433-e1fa-4715-bd72-d23a2db3c8b0_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Borrowings_0ac8638d-87ea-4a98-bd5f-321d67ee73d9_terseLabel_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Funding advances from collaborator principal amount</link:label>
    <link:label id="lab_ifrs-full_Borrowings_label_en-US" xlink:label="lab_ifrs-full_Borrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Borrowings" xlink:to="lab_ifrs-full_Borrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_db87be2f-425d-454c-bcc6-665ff5d37c85_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_f4c21d32-f612-4a07-96f6-58a49a80c29a_terseLabel_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents as stated in the statement of financial position</link:label>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_label_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents As Stated In Statement Of Financial Position</link:label>
    <link:label id="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_documentation_en-US" xlink:label="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents as stated in statement of financial position.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:href="legn-20250331.xsd#legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:to="lab_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_3101ad0e-8b0e-4d67-bbe8-46a670f4d9ac_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReceivables_a581833f-68c1-4904-a2cf-250d8a3d2bf5_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables" xlink:to="lab_ifrs-full_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_4dc2f308-8d6b-4d67-8726-90440891cea5_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top of Range</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_0390eeaf-71ce-4728-ab22-7efd67455f30_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net other comprehensive income/(loss)</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets_ad23a1e1-3214-479c-8f29-0282b47fcc1b_totalLabel_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets_label_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments Other Receivables And Other Assets</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets_documentation_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:href="legn-20250331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:to="lab_legn_PrepaymentsOtherReceivablesAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_9ffdc077-8317-4bd2-8c19-22ee9c8c5c21_negatedTerseLabel_en-US" xlink:label="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepayment to collaborator for collaboration assets</link:label>
    <link:label id="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_label_en-US" xlink:label="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment To Collaborator For Collaboration Right Of Use Assets</link:label>
    <link:label id="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_documentation_en-US" xlink:label="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayment To Collaborator For Collaboration Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:href="legn-20250331.xsd#legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:to="lab_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncome_cda490f2-9052-4a8d-aa2e-6d5ed059c313_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_FinanceIncome_label_en-US" xlink:label="lab_ifrs-full_FinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncome" xlink:to="lab_ifrs-full_FinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_1ffb2330-5880-4ee4-9632-95a8b99f6d42_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Borrowings [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets_11439fd7-80cc-461a-9479-af3333f8830c_terseLabel_en-US" xlink:label="lab_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property, plant and equipment</link:label>
    <link:label id="lab_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets_label_en-US" xlink:label="lab_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Disposals Of Property, Plant And Equipment, Intangible Assets Other Than Goodwill, Investment Property And Other Non-current Assets</link:label>
    <link:label id="lab_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets_documentation_en-US" xlink:label="lab_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Disposals Of Property, Plant And Equipment, Intangible Assets Other Than Goodwill, Investment Property And Other Non-current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" xlink:href="legn-20250331.xsd#legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" xlink:to="lab_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_62c8566c-7878-4ba2-ad8f-ffd16a0acc58_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_5074cc7a-9a92-4491-8ebd-ec33a4177a5a_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_134d0979-a151-4c03-af42-918baa4319bb_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash (used in)/provided by operations</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_23026745-6963-4d1b-8666-35215347e5ab_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_5d46fb8d-f314-4cc6-9026-807a2c0f9774_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToAbstract_87ce5594-037f-4aee-8dbb-26785a40fbbd_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to:</link:label>
    <link:label id="lab_ifrs-full_ProfitLossAttributableToAbstract_label_en-US" xlink:label="lab_ifrs-full_ProfitLossAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss), attributable to [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract" xlink:to="lab_ifrs-full_ProfitLossAttributableToAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_SellingAndDistributionExpenses_2f8d5216-5fc0-4730-b7be-3bde954646eb_negatedTerseLabel_en-US" xlink:label="lab_legn_SellingAndDistributionExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Selling and distribution expenses</link:label>
    <link:label id="lab_legn_SellingAndDistributionExpenses_label_en-US" xlink:label="lab_legn_SellingAndDistributionExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling And Distribution Expenses</link:label>
    <link:label id="lab_legn_SellingAndDistributionExpenses_documentation_en-US" xlink:label="lab_legn_SellingAndDistributionExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selling and distribution expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SellingAndDistributionExpenses" xlink:href="legn-20250331.xsd#legn_SellingAndDistributionExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_SellingAndDistributionExpenses" xlink:to="lab_legn_SellingAndDistributionExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_df2ef64c-b4a7-46b6-9086-69a01589ffdc_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income received</link:label>
    <link:label id="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance income received, classified as operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="lab_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_4a87e983-198d-4a6d-8256-770962b012a1_periodStartLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_d07348ab-7365-4b00-9934-54ed6b6ef0e5_periodEndLabel_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_label_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital And Share Premium</link:label>
    <link:label id="lab_legn_ShareCapitalAndSharePremium_documentation_en-US" xlink:label="lab_legn_ShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ShareCapitalAndSharePremium" xlink:to="lab_legn_ShareCapitalAndSharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities_90c001ae-da6a-4c68-8dc1-c8c257878dd7_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase/(decrease) in other non-current liabilities</link:label>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities_label_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase Decrease In Other Non Current Liabilities</link:label>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities_documentation_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other non current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" xlink:href="legn-20250331.xsd#legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" xlink:to="lab_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract_295c6d89-9662-4967-a8ac-717add0beff7_terseLabel_en-US" xlink:label="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER COMPREHENSIVE INCOME/(LOSS)</link:label>
    <link:label id="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract_label_en-US" xlink:label="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange differences on translation [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExchangeDifferencesOnTranslationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:to="lab_ifrs-full_ExchangeDifferencesOnTranslationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_7b2e7872-b510-4417-a94c-5c0568dbbfbd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION INTEREST-BEARING ADVANCED FUNDING</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBorrowingsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of borrowings [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_3e1a425c-47f0-435f-beea-8a46c7a3ff53_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on asset impairment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_e7c58867-3be3-41a1-9fb6-af59326dd230_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue and other revenue</link:label>
    <link:label id="lab_ifrs-full_RevenueFromContractsWithCustomers_label_en-US" xlink:label="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from contracts with customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromContractsWithCustomers" xlink:to="lab_ifrs-full_RevenueFromContractsWithCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilities_a15cfa17-af63-4d00-be74-d61572db5476_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax payable</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxLiabilities" xlink:to="lab_ifrs-full_CurrentTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_067ccfbd-255e-4081-b2bb-4640214429c6_terseLabel_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Pledged deposits</link:label>
    <link:label id="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term deposits, classified as cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="lab_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_945a32b7-86f4-4255-8769-b7af24674388_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_07f12e30-4f7a-4814-8d98-5e3ffdf5745a_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before tax</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_edcab896-2e03-475c-a909-8e93cc953b97_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_label_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]</link:label>
    <link:label id="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_documentation_en-US" xlink:label="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" xlink:to="lab_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_f4a8f3fd-916d-499c-8ff0-664a0cd43464_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue over time</link:label>
    <link:label id="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember_label_en-US" xlink:label="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goods or services transferred over time [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="lab_ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_826c806e-de41-4aea-a90f-4d4d4fedc81d_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_legn_DisclosureOfOtherPayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Other Payables And Accruals [Abstract]</link:label>
    <link:label id="lab_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_documentation_en-US" xlink:label="lab_legn_DisclosureOfOtherPayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of other payables and accruals.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherPayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract" xlink:to="lab_legn_DisclosureOfOtherPayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock_a39bdef2-a860-4cf3-9f75-77b7eca2e2db_terseLabel_en-US" xlink:label="lab_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCE INCOME AND FINANCE COSTS</link:label>
    <link:label id="lab_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock_label_en-US" xlink:label="lab_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entire Disclosure Of Finance Income and Costs Explanatory [Text Block]</link:label>
    <link:label id="lab_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of finance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" xlink:href="legn-20250331.xsd#legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" xlink:to="lab_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForInventoryReserveProvision_8f62b932-f559-47d1-bd4e-07b47f0e2760_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for inventory reserve</link:label>
    <link:label id="lab_legn_AdjustmentsForInventoryReserveProvision_label_en-US" xlink:label="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Inventory Reserve Provision</link:label>
    <link:label id="lab_legn_AdjustmentsForInventoryReserveProvision_documentation_en-US" xlink:label="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Inventory Reserve Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForInventoryReserveProvision" xlink:href="legn-20250331.xsd#legn_AdjustmentsForInventoryReserveProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForInventoryReserveProvision" xlink:to="lab_legn_AdjustmentsForInventoryReserveProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_7d62148c-4d8a-46cb-a8ac-df5680b4db66_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_c1424deb-338d-4d88-9375-0c0ca4f7325d_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Prepayments, Other Receivables and Other Assets</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:to="lab_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_06d42f2b-631e-42f2-8e4b-31588753ff3b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeasesRollForward_70e9aa04-5367-4d3c-a286-24e51224df41_terseLabel_en-US" xlink:label="lab_legn_LeasesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Roll Forward]</link:label>
    <link:label id="lab_legn_LeasesRollForward_label_en-US" xlink:label="lab_legn_LeasesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Roll Forward]</link:label>
    <link:label id="lab_legn_LeasesRollForward_documentation_en-US" xlink:label="lab_legn_LeasesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesRollForward" xlink:href="legn-20250331.xsd#legn_LeasesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeasesRollForward" xlink:to="lab_legn_LeasesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_cbc9668e-4937-4a8f-84f4-9f3689098011_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities arising from financing activities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="lab_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_f5f24002-8bd9-4f73-b53c-72d125b75d7e_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NON-CURRENT LIABILITIES</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_NoncurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ValueAddedTaxReceivables_6e56b70d-1735-46a3-a2e3-a96dbbdda3bd_verboseLabel_en-US" xlink:label="lab_ifrs-full_ValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">VAT recoverable</link:label>
    <link:label id="lab_ifrs-full_ValueAddedTaxReceivables_label_en-US" xlink:label="lab_ifrs-full_ValueAddedTaxReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value added tax receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ValueAddedTaxReceivables" xlink:to="lab_ifrs-full_ValueAddedTaxReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_16e1318f-bd6b-4b5d-8b0c-3d0e68242fc0_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_fa83ec50-9527-4250-b879-bf8cc431bf8b_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares in issue</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_c5932d80-e455-4f70-a2be-e611ffbb49aa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_7716b1e9-1767-4e08-93b6-a5497dca8644_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_deee4eeb-d8a1-49d3-8f09-4ddb886d7133_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_caf2a76a-cdc2-4d40-91e3-7e8a11becac3_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_1d4792e8-53cc-4e72-8ff4-989a3f493149_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_468f5d35-4e4e-4405-8d39-7f71782eaaaf_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_dc213c27-0eb3-4c69-8648-238345c40850_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_334e5dc3-119d-406f-bd05-979ede9e0b0d_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LesseeLeasingArrangementsLeasesTerm_4b663899-7d5f-4439-a475-bfe3f625c013_terseLabel_en-US" xlink:label="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, lease terms</link:label>
    <link:label id="lab_legn_LesseeLeasingArrangementsLeasesTerm_label_en-US" xlink:label="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements Leases Term</link:label>
    <link:label id="lab_legn_LesseeLeasingArrangementsLeasesTerm_documentation_en-US" xlink:label="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee leasing arrangements leases term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeasingArrangementsLeasesTerm" xlink:href="legn-20250331.xsd#legn_LesseeLeasingArrangementsLeasesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LesseeLeasingArrangementsLeasesTerm" xlink:to="lab_legn_LesseeLeasingArrangementsLeasesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities_53b91213-1505-441b-8b07-2c320e2a2ce6_terseLabel_en-US" xlink:label="lab_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash receipts of investment income</link:label>
    <link:label id="lab_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Receipts Of Investment Income Classified As Investing Activities</link:label>
    <link:label id="lab_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash receipts of investment income classified as investing activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" xlink:href="legn-20250331.xsd#legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" xlink:to="lab_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract_8b3dbadf-1071-48c3-9a69-a9ca70406b08_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Attributable to:</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="lab_ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_088e0385-8253-4189-85e9-221ca4f6f9c8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_9faa6022-57ef-4630-ba31-2b07bc72e01a_terseLabel_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of vesting of restricted share units</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_label_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium</link:label>
    <link:label id="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_documentation_en-US" xlink:label="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of vested restricted stock units, share capital and share premium.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:href="legn-20250331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:to="lab_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent_a3ef205b-b01b-4020-91f3-915c9c0cb594_terseLabel_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in contract liabilities, net</link:label>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent_label_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Contract Liabilities, Current</link:label>
    <link:label id="lab_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent_documentation_en-US" xlink:label="lab_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Contract Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" xlink:href="legn-20250331.xsd#legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" xlink:to="lab_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_56580e28-c16e-4c0b-80bd-21ba4a1d6297_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value gains on financial assets measured at fair value through profit or loss</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFairValueGainsLosses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for fair value losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="lab_ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Other Income and Expense [Abstract]</link:label>
    <link:label id="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract_documentation_en-US" xlink:label="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Other Income and Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:to="lab_legn_DisclosureOfOtherIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_c3ac6ea1-d6b1-4706-84f6-2e949ad51727_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained accumulated losses</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_d77f0ddf-7e18-4987-9380-b815c1ad29f1_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Disclosure of Timing of transfer of Goods or Services</link:label>
    <link:label id="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Timing Of Transfer Of Goods Or Services [Table Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Timing Of Transfer Of Goods Or Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:to="lab_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_6b65eaac-d368-4420-9f8e-eedee8993fe1_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationExpense_b8ec1454-1942-4e0a-acbd-9dc0c6b06305_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ecc2e376-e6f7-4c7a-935b-926a8d5dcf04_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Classes Of Share Capital [Line Items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_2e9395ba-7f4c-4f4b-b8fa-b141690e73f9_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_96b490b3-64ec-4b15-bedb-3313bacc3c6c_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive income/(loss) for the period</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_e3666bb2-0c17-4e29-99e9-de70881b1b5a_terseLabel_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_label_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Prepayments Other Receivables And Other Assets Explanatory [Text Block]</link:label>
    <link:label id="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_documentation_en-US" xlink:label="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of prepayments, other receivables and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:to="lab_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_ab6dc352-35b3-4b7e-837d-a3353c5f7f63_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_ifrs-full_Equity_173dd2eb-2b2f-4690-b5d6-b27c1c2ce1be_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ifrs-full_Equity_95147b42-94ad-42f0-94d5-7f73623ff64a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_CollaborationPayable_ad787c0e-2e93-4724-87d4-afbe3ca73066_terseLabel_en-US" xlink:label="lab_legn_CollaborationPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration payable</link:label>
    <link:label id="lab_legn_CollaborationPayable_label_en-US" xlink:label="lab_legn_CollaborationPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Payable</link:label>
    <link:label id="lab_legn_CollaborationPayable_documentation_en-US" xlink:label="lab_legn_CollaborationPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPayable" xlink:href="legn-20250331.xsd#legn_CollaborationPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_CollaborationPayable" xlink:to="lab_legn_CollaborationPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_2ba336f9-9451-4aad-8d32-0bd002d31cf6_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on asset impairment</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_cd25013e-e7a9-46bc-bcb6-1180b1a60819_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in trade receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_A110InterestBearingLoansMember_6d56b60c-4d8d-4850-b152-c34fbc17c1cc_terseLabel_en-US" xlink:label="lab_legn_A110InterestBearingLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">11.0% Interest Bearing Loans</link:label>
    <link:label id="lab_legn_A110InterestBearingLoansMember_label_en-US" xlink:label="lab_legn_A110InterestBearingLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">11.0% Interest Bearing Loans [Member]</link:label>
    <link:label id="lab_legn_A110InterestBearingLoansMember_documentation_en-US" xlink:label="lab_legn_A110InterestBearingLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">11.0% Interest Bearing Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_A110InterestBearingLoansMember" xlink:href="legn-20250331.xsd#legn_A110InterestBearingLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_A110InterestBearingLoansMember" xlink:to="lab_legn_A110InterestBearingLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_5ba2e25c-176f-42ca-8a0c-b4ae4d79730b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="lab_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_d0e4cd6f-5533-4db0-bc87-ef5929b3f784_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Revenue by Geographic Area</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinanceLeaseReceivables_b0feb954-69d1-4ad4-94fa-cb8e0f92b403_terseLabel_en-US" xlink:label="lab_ifrs-full_FinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease receivables</link:label>
    <link:label id="lab_ifrs-full_FinanceLeaseReceivables_label_en-US" xlink:label="lab_ifrs-full_FinanceLeaseReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance lease receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceLeaseReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceLeaseReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinanceLeaseReceivables" xlink:to="lab_ifrs-full_FinanceLeaseReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued_f6f129ef-3a7c-4fdd-8d29-ece6d2e8e033_terseLabel_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest accrued on funding advances</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued_label_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Bearing Borrowings Funded Interests Accrued</link:label>
    <link:label id="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued_documentation_en-US" xlink:label="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest bearing borrowings funded interests accrued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:href="legn-20250331.xsd#legn_InterestBearingBorrowingsFundedInterestsAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:to="lab_legn_InterestBearingBorrowingsFundedInterestsAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ff01ebd9-ad5d-45c5-a31b-f627d6230e29_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of exchange differences on translation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="lab_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_c310b609-898a-4246-9031-39a8ec6b70e3_terseLabel_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments Other Receivable and Other Assets</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_label_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments Other Receivables And Other Assets [Member]</link:label>
    <link:label id="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_documentation_en-US" xlink:label="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayments other receivables and other assets.,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:href="legn-20250331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:to="lab_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdvancePaymentsForPropertyPlantAndEquipment_77cdac8f-75f5-485c-aff1-ad9ebcf2b1cb_terseLabel_en-US" xlink:label="lab_legn_AdvancePaymentsForPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advance payments for property, plant and equipment</link:label>
    <link:label id="lab_legn_AdvancePaymentsForPropertyPlantAndEquipment_label_en-US" xlink:label="lab_legn_AdvancePaymentsForPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advance Payments For Property Plant And Equipment</link:label>
    <link:label id="lab_legn_AdvancePaymentsForPropertyPlantAndEquipment_documentation_en-US" xlink:label="lab_legn_AdvancePaymentsForPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advance payments for property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdvancePaymentsForPropertyPlantAndEquipment" xlink:href="legn-20250331.xsd#legn_AdvancePaymentsForPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdvancePaymentsForPropertyPlantAndEquipment" xlink:to="lab_legn_AdvancePaymentsForPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_d77cd5e4-beb1-4b38-8275-f9202535f0ce_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration interest-bearing advanced funding</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnBorrowings_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnBorrowings" xlink:to="lab_ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_ab06efac-3d03-427a-8edb-ba5d79608c0e_totalLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_ifrs-full_Revenue_58bf4180-c826-4d3d-b49c-d95913220d43_terseLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_ba8cd251-89e2-4c16-a708-325b77cbf031_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Detailed Information About Borrowings [Table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_d4738155-3147-4357-8ce9-f90b3d11a687_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Decrease)/increase in other payables and accruals</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentGovernmentGrants_d8be4a68-4bc8-4897-ae16-ac4a2a67217f_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants</link:label>
    <link:label id="lab_ifrs-full_NoncurrentGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_NoncurrentGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentGovernmentGrants" xlink:to="lab_ifrs-full_NoncurrentGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_3850d854-a5dc-4c87-b488-ada59a637372_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_LeaseAbstract_label_en-US" xlink:label="lab_legn_LeaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease [Abstract]</link:label>
    <link:label id="lab_legn_LeaseAbstract_documentation_en-US" xlink:label="lab_legn_LeaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract" xlink:href="legn-20250331.xsd#legn_LeaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_LeaseAbstract" xlink:to="lab_legn_LeaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_8bf0ff9b-a4e0-46ff-8029-a5a0e9e38014_terseLabel_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:label id="lab_ifrs-full_CounterpartiesAxis_label_en-US" xlink:label="lab_ifrs-full_CounterpartiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CounterpartiesAxis" xlink:to="lab_ifrs-full_CounterpartiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_8cdcaece-91be-4cd7-9d0b-3c8a83af3e5f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Finance income</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForFinanceIncome_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for finance income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForFinanceIncome" xlink:to="lab_ifrs-full_AdjustmentsForFinanceIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentGovernmentGrants_25a5aaf5-33fc-43c4-bdc9-2afafe137c6b_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government grants</link:label>
    <link:label id="lab_ifrs-full_CurrentGovernmentGrants_label_en-US" xlink:label="lab_ifrs-full_CurrentGovernmentGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentGovernmentGrants" xlink:to="lab_ifrs-full_CurrentGovernmentGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeDomain_5288fd02-26df-41a0-8813-e5d7ae0741dc_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:label id="lab_ifrs-full_RangeDomain_label_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain" xlink:to="lab_ifrs-full_RangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_TimesDepositsCurrentAndNoncurrent_4058bf33-3eb9-4ba7-8853-7f1079a3eb1f_terseLabel_en-US" xlink:label="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_legn_TimesDepositsCurrentAndNoncurrent_label_en-US" xlink:label="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Times Deposits Current And Noncurrent</link:label>
    <link:label id="lab_legn_TimesDepositsCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Times deposits current and noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsCurrentAndNoncurrent" xlink:href="legn-20250331.xsd#legn_TimesDepositsCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_TimesDepositsCurrentAndNoncurrent" xlink:to="lab_legn_TimesDepositsCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_4ac93c04-f8d7-499a-9333-0b13cfb3313f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_ExerciseOfShareOption_c29ff7e7-3d77-435f-955e-8d7ea6f7125a_terseLabel_en-US" xlink:label="lab_legn_ExerciseOfShareOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of share options</link:label>
    <link:label id="lab_legn_ExerciseOfShareOption_label_en-US" xlink:label="lab_legn_ExerciseOfShareOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Of Share Option</link:label>
    <link:label id="lab_legn_ExerciseOfShareOption_documentation_en-US" xlink:label="lab_legn_ExerciseOfShareOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise of share option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOption" xlink:href="legn-20250331.xsd#legn_ExerciseOfShareOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_ExerciseOfShareOption" xlink:to="lab_legn_ExerciseOfShareOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_2c5b3756-72b7-4b72-9d09-bdabd3328c0f_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_aa087ffb-e5fc-4e7e-9c4f-583b7d46ca26_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AuthorisedAbstract_626e4de5-da78-47de-b2c9-7a970938ac4a_terseLabel_en-US" xlink:label="lab_legn_AuthorisedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized:</link:label>
    <link:label id="lab_legn_AuthorisedAbstract_label_en-US" xlink:label="lab_legn_AuthorisedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Authorised [Abstract]</link:label>
    <link:label id="lab_legn_AuthorisedAbstract_documentation_en-US" xlink:label="lab_legn_AuthorisedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Authorised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorisedAbstract" xlink:href="legn-20250331.xsd#legn_AuthorisedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AuthorisedAbstract" xlink:to="lab_legn_AuthorisedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_RightOfUseAssetsRollForward_4173a0ef-c95d-49db-adc9-25fa486ebebd_terseLabel_en-US" xlink:label="lab_legn_RightOfUseAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-Use Assets [Roll Forward]</link:label>
    <link:label id="lab_legn_RightOfUseAssetsRollForward_label_en-US" xlink:label="lab_legn_RightOfUseAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Assets [Roll Forward]</link:label>
    <link:label id="lab_legn_RightOfUseAssetsRollForward_documentation_en-US" xlink:label="lab_legn_RightOfUseAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RightOfUseAssetsRollForward" xlink:href="legn-20250331.xsd#legn_RightOfUseAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_RightOfUseAssetsRollForward" xlink:to="lab_legn_RightOfUseAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_legn_AdditionInTimeDeposits_b64e5506-609a-4a77-ac50-6d2eba673f1e_negatedTerseLabel_en-US" xlink:label="lab_legn_AdditionInTimeDeposits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Addition in time deposits</link:label>
    <link:label id="lab_legn_AdditionInTimeDeposits_label_en-US" xlink:label="lab_legn_AdditionInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Addition In Time Deposits</link:label>
    <link:label id="lab_legn_AdditionInTimeDeposits_documentation_en-US" xlink:label="lab_legn_AdditionInTimeDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Addition in time deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdditionInTimeDeposits" xlink:href="legn-20250331.xsd#legn_AdditionInTimeDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_legn_AdditionInTimeDeposits" xlink:to="lab_legn_AdditionInTimeDeposits" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>legn-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:9fafd2bc-3cfd-4d2f-adf8-3916722ba5cf,g:99013260-2431-4a14-8f08-d911c15b56e6-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://legendbiotech.com/role/COVER" xlink:type="simple" xlink:href="legn-20250331.xsd#COVER"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_78ff1235-6ce4-4ced-8a8e-3a484d5a21dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_DocumentType_78ff1235-6ce4-4ced-8a8e-3a484d5a21dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_18b17a4c-9072-4e01-92c1-f75ac5a4be68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_EntityRegistrantName_18b17a4c-9072-4e01-92c1-f75ac5a4be68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d1aa4bfa-cef0-41a0-9054-f7f9b88a4e61" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_EntityCentralIndexKey_d1aa4bfa-cef0-41a0-9054-f7f9b88a4e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3e7d8acf-e745-4364-9e80-5ba15d03e1e0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_DocumentPeriodEndDate_3e7d8acf-e745-4364-9e80-5ba15d03e1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_da1ed4a9-28ae-4b55-905f-86181dee9cef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_DocumentFiscalYearFocus_da1ed4a9-28ae-4b55-905f-86181dee9cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_57c0f6fb-dc41-4155-bca2-ef9f7c9a579b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_DocumentFiscalPeriodFocus_57c0f6fb-dc41-4155-bca2-ef9f7c9a579b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_24d3c05a-ca85-4e8c-9a6d-87fc86144274" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_CurrentFiscalYearEndDate_24d3c05a-ca85-4e8c-9a6d-87fc86144274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4b9bcc82-3289-49e8-b2e1-0222f11b0afd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_674b6fdd-da28-4134-8b79-6040ed757bdd" xlink:to="loc_dei_AmendmentFlag_4b9bcc82-3289-49e8-b2e1-0222f11b0afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueAbstract_0695fec5-e4bf-4faf-a106-2d986ff670b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_RevenueAbstract_0695fec5-e4bf-4faf-a106-2d986ff670b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty_8ffcdc60-c781-4663-a557-32017f46efcc" xlink:href="legn-20250331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_0695fec5-e4bf-4faf-a106-2d986ff670b3" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualProperty_8ffcdc60-c781-4663-a557-32017f46efcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_9ff66d1f-c856-4701-8cb7-03478bf37195" xlink:href="legn-20250331.xsd#legn_CollaborationRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_0695fec5-e4bf-4faf-a106-2d986ff670b3" xlink:to="loc_legn_CollaborationRevenue_9ff66d1f-c856-4701-8cb7-03478bf37195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_787ba9d0-b2b6-4b78-822d-658e2d358445" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_0695fec5-e4bf-4faf-a106-2d986ff670b3" xlink:to="loc_ifrs-full_OtherRevenue_787ba9d0-b2b6-4b78-822d-658e2d358445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_03e014e2-8557-40b6-99b0-84e1393ff0cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RevenueAbstract_0695fec5-e4bf-4faf-a106-2d986ff670b3" xlink:to="loc_ifrs-full_Revenue_03e014e2-8557-40b6-99b0-84e1393ff0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CostOfSales_a3a7a2dc-6821-468c-b1d4-1df216e112ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_CostOfSales_a3a7a2dc-6821-468c-b1d4-1df216e112ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CostOfLicenseAndOtherRevenue_8def8a5d-d704-4e53-88ca-16cbc027e31f" xlink:href="legn-20250331.xsd#legn_CostOfLicenseAndOtherRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_legn_CostOfLicenseAndOtherRevenue_8def8a5d-d704-4e53-88ca-16cbc027e31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_314d0d03-94db-4178-b1d5-d5f3255085ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_314d0d03-94db-4178-b1d5-d5f3255085ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdministrativeExpense_046447ee-3ac7-451f-9219-88969de071ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_AdministrativeExpense_046447ee-3ac7-451f-9219-88969de071ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_SellingAndDistributionExpenses_ebac34eb-177f-4bcc-a8fc-a8dea28c7d19" xlink:href="legn-20250331.xsd#legn_SellingAndDistributionExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_legn_SellingAndDistributionExpenses_ebac34eb-177f-4bcc-a8fc-a8dea28c7d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_a94cf64a-52b3-47eb-96d7-cdb8dd737bb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss_a94cf64a-52b3-47eb-96d7-cdb8dd737bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_d6966780-21df-4595-b24b-55cae3c22be5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_FinanceCosts_d6966780-21df-4595-b24b-55cae3c22be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_6c4992a2-08b0-416d-a76f-563a7107f4bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_FinanceIncome_6c4992a2-08b0-416d-a76f-563a7107f4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_aeb2afac-6d56-40f1-ab06-c639437bb2bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_OtherGainsLosses_aeb2afac-6d56-40f1-ab06-c639437bb2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_452f882a-194d-45b4-b96e-2ee4e3f86121" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_452f882a-194d-45b4-b96e-2ee4e3f86121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_05428094-be3c-4d23-8a09-3e48220db425" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_05428094-be3c-4d23-8a09-3e48220db425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_fc2f37a9-c3ef-4707-85e9-b0093d90faef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_ProfitLoss_fc2f37a9-c3ef-4707-85e9-b0093d90faef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToAbstract_ca257e90-8eea-43e3-89a6-7a82d1297903" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_ProfitLossAttributableToAbstract_ca257e90-8eea-43e3-89a6-7a82d1297903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_fcc4cc8f-d703-4c63-86a4-84375ec117c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ProfitLossAttributableToAbstract_ca257e90-8eea-43e3-89a6-7a82d1297903" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_fcc4cc8f-d703-4c63-86a4-84375ec117c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_a35959d5-a9d0-4cc7-9321-3ea4f6550f20" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_EarningsPerShareAbstract_a35959d5-a9d0-4cc7-9321-3ea4f6550f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_42c02c74-12f3-444d-a73b-fb0b006b6bfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a35959d5-a9d0-4cc7-9321-3ea4f6550f20" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_42c02c74-12f3-444d-a73b-fb0b006b6bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_5c4bae80-fb49-4377-be83-83edf7e3da51" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_a35959d5-a9d0-4cc7-9321-3ea4f6550f20" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_5c4bae80-fb49-4377-be83-83edf7e3da51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_2612dcb2-1aed-45af-b3ad-75f67ce9cec0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExchangeDifferencesOnTranslationAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_2612dcb2-1aed-45af-b3ad-75f67ce9cec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_e303ec42-d0b0-411e-ac52-b426f753d7db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_2612dcb2-1aed-45af-b3ad-75f67ce9cec0" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_e303ec42-d0b0-411e-ac52-b426f753d7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_4d813ab9-b64c-4d5f-aa9d-e4b037c951e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_2612dcb2-1aed-45af-b3ad-75f67ce9cec0" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_4d813ab9-b64c-4d5f-aa9d-e4b037c951e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncome_6f145b11-5462-4d7b-a4e6-87f7d26939bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_2612dcb2-1aed-45af-b3ad-75f67ce9cec0" xlink:to="loc_ifrs-full_OtherComprehensiveIncome_6f145b11-5462-4d7b-a4e6-87f7d26939bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_259ca86b-52af-41a5-82ae-cdbe875a59e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExchangeDifferencesOnTranslationAbstract_2612dcb2-1aed-45af-b3ad-75f67ce9cec0" xlink:to="loc_ifrs-full_ComprehensiveIncome_259ca86b-52af-41a5-82ae-cdbe875a59e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_32f79d7e-38f8-4fd6-8732-551eb26ac520" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_3d801d05-8131-4b34-a624-eb3046db677c" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_32f79d7e-38f8-4fd6-8732-551eb26ac520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_87f5d866-c6f5-4197-9e97-12b847620f48" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComprehensiveIncomeAttributableToAbstract_32f79d7e-38f8-4fd6-8732-551eb26ac520" xlink:to="loc_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_87f5d866-c6f5-4197-9e97-12b847620f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_f3d1b5aa-bb7b-4e4f-9e96-967f8bda23a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_f3d1b5aa-bb7b-4e4f-9e96-967f8bda23a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdvancePaymentsForPropertyPlantAndEquipment_11d9e304-02e1-4cbf-b7a9-0647c5b13b17" xlink:href="legn-20250331.xsd#legn_AdvancePaymentsForPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_legn_AdvancePaymentsForPropertyPlantAndEquipment_11d9e304-02e1-4cbf-b7a9-0647c5b13b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_039d2e8c-bf67-4490-9450-5fd057efe01f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_ifrs-full_RightofuseAssets_039d2e8c-bf67-4490-9450-5fd057efe01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsNonCurrent_d23a85af-549c-4572-970f-50c0113f9dd2" xlink:href="legn-20250331.xsd#legn_TimesDepositsNonCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_legn_TimesDepositsNonCurrent_d23a85af-549c-4572-970f-50c0113f9dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_660d10ca-75cf-48d4-86a3-720b20f642dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_660d10ca-75cf-48d4-86a3-720b20f642dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPrepaidLeases_b0023b05-0f21-48d4-b5a4-74242310a2b9" xlink:href="legn-20250331.xsd#legn_CollaborationPrepaidLeases"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_legn_CollaborationPrepaidLeases_b0023b05-0f21-48d4-b5a4-74242310a2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_40fbc614-5b38-4d85-b897-7f8c241ce624" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentNonfinancialAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_ifrs-full_OtherNoncurrentNonfinancialAssets_40fbc614-5b38-4d85-b897-7f8c241ce624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_81f1bf4a-8f7c-45e4-8b15-f0e9ca375032" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_10df279d-e1b5-4845-a03c-1f3536197b17" xlink:to="loc_ifrs-full_NoncurrentAssets_81f1bf4a-8f7c-45e4-8b15-f0e9ca375032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_6de8c361-25c8-47a9-a390-dbfbc9591fcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:to="loc_ifrs-full_Inventories_6de8c361-25c8-47a9-a390-dbfbc9591fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTradeReceivables_6e10b60c-b3e8-4193-8628-10eef90bab7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:to="loc_ifrs-full_CurrentTradeReceivables_6e10b60c-b3e8-4193-8628-10eef90bab7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_b8487020-e722-4dfa-982e-83085d69f51c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:to="loc_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_b8487020-e722-4dfa-982e-83085d69f51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PledgedDeposits_1bc2fce1-afac-465e-86dc-a368b49ce0f6" xlink:href="legn-20250331.xsd#legn_PledgedDeposits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:to="loc_legn_PledgedDeposits_1bc2fce1-afac-465e-86dc-a368b49ce0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDeposits_375f2068-0887-4332-ae58-adb5f8fef496" xlink:href="legn-20250331.xsd#legn_TimesDeposits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:to="loc_legn_TimesDeposits_375f2068-0887-4332-ae58-adb5f8fef496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_cf800afb-4112-4eeb-9717-09b07ab5ae40" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:to="loc_ifrs-full_CashAndCashEquivalents_cf800afb-4112-4eeb-9717-09b07ab5ae40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_83c67911-a24b-402a-ba11-ffb033fae997" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_ee355775-9a6a-434c-afa5-03389ae70bcc" xlink:to="loc_ifrs-full_CurrentAssets_83c67911-a24b-402a-ba11-ffb033fae997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_8da6f1fa-a08d-4a1d-92c2-7f3fb5ac5dda" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_Assets_8da6f1fa-a08d-4a1d-92c2-7f3fb5ac5dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_9aa3ca96-1a95-4a11-9aae-18d32ecacdd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:to="loc_ifrs-full_TradeAndOtherPayablesToTradeSuppliers_9aa3ca96-1a95-4a11-9aae-18d32ecacdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent_cbf5b594-5d53-457d-81a5-5154c844829c" xlink:href="legn-20250331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:to="loc_legn_OtherPayablesAndAccrualsCurrent_cbf5b594-5d53-457d-81a5-5154c844829c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentGovernmentGrants_489219a7-3c8d-4d14-a97a-8f4854a3dc02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:to="loc_ifrs-full_CurrentGovernmentGrants_489219a7-3c8d-4d14-a97a-8f4854a3dc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_0d75f94d-cecd-41a5-a1bf-d7c851806155" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_0d75f94d-cecd-41a5-a1bf-d7c851806155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxLiabilities_86a0e511-5c3d-4518-bd4a-188040ad1a6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:to="loc_ifrs-full_CurrentTaxLiabilities_86a0e511-5c3d-4518-bd4a-188040ad1a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_e2b1b640-b2d5-45ed-bd4a-7e8bfa13fe2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:to="loc_ifrs-full_CurrentContractLiabilities_e2b1b640-b2d5-45ed-bd4a-7e8bfa13fe2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_a21dcf86-667c-455f-8d0d-72ba808609f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_bd975ed3-33c6-424e-8d8a-2b331ab9ebf1" xlink:to="loc_ifrs-full_CurrentLiabilities_a21dcf86-667c-455f-8d0d-72ba808609f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a700ac0a-01b2-4834-aadc-02a5b46ab78b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a700ac0a-01b2-4834-aadc-02a5b46ab78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LongtermBorrowings_da404979-6018-466b-b8e1-6f2f953ad7dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a700ac0a-01b2-4834-aadc-02a5b46ab78b" xlink:to="loc_ifrs-full_LongtermBorrowings_da404979-6018-466b-b8e1-6f2f953ad7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_f1625014-7d9d-44a8-930c-074942159ce5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a700ac0a-01b2-4834-aadc-02a5b46ab78b" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_f1625014-7d9d-44a8-930c-074942159ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentGovernmentGrants_9bb7a6f7-b918-4907-a57f-a98336a764ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentGovernmentGrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a700ac0a-01b2-4834-aadc-02a5b46ab78b" xlink:to="loc_ifrs-full_NoncurrentGovernmentGrants_9bb7a6f7-b918-4907-a57f-a98336a764ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLiabilities_41b21a83-6b55-48f7-b906-0f3205dacd5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentLiabilitiesAbstract_a700ac0a-01b2-4834-aadc-02a5b46ab78b" xlink:to="loc_ifrs-full_NoncurrentLiabilities_41b21a83-6b55-48f7-b906-0f3205dacd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_054b7e54-1891-4228-b137-1f771cfe638b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_Liabilities_054b7e54-1891-4228-b137-1f771cfe638b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_2ae92f78-0d85-4507-a470-bbbe99d55e00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_EquityAbstract_2ae92f78-0d85-4507-a470-bbbe99d55e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_3afb18bb-cd0c-4dd7-b774-0496986f54a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_2ae92f78-0d85-4507-a470-bbbe99d55e00" xlink:to="loc_ifrs-full_IssuedCapital_3afb18bb-cd0c-4dd7-b774-0496986f54a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_35b1a4c5-a6a4-4833-89cc-b34d6b446e01" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_2ae92f78-0d85-4507-a470-bbbe99d55e00" xlink:to="loc_ifrs-full_OtherReserves_35b1a4c5-a6a4-4833-89cc-b34d6b446e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAttributableToOwnersOfParent_18d3c32b-8d86-41b2-ae3b-0e7e5bca0468" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_2ae92f78-0d85-4507-a470-bbbe99d55e00" xlink:to="loc_ifrs-full_EquityAttributableToOwnersOfParent_18d3c32b-8d86-41b2-ae3b-0e7e5bca0468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_2f5d0b58-1f8b-4a21-b0b8-607a20dec03e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_2ae92f78-0d85-4507-a470-bbbe99d55e00" xlink:to="loc_ifrs-full_Equity_2f5d0b58-1f8b-4a21-b0b8-607a20dec03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_80dd17d7-72eb-4835-ab2a-06a83f66404b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_ea3e4ffd-7ce2-49c6-b4c1-58aea5f9c184" xlink:to="loc_ifrs-full_EquityAndLiabilities_80dd17d7-72eb-4835-ab2a-06a83f66404b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_d7be0923-265d-4a42-a9cd-6b0f0d5716cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_4178f3b7-e78f-4342-b8a1-63fab64eb145" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_d7be0923-265d-4a42-a9cd-6b0f0d5716cd" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_4178f3b7-e78f-4342-b8a1-63fab64eb145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_4178f3b7-e78f-4342-b8a1-63fab64eb145" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_b377b0dd-50f8-4b9e-9af4-b1c8283ee4d4" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_f8853bbc-7068-48ac-828c-991a315f64b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_IssuedCapitalMember_f8853bbc-7068-48ac-828c-991a315f64b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_74a91f07-9dbf-434c-861b-c85f5097aa81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_SharePremiumMember_74a91f07-9dbf-434c-861b-c85f5097aa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_acd5cab6-6702-409e-ad51-cd83a204639b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_acd5cab6-6702-409e-ad51-cd83a204639b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_da0c8e82-72bf-4c8a-af14-9f1400ed2335" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_da0c8e82-72bf-4c8a-af14-9f1400ed2335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_646d4580-fecb-4f37-91a3-e974d22e1f60" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_505faeb6-a931-4695-9fe6-35bca2a9834c" xlink:to="loc_ifrs-full_RetainedEarningsMember_646d4580-fecb-4f37-91a3-e974d22e1f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_4178f3b7-e78f-4342-b8a1-63fab64eb145" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:href="legn-20250331.xsd#legn_StatementOfChangesInEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:to="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_8b7ed571-a266-49a5-9346-bf9cba98720f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_Equity_8b7ed571-a266-49a5-9346-bf9cba98720f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_95cc5149-3098-445f-8480-1a1e5a2a6fb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_ProfitLoss_95cc5149-3098-445f-8480-1a1e5a2a6fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_d1bf4aec-edc1-45a9-a180-9e481f332adf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_d1bf4aec-edc1-45a9-a180-9e481f332adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a9addd79-1838-4224-a711-035313baf001" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_d1bf4aec-edc1-45a9-a180-9e481f332adf" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a9addd79-1838-4224-a711-035313baf001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1ee17380-5f89-4508-98f3-b11058532902" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_ComprehensiveIncome_1ee17380-5f89-4508-98f3-b11058532902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7190825a-ac1a-40cf-9b1b-5f6f27221001" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7190825a-ac1a-40cf-9b1b-5f6f27221001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_23719f19-186c-4be2-9ad5-514076498a2f" xlink:href="legn-20250331.xsd#legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity_23719f19-186c-4be2-9ad5-514076498a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cb5acddd-8c62-437e-b7de-d53b72e92648" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_cb5acddd-8c62-437e-b7de-d53b72e92648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_c838341a-f44a-4177-8f15-ebae8f4cd5ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_StatementOfChangesInEquityRollForward_42baa525-8ae1-4b27-a22c-5ffcd7274f3c" xlink:to="loc_ifrs-full_Equity_c838341a-f44a-4177-8f15-ebae8f4cd5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReserves_ddee2aca-b88d-4f77-9cb0-04dec636de06" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_6e40c8b1-9a00-409d-aec9-03b754df9546" xlink:to="loc_ifrs-full_OtherReserves_ddee2aca-b88d-4f77-9cb0-04dec636de06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="legn-20250331.xsd#UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_786d98c1-2a21-42e6-a78d-40b1edcc8ef5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_786d98c1-2a21-42e6-a78d-40b1edcc8ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_b35c113a-bb70-483e-a99b-65672183feee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_786d98c1-2a21-42e6-a78d-40b1edcc8ef5" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_b35c113a-bb70-483e-a99b-65672183feee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_786d98c1-2a21-42e6-a78d-40b1edcc8ef5" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceIncome_7af84cfe-35e8-44a0-8ffa-603df7ef649d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForFinanceIncome_7af84cfe-35e8-44a0-8ffa-603df7ef649d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFinanceCosts_0c094b14-05f3-4d61-b334-8a67d7787c68" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFinanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForFinanceCosts_0c094b14-05f3-4d61-b334-8a67d7787c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForInventoryReserveProvision_7b4ba4ff-3320-4ea3-8839-818ba238d4b9" xlink:href="legn-20250331.xsd#legn_AdjustmentsForInventoryReserveProvision"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_AdjustmentsForInventoryReserveProvision_7b4ba4ff-3320-4ea3-8839-818ba238d4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_67abc63d-b8bd-4ae1-ac46-0466d409f0d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_67abc63d-b8bd-4ae1-ac46-0466d409f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationExpense_5d9b9153-2cb1-4919-8eda-1794a35e353d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationExpense_5d9b9153-2cb1-4919-8eda-1794a35e353d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_f8215363-c544-454d-8bcb-86ca223e09b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_f8215363-c544-454d-8bcb-86ca223e09b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForAmortisationExpense_27ea658f-67e3-4537-9501-ce4db079a199" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForAmortisationExpense_27ea658f-67e3-4537-9501-ce4db079a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_493601bf-ab1c-4867-b421-eee297731316" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDepreciationOfRightOfUseAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_AdjustmentsForDepreciationOfRightOfUseAssets_493601bf-ab1c-4867-b421-eee297731316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_4e4801f9-fec2-4945-a529-8b6c961161df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForFairValueGainsLosses_4e4801f9-fec2-4945-a529-8b6c961161df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7495c205-b6dc-4828-934b-a013f6c2bd31" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_7495c205-b6dc-4828-934b-a013f6c2bd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_e2711d86-3b62-4c1d-800b-274e82cfcb1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_e2711d86-3b62-4c1d-800b-274e82cfcb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DeferredGovernmentGrant_ddac6c87-3b36-4aba-9558-021d0097edb0" xlink:href="legn-20250331.xsd#legn_DeferredGovernmentGrant"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_DeferredGovernmentGrant_ddac6c87-3b36-4aba-9558-021d0097edb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_d842f677-9a60-4790-84fb-e48da7f89394" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_d842f677-9a60-4790-84fb-e48da7f89394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_39dc928e-87c5-4691-be7e-d0299a0b7e56" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_39dc928e-87c5-4691-be7e-d0299a0b7e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_10993c24-a067-40cd-b80a-a5fc76cddf93" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets_10993c24-a067-40cd-b80a-a5fc76cddf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets_24c8bbad-0b68-48f8-b82f-dcf3bd813323" xlink:href="legn-20250331.xsd#legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets_24c8bbad-0b68-48f8-b82f-dcf3bd813323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1cfb4839-1a1c-40f7-9db4-8d1dca64f11a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_1cfb4839-1a1c-40f7-9db4-8d1dca64f11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_987fc6b3-b9e6-42d1-968a-c8971afbdf92" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_987fc6b3-b9e6-42d1-968a-c8971afbdf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_cf7f09bb-3804-4a7a-b806-8a4b332e2c9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_cf7f09bb-3804-4a7a-b806-8a4b332e2c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities_feb7605e-8671-4f4c-9e84-8d212a8d91cc" xlink:href="legn-20250331.xsd#legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities_feb7605e-8671-4f4c-9e84-8d212a8d91cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent_91d5e08e-7842-4b22-bee0-6655783a5f99" xlink:href="legn-20250331.xsd#legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent_91d5e08e-7842-4b22-bee0-6655783a5f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_bc40b9a4-5da6-47cd-a9b4-609974b98d3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_bc40b9a4-5da6-47cd-a9b4-609974b98d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_291215cb-cfd3-4bcb-a2f2-9056ee94188c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_291215cb-cfd3-4bcb-a2f2-9056ee94188c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_ed95cd36-84b9-4bc9-b5c5-01cf7c85e97d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_ed95cd36-84b9-4bc9-b5c5-01cf7c85e97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities_35d8adea-ac03-4e50-9d7f-a28250f63825" xlink:href="legn-20250331.xsd#legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ad2ebd6-8043-4ab5-b1ba-c079d1e6e86f" xlink:to="loc_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities_35d8adea-ac03-4e50-9d7f-a28250f63825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_5ec12747-fa8f-4cbf-bab7-9095059da3bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_786d98c1-2a21-42e6-a78d-40b1edcc8ef5" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_5ec12747-fa8f-4cbf-bab7-9095059da3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8aea173e-b086-4d94-ab94-b26888e2f285" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_8aea173e-b086-4d94-ab94-b26888e2f285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_c079c429-abed-4126-b76d-c4f80f15b752" xlink:href="legn-20250331.xsd#legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets_c079c429-abed-4126-b76d-c4f80f15b752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities_c2a01763-3ff6-4c60-b9cf-31862e1c150f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities_c2a01763-3ff6-4c60-b9cf-31862e1c150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities_3402a74b-9d37-4b5a-b616-074464fc6547" xlink:href="legn-20250331.xsd#legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities_3402a74b-9d37-4b5a-b616-074464fc6547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets_aeb094ae-ecf6-4551-94c1-4fff335e1d1e" xlink:href="legn-20250331.xsd#legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets_aeb094ae-ecf6-4551-94c1-4fff335e1d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AdditionInTimeDeposits_ca2f0633-741a-4609-85d0-24e495056ed9" xlink:href="legn-20250331.xsd#legn_AdditionInTimeDeposits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_legn_AdditionInTimeDeposits_ca2f0633-741a-4609-85d0-24e495056ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DecreaseInTimeDeposits_a6a88816-2a8b-45ef-be8b-efc5b5477160" xlink:href="legn-20250331.xsd#legn_DecreaseInTimeDeposits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_legn_DecreaseInTimeDeposits_a6a88816-2a8b-45ef-be8b-efc5b5477160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_55f8956e-6efa-4c53-9839-d70c8fa52548" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_76b96f4d-93c6-477b-9111-58e17409a9bf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_55f8956e-6efa-4c53-9839-d70c8fa52548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_5b30a916-e442-4b6a-924a-7a22984d9db7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_5b30a916-e442-4b6a-924a-7a22984d9db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_28ab030a-bfa2-4fc1-98d5-249fcd183b8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_5b30a916-e442-4b6a-924a-7a22984d9db7" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_28ab030a-bfa2-4fc1-98d5-249fcd183b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_89c39a80-e40f-41e6-af43-9b95232177db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_5b30a916-e442-4b6a-924a-7a22984d9db7" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_89c39a80-e40f-41e6-af43-9b95232177db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7e8be1d2-6dd1-426a-9b8f-c92621c18321" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_5b30a916-e442-4b6a-924a-7a22984d9db7" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_7e8be1d2-6dd1-426a-9b8f-c92621c18321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_db39e4a5-7b43-44f4-99a3-addf286217df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_db39e4a5-7b43-44f4-99a3-addf286217df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_a5bcef2e-00f4-4950-b3f8-4386a54209ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_a5bcef2e-00f4-4950-b3f8-4386a54209ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_e0400ae9-a735-489f-bcfe-44936dfa339e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_CashAndCashEquivalents_e0400ae9-a735-489f-bcfe-44936dfa339e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1090dfb6-3c03-4bb7-8aff-77ae564921fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1090dfb6-3c03-4bb7-8aff-77ae564921fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsAbstract_c38b56f0-e0b0-4e2b-b83b-31b57a9db1ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_903a4cfd-70f7-4e4f-b791-ac0561c73116" xlink:to="loc_ifrs-full_CashAndCashEquivalentsAbstract_c38b56f0-e0b0-4e2b-b83b-31b57a9db1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_03afdeba-562f-4c41-9490-b602d850e752" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_c38b56f0-e0b0-4e2b-b83b-31b57a9db1ec" xlink:to="loc_ifrs-full_Cash_03afdeba-562f-4c41-9490-b602d850e752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_41cdd54e-7030-4369-9e8e-3826af90391a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_c38b56f0-e0b0-4e2b-b83b-31b57a9db1ec" xlink:to="loc_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_41cdd54e-7030-4369-9e8e-3826af90391a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_TimesDepositsCurrentAndNoncurrent_cd0caaf4-fc1b-4c2e-8d23-f2ba44ccd036" xlink:href="legn-20250331.xsd#legn_TimesDepositsCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_c38b56f0-e0b0-4e2b-b83b-31b57a9db1ec" xlink:to="loc_legn_TimesDepositsCurrentAndNoncurrent_cd0caaf4-fc1b-4c2e-8d23-f2ba44ccd036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_40373e39-121d-4636-b38b-aeb3b514be99" xlink:href="legn-20250331.xsd#legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_c38b56f0-e0b0-4e2b-b83b-31b57a9db1ec" xlink:to="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition_40373e39-121d-4636-b38b-aeb3b514be99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows_0b0a2a32-9e00-4af9-a8fe-a389a4d8a89c" xlink:href="legn-20250331.xsd#legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashAndCashEquivalentsAbstract_c38b56f0-e0b0-4e2b-b83b-31b57a9db1ec" xlink:to="loc_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows_0b0a2a32-9e00-4af9-a8fe-a389a4d8a89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CORPORATEINFORMATION" xlink:type="simple" xlink:href="legn-20250331.xsd#CORPORATEINFORMATION"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/CORPORATEINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_e5c61b83-9744-4e4d-9d91-076c1f632707" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_0f028393-4a74-4fe1-934d-a2392f9e636e" xlink:href="legn-20250331.xsd#legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract_e5c61b83-9744-4e4d-9d91-076c1f632707" xlink:to="loc_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_0f028393-4a74-4fe1-934d-a2392f9e636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/BASISOFPREPARATION" xlink:type="simple" xlink:href="legn-20250331.xsd#BASISOFPREPARATION"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/BASISOFPREPARATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_BasisOfPreparationAbstract_4f3f8738-3bc8-4bf8-95e0-e0483c41c26f" xlink:href="legn-20250331.xsd#legn_BasisOfPreparationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_03ac4097-2054-407e-ac60-9378ead1b978" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_BasisOfPreparationAbstract_4f3f8738-3bc8-4bf8-95e0-e0483c41c26f" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_03ac4097-2054-407e-ac60-9378ead1b978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY" xlink:type="simple" xlink:href="legn-20250331.xsd#NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_0a4f4b2e-6aeb-49ad-83b4-bf1627a5b654" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_7e98d5a5-30ac-4702-9617-0c744b9a1d63" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_0a4f4b2e-6aeb-49ad-83b4-bf1627a5b654" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_7e98d5a5-30ac-4702-9617-0c744b9a1d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUE" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_d888a68e-f7e7-4d93-9d74-1244bb1226ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueExplanatory_5d2b27c9-9ef7-45d0-9108-352c03ab05d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_d888a68e-f7e7-4d93-9d74-1244bb1226ff" xlink:to="loc_ifrs-full_DisclosureOfRevenueExplanatory_5d2b27c9-9ef7-45d0-9108-352c03ab05d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENET" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHEREXPENSEINCOMENET"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_2c962358-10db-45b7-b088-9c003265bb91" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_d2f70b42-2e65-4ac6-b663-e4b26fc46720" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_2c962358-10db-45b7-b088-9c003265bb91" xlink:to="loc_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_d2f70b42-2e65-4ac6-b663-e4b26fc46720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTS" xlink:type="simple" xlink:href="legn-20250331.xsd#FINANCEINCOMEANDFINANCECOSTS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_FinanceIncomeAndFinanceCostsAbstract_3cc8083c-2a41-48b6-a1bf-7f229e5aa74a" xlink:href="legn-20250331.xsd#legn_FinanceIncomeAndFinanceCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock_cbb3326b-24e9-472b-86e7-d67f5143ca5d" xlink:href="legn-20250331.xsd#legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_FinanceIncomeAndFinanceCostsAbstract_3cc8083c-2a41-48b6-a1bf-7f229e5aa74a" xlink:to="loc_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock_cbb3326b-24e9-472b-86e7-d67f5143ca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT" xlink:type="simple" xlink:href="legn-20250331.xsd#LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_209cebcd-1128-43fc-b6b3-7c4b4888dd58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_2563e31f-cb8c-48e6-aabd-d81f4d32d3ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_209cebcd-1128-43fc-b6b3-7c4b4888dd58" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_2563e31f-cb8c-48e6-aabd-d81f4d32d3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASES" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_4489e6ab-8c70-4816-9c93-351f40774db7" xlink:href="legn-20250331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_fc163a0e-3a28-49d7-abe7-24044158a820" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_4489e6ab-8c70-4816-9c93-351f40774db7" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_fc163a0e-3a28-49d7-abe7-24044158a820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINVENTORIESNET"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_11a1c933-4587-4a6d-b73f-f296165a23ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfInventoriesExplanatory_025e386e-17ea-47f2-b45d-8177aa178468" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_11a1c933-4587-4a6d-b73f-f296165a23ab" xlink:to="loc_ifrs-full_DisclosureOfInventoriesExplanatory_025e386e-17ea-47f2-b45d-8177aa178468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" xlink:type="simple" xlink:href="legn-20250331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_f50cc277-1c1e-437e-92ad-a80f93225e41" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_090cfad9-2f1e-4c56-830f-89f695e63d50" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_f50cc277-1c1e-437e-92ad-a80f93225e41" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock_090cfad9-2f1e-4c56-830f-89f695e63d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS" xlink:type="simple" xlink:href="legn-20250331.xsd#CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_8ee1638b-6e1f-41f1-a4ba-d1dbac1fb406" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_d9e7f942-ced7-4d74-96a4-9b1828a2f031" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_8ee1638b-6e1f-41f1-a4ba-d1dbac1fb406" xlink:to="loc_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_d9e7f942-ced7-4d74-96a4-9b1828a2f031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHERPAYABLESANDACCRUALS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_cf8b9c5d-0f31-4fe4-b835-14ff70185a76" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherPayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock_b44ab189-04c3-40c9-a35d-0f29a4ee98c4" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_cf8b9c5d-0f31-4fe4-b835-14ff70185a76" xlink:to="loc_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock_b44ab189-04c3-40c9-a35d-0f29a4ee98c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDING"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_d47b9628-5f0b-422b-bcfa-fa3a205a6f40" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_a623fac3-1c06-49a3-9023-b6997ad40bb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_d47b9628-5f0b-422b-bcfa-fa3a205a6f40" xlink:to="loc_ifrs-full_DisclosureOfBorrowingsExplanatory_a623fac3-1c06-49a3-9023-b6997ad40bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM" xlink:type="simple" xlink:href="legn-20250331.xsd#SHARECAPITALANDSHAREPREMIUM"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_dbaaab1f-520f-45fa-834f-354df9eebd2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_86bc7138-37a3-4dc8-9287-3f020d9e3c58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_dbaaab1f-520f-45fa-834f-354df9eebd2d" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_86bc7138-37a3-4dc8-9287-3f020d9e3c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="legn-20250331.xsd#APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_13067848-e38f-4fc9-8509-ea7ce0530955" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_c26b626c-9613-4917-a778-5d6f0542b1f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_13067848-e38f-4fc9-8509-ea7ce0530955" xlink:to="loc_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_c26b626c-9613-4917-a778-5d6f0542b1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUETables" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ab03f3c6-4c8b-47ea-a5d5-fa156486d9a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_3f3215d5-f1c5-4b48-9a74-abc8afcf54fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ab03f3c6-4c8b-47ea-a5d5-fa156486d9a8" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_3f3215d5-f1c5-4b48-9a74-abc8afcf54fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_2dcc10df-1a33-47e8-a42f-0c98cfb4f1b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ab03f3c6-4c8b-47ea-a5d5-fa156486d9a8" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_2dcc10df-1a33-47e8-a42f-0c98cfb4f1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_bdec46e8-6a40-4189-bd8d-6679beb870ae" xlink:href="legn-20250331.xsd#legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ab03f3c6-4c8b-47ea-a5d5-fa156486d9a8" xlink:to="loc_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock_bdec46e8-6a40-4189-bd8d-6679beb870ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock_bc387a31-ab6a-409d-a7bf-f1c189db753e" xlink:href="legn-20250331.xsd#legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_ab03f3c6-4c8b-47ea-a5d5-fa156486d9a8" xlink:to="loc_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock_bc387a31-ab6a-409d-a7bf-f1c189db753e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHEREXPENSEINCOMENETTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_cb3ac9e5-404d-4244-9634-adca0ae405f9" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_1c84cb8d-7d18-4707-b811-889bcf33efb1" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_cb3ac9e5-404d-4244-9634-adca0ae405f9" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock_1c84cb8d-7d18-4707-b811-889bcf33efb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSTables" xlink:type="simple" xlink:href="legn-20250331.xsd#FINANCEINCOMEANDFINANCECOSTSTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_FinanceIncomeAndFinanceCostsAbstract_ba5b4842-6ccb-4764-9dda-37c899ab210e" xlink:href="legn-20250331.xsd#legn_FinanceIncomeAndFinanceCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinanceCostExplanatory_23c23f0c-0a6c-4640-a152-2a447bfb5e63" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_FinanceIncomeAndFinanceCostsAbstract_ba5b4842-6ccb-4764-9dda-37c899ab210e" xlink:to="loc_ifrs-full_DisclosureOfFinanceCostExplanatory_23c23f0c-0a6c-4640-a152-2a447bfb5e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables" xlink:type="simple" xlink:href="legn-20250331.xsd#LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_a6898d74-fdd1-4c49-87ed-091169fdd0f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareExplanatory_c520d14e-967f-4939-8556-f1c65bcc468a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_a6898d74-fdd1-4c49-87ed-091169fdd0f5" xlink:to="loc_ifrs-full_EarningsPerShareExplanatory_c520d14e-967f-4939-8556-f1c65bcc468a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESTables" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_3c31a55e-f614-403a-997d-b9f2422de616" xlink:href="legn-20250331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_f49c2a5d-ead5-4529-aedd-aea1f4f75dd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_3c31a55e-f614-403a-997d-b9f2422de616" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_f49c2a5d-ead5-4529-aedd-aea1f4f75dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeaseLiabilitiesTextBlock_954e5990-305a-44b5-b26d-a4b342369d7f" xlink:href="legn-20250331.xsd#legn_LesseeLeaseLiabilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_3c31a55e-f614-403a-997d-b9f2422de616" xlink:to="loc_legn_LesseeLeaseLiabilitiesTextBlock_954e5990-305a-44b5-b26d-a4b342369d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINVENTORIESNETTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_a0ba66ab-810d-4bc6-825a-24e86cb7331b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_88ee0d18-735f-4a2d-8156-54560a5facd8" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_a0ba66ab-810d-4bc6-825a-24e86cb7331b" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock_88ee0d18-735f-4a2d-8156-54560a5facd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" xlink:type="simple" xlink:href="legn-20250331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_a1398d7f-a968-4e08-94bb-ffdae7899174" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_d1b0334d-8035-4091-9b93-a6470229a8da" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_a1398d7f-a968-4e08-94bb-ffdae7899174" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock_d1b0334d-8035-4091-9b93-a6470229a8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables" xlink:type="simple" xlink:href="legn-20250331.xsd#CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_e7865390-5d4c-4eae-99fa-05c14f87191a" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock_786fbf0f-d1a8-4305-9e5e-22e22750c39a" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_e7865390-5d4c-4eae-99fa-05c14f87191a" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock_786fbf0f-d1a8-4305-9e5e-22e22750c39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHERPAYABLESANDACCRUALSTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_4d991d6d-3e5a-4487-b5e2-926d7b89b171" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherPayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock_73d4f236-727d-41c6-85c6-3b20915b62b9" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_4d991d6d-3e5a-4487-b5e2-926d7b89b171" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock_73d4f236-727d-41c6-85c6-3b20915b62b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_81fd9458-0d8d-4ff7-a672-9d92499294c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_02dff7b8-dbd5-40d2-a464-6928fd957edd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_81fd9458-0d8d-4ff7-a672-9d92499294c2" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_02dff7b8-dbd5-40d2-a464-6928fd957edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" xlink:type="simple" xlink:href="legn-20250331.xsd#SHARECAPITALANDSHAREPREMIUMTables"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a41171f3-7ad5-4e8e-9b54-0cfbb7d09f6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_536a77f9-0bf1-49ab-abdf-cac279c5393d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a41171f3-7ad5-4e8e-9b54-0cfbb7d09f6c" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_536a77f9-0bf1-49ab-abdf-cac279c5393d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_b0c14891-259e-415b-afbe-eea4c52685b5" xlink:href="legn-20250331.xsd#legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_a41171f3-7ad5-4e8e-9b54-0cfbb7d09f6c" xlink:to="loc_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock_b0c14891-259e-415b-afbe-eea4c52685b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUESummaryofAnalysisofRevenueDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_78a702f8-13a0-4b2a-9fa0-3e8e63861d5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8116d3b9-b174-467e-904a-ab903855b3a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_78a702f8-13a0-4b2a-9fa0-3e8e63861d5e" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8116d3b9-b174-467e-904a-ab903855b3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesAxis_258d68e0-1d3f-4d63-9845-75f42a10c0cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8116d3b9-b174-467e-904a-ab903855b3a4" xlink:to="loc_ifrs-full_CounterpartiesAxis_258d68e0-1d3f-4d63-9845-75f42a10c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CounterpartiesDomain_0868a254-af1d-4e11-b535-5b1f1571cd22" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesAxis_258d68e0-1d3f-4d63-9845-75f42a10c0cc" xlink:to="loc_ifrs-full_CounterpartiesDomain_0868a254-af1d-4e11-b535-5b1f1571cd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NovartisMember_9cf6d32c-2ca4-4007-a9fd-0a1f6ec5be30" xlink:href="legn-20250331.xsd#legn_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CounterpartiesDomain_0868a254-af1d-4e11-b535-5b1f1571cd22" xlink:to="loc_legn_NovartisMember_9cf6d32c-2ca4-4007-a9fd-0a1f6ec5be30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_8116d3b9-b174-467e-904a-ab903855b3a4" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RevenueFromLicensingOfIntellectualProperty_574d9127-5196-406e-a574-75b6cb4ad9d1" xlink:href="legn-20250331.xsd#legn_RevenueFromLicensingOfIntellectualProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_legn_RevenueFromLicensingOfIntellectualProperty_574d9127-5196-406e-a574-75b6cb4ad9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_081c31c6-5107-4d86-aad8-bab80c34cd41" xlink:href="legn-20250331.xsd#legn_CollaborationRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_legn_CollaborationRevenue_081c31c6-5107-4d86-aad8-bab80c34cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherRevenue_0fd35871-21b3-42d3-80dd-30743b14dffe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_ifrs-full_OtherRevenue_0fd35871-21b3-42d3-80dd-30743b14dffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_1d790266-901b-4d0b-a64c-cdc90d6b88f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_b689ae6f-73dc-4696-9cac-3762509ee8ed" xlink:to="loc_ifrs-full_Revenue_1d790266-901b-4d0b-a64c-cdc90d6b88f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUESummaryofRevenueDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_6fb4b4ee-d4a3-44d9-82e6-424293b28d32" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_91046eed-12e6-44ac-aa63-83eae0fba146" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_6fb4b4ee-d4a3-44d9-82e6-424293b28d32" xlink:to="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_91046eed-12e6-44ac-aa63-83eae0fba146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_91046eed-12e6-44ac-aa63-83eae0fba146" xlink:to="loc_srt_StatementGeographicalAxis_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3dea9eb1-1981-4efb-a6e3-dc6c1045a49c" xlink:to="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2e2e3a1b-14e6-49cb-bb6a-958bcd7d3a42" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:to="loc_country_US_2e2e3a1b-14e6-49cb-bb6a-958bcd7d3a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_647e1c53-489f-4327-99b5-ba7612901ac8" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:to="loc_country_CN_647e1c53-489f-4327-99b5-ba7612901ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_59c68b80-81a2-43a2-80f7-481c5728e70d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_994d87e3-10bc-4374-94e3-eacb432580a4" xlink:to="loc_srt_EuropeMember_59c68b80-81a2-43a2-80f7-481c5728e70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfOperatingSegmentsTable_91046eed-12e6-44ac-aa63-83eae0fba146" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromContractsWithCustomers_460e0e63-e411-4752-bb95-b327639ac149" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:to="loc_ifrs-full_RevenueFromContractsWithCustomers_460e0e63-e411-4752-bb95-b327639ac149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationRevenue_38af8017-a6a5-4323-835d-3dc4dd92a657" xlink:href="legn-20250331.xsd#legn_CollaborationRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:to="loc_legn_CollaborationRevenue_38af8017-a6a5-4323-835d-3dc4dd92a657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_8e97f8d2-4f5a-47c4-ba7e-886c1b714257" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_d9714673-2933-496a-aaa0-5f8918af169c" xlink:to="loc_ifrs-full_Revenue_8e97f8d2-4f5a-47c4-ba7e-886c1b714257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_57aea579-ec20-40d1-924d-65b64233706f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_78a1f072-90d7-401c-be58-d5f8e5b6114d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_57aea579-ec20-40d1-924d-65b64233706f" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_78a1f072-90d7-401c-be58-d5f8e5b6114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_8ee5edc4-ee03-4548-8955-4692fdad97fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_78a1f072-90d7-401c-be58-d5f8e5b6114d" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_8ee5edc4-ee03-4548-8955-4692fdad97fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_8ee5edc4-ee03-4548-8955-4692fdad97fc" xlink:to="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1502ea79-d24a-4efd-ac83-e891d80499ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_1502ea79-d24a-4efd-ac83-e891d80499ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_b744e4e7-1f63-4758-b254-10d18d0b649e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_ad296bbe-f26f-4ab7-8586-cf0d3a412fe5" xlink:to="loc_ifrs-full_GoodsOrServicesTransferredOverTimeMember_b744e4e7-1f63-4758-b254-10d18d0b649e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_9d50d33c-c06d-4fef-b3b1-334a31c6a276" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_78a1f072-90d7-401c-be58-d5f8e5b6114d" xlink:to="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_9d50d33c-c06d-4fef-b3b1-334a31c6a276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_95332b2d-7633-4fb2-978f-8498155eeb11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_9d50d33c-c06d-4fef-b3b1-334a31c6a276" xlink:to="loc_ifrs-full_Revenue_95332b2d-7633-4fb2-978f-8498155eeb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#REVENUESummaryofDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_3642cf89-b75a-4224-93f3-d4e3a02647bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentContractLiabilities_67d61494-e848-4344-8b94-52e772a4efef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_3642cf89-b75a-4224-93f3-d4e3a02647bb" xlink:to="loc_ifrs-full_CurrentContractLiabilities_67d61494-e848-4344-8b94-52e772a4efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_95c952bd-6c26-496f-8036-e9f29ea23ac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_3642cf89-b75a-4224-93f3-d4e3a02647bb" xlink:to="loc_ifrs-full_ContractLiabilities_95c952bd-6c26-496f-8036-e9f29ea23ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHEREXPENSEINCOMENETDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_78b1414b-993e-465e-a60d-36614b8b6a85" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_8d9102cf-93ff-44b4-addc-4d418bc2ea16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_78b1414b-993e-465e-a60d-36614b8b6a85" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_8d9102cf-93ff-44b4-addc-4d418bc2ea16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_39fde9c5-d07d-45d8-a05c-3d68be62a8eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_78b1414b-993e-465e-a60d-36614b8b6a85" xlink:to="loc_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_39fde9c5-d07d-45d8-a05c-3d68be62a8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherMiscellaneousIncomeExpense_a93b40aa-4cd0-46ad-9336-7e8e452200e6" xlink:href="legn-20250331.xsd#legn_OtherMiscellaneousIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_78b1414b-993e-465e-a60d-36614b8b6a85" xlink:to="loc_legn_OtherMiscellaneousIncomeExpense_a93b40aa-4cd0-46ad-9336-7e8e452200e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherGainsLosses_6810abae-6a07-4591-a9b8-074315490cda" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherIncomeAndExpenseAbstract_78b1414b-993e-465e-a60d-36614b8b6a85" xlink:to="loc_ifrs-full_OtherGainsLosses_6810abae-6a07-4591-a9b8-074315490cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSNarrativeDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#FINANCEINCOMEANDFINANCECOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_FinanceIncomeAndFinanceCostsAbstract_8a640589-53cd-4770-a7c9-7e14b66a38c4" xlink:href="legn-20250331.xsd#legn_FinanceIncomeAndFinanceCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceIncome_7a835b54-6681-4e68-8344-98ad9663a6eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_FinanceIncomeAndFinanceCostsAbstract_8a640589-53cd-4770-a7c9-7e14b66a38c4" xlink:to="loc_ifrs-full_FinanceIncome_7a835b54-6681-4e68-8344-98ad9663a6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_FinanceIncomeAndFinanceCostsAbstract_1ebfc31f-88fc-4ce4-a729-8dee578a117a" xlink:href="legn-20250331.xsd#legn_FinanceIncomeAndFinanceCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_2e8eb54b-e35c-4b3f-93df-054e8607d553" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_FinanceIncomeAndFinanceCostsAbstract_1ebfc31f-88fc-4ce4-a729-8dee578a117a" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_2e8eb54b-e35c-4b3f-93df-054e8607d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnBorrowings_6eabc6d0-9ca7-4ce1-b6e2-913fb99d1326" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_FinanceIncomeAndFinanceCostsAbstract_1ebfc31f-88fc-4ce4-a729-8dee578a117a" xlink:to="loc_ifrs-full_InterestExpenseOnBorrowings_6eabc6d0-9ca7-4ce1-b6e2-913fb99d1326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceCosts_dc577d71-6155-42ea-a6cd-d79f0d40d62f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_FinanceIncomeAndFinanceCostsAbstract_1ebfc31f-88fc-4ce4-a729-8dee578a117a" xlink:to="loc_ifrs-full_FinanceCosts_dc577d71-6155-42ea-a6cd-d79f0d40d62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsPerShareAbstract_fe87b8b2-6f11-4a67-aa63-359bbf2cd0ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_86853fa3-3867-4c8c-b5a9-9b3be66c0b2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_fe87b8b2-6f11-4a67-aa63-359bbf2cd0ff" xlink:to="loc_ifrs-full_ProfitLossAttributableToOwnersOfParent_86853fa3-3867-4c8c-b5a9-9b3be66c0b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_f939ebd3-80fd-423b-9abf-805a6f91be61" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BasicEarningsPerShareAbstract_fe87b8b2-6f11-4a67-aa63-359bbf2cd0ff" xlink:to="loc_ifrs-full_WeightedAverageShares_f939ebd3-80fd-423b-9abf-805a6f91be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_c8123696-1dc5-4c1a-a0de-c18d64a4c46b" xlink:href="legn-20250331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:href="legn-20250331.xsd#legn_LeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_c8123696-1dc5-4c1a-a0de-c18d64a4c46b" xlink:to="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_8f2b88ff-9c18-494e-974b-ae668904ab91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:to="loc_ifrs-full_RangeAxis_8f2b88ff-9c18-494e-974b-ae668904ab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_8f2b88ff-9c18-494e-974b-ae668904ab91" xlink:to="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_e7d572b9-a02b-46c2-9211-5f7eff76c63d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:to="loc_ifrs-full_BottomOfRangeMember_e7d572b9-a02b-46c2-9211-5f7eff76c63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_9ca5e180-e6da-4ac7-ba94-a48a017f83c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_6a37b2f1-9eed-4b30-b1d7-739e6b74e764" xlink:to="loc_ifrs-full_TopOfRangeMember_9ca5e180-e6da-4ac7-ba94-a48a017f83c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_df6bf260-073e-4672-affb-e5831c9e8017" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_df6bf260-073e-4672-affb-e5831c9e8017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_29dacd10-aa80-4815-a63c-373f3ae76bff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_df6bf260-073e-4672-affb-e5831c9e8017" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_29dacd10-aa80-4815-a63c-373f3ae76bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_8cbea270-ceae-455f-9001-d135583cd1a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_29dacd10-aa80-4815-a63c-373f3ae76bff" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_8cbea270-ceae-455f-9001-d135583cd1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LandMember_684af50e-1b99-42cd-b3c3-c4f958173efa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_8cbea270-ceae-455f-9001-d135583cd1a1" xlink:to="loc_ifrs-full_LandMember_684af50e-1b99-42cd-b3c3-c4f958173efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:href="legn-20250331.xsd#legn_LeasesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesTable_2d061a79-c67e-4528-a83f-baab51721542" xlink:to="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LesseeLeasingArrangementsLeasesTerm_1c005ad6-8b7b-4856-b12f-bfd6afc7a9b7" xlink:href="legn-20250331.xsd#legn_LesseeLeasingArrangementsLeasesTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:to="loc_legn_LesseeLeasingArrangementsLeasesTerm_1c005ad6-8b7b-4856-b12f-bfd6afc7a9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OngoingLeasePaymentsUnderTheLandLease_37749a00-df9a-413d-a0a4-d6e3dd754da1" xlink:href="legn-20250331.xsd#legn_OngoingLeasePaymentsUnderTheLandLease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesLineItems_30543e79-03d0-4173-9583-1d63ea63209a" xlink:to="loc_legn_OngoingLeasePaymentsUnderTheLandLease_37749a00-df9a-413d-a0a4-d6e3dd754da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_6c89c47c-105b-4f30-9b7c-f6c51aa1be18" xlink:href="legn-20250331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:href="legn-20250331.xsd#legn_RightOfUseAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_6c89c47c-105b-4f30-9b7c-f6c51aa1be18" xlink:to="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b2b23519-242e-40e8-83f3-3b3dddf0d982" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:to="loc_ifrs-full_RightofuseAssets_b2b23519-242e-40e8-83f3-3b3dddf0d982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_b8ff7520-69e0-4960-82fa-a28ec336c147" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_b8ff7520-69e0-4960-82fa-a28ec336c147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets_7a78dfc8-2bd7-40a9-9711-196691573285" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets_7a78dfc8-2bd7-40a9-9711-196691573285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_a9010fb8-1d23-4258-9df7-b57d34389a88" xlink:href="legn-20250331.xsd#legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:to="loc_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate_a9010fb8-1d23-4258-9df7-b57d34389a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_7b89f905-52e4-4188-a59f-caf72012c095" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_7b89f905-52e4-4188-a59f-caf72012c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_2c9db94a-4912-469a-b536-78b4eabd86ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_RightOfUseAssetsRollForward_81ac6d3d-abc5-44b2-aa06-7096d08e98e6" xlink:to="loc_ifrs-full_RightofuseAssets_2c9db94a-4912-469a-b536-78b4eabd86ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeaseAbstract_b098356d-d381-47da-a024-7b53aaa44b72" xlink:href="legn-20250331.xsd#legn_LeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0382a269-2ef8-40e8-834a-03c21b9d7178" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeaseAbstract_b098356d-d381-47da-a024-7b53aaa44b72" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0382a269-2ef8-40e8-834a-03c21b9d7178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d1003650-f876-4e01-8a4f-09999ba370e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0382a269-2ef8-40e8-834a-03c21b9d7178" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d1003650-f876-4e01-8a4f-09999ba370e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_03d45b57-6335-4baa-870a-a1fc38bde289" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_d1003650-f876-4e01-8a4f-09999ba370e1" xlink:to="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_03d45b57-6335-4baa-870a-a1fc38bde289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_5beb6ddb-0ea2-4672-befa-42657587ff6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain_03d45b57-6335-4baa-870a-a1fc38bde289" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_5beb6ddb-0ea2-4672-befa-42657587ff6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:href="legn-20250331.xsd#legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable_0382a269-2ef8-40e8-834a-03c21b9d7178" xlink:to="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:href="legn-20250331.xsd#legn_LeasesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:to="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_afb99b53-f1cb-4706-a37e-15b7b23219e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_ifrs-full_LeaseLiabilities_afb99b53-f1cb-4706-a37e-15b7b23219e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseInLeaseLiabilities_7ef11c3f-dafc-4b26-8110-651d5fa73f78" xlink:href="legn-20250331.xsd#legn_IncreaseInLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_legn_IncreaseInLeaseLiabilities_7ef11c3f-dafc-4b26-8110-651d5fa73f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_IncreaseOfLeaseLiabilitiesBalance_c8a5f1ad-0caa-450a-8041-85888c3f0431" xlink:href="legn-20250331.xsd#legn_IncreaseOfLeaseLiabilitiesBalance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_legn_IncreaseOfLeaseLiabilitiesBalance_c8a5f1ad-0caa-450a-8041-85888c3f0431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_c9fcaec4-4bdf-4af6-82b7-6ac73dab796f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_ifrs-full_CashOutflowForLeases_c9fcaec4-4bdf-4af6-82b7-6ac73dab796f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_c265f07d-164e-4797-9f6f-978671f633cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities_c265f07d-164e-4797-9f6f-978671f633cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_9503031f-d9fc-484c-b7cb-2e5e91032321" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_LeasesRollForward_e8f2f1fb-f2e8-4c2b-b219-de530e479abc" xlink:to="loc_ifrs-full_LeaseLiabilities_9503031f-d9fc-484c-b7cb-2e5e91032321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems_37b1e74d-6ce6-4dee-8135-d5e31c1727f8" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_a40c9da7-f60c-4304-a7cf-02433e523a3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_a40c9da7-f60c-4304-a7cf-02433e523a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_a03fd150-4311-4c5f-9e9e-ac2857a9fe0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_a03fd150-4311-4c5f-9e9e-ac2857a9fe0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_cbf11be1-35e9-416f-88f1-14818d8a56f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_95dd4347-ecbc-4c24-87d4-19904b2bcd42" xlink:to="loc_ifrs-full_LeaseLiabilities_cbf11be1-35e9-416f-88f1-14818d8a56f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_c00fca8b-2deb-4ffd-8248-b4ae48697789" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RawMaterials_71a4e274-7afa-49e0-b209-9ea89f85f6bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_c00fca8b-2deb-4ffd-8248-b4ae48697789" xlink:to="loc_ifrs-full_RawMaterials_71a4e274-7afa-49e0-b209-9ea89f85f6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WorkInProgress_412843b2-2a34-4686-829f-d22a16730051" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WorkInProgress"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_c00fca8b-2deb-4ffd-8248-b4ae48697789" xlink:to="loc_ifrs-full_WorkInProgress_412843b2-2a34-4686-829f-d22a16730051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinishedGoods_ac7067c9-82a2-4a9a-a588-f5a7a9f774e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_c00fca8b-2deb-4ffd-8248-b4ae48697789" xlink:to="loc_ifrs-full_FinishedGoods_ac7067c9-82a2-4a9a-a588-f5a7a9f774e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Inventories_c112f155-3016-4982-a24b-b7d6e1c0de7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_c00fca8b-2deb-4ffd-8248-b4ae48697789" xlink:to="loc_ifrs-full_Inventories_c112f155-3016-4982-a24b-b7d6e1c0de7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINVENTORIESNETAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfInventoriesAbstract_44bc8ce1-7ef8-41c7-b4c7-f21a92099b07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InventoryReserve_11c081f3-4d8e-4aa5-9107-93ecec6b7d5d" xlink:href="legn-20250331.xsd#legn_InventoryReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfInventoriesAbstract_44bc8ce1-7ef8-41c7-b4c7-f21a92099b07" xlink:to="loc_legn_InventoryReserve_11c081f3-4d8e-4aa5-9107-93ecec6b7d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_a533505f-e374-49ba-aabf-e2913e1fc3bf" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_a5027040-46f2-4974-a0c0-1b59a89a13ff" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract_a533505f-e374-49ba-aabf-e2913e1fc3bf" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_a5027040-46f2-4974-a0c0-1b59a89a13ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_725a6149-cac6-49eb-ab1c-a46e1751b003" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_a5027040-46f2-4974-a0c0-1b59a89a13ff" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_725a6149-cac6-49eb-ab1c-a46e1751b003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_e0088953-e404-4a0d-b84e-5f7232c1577f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsAxis_725a6149-cac6-49eb-ab1c-a46e1751b003" xlink:to="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_e0088953-e404-4a0d-b84e-5f7232c1577f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_e6172894-1c76-4aa3-a207-9d3787cdcf63" xlink:href="legn-20250331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialInstrumentsDomain_e0088953-e404-4a0d-b84e-5f7232c1577f" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssetsMember_e6172894-1c76-4aa3-a207-9d3787cdcf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:href="legn-20250331.xsd#legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable_a5027040-46f2-4974-a0c0-1b59a89a13ff" xlink:to="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherCollaborationReceivables_b3ae2fea-accf-45f4-82c4-626416c9bbf0" xlink:href="legn-20250331.xsd#legn_OtherCollaborationReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_legn_OtherCollaborationReceivables_b3ae2fea-accf-45f4-82c4-626416c9bbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_d8e97c2e-b47d-4649-a2d4-fc05f2041c2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_OtherReceivables_d8e97c2e-b47d-4649-a2d4-fc05f2041c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinanceLeaseReceivables_2501e2d4-4754-40ca-a1ae-1e3cee231641" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceLeaseReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_FinanceLeaseReceivables_2501e2d4-4754-40ca-a1ae-1e3cee231641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ValueAddedTaxReceivables_63edaba4-9c5b-4661-804f-8ec759873a35" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ValueAddedTaxReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_ValueAddedTaxReceivables_63edaba4-9c5b-4661-804f-8ec759873a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Prepayments_1261f931-65d2-46da-93fb-630c69825564" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Prepayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_ifrs-full_Prepayments_1261f931-65d2-46da-93fb-630c69825564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_0a20d883-04b8-4e18-9474-84e04a784220" xlink:href="legn-20250331.xsd#legn_PrepaymentsOtherReceivablesAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems_249d7edf-4afe-4557-a56d-937093ecd01c" xlink:to="loc_legn_PrepaymentsOtherReceivablesAndOtherAssets_0a20d883-04b8-4e18-9474-84e04a784220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_c19f6156-bdbb-482d-bd10-bb1c3c763889" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_ab6be098-feba-41ce-9459-2a131a839b64" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_c19f6156-bdbb-482d-bd10-bb1c3c763889" xlink:to="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_ab6be098-feba-41ce-9459-2a131a839b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_1bdef293-0f1f-44f6-a7a2-4127b700f3b7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_ab6be098-feba-41ce-9459-2a131a839b64" xlink:to="loc_srt_CurrencyAxis_1bdef293-0f1f-44f6-a7a2-4127b700f3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1bdef293-0f1f-44f6-a7a2-4127b700f3b7" xlink:to="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_443fcf01-3c99-45fe-b660-b7a23be2374d" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:to="loc_currency_USD_443fcf01-3c99-45fe-b660-b7a23be2374d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_8b5ecb8b-a655-499a-9dfb-75583aea2ffe" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:to="loc_currency_CNY_8b5ecb8b-a655-499a-9dfb-75583aea2ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_f2554ceb-2104-4ec7-94ef-314419840879" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_f27502b3-db0e-4bb7-8c2b-679254549ed2" xlink:to="loc_currency_EUR_f2554ceb-2104-4ec7-94ef-314419840879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_ab6be098-feba-41ce-9459-2a131a839b64" xlink:to="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndBankBalancesAtCentralBanks_9b73e1ba-f12d-4cab-a5aa-32f130a40174" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndBankBalancesAtCentralBanks"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_ifrs-full_CashAndBankBalancesAtCentralBanks_9b73e1ba-f12d-4cab-a5aa-32f130a40174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PledgedShortTermDeposits_6f06af66-c9a7-404e-bc5b-2576350d90a7" xlink:href="legn-20250331.xsd#legn_PledgedShortTermDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_legn_PledgedShortTermDeposits_6f06af66-c9a7-404e-bc5b-2576350d90a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DepositsFromBank_45c64ea1-2292-4b4b-a145-2df8db43fc0e" xlink:href="legn-20250331.xsd#legn_DepositsFromBank"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_legn_DepositsFromBank_45c64ea1-2292-4b4b-a145-2df8db43fc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_5cbbbc97-926d-429a-a8e1-f194f9568017" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_38165b50-8493-4d4f-8a63-1e438cc8c070" xlink:to="loc_ifrs-full_CashAndCashEquivalents_5cbbbc97-926d-429a-a8e1-f194f9568017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_6ac41b23-ca88-4225-8843-0d0596d0737e" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_1bbdc588-ed2b-4b72-bb55-85eec56dd163" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract_6ac41b23-ca88-4225-8843-0d0596d0737e" xlink:to="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_1bbdc588-ed2b-4b72-bb55-85eec56dd163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_11984e26-b9cd-4bad-bf56-f8fd21fe50c1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_1bbdc588-ed2b-4b72-bb55-85eec56dd163" xlink:to="loc_srt_CurrencyAxis_11984e26-b9cd-4bad-bf56-f8fd21fe50c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_2cf88e0c-dbc2-4301-8234-7ab962477f1e" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_11984e26-b9cd-4bad-bf56-f8fd21fe50c1" xlink:to="loc_currency_AllCurrenciesDomain_2cf88e0c-dbc2-4301-8234-7ab962477f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CNY_c1872c32-b7e6-44dd-90f2-0284e9442328" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_CNY"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_2cf88e0c-dbc2-4301-8234-7ab962477f1e" xlink:to="loc_currency_CNY_c1872c32-b7e6-44dd-90f2-0284e9442328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_1acd1210-e3f5-40d0-aedf-704c42e207d6" xlink:href="legn-20250331.xsd#legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable_1bbdc588-ed2b-4b72-bb55-85eec56dd163" xlink:to="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_1acd1210-e3f5-40d0-aedf-704c42e207d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a09869c2-5ae6-4a0b-92b7-b563212eadae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems_1acd1210-e3f5-40d0-aedf-704c42e207d6" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a09869c2-5ae6-4a0b-92b7-b563212eadae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#OTHERPAYABLESANDACCRUALSDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:href="legn-20250331.xsd#legn_DisclosureOfOtherPayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AccruedPayroll_9d889677-923b-46bd-81c2-b10b16b6afee" xlink:href="legn-20250331.xsd#legn_AccruedPayroll"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:to="loc_legn_AccruedPayroll_9d889677-923b-46bd-81c2-b10b16b6afee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AccruedExpense_fd42db89-ba80-444d-9a63-876df1fbca0d" xlink:href="legn-20250331.xsd#legn_AccruedExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:to="loc_legn_AccruedExpense_fd42db89-ba80-444d-9a63-876df1fbca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_CollaborationPayable_15309005-3ee3-4711-8607-6659414663e8" xlink:href="legn-20250331.xsd#legn_CollaborationPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:to="loc_legn_CollaborationPayable_15309005-3ee3-4711-8607-6659414663e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherPayables_a2c91c90-0621-4b30-82d8-dcf47faef2eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:to="loc_ifrs-full_OtherPayables_a2c91c90-0621-4b30-82d8-dcf47faef2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_PayableForCollaborationAssets_e2c17a2a-72c5-49af-ae47-d4c52c7eb484" xlink:href="legn-20250331.xsd#legn_PayableForCollaborationAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:to="loc_legn_PayableForCollaborationAssets_e2c17a2a-72c5-49af-ae47-d4c52c7eb484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherTaxPayables_8996f725-95b0-4737-b2b4-ada1c34150f5" xlink:href="legn-20250331.xsd#legn_OtherTaxPayables"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:to="loc_legn_OtherTaxPayables_8996f725-95b0-4737-b2b4-ada1c34150f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_OtherPayablesAndAccrualsCurrent_b8312464-1aea-4b13-aec9-990143afb911" xlink:href="legn-20250331.xsd#legn_OtherPayablesAndAccrualsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_DisclosureOfOtherPayablesAndAccrualsAbstract_e3904d8b-1c0b-40a0-a153-e33485945f8c" xlink:to="loc_legn_OtherPayablesAndAccrualsCurrent_b8312464-1aea-4b13-aec9-990143afb911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_f6b38191-05c2-4b74-850c-85f5a397e2c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2b52248f-823b-4641-ad52-f4ed8f815d58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_f6b38191-05c2-4b74-850c-85f5a397e2c9" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2b52248f-823b-4641-ad52-f4ed8f815d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameAxis_ab6a2201-ee75-44af-8acf-a8ce69228ae8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2b52248f-823b-4641-ad52-f4ed8f815d58" xlink:to="loc_ifrs-full_BorrowingsByNameAxis_ab6a2201-ee75-44af-8acf-a8ce69228ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsByNameDomain_b969ac43-7c3e-4b2c-ba1f-121ca0d0a671" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsByNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameAxis_ab6a2201-ee75-44af-8acf-a8ce69228ae8" xlink:to="loc_ifrs-full_BorrowingsByNameDomain_b969ac43-7c3e-4b2c-ba1f-121ca0d0a671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_A110InterestBearingLoansMember_0aacc4a9-d4b4-4267-8830-d3045e5c4d25" xlink:href="legn-20250331.xsd#legn_A110InterestBearingLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BorrowingsByNameDomain_b969ac43-7c3e-4b2c-ba1f-121ca0d0a671" xlink:to="loc_legn_A110InterestBearingLoansMember_0aacc4a9-d4b4-4267-8830-d3045e5c4d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_2b52248f-823b-4641-ad52-f4ed8f815d58" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsInterestRate_70fc7d08-acd0-47e0-a568-aa549942026b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:to="loc_ifrs-full_BorrowingsInterestRate_70fc7d08-acd0-47e0-a568-aa549942026b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_76ecba35-01e8-41e7-8f05-bda42a7ae83c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_b42c14b1-e1a2-4f3a-a043-87dab3d15506" xlink:to="loc_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived_76ecba35-01e8-41e7-8f05-bda42a7ae83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_40524d49-ba28-4ab4-859e-4f6b820bf025" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Borrowings_8647b733-7602-408a-81f4-3aa90c03232e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_40524d49-ba28-4ab4-859e-4f6b820bf025" xlink:to="loc_ifrs-full_Borrowings_8647b733-7602-408a-81f4-3aa90c03232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued_321a5f56-ffbb-40ee-b68b-7dffa5d59268" xlink:href="legn-20250331.xsd#legn_InterestBearingBorrowingsFundedInterestsAccrued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_40524d49-ba28-4ab4-859e-4f6b820bf025" xlink:to="loc_legn_InterestBearingBorrowingsFundedInterestsAccrued_321a5f56-ffbb-40ee-b68b-7dffa5d59268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_82402323-1766-428e-94d2-cf774eda2b16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_40524d49-ba28-4ab4-859e-4f6b820bf025" xlink:to="loc_ifrs-full_BorrowingsAdjustmentToInterestRateBasis_82402323-1766-428e-94d2-cf774eda2b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_NumberOfBorrowingBatches_fb1366e8-1f10-48da-81ea-603c452143d9" xlink:href="legn-20250331.xsd#legn_NumberOfBorrowingBatches"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract_40524d49-ba28-4ab4-859e-4f6b820bf025" xlink:to="loc_legn_NumberOfBorrowingBatches_fb1366e8-1f10-48da-81ea-603c452143d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_5994dc98-1ae5-4e92-9146-758466e2e64b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8047d952-5ff4-40a1-a15e-7ffaf054d9f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_5994dc98-1ae5-4e92-9146-758466e2e64b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8047d952-5ff4-40a1-a15e-7ffaf054d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_b0e75003-0a83-4709-a2a6-b19658ce0951" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8047d952-5ff4-40a1-a15e-7ffaf054d9f4" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_b0e75003-0a83-4709-a2a6-b19658ce0951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_0a67390b-4c58-43dc-b533-9de683fe72da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_b0e75003-0a83-4709-a2a6-b19658ce0951" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_0a67390b-4c58-43dc-b533-9de683fe72da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_12c1628f-6e3b-4f2b-a842-9c648c583df7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_0a67390b-4c58-43dc-b533-9de683fe72da" xlink:to="loc_ifrs-full_OrdinarySharesMember_12c1628f-6e3b-4f2b-a842-9c648c583df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_8047d952-5ff4-40a1-a15e-7ffaf054d9f4" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:href="legn-20250331.xsd#legn_AuthorisedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:to="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesAuthorised_9ed0b36c-bf19-4647-965e-c38e2e0e9049" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:to="loc_ifrs-full_NumberOfSharesAuthorised_9ed0b36c-bf19-4647-965e-c38e2e0e9049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_b9517afe-b10e-4739-aeec-9e41cfba5225" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:to="loc_ifrs-full_ParValuePerShare_b9517afe-b10e-4739-aeec-9e41cfba5225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_AuthorizedShareCapital_59d82cdc-5400-4197-b353-a53825ab0ef7" xlink:href="legn-20250331.xsd#legn_AuthorizedShareCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_AuthorisedAbstract_4c200131-ecf7-4d58-8e98-228f21d828fe" xlink:to="loc_legn_AuthorizedShareCapital_59d82cdc-5400-4197-b353-a53825ab0ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_e970da61-86d1-4127-99a9-b109c5675164" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_91ebc30f-e645-4fa2-aa3e-4ed7d4223052" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:to="loc_ifrs-full_NumberOfSharesIssuedAndFullyPaid_91ebc30f-e645-4fa2-aa3e-4ed7d4223052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ParValuePerShare_d96b0c8c-75d6-4f80-bf67-c9951756b28e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:to="loc_ifrs-full_ParValuePerShare_d96b0c8c-75d6-4f80-bf67-c9951756b28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_746146d0-c979-47b2-86f1-00d829ad7907" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NumberOfSharesIssuedAbstract_4b98d0e6-8273-4515-95ff-1d5302e7dac7" xlink:to="loc_ifrs-full_IssuedCapital_746146d0-c979-47b2-86f1-00d829ad7907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="simple" xlink:href="legn-20250331.xsd#SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"/>
  <link:presentationLink xlink:role="http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_3ac01c78-bc90-4854-960c-e62943476c8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_64a947ec-0f75-4082-9d13-8c6d587f2378" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_3ac01c78-bc90-4854-960c-e62943476c8a" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_64a947ec-0f75-4082-9d13-8c6d587f2378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_82333bbe-b5b0-42ba-af89-89cf946d4242" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_64a947ec-0f75-4082-9d13-8c6d587f2378" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_82333bbe-b5b0-42ba-af89-89cf946d4242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_82333bbe-b5b0-42ba-af89-89cf946d4242" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_5a2782e5-5a60-4395-a775-ecab0b7dabdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:to="loc_ifrs-full_IssuedCapitalMember_5a2782e5-5a60-4395-a775-ecab0b7dabdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalMember_182e6781-21b4-48df-89a8-4ba0dd015342" xlink:href="legn-20250331.xsd#legn_ShareCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:to="loc_legn_ShareCapitalMember_182e6781-21b4-48df-89a8-4ba0dd015342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_17169875-f42f-4509-986c-0f1e7a66917d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_5e0ba8a3-2f5f-4f75-b895-a1c3514d17c3" xlink:to="loc_ifrs-full_SharePremiumMember_17169875-f42f-4509-986c-0f1e7a66917d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7a55b621-8cd5-42b3-836d-a629aaa069f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_64a947ec-0f75-4082-9d13-8c6d587f2378" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7a55b621-8cd5-42b3-836d-a629aaa069f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:href="legn-20250331.xsd#legn_ShareCapitalRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7a55b621-8cd5-42b3-836d-a629aaa069f2" xlink:to="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_7f6ecec6-e34d-406b-8271-61907ea888cb" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_7f6ecec6-e34d-406b-8271-61907ea888cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_1d0b0da7-4c90-4157-bf6e-48359720cf0d" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ShareCapitalAndSharePremium_1d0b0da7-4c90-4157-bf6e-48359720cf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_1f98fe0f-5dc7-4f4e-8f91-c68257f1acda" xlink:href="legn-20250331.xsd#legn_ExerciseOfShareOptionNumberOfSharesInIssue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ExerciseOfShareOptionNumberOfSharesInIssue_1f98fe0f-5dc7-4f4e-8f91-c68257f1acda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ExerciseOfShareOption_84d40e7a-ae5e-4a3f-a7b5-b0eb9681faff" xlink:href="legn-20250331.xsd#legn_ExerciseOfShareOption"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ExerciseOfShareOption_84d40e7a-ae5e-4a3f-a7b5-b0eb9681faff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_60b2c83c-a6c4-4e45-a17d-fe30cbc1ec11" xlink:href="legn-20250331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue_60b2c83c-a6c4-4e45-a17d-fe30cbc1ec11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_44668bba-6f67-4dc5-963f-80d337577306" xlink:href="legn-20250331.xsd#legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium_44668bba-6f67-4dc5-963f-80d337577306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_6ae6f8c3-98b7-4033-9682-a81d26941904" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue_6ae6f8c3-98b7-4033-9682-a81d26941904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_legn_ShareCapitalAndSharePremium_eb4f0077-bafe-4c06-a476-fc9729d422c1" xlink:href="legn-20250331.xsd#legn_ShareCapitalAndSharePremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_legn_ShareCapitalRollForward_5c53edc8-d313-4f6b-b581-93eedc38a6cb" xlink:to="loc_legn_ShareCapitalAndSharePremium_eb4f0077-bafe-4c06-a476-fc9729d422c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>legendlogo.jpg
<TEXT>
begin 644 legendlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !8 -,# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4F8*I).
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M6VJK"FJ6HE>$-GRI02LJ9[[75ES[45Y[33LSK3NKH^3_ -HGQEK7QN^,=O\
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M/B-:4H.2O]F2ZKMW]?5GH'_!1[_DW>/_ +#-K_Z!+7Q_^P-_R=#X7_ZX7O\
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M,#"G.=U>S_\ #T76O^A L/\ P8O_ /&ZJ;K<SY8JPHJG;WGJ?5&D:/J?A_\
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M89'4X(]_8C@CD5M0J*JDW\2,ZL73T6S/TU^&O_*.R\_[$_5O_0+BOAG]D/\
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M*NM0ZMXK\,VVLZC#;K:QW$TDBE8@S,%^5@,;G8_C7,?\,:_!C_H0['_O]/\
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MBBKHZS2_K8FI\)TWP7USX7MXKEMO!_B77M6U6>V8&#5;W4KB/RP58D"YR@/
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E%C\F8D[99'5>0/FP#VSS116\9.\5?I_F9.*U9]/4445S&Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>q125-pipeline51225001.jpg
<TEXT>
begin 644 q125-pipeline51225001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" , !54# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@!:*2B@
M!:*2B@ HHHH **** "BBB@ HKGO%WBRU\*::)Y5\VYE)6" '&XCJ3Z 5Y,WC
M/QKXAN7^P271 Y\JQA.$'X G\S6U.C*:OLCGJXF%-\N[/>J*\+T_XB^*-!OA
M#JOF7"*?G@NH]C@>QP"#]<U[+HVL6FNZ5#J%DY:&4=#U4]U/N*52C*&K'1Q$
M*NBW+]%%%9&X4444 %%%% !15+69Y+;0]0N(6V2Q6TCHV.C!20:\*@\>>,KJ
M98;?4IYI6Z)';HS'\ M:TZ+J)M'/6Q$:32:W/H*BO!Y/%_C^S0SSRWL<:]6E
MLE"_CE*[#P7\3&UB^CTS5XXXKF4[89X^%=O[I'8G]:J6'G%7W)AC*<I<KNO4
M](HKAOB<FO/HUM_8WVDQ^8?M ML[R,?+TYQUS^%6?APNMKX;8:W]H#^<?(%Q
MGS F!USSC.<9_EBH]G[G/<T]K^\]G;YG84445F;!1110 4444 %%>'?%LD>,
MDY_Y=$_]":O1M.%^WPOM1IA/VXZ:ODXZ[MO;W]/>MI4K14K[G/#$<TY0ML=7
M17D_PVC\5+XBE.H#4%L?+;SOMF_!;MC=WSZ=J]8J*D.1VO<NC4]I'FM8****
M@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'"[L8R1FO8+N1HK.>1#AEC9@?<"OGGQ-_P E U#_ *_S_P"A5]!WW_(/N?\
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M2)F)[G8,U&(II)22L:X.JY.4&[VV9J9HS117*=P9HS110 9HS110 9HS110
M9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS1
M10 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9
MHS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS11
M0 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9H
MS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110
M 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS
M110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110 9HS110
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MFC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC-
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M@_\ "9^'?^@I%_WRW^%'_"9^'?\ H*1?]\M_A19A[>E_,OO-ZBL'_A,_#O\
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M  H_L;2O^@;9_P#?A?\ "KM%%PY(]BE_8VE?] VS_P"_"_X4?V-I7_0-L_\
MOPO^%7:*+AR1[%+^QM*_Z!MG_P!^%_PH_L;2O^@;9_\ ?A?\*NT47#DCV*7]
MC:5_T#;/_OPO^%']C:5_T#;/_OPO^%7:*+AR1[%+^QM*_P"@;9_]^%_PH_L;
M2O\ H&V?_?A?\*NT47#DCV*7]C:5_P! VS_[\+_A1_8VE?\ 0-L_^_"_X5=H
MHN')'L4O[&TK_H&V?_?A?\*/[&TK_H&V?_?A?\*NT47#DCV*7]C:5_T#;/\
M[\+_ (4?V-I7_0-L_P#OPO\ A5VBBX<D>Q2_L;2O^@;9_P#?A?\ "C^QM*_Z
M!MG_ -^%_P *NT47#DCV*7]C:5_T#;/_ +\+_A1_8VE?] VS_P"_"_X5=HHN
M')'L4O[&TK_H&V?_ 'X7_"C^QM*_Z!MG_P!^%_PJ[11<.2/8I?V-I7_0-L_^
M_"_X4?V-I7_0-L_^_"_X5=HHN')'L4O[&TK_ *!MG_WX7_"C^QM*_P"@;9_]
M^%_PJ[11<.2/8I?V-I7_ $#;/_OPO^%']C:5_P! VS_[\+_A5VBBX<D>Q2_L
M;2O^@;9_]^%_PH_L;2O^@;9_]^%_PJ[11<.2/8I?V-I7_0-L_P#OPO\ A1_8
MVE?] VS_ ._"_P"%7:*+AR1[%+^QM*_Z!MG_ -^%_P */[&TK_H&V?\ WX7_
M  J[11<.2/8I?V-I7_0-L_\ OPO^%']C:5_T#;/_ +\+_A5VBBX<D>Q2_L;2
MO^@;9_\ ?A?\*/[&TK_H&V?_ 'X7_"KM%%PY(]BE_8VE?] VS_[\+_A1_8VE
M?] VS_[\+_A5VBBX<D>Q2_L;2O\ H&V?_?A?\*/[&TK_ *!MG_WX7_"KM%%P
MY(]BE_8VE?\ 0-L_^_"_X4?V-I7_ $#;/_OPO^%7:*+AR1[%+^QM*_Z!MG_W
MX7_"C^QM*_Z!MG_WX7_"KM%%PY(]BE_8VE?] VS_ ._"_P"%']C:5_T#;/\
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M_"KM%%PY(]BE_8VE?] VS_[\+_A1_8VE?] VS_[\+_A5VBBX<D>Q2_L;2O\
MH&V?_?A?\*/[&TK_ *!MG_WX7_"KM%%PY(]BE_8VE?\ 0-L_^_"_X4?V-I7_
M $#;/_OPO^%7:*+AR1[%+^QM*_Z!MG_WX7_"C^QM*_Z!MG_WX7_"KM%%PY(]
MBE_8VE?] VS_ ._"_P"%']C:5_T#;/\ [\+_ (5=HHN')'L4O[&TK_H&V?\
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MQ2_L;2O^@;9_]^%_PH_L;2O^@;9_]^%_PJ[11<.2/8I?V-I7_0-L_P#OPO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!5\'M@#(('('0XH]D^6X/$+FY?D>X45X;X,\-+XNU/Q#:WNI7T-K#,"8H)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!:*2B@"O=6%O=C]ZGS=F'!%5H]($7"7ERJ^@8#^E:-
M%82PU*4N9QU-(UIQ7*GH10VT<'*@LQZNQRQ_&B[)2RG920PC8@CMQ4M,FC\Z
M"2(G =2N?J*U45%6B2I7E>1E+>O';/#%;DPP0#?(LFUE.S<,#'TY]3TIBWEV
M+J!(R'22[9&#MSM\K=@<>O/;]:G72I"C!KDH)8PLJ(."0FW()[>WM4ATH;PR
MSN-LHE48'!V;"/Q'Y&E9G5STE?\ X.__  Y7CUN25S!';1M<[]H19P5^Z6Y8
M#KQC'KWIFHZM*@N+98Q'+Y1=")07&"O4#I][CZ5)#H9@(>.[82K@(PC&  I7
MI]#^=$NA"621C=/AE<#Y1D%MI))[_=%'O6&GAU-/I\Q!J5VUZBB!-JQS>9&)
M.K*5 P2!QS[=?:FG7CY1*6\<C(':39-E0%*CY3CG[P].]32:,)8R'N'WN) [
M!0-V_!/';&!5*^TN:-2L)EDEG#JSHBA1N*<$=A\O7V-#YD."H2:7^99;71YD
MT<<,;LK[$ EY)$@C.[CY>3D=<BA=>4RP1M$BLY57!EY!+E!M&/F&0<].*G_L
MK[ZF=O+,OFJH4#!\SS#D]^>/I1%I7DS+)'<,HSEQM&6^=F SV^\1]*/>(OA[
M;?F+=ZF;2\2%HD*N#@^: Q.UFX7T^7&?>H&U2>::T$$2JK2)YFY^H:,MCI_G
M%3SZ4L]\;@S,%)!9-HY(5EZ]AANGK3(-',*IFY9G1T96V <*NS&/H33U$G14
M?.WGN0Q:J]U-:?NS$KNLF ^=T;1R$9XX/R]/IS2VFO)=*A$2_/@C9)NPI1F&
M>.#\I!':I(-&$/E_Z0[&+8(R5'"J& !]>';FD71V2VBA6[8>3@1G8.%"E<$=
MS@]?I2]XJ3P[O;Y;B)K3/;RW(M?]'BC#.WF<AM@?&,=.0,^O:F07_P#:%Y'&
M=OEF&=)$1]Z,08^0>XPQ_,U(FBA()(%NI!#(@5EVCD[ F<_0 X]:F%A*CI,+
MC?.BR ;E 4AL<8'094?K1J)NBOA_7M_F4K/^T);&QE@E4EK6/?O;)R1UQ3XF
MU>1N9X!@D;>"<_Y'\ZFBT=8UM!Y[Y@C2,XXWA?6E;1HF60"5U+R!R1]"/ZFB
MS&ZE.[V^X;;KJ@EC,LT)BS\V#G//TK4(!!!&0>H-91T4$G;=2JN,!1T%7;.U
M^QPF,2/)EMV6ZTU<RJN#U3_"QYG'X4\7^"M7O)/"<=M>Z==-N\B=@"G7&<LO
M3.,@\]Q6CX5\':T_BN3Q5XHDA^W;2(8(B"$RNW)QP !D #/7.:]#HK9U&T<2
MHQ3/./"OA'6-+O?%<EW;HBZ@KBWQ(IW9+XS@\?>'6G^$/!FJ6/P^UC0]01+>
MYO'E\L[PP :-5!./<5Z)12=1L:HQ7]=SRSPYX5\5CPIJ?A;4[>VM+)X7-O<"
M0,QD+ X.UC\O7MFJ$?AGQ\W@Z7PK_9VGQ629;SO-7?-\^_ PWKW(' KV*BG[
M5]B?81M:[['F-Y\/M2U/X>:/8G9;:SIA=HPS@JP+$D;AG&<*<^HJ2'3_ (BZ
M_J=BFK2QZ196S9E>SGVM..,Y"L<DX]@,GBO2J*/:,?L8]SR^Z\,^+-!\>7^N
MZ#9VFH1WP;_7N%\O<02#E@>".V>*7PMX0\1Z=KOB&[U2"!FU&UE EBD&UI6.
M< =0.3U]*]/HH]H[6#V,;W/']"T#XB>%="GLM-LK&1;J1F96E4R0L0!O!W <
M@#UZ=/7>T/X?7.G?#O4]&EFC&HZ@I9B#E4; VKGTXY/N:]"HH=5L(T(H\KTC
MPGXKN? VH>%=2M[:SMT0&SF$@8N_F;R&VL?E_ =:H2^&?'U[X.7PV^FZ?!:6
MV"K"5=\V&R!D,0.N<D#./S]CHH]J^PO81M:[['EOB#P7?W/@SPZ5EAL]9TP+
M$B22J!(V1A0W3=E01^-<KX_N?%5Y_9$/B."RMYM["&WMV#.WW06;#,.> .?7
MBO9?$7AO3?%&GBSU*-V16WHT;[61L8R/S[YK#T7X8^']%U*._!NKRXB(:,W4
M@8(1T(  Y'OFKC42U9%2BV[1V*7C/P;JT_B.U\3^''A.H0J%D@E( DP",C/'
M0X(..*N>'$\;76M)=:[:Z;86,<;*;>%0S.QZ$$,V,?7\.X[2BL^=VL;>R7-S
M)G!?#SPOJOA_4]>GU&!(X[R1&A*R!L@,Y/3I]X53\*>!;^W/BFVUB$16VJ?+
M&R2*QQESGCH1N!YKTFBAU&[^8E1BK+M^IY/I>B?$+PK;R:1IMEIM_9[R8KB4
MK\F?0%@??!!YKT?0;?4;71;:'5IH9KY5_?20KM4G_P#5CG K1HI2FY#A34-F
M>=^+?".J^*_'.FM<6Z_V!:@!V\T MGYFX!R,X"_AFI-?^%6@2Z%=KHVG"'4=
MF8'-PY&X'./F8CGISZUZ!13]I)6MT$Z,'>ZW/*M3\$>(=9^'6FZ=<11IJFF2
M$(C2J1+%C P1P"!@<_W:I>)/#GQ"\7:=:+J-C8QFV;"Q12*&8D<NQW$=N@/?
MI7L5%-56B70B^K//?B%X5UK5;_1M6T2*.>YL&R87<+DA@RGD@$9'/-1^)/"G
MB'7(=&\0P+;VWB.R4>; &^0X8L #DCCGJ<')YKT:BDJC5O(IT8MM]SR]?"_B
MWQ?XCT^^\5P6ME9V!W+!"P;><@GHS=2!DD]!Q6G_ ,(OJO\ PM\>(?(3^S?+
MV^9Y@SGRMOW>O6N]HH]HP5&/XW/+9O"7BCPIXDOM0\+06E_9WK%FMK@@;#DG
M')7IDX(/0\UOV&B^)-7\-ZQ:>(Y+.&:^0K!';H/W''<CJ,X.,GOSSQV=%#J-
M@J27H>/67AOXA6_A>Y\+K9V"6!5\3M(I9P3DJN&[GN0.O6M(?#J_O_AC::+<
M^7;ZI:S/-'E@RG+-\I(SP0?S KT^BFZK$J$>OH>7C3?B5K;V5A?RQZ3:6Y'F
MW=K/B24#CG:Q)..V ,U;\5>#=:C\51>*/#)AEN]H6:VG(P^%VYYX((P#DCIG
M/IZ+11[1WT'[%6LVSCO#$?C.XU=KO7[?3[*S$95;6!0S%O[P()Q^?X=ZI_#C
MPOJOAV[UR34H$C6[D1H=L@;(!?/3I]X5WM%)S>J[C5-)IWV,KQ)H,'B30;G2
MYV*"4#9(!DHP.0?S_2O/K*P^)^AZ:-$LH+&>VC!2*[,B[D7VRP/'NIKU:BB,
MVE8)4U)WO9GG%C\/;K2/AWJVF1,ESJVH*"Y5L+D$84$^G/)]:J7_ (*UR?X3
M:7H,=LAU&WNFDDC\U<!=TAZYQ_$*]2HI^TD3[&.WE8\U\0^#M9U"X\'O;6Z,
M--BB6YS*HVE2F<<\_=/2KOCWPOJNN^(- N]/@22&SDW3%I NT;U/0]> :[VB
ME[1Z#=&+37<X)_"^JM\7X_$(@3^S5CVF3S!G/E%?N]>M9DGACQ;X2\2ZC?\
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MHH D\SVH\SVJ/(]11D>HI@2>9[4>9[5'D>HHR/44 2>9[4>9[5'D>HHR/44
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M#7B.XM]-TZ]OX6MOLXOXT9%RS!N7P!Q[]A69X^M]-@O=/^RQV4-\]J#?P6+
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M9/K110 9/K1D^M%% %BRO[K3KN.ZL[B2&>,Y5T;!KZCTR[:\T^VN' #2Q*Y
M]2 :^5*^HO#_ /R!;'_KWC_]!%<V(Z'=@WJT>+?%'6KZZ\8W=BUQ(+6UV+'$
MK$+RH))'<Y/6N)\Z3_GH_P#WT:Z;XC_\E U;_?3_ -%K7+5M!>ZCEJMN;'^=
M)_ST?_OHT>=)_P ]'_[Z-,HJB!_G2?\ /1_^^C1YTG_/1_\ OHTRB@!_G2?\
M]'_[Z-'G2?\ /1_^^C3** '^=)_ST?\ [Z-'G2?\]'_[Z-,HH ?YTG_/1_\
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M_?1H\Z3_ )Z/_P!]&F44 /\ .D_YZ/\ ]]&CSI/^>C_]]&F44 /\Z3_GH_\
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MN?Y8IFI:[/JOB.36KJ"!II)5E>$ ^6<8XQG.#CUKM_\ A3M]_P!!6#_OT?\
M&C_A3M]_T%8/^_1_QI>TI]QNC6?0P5^(WB'^W)M2ENC-'-N#V,CN;;:PQMV;
MN@^M8FB:Y=Z!J7VZR$>XJT;QR+N21&ZJP[@UW/\ PIV^_P"@K!_WZ/\ C1_P
MIV^_Z"L'_?H_XT<],;I5GK8Y+6?%-QJ^FP:;'8V5A8PR&806D94,Y&-QR22<
M<5/IOC*:PT*+2)=(TN^M8I6E3[7$[$,W7HP%=-_PIV^_Z"L'_?H_XT?\*=OO
M^@K!_P!^C_C1ST[6#V5:]['G=Y<"[O)KA8(K<2,6$4((1,]E!)XJ"O2_^%.W
MW_05@_[]'_&C_A3M]_T%8/\ OT?\:?M8=R?J]7L</JFMW.JV>FVL\<2II\'D
M1% 067.<MD]?IBLRO2_^%.WW_05@_P"_1_QH_P"%.WW_ $%8/^_1_P :%5@N
MH.A5>Z/-**]+_P"%.WW_ $%8/^_1_P :/^%.WW_05@_[]'_&G[6'<7U>IV/-
M*^C/ /\ R)VE?]<!_6N!A^#ESYR^?JL?EY^;9"<X]LFO6-)T^+3;&"T@7;#"
M@1 ?0"L:TXR22.G#4I0;<D<%\:?^0#IO_7R?_037BU?37BOPS:^*M'-C<NT;
M*PDBE49*,.,X[C!/%>:M\&;A3@:S&1_U[G_XJG2J14;,FO1G*=XH\OHKT_\
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M+0_]^3_C1[6'</J]3L>9T5Z9_P *<O?^@M#_ -^3_C1_PIR]_P"@M#_WY/\
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M4KTS_A3E[_T%H?\ OR?\:/\ A3E[_P!!:'_OR?\ &CVL.XGAZKZ'F=%>F?\
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M C/6B@]:*H0"EHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\S@=2!G)%<AI\-^MWX'CUZ]631Y(XY;+RHPGES!1Y:.>I[?6NJUC_DK?AO\
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M'@?Q/_Y*!J'^[%_Z+6OHJS_X\H/^N:_RKYU^)_\ R4#4/]V+_P!%K7T59_\
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M?6E^_@"&SN8IY1=0N4C<,0JJN20.F*S;:]TN#P7XXM[^: 22:E=>3$[#<SD
M(5'7[V/RHCAXVN[_ -.PG4=]#T/6/&&@Z!>)::G?^1.\8E5/*=\J21G*J1U!
MJ]I.KV.N6(O=.G\ZW+%0^QEY'7A@#7ED?]JVOBWP\HU"VT^^7P[&LDMZN0/G
M;Y3DCYNGY&N]:\\1?V=9G3?[*U67#"XG\XQINSQM SVZ_2IJ48Q2L]7Y_P#
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MJO//I7-Z-_R023_KQN?_ $-Z9XG1G^!E@54G;:6C-@=!\G--4:?-RZ_%;?\
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MLK2/LZ '\?R'K7$0-=:-X*T'Q-8#]]#]HLY/=79]I/T))^N*]P"JJA0H"CC
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MQ-NCB1#@+E5 X'05)11<!B11QEC'&J[CEMHQD^II719$*.H93U##(-.HH 0
M*H50 !P .U+110 4444 %9D__(0D_#^5:=9D_P#R$'_#^5- >.?&7_D/Z?\
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M26%QE70Y5A[&I:QO#5[/>V-PTMS]KBCN7CM[K:!Y\8QAOE !Y)&0,';FMF@
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MCMX(X8D"1QJ$11T  P!0 ^BBB@ HHHH *R8?]8_^\?YUK5DP_P"L?_>/\Z:
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MM'NKUK.#^S[D&2[D.PM.PD.[=G&U0<= 1D8H [>^U&STR%9KVYCMXV8(&D;
M+'M^AJO%KNESA&AO8G5RX5E.0=HW-S[ @UC^+94ALM%FCO([>-;^,BYD^=5'
MEOAB2>?KGO5.^O1=2Z;/;ZG#?/''> W%L  &\K('!.",CO0!V44B31)+&P>-
MU#*PZ$'H:@_M*S^TI;?:$,S2F$(.3O";ROL=O->?:GJ4D>D7LM[JMW;7J:;
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M*&R 0W]TY-7"-6&J7X$MPEHV:^G:?;Z7IEOI]LI$$$8C4-R2!Z^]654* %
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M^AK-MON5I/\ ZMOH:S+8_)30'B?Q>_Y'./\ Z\T_]":O9_"'_(EZ'_UX0_\
MH KQCXO?\CG'_P!>:?\ H35[/X0_Y$O0_P#KPA_] %>AB?\ =Z9S4OXLC7FF
MBMX))YI%CBC4N[L<!5 R23Z4T0P/"5$49C<[B-HPQ/.??UK-\5?\BAK7_7A/
M_P"BS7-WDETHU>\2^O$>RFM!;QI,PC4%(MP*CA@<G(.?PKSCI.REM+*\DWRV
M]O/(F4W.BL5SU'MUZ5+]GA((\J/!<.?E'+#&#]>!S[5Y_-*^F0ZS'9W+JYUA
M!=^;>.IB@9 0Q;YB@)XW@=._&1:L/M=]=Z;:3:I)):2O=%397LCAD41[5,N%
M9L$MS^&3S0!U=[I]@UK?/)%%"9X72:=$ ?:1R2<<T:=8Z?'IT:VL$+02QJ2P
MC \T8X+<<\>M<,=1:XTV-=8U6X@C_LMC;-YYC^T3!Y%;)&-[!1'\ISG<>#3!
M>ZD'@@6^ALVCM+3[")KUX@^44L1&J$2Y;*D'I@=.M '?74>FP7$=S<PVZS2R
M)$DK1@LS9^49QGJ.*LK!"NS;%&-A)3"CY2<Y(].I_.N"N+F.?5;<76H3'4UU
MP+]C,QVI"'(0B/I@KM.[')/7M7H- $26MO'"T*01+$^=R*@"MGKD>].,4;,C
M-&A,9RA*CY>,<>G%/HH ABM+:"626*WBCDE.9'1 "Y]SWIT,$-M$(H(DBC&2
M$10H&>3P*DHH **** "BBB@".X_X]I?]P_RK%O?^0+>_]>[_ /H)K:N/^/:7
M_</\JQ;T_P#$EO?^O=__ $$U4=T)['C/PA_Y'R+_ *]Y/Y5]"5\]_"'_ )'R
M+_KWD_E7T)79F'\;Y&&&^ JWVI6>F_9S>3K"+B98(BV<-(V<+[9P>M-GU6QM
MI+I)[E(S:Q+--NR B,6"G/3DJWY5E>*].35?[(M9H&FMVOOWP )VJ891DGMR
M1SZXKG&LM8>[U9+NVFN)+,:?B0+G[9'%.\A(]6V8R/[WU%<)T'7Q^(]-ECE=
M6N=T04O$;242 -P&V;=Q!P>0,4R#Q1I-S:RW4<TPMXAEI9+65%^]MP"RC)SQ
M@9.>U.L-1M]2U-Y+:REVQPA3>2P-&<D_ZL;@">F3V''>L*.UN4\$6^;>8O;Z
M@+AX@A+E%N]YPO4_*,X[T :]WJFC7FGK>W$LHAL[J,E3#(LB2Y 53'MW9.\<
M8YR*G;Q%IJV\4Q>YQ*Q2./[)+YC$#)Q'MW$#UQBL":.&_;5+^:'4!82WEL4D
M@C9)/W:C]YM(W;0V!D#/&1TS2)JMU8Z<2(KJ>62ZDAL+NYM7=XH"%)=\+NQD
M' /+87MR #H)O$>EP6]K.;AY([M2T'DP22EP,9.%4D8R.M-NO$NFV<1EN/MB
M1",2M)]@G*JI&<DA,#CKGIWK#N+;2H;32RLFLQ106\T<-S;1R!BQ92V\!=VY
MBN1D 'FK@74=3T_0M.U")Q++&EQJ+%<#" '8>V6<KD>@:@#4?7]-COELWG82
MED0GRGVJS8VJS8VJQR, D'D>M+'KVFR:C]A2X8S[VB!\IPA=1DH'QM+  Y .
M>#Z5S=]'*#J^E_9[AKJ\U2">!EA8HT?[DEM^,#;L;.3V]Q4%I!<#7;<%;LR+
MJL\S6#0$01(=X\X28Y)!#<L1ER  >@!LL^B>([X1"[NY Z9\G=+'#<*C=1D!
M7 )&=IYR,Y%=)7)6$K7OBBRN(HKWRH[>57MKFV\M;(G;PI"@$DC'5N.00.O6
MT %%%% !1110!4U#_4I_OC^1IB?=%/U#_4I_OC^1IB?=%,!U%%% !1110 44
M44 %%%% !1110!'WHH[T50@HHHH X#X<@C6/%>0?^0@?_0GJ+PTN?&7C;*\$
MCJ/]ZO1**W=>[D[;V_"QFJ=DEV/"8["\F^'>D7L"S&&RU"1YO*7<R E<-@\'
M&#^=;VF?8-7U:\U*#6M1U.X@TV96EEM!'& 5("$^OS$].U>L4@  P !]*TEB
M[IZ=_P ?D2J-NIYSX5DN+/X/R3V5HDUT%F81M'NW'>1DCO@=O:N1EU./4)?#
M,O\ :MY>3QW<9N8WA$<-LVY?E7"@=CT/0=J]UI  .@ I1Q*4G+EW=P=*Z2N>
M4:?XCT[P[XS\72:D)-DTH5=L98,1N^4^F<]_0U!:>'+N3X/2R21O'<PW#7]N
M",,JC /Z!C^5>@:-X9&DZ]K&IFZ\[^T75_*\O'EX)/7)SU]!4WB;1[W7-,^P
MVFIM8+(2)V6(.9(R""O48JW7CS+E\KOT0O9NVOF<W\-(9KV#4_$EXH^T:E<'
M;[(OI[9)'_ 17>U4TO3H-(TNVT^V!\FWC"+GJ?<^Y/-6ZYJL^>;DC6$>6-@H
MHHK,H**** "BBB@ HHHH \H^-/W=$^L__M.NO^$O_)/[7_KK+_Z$:Y#XT_=T
M3ZS_ /M.NO\ A+_R3^U_ZZR_^A&NZI_N<?7_ #.>/\=G<4445YQTA1110 44
M44 %%%% !1110 4444 %%%% !1110 5D0_??_>-:]9$/WW_WC30'G7QE_P"0
M-IG_ %\-_P"@UL?!C_D2IO\ K]D_]!2L?XR_\@;3/^OAO_0:V/@Q_P B5-_U
M^R?^@I7H2_W->IS+^.>B4445YQTA1110 4444 %%%% !1110 4444 %%%% !
M1110 5F3_P#(0?\ #^5:=9D__(0?\/Y4T!XY\9?^0_I__7K_ .S&O5_!'_(C
MZ+_UZ1_RKRCXR_\ (?T__KU_]F->K^"/^1'T7_KTC_E7?7_W:!S4_P"+(WZ*
M**\\Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R8?]8_\ O'^=:U9,
M/^L?_>/\Z: \.^+'_([/_P!>\?\ 6O:_!G_(DZ)_UY1?^@BO%/BQ_P CL_\
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M2?\ /$?]]4?VA)_SQ'_?5%@-"BL_^T)/^>(_[ZH_M"3_ )XC_OJBP&A16?\
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M.QN7:*I?VBO_ #R>C^T5_P">3T6 NT52_M%?^>3T?VBO_/)Z+ 7:*I?VBO\
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M44 %%%% !1110 4444 %%%% #*2CO15""BBB@ HHH% "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112 **** "BBB@ H
MHHH ****8!1110 4444 %%%% !1110 4444 %%%% !6/XKB\[PCJZ#D_9)2/
MP4G^E;%1SPI<6\D$@S'(I1AZ@C!H0,SO#$HF\*:1)GK9Q9^NP9K5KC+7P7J]
MC;1VMIXMO(K>,;8XQ IVCTZU-_PBVO\ _0Y7O_@.G^--I=R4WV.MHKDO^$6U
M_P#Z'*]_\!T_QH_X1;7_ /H<KW_P'3_&E9=QW?8ZVBN2_P"$6U__ *'*]_\
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MBR[A=]CK:*Y+_A%M?_Z'*]_\!T_QH_X1;7_^ARO?_ =/\:++N%WV.MHKDO\
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MO<1&#>P)&&*MD8S[@U6_X1;7_P#H<KW_ ,!T_P :/^$5U_\ Z'*]_P# =/\
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M_P!#G>_^ Z?XT67<=WV.NHKD?^$5U_\ Z'.]_P# =/\ &C_A%=?_ .ASO?\
MP'3_ !HLNX7?8ZZBN1_X177_ /H<[W_P'3_&C_A%=?\ ^ASO?_ =/\:++N%W
MV.NHKD?^$5U__H<[W_P'3_&C_A%=?_Z'.]_\!T_QHLNX7?8ZZBN1_P"$5U__
M *'.]_\  =/\:/\ A%=?_P"ASO?_  '3_&BR[BN^QUU%<C_PBNO_ /0YWO\
MX#I_C1_PBNO_ /0YWO\ X#I_C19=QW?8ZZBN1_X177_^ASO?_ =/\:/^$5U_
M_H<[W_P'3_&BR[A=]CKJ*Y'_ (177_\ H<[W_P !T_QH_P"$5U__ *'.]_\
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MRN)[W29M.>*78JR9^<8Z\@=.E=!7DOA#Q7J%EX UW5KNZGO)[>55A-Q(SX+
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M-3[/2]S3VOO<MCT.BBBLS4**** "BBB@ I:2EH ****0!1110 4444 %%%%
M!1113 *!12T %%%%( HHHH&%%%% !1110 4444 %)2T4 %%%% @HHHH ****
M "BBB@ HHHH **** "BBB@84444""BBB@ HHHH **** "BBB@ HHHH 6BBB@
M84444 %%%% !1110 444"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH$
M%%%% !1110,**** "BBB@ HHHH$%%%% !1110 4444#"BBB@ HHI10 4444@
M"BBB@ HHHH ****8$?>BCO13$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !14<]Q#:P//<31PPH,M)(P55'N363_ ,)?X;_Z#NG?
M^!"_XT)-B<DMSA;SPE?>,?B'?3ZQ:W=MI42%(9!A2X7A0"<]22U5_%/PO32]
M/AO/#8O9[R.9249PQV\\C '(.*]"_P"$O\-_]!W3_P#P(7_&C_A+_#?_ $'=
M/_\  A?\:UYYHP=*FT[O5G%>)=+U]M6T3QAIVG/)>10H+JSQ\RL,YXZD'<1Q
MZ"JEQ:^)_$'CK0M:O-!EL[>*2-=H.XHBODENF.I["O0/^$O\-_\ 0=T__P "
M%_QH_P"$O\-_]!W3_P#P(7_&A2EV!TX-_$</=Z=X@\(>/+[6-*TE]3LM0W%D
MCSD%B&(.,D$-WQC!_*7PCI6O+\1[[5]6TQK5;B!B2IR@)V$+GN<#\P:[/_A+
M_#?_ $'=/_\  A?\:/\ A+_#?_0=T_\ \"%_QHYI6V!0@G?F\SDOASH.I6 \
M11W]I+:BZ91$TBXW?ZS)'YBJGP^M=?T&2]T*\T29()2\AN^=H(3  .,'.!WK
MN/\ A+_#?_0=T_\ \"%_QH_X2_PW_P!!W3__  (7_&ARD[Z;C4(*UI;'">$?
M!VH7'@36]'U"VDLYKJ4-%YHQRH!!^F15:*?QK9^%G\)CPW*[E&MUNP?E$;9S
MS]WH2,YKT3_A+_#?_0=T_P#\"%_QH_X2_P -_P#0=T__ ,"%_P :.>75"]G!
M))2\C@/$'@G4K+X<Z9I-I;O=WB7?GSB$9P2K9_ <"MCXAZ-J.I^"]+M+&SEG
MN(IHV>-!DJ!&P.?Q(KI_^$O\-_\ 0=T__P "%_QH_P"$O\-_]!W3_P#P(7_&
MCFEH[![.G9J^YPGBS0-836=!UF+2FU2VM;6*.2SQDAESD%>>N>N#R.:BLM.U
MZ\^)&F:W<^'7T^TQC9'@B-=K*-V,8.3Z#C%>@?\ "7^&_P#H.Z?_ .!"_P"-
M'_"7^&_^@[I__@0O^-'/*UK![.%[\QRWA'1=2LOB+XBOKFSEBM;AI?*E8?*^
M9 1C\*W?B!8W6I>"K^TLH'GN',>V-!DG$BD_H#5S_A+_  W_ -!W3_\ P(7_
M !H_X2_PW_T'=/\ _ A?\:EN5[V*2@HN-]R#P3I\MAX0TVWN[8PW,:$.KKAE
M.XU)XRM+B^\(:G:VL32SR181%&2QR*G@\4Z!<S+##K5@\CG"JMPN2?0<UK4F
MW>[+23CRIGB_B.PNM-^#6C6E[ \%PE^=T;C!&3,1^A%3ZF_B[Q-H&G>'E\/M
M!$%B+78;,;J%^4YZ =SR37=^.M$LM=T*.VO]4CTZ&.=9?.DQC(5ACDC^]^E6
M++Q%X=L[&WM1K^FN(8ECW?:4&<#&>OM6G/I>VI@Z7O--V5D<AXO\"WH@T6]T
MB"*]FTR".WDMY5!$JIR#@\'G.1[T_0UU#4=;L\^ --TRUB;=/-- JL,="AV@
MYSST/U'6NS_X2OP[_P!!W3?_  *3_&C_ (2OP[_T'=-_\"D_QJ>:5K-%\D.:
MZ9R?AW1=2M?BKK6HSV<L=G-'((YF'RL2R$8_(UD^&/#NL6GAGQ?;W&GSQS7<
M6($9>9#A^GYC\Z]"_P"$K\._]!W3?_ I/\:/^$K\._\ 0=TW_P "D_QHYI=@
M]G#OW_$Y70-&U&V^$U]ILUG*EZ\-P%@8?,2V<?G65:^"-2U/X71:9+ UMJ-O
M=//%'+\N[J,'TR#^>*[_ /X2OP[_ -!W3?\ P*3_ !H_X2OP[_T'=-_\"D_Q
MHYI=@]G!Z-]+'G%FFMFU@TX?#K3OMJ;4:[GMD$; =2>,9/J&_"O6K>)8;:*)
M8HXE1 HCC^ZF!T'3@5F?\)7X=_Z#NF_^!2?XT?\ "5^'?^@[IO\ X%)_C2DW
M+H5!1CU//H_!EYXP\;:K?:];7EI8](",*S $*N,@_P ()/N:B\2_#=]"%AJ'
MA=+RYN8IPS(S!B,<JPP!T(_45Z-_PE?AW_H.Z;_X%)_C1_PE?AW_ *#NF_\
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MR/\ A*_#O_0=TW_P*3_&C_A*_#O_ $'=-_\  I/\:+,.:/<UZ6L?_A*_#O\
MT'=-_P# I/\ &C_A*_#O_0=TW_P*3_&EROL'-'N;%%8__"5^'?\ H.Z;_P"!
M2?XT?\)7X=_Z#NF_^!2?XT<K[!S1[FQ16/\ \)7X=_Z#NF_^!2?XT?\ "5^'
M?^@[IO\ X%)_C1ROL'-'N;%%8_\ PE?AW_H.Z;_X%)_C1_PE?AW_ *#NF_\
M@4G^-'*^P<T>YL45C_\ "5^'?^@[IO\ X%)_C1_PE?AW_H.Z;_X%)_C3Y6'-
M'N;%%8__  E?AW_H.Z;_ .!2?XT?\)7X=_Z#NF_^!2?XT68<T>YL4M8__"5^
M'?\ H.Z;_P"!2?XT?\)9X=_Z#NF_^!2?XTN5]@YH]S8HK'_X2SP[_P!!W3?_
M  *3_&C_ (2SP[_T'=-_\"D_QHY7V'S1[FQ16/\ \)9X=_Z#NF_^!2?XT?\
M"6>'?^@[IO\ X%)_C1ROL'/'N;%%8_\ PEGAW_H.Z;_X%)_C1_PEGAW_ *#N
MF_\ @4G^-'*^P<\>YL45C_\ "6>'?^@[IO\ X%)_C1_PEGAW_H.Z;_X%)_C1
MROL'/'N;%%8__"6>'?\ H.Z;_P"!2?XT?\)9X=_Z#NF_^!2?XT<K[!SQ[FO1
M6/\ \)7X=_Z#NF_^!2?XTO\ PE?AW_H.Z;_X%)_C1RL.>/<V**Q_^$L\._\
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MN;%%8_\ PEGAW_H.Z;_X%)_C2_\ "6>'?^@[IO\ X%)_C1ROL/FCW-BBL?\
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M -!W3?\ P*3_ !H_X2SP[_T'=-_\"D_QHY7V#GCW-BBL?_A+/#O_ $'=-_\
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MWKT+XQ_\C?:_]>*?^AR5Y[5T_@1C7_B,****T,0HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >N?!B\F,&JVK2$PH\3HA/"EMP./KM'Y5ZT.17COP9_UFL?]L?\ V>O8
M1T%<-;XV>KAOX2'4445D;A1110 4444 %%%%, HHHH C[T49I,TQ"T4F:,T
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MSJ'_ '\3_P"(H_X5!HG_ #\ZA_W\3_XBCVT0^JU#Q:BO:?\ A4&B?\_.H?\
M?Q/_ (BC_A4&B?\ /SJ'_?Q/_B*/;1#ZK4/%J*]I_P"%0:)_S\ZA_P!_$_\
MB*/^%0:)_P _.H?]_$_^(H]M$/JM0\6HKVG_ (5!HG_/SJ'_ '\3_P"(H_X5
M!HG_ #\ZA_W\3_XBCVT0^JU#Q:BO:?\ A4&B?\_.H?\ ?Q/_ (BC_A4&B?\
M/SJ'_?Q/_B*/;1#ZK4/%J*]I_P"%0:)_S\ZA_P!_$_\ B*/^%0:)_P _.H?]
M_$_^(H]M$/JM0\6HKVG_ (5!HG_/SJ'_ '\3_P"(H_X5!HG_ #\ZA_W\3_XB
MCVT0^JU#Q:BO:?\ A4&B?\_.H?\ ?Q/_ (BC_A4&B?\ /SJ'_?Q/_B*/;1#Z
MK4/%J*]I_P"%0:)_S\ZA_P!_$_\ B*/^%0:)_P _.H?]_$_^(H]M$/JM0\6H
MKVG_ (5!HG_/SJ'_ '\3_P"(H_X5!HG_ #\ZA_W\3_XBCVT0^JU#Q:BO:?\
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M#U4>*U;TW4KO2-1AO[&7RKF$DQOM#8)&.A!'0UZ__P *@T3_ )^=0_[^)_\
M$4?\*@T/_GYU#_OXG_Q%/VT!?5:B/%W=I'9V.68DD^]-KVK_ (5!H?\ S\ZA
M_P!_$_\ B*/^%0:'_P _.H?]_$_^(H]M /JM0\5HKVK_ (5!H?\ S\ZA_P!_
M$_\ B*/^%0:'_P _.H?]_$_^(H]M$/JM0\5HKVK_ (5!H?\ S\ZA_P!_$_\
MB*/^%0:'_P _.H?]_$_^(H]M$/JM0\5HKVK_ (5!H?\ S\ZA_P!_$_\ B*/^
M%0:'_P _.H?]_$_^(H]M$/JM0\5HKVK_ (5!H?\ S\ZA_P!_$_\ B*/^%0:'
M_P _.H?]_$_^(H]M$/JM0\5HKVK_ (5!H?\ S\ZA_P!_$_\ B*/^%0:'_P _
M.H?]_$_^(H]M$/JM0\5HKVK_ (4_H?\ S\ZA_P!_$_\ B*/^%/Z'_P _.H?]
M_$_^(H]M /JM0\5HKVK_ (4_H?\ S\ZA_P!_$_\ B*/^%/Z'_P _.H?]_$_^
M(H]M /JM0\5HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O
M /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM
M0\4HKVO_ (4_H?\ S\ZA_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4H
MKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_
M (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_
MH?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\
MS\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC
M_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_
M$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\
MB*/^%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^
M%/Z'_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'
M_P _.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _
M.H_]_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]
M_$_^(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^
M(H]O /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O
M /JM0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM
M0\4HKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0\4H
MKVO_ (4_H?\ S\ZC_P!_$_\ B*/^%/Z'_P _.H_]_$_^(H]O /JM0R/@R#OU
M@XX_<_\ L]>Q+TK!\/>&K'P[9_9;&(JA.YF8Y9SZDUO#@5RSES2;1WTH.$%%
MBT4F:,U)8M%)FC- "T444 %%%% !129HH C[T4=Z*H HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *,"BB@ P*,"BBD 8%&!110 8
M%&!110 8%&!110 8%&!113 ,"EP***0!@48%%% !@48%%% !@4444 <!K'C?
M4]/UVXL88;0Q1R;071B<<?[5>D);HR*Q)R17B7B?_D;KW_KL/Z5[E%_JD^E7
M4225CHK12C&Q']EC]6H^RQ^K5/165S @^RQ^K4?98_5JGHHN!!]EC]6H^RQ^
MK5/12N!!]EC]6H^RQ^K5/11<"#[+'ZM1]EC]6J>BBX$'V6/U:C[+'ZM4]%.X
M$'V6/U:C[+'ZM4]%%P(/LL?JU'V6/U:IZ*+@5GM0%RA.?0UG7T[6^FW4\>-\
M4+NN1QD FMJN<U-B=(U(?],)?_033CN"W.?\%>)M0U[6I;2]\GRE@:0>6F#D
M,H]?<UWOV:/W_.O*OAA_R,\__7H__H25ZW55=):&U>*C.R(?LL?O^='V6/W_
M #J:BL[F)#]EC]_SH^RQ^_YU-11<"'[+'[_G1]EC]_SJ:BBX$/V6/W_.C[+'
M[_G4U%%P(?LL?O\ G1]EC]_SJ:BBX$/V6/W_ #H^RQ^_YU-11<"'[+'[_G1]
MEC]_SJ:BBX$/V:/W_.C[-'[_ )U-11<"C-'Y3 =0>AK.UJ]DTW1KJ\B5&DA3
M<H<<'ZUI:@<)%_O5A>*?^14U#_KE_45<=65!7DD97@_Q5>>(=8DL[J"WCC6!
MI 8@0<@J.Y/K7<?94]37E7PQ_P"1GF_Z]'_]"6O7*=56E9&E>*C.R(/LJ>IH
M^RIZFIZ*BYB0?94]31]E3U-3T47 @^RIZFC[*GJ:GHI7 @^RIZFC[*GJ:GHH
M @^RIZFC[*GJ:GHH @^RIZFC[*GJ:GHH @^RIZFC[*GJ:GHIW @^RIZFC[*G
MJ:GHHN!1EC\I@#R#T-4M3O1IVF7%YY?F>2A?9G&<>]7]0.$C_P![^E8OB7GP
MOJ/_ %P:JCJ.*O)(I>%O%B^)-2ELS8FWV0F7=YN[."!C&T>M=9]E3U->6_"[
M_D9+G_KT;_T-*]9IU%:5D:5H*,[(@^RIZFC[*GJ:GHJ+F1!]E3U-'V5/4U/1
M1<"#[*GJ:/LJ>IJ>BBX$'V5/4T?94]34]%%P(/LJ>IH^RIZFIZ*+@0?94]31
M]E3U-3T47 @^RIZFC[,GJ:GHHN!#]F3U-'V9?4U-11<"BZ^6^T_@:I:K>'3M
M*NKQ4#M#&7"DX!Q5V^;$T7N#63XE_P"18U'_ *]V_E51U*BKR2,OPGXLF\1Z
MI+9RVD<*I 9=RL23AE&/UKL?LP_O?I7EGPO_ .1EN?\ KS;_ -#2O6J=16E9
M&E>*C.R(/LP_O?I1]F'][]*GHK.YB0?9A_>_2C[,/[WZ5/11<"#[,/[WZ4?9
MA_>_2IZ*+@0?9A_>_2C[,/[WZ5/11<"#[,/[WZ4?9A_>_2IZ*+@0?9A_>_2C
M[,/[WZ5/11<"#[,/[WZ4?9A_>_2IZ*+@0?9A_>_2@VPQPWZ5/11<"BPVL5(Y
M%<MXQ\1WGA\67V2.!_/W[O-4G&W;C&"/4UU%VV+M1_L_U->?_$[[NE_]M?\
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MXX(8I)9(XD1Y2&D95 +G&,D]S@ 5)7-.2D[I&L59!1114C"BBB@"EJ7W(O\
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M7U'_ *X-_*MK4O\ 5Q?[W]*Q?$G_ "*^H_\ 7!OY5<=T.'Q(XWX7?\C)<_\
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MUD7WA>UUFZ585DMA<2!>0@QDUSEYJ/B#Q%IVM0QZ)-9::VF31QI=)BXFG*D
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M )&Z^_Z[#^E>Y1?ZI/I5U=D=5?X8^@^LA_$-K'%),4E:,7!M8=B[FN)!G<$
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MLFW[RC_:'!QWSQT-9L7AV1?$5M+&DT.GV<\EPB/<;E9W5@=B#[HR['D\8P
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M_P -AHRZ=J"WT>F+$4>U=075 " 2,$YKH+C63-:.8=/U/;N"2L(&CD16!^=
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MCZXJQ1=@Y23U9%;6T%G;K!;1)%$GW408 J6BBD0%%%% !1110 4444 %%%%
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M(U"#2/$&H6%I*US/+>036X0YN(7SM8#N5)R/4%AW%>@6JD6< 88(C7@CH<4
M5'UW3DTZVOQ,SP76/L_EQ.[2Y!("J!N/ )Z=!4]OJ5G=:=]OBG7[+M9C(P*[
M0N=V0>1C!R#TQ7();7,/A/PJLJ7=K]GV&:>"$M-;GRF'W<'J3M.5( /3N-30
M'2T\/BVO+6X97-S)\]LY::/>3N=<<.X;.TX)R<#L "XOB?37MYYHS<$01K,Z
MM;O&WE$X\P!P-RCDDC/2MA6#*&4@J1D$=ZY32[ZWO)+[5-0CN(96MF @EM9(
MUM[=>2I9E +'.3@^@' R=CPU'-#X6TF*Y!$Z6<2N&Z@A!G- &I1110 4444
M90_X^I?]XU/4(_X^I?\ ?/\ .IJH HHHH **** "BBB@ HHHH **** (^]%'
M>BJ$%%%% '(^$?\ D8/$O_7U_P"S/5>PT^TU#QKKJW=O',%5=H=<XR!T]ZZV
MVL+6TFGFMX%CDG;=*PZN>>3^9HBL+6"[FNHX%6>;_6..K?6JYM6;.IJVNIY?
MYDY\#6J9_P!'_M!EDW$[<8! ..V<UMV-C*FNK<QR:1"IM9 \%C*3O7:><8]2
M/RKLHM)T^"R>RCM(A;.<M$5RI/X_2H[/0],T\N;6RBB9QM9@,DCTR>U4YHMU
MDTSD/#5GIUMX.N=5GM3),%E5V5B&*], ]JRI]JP:+<0PZ=;JUPK1K;,3,!G^
M,D\UZ7;:?:6EH;6"W1+<YS&!D'/6J2>&-%3[NG0 [@V<'((]/2CG5[@JRNVS
MF;:'2IO&>N#5!;E !M\\C X&2,]ZQ&+GP#&"6,0U3$6?[NP_US770^&%N/$.
MJ76I6L4MK.5,.3DY'TY%;DND:?-91V<EI$;:(ADCQ@*>>?U-',D-U8QMUV.)
MU42S>/+I)H["3$*B%;]B(]N!]WWSG]:C_LU%\,&UN-5LT4W^Z#8S21;L8*,<
M<#O7=7^DZ?J87[;:1S%?NEAR/QZTO]DZ?]@^P_8X?LO7RM@QGU^OO2YR565D
MCF/#\L4?BB6WN-/MH+[R,^;92'RF7CJO0=J[.J5AI&GZ7N^Q6D<);[Q4<G\3
MS5VID[LRJ24G=!1112("BBB@ HHHI %%%% !1110 4444 %%%%, HHI:0"44
MM% "44M% "44M% "44M% "44M% 'C?B;_D;;W_KL/Z5[E%_J4^E>&^)O^1NO
M?^NP_I7N47^J3Z5=79'57^&/H/HHHK$Y@HHHH :Z)*A21%=&&"K#(-.HHH *
M*** "BBB@ HHHH **** "BBB@ KFM2_Y!6I?]<9?_0372US6I?\ (*U+_KC+
M_P"@FJCN-;HXGX8?\C//_P!>C_\ H25ZW7DGPP_Y&>?_ *]'_P#0DKUNKK?$
M;XG^(%%%%9'.%%%% !1110 4444 %%%% !1110 4444 %%%% %'4ON1?[]87
MBC_D5-0_ZY?U%;NI?<B_WZPO%'_(J:A_UR_J*N&Z*A\2..^&/_(SS?\ 7H__
M *$M>N5Y'\,?^1GF_P"O1_\ T):]<JJWQ&V)_B!11161SA1110 4444 %%%%
M !1110 4444 %%%% !1110!2U+_5Q?[W]*Q?$G_(KZC_ -<&K:U+_5Q?[W]*
MQ?$G_(KZC_UP;^57'=%0^)'&_"[_ )&2Y_Z]&_\ 0TKUFO)OA=_R,ES_ ->C
M?^AI7K-56^(UQ/\ $"BBBLC **** "BBB@ HHHH **** "BBB@ HHHH ****
M *%__KH?H:R?$O\ R+&H_P#7NW\JUK__ %T/T-9/B7_D6-1_Z]V_E5QW14/B
M1Q7PO_Y&6Y_Z\V_]#2O6J\E^%_\ R,MS_P!>;?\ H:5ZU55OB-<3_$"BFNZQ
MH7=@JJ,EF. *(Y(YD#QNKH>C*<@UD8#J*** "BBB@ HHHH **** "BBB@ HH
MHH **** ,Z]_X_$_W/ZFN!^)OW=+_P"VO_LE=]>_\?B?[G]37 _$W[NE_P#;
M7_V2M:7Q(VP_\1'4?#[_ )$VS_WI/_0S73US'P^_Y$VS_P!Z3_T,UT]1/XF1
M5^-D*6L,=S+<H@664*)&!^]C.,CIGGK4U%%20%%%% !1110 4444 %%%% $5
MS;0WD!@N$$D3$$J3P<'//J..G>I:** "BBB@ HHHH RQ_P ?4O\ OG^=35"/
M^/J7_>-350!1110 4444P"BBBD 4444 %%%% $=%%%,04444 %%%% !1110
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MS_\ /:3_ +Z-&V;_ )[2?]]&BP$VHR*SQQ Y8')]JQ?%/_(JZA_UR_J*U(X
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MIK+S<?\ /9_SI&2608>1F'H318!(V#SR..C,2*L4R.,(,4\4P%HHHH ****
M"BBB@04444 %%%% $=%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHP?2C!]* "BC!]*,'TH **,'THP?2F(**,'THP?2@ HI
M<'THP?2@8E%+@^E&#Z4 )12X/I1@^E "44N#Z48/I0 E%+@^E)2 **** "BB
MB@ HHHH **** "BBBF 4"BEI %%%% !1110 4444 %%%% !111@^E !11@^E
M&#Z4  I:,'THP?2D 448/I1@^E !11@^E&#Z4 %%&#Z48/I3 **,'THP?2@
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MZ444 ,>-74@CGL:H(VX5I5D0'EOK30$]%%%4(**** "BBB@ HHHH ,T9HHH
M,TM)2T@"BBB@ HHI* #-&:**8!FC-%% !FC-%%(!:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HS110 9I:2B@!:*2B@!:*2B@!:*2B@!:*2B@"
M/O11WHJ@"BBB@ HHI-R[MNX9],T!<6BD5E894@CU!I: "BBB@ HHHH ****
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M^*@TD18-Y;'.5R.#@\9KUCQ=I)UKPO?V<<32SF%S @D*9DVD+SD#OWXJC<^
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MHH **** %HHS1FD 449HS0 4444""BBB@ HHHS0,**,T9H **,T9H **,T4
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MHHH **** "BBB@ J.?\ X]Y/]T_RJ2HY_P#CWD_W3_*@#!NO^0/=_P#7!_\
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M++%>6D\C22V-TUN9&ZNNU70GWVNH)[D&M:LS1+.:V@N9[E=EQ>7#7$B9SLR
MJKD=2%50?<&M.@ HHHH **** "BBB@ HHHH *Q[?JWUK8K'M^K?6F@+%%%%4
M 4444 %%%% !1110(***!0 M%%%( HHHH 2BBBF 4444 %%%% !2T"BD 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1113 ****0!1110 4444
M#"BBB@ HHHH C[T4=Z*HD***IZAID.HB,3/*NS./+;'7_P#503-R4;Q5V7*:
MKJQ(5@2O4 ]*Y/0M*BOOM+337&89MJ[9,<>]+97MQ9:AK+P6;7&)BSD,%"@%
MJKE.&..=HRG&RE?SVOTL=;16._B"(:;;74<+O+<';'"#R6S@\TD6N/\ Z5%=
M6;07,$)F\LOD. ,\&ERLZ/K=&Z5_S]1\OAVQFF9V,^UVWM&)#M)]<5JHBQHJ
M(H55& !V%8UEKTMW"\YTZ98%C+!E^;>V0-HXY_\ K40ZY.+NVAO+!K9;GB)B
MX;\QVZBFTS*G6PT/>AIS>3_R-JC-8+^(+AIKN.WTUIOLKD.PDP,#//3VZ5%?
M:C:7UMI=RT+N))P% DV[&SWXYI<K*EC:5FXO;U76W8Z.BLBZUJ5;V2ULK)KI
MX1F4A]H7V]Z8_B*(V-M/!"TDMP_EI$6 PW?)_$?G1RLMXNBFTWMZ^FG?Y&U1
M5"POY[F66"YLI+:6/GD[E8>S5?I-6-H3C-<T0HHHI%A1110 4444 177_'G-
M_P!<V_E7&>#/^1CB_P!Q_P"5=G=?\><W_7-OY5QG@S_D8XO]Q_Y5<?A9X^/_
M -ZH>OZH]+HHHK$]D**** "BBB@ HHHH **** "BBB@ HHHH **** "J6I_Z
MB/\ WQ_(U=JEJ?\ J(_]\?R-- 5)/^/9_P#=/\JX+PS_ ,C#:_\  _\ T UW
MLG_'L_\ NG^5<%X9_P"1AM?^!_\ H!K:&S/&S'_>:'K^J/5:SM?O9=-\.ZE?
M0 &:WMI)4R,C<%)&:T:;)&DT3QR(KHX*LK#((/4&L#V3%L]-.G7-K<?VQ<.&
MC83I=3&03G&=R@G"$8)^48QGBL3PUXE&H:O<AM2CN%U")[FWA60$V^QBH3';
M*%&QZAJW5\*Z8L;QM]ID0PM;H)+EV\J-AAE3)^7CC(YQWJ_/IMK<?9=\>/LC
M[X=IV[3M*XX[;6(Q0!P_AK4IV.ANDNK/(]D;F_\ M+O(LR>7UC4DDMO*_<'0
M^XK?O?$5VTMR--M4*6EG]KF^V*\3$$N%4*1D']VQR1Z>M:D.BV,$6G1Q1LHT
MY=EL0YRJ[=N">XQZ^@/:FZAH-CJ<_G7 F#M%Y,GE3-'YD><[6VD9')_,^IH
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M **** "BBB@ HHHH **** "BBB@ HHHI@%%%%( HHHH **** "BBB@84444
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M?^HC_P!\?R-7:I:G_J(_]\?R-- 5)/\ CV?_ '3_ "K@O#/_ ",-K_P/_P!
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M1110 4444 %%%%, HHHI %%%% !1110,**** "BBB@ HHHH CHHHJB0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHI#"BBB@ HHHH **** (KK_ (\YO^N;
M?RKC/!G_ ",<7^X_\J[.Z_X\YO\ KFW\JXSP9_R,<7^X_P#*M(_"SQ\?_O5'
MU_5'I=%%%8'LA1110 4444 %%%% !1110 4444 %%%% !1110 52U/\ U$?^
M^/Y&KM4M3_U$?^^/Y&A 5)/^/9_]T_RK@O#/_(PVO_ __0#7>R?\>S_[I_E7
M!>&?^1AM?^!_^@&MX;,\;,?]YH>OZH]5HHHK ]D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "HY_^/>3_=/\JDJ.?_CWD_W3_*@# NO^0/>?]<'_ /03
M7)>$O^1GL_\ @?\ Z U=;=?\@>[_ .N#_P#H)KDO"7_(SV?_  /_ - :MX_"
MSP\P_P![H^J_-'J%%%%8'N!1110 4444 %%%% !1110 4444 %%%% !1110
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M5?*7TH\M?2BPRU_:%O\ WC_WR:/[0M_[Q_[Y-5?+7TH\M?2BP%K^T+?^\?\
MODT?VA;_ -X_]\FJOEKZ4>6OI18"U_:%O_>/_?)H_M"W_O'_ +Y-5?+7TH\M
M?2BP%K^T+?\ O'_ODT?VA;_WC_WR:J^6OI1Y:^E%@+7]H6_]X_\ ?)H_M"W_
M +Q_[Y-5?+7TH\M?2BP%K^T+?^\?^^31_:%O_>/_ 'R:J^6OI1Y:^E%@)IM1
M381"&9ST)& *KVZ%5YIX11VIW2BP"T4E% "T444 %%%% !111B@0448HQ3 *
M*** "BBB@84444 %%%% !11BC% @HHQ1B@!11112&%%%% !1110 4444 %%%
M% !1110 4444P"BBBD 4444 %%%% !1110 4444 %%%% !1110!'1115$A11
M10 4444 %%%% !1110 4444 %%%% PHI,T9I +129HS0 M%%% !1113$%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M***2C- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T
M +129HS0 M%%% !1110 M!I,T4 %%%% PHHHH **** "BBB@ HHHI %+249H
M 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %I**6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!:*3-&: %HI,T4 .HI,T9H 6BDS1F@0II***!A1110 4444 %+249I
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M%%@&8/I1@^E/HH 9@^E&#Z4^B@!F#Z48/I3Z* &8/I1@^E/HH ;CVHQ3J*+
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MY709].E<ZC++;>89HXL*P#MF0E5*G<#\QRV0!G&!0;#1S$RRW%S%!)"I,:A
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M.=KB:XCF>1]H?S%,:KC"A>"(P1COSUK/6;3+#78I!+),;=2K/@DO)+*X+'
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M"[BN!J,CEG<)')@!9&(#M@*""21UX^?C&10!>?7=.C+!IVW!@NT1.68D,1@
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M.<BFR-H>E3IJ-L&E>%"A140G"0.0VYEW<K&0"#@X^M &Q'K]F?,$NZ,H[)M
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M8Y'/'-9\>G>'95GDBNFQ-',CG?U5QN)&1V7.T]-I/6@#1B\2V,ETL)$R!F=
M[Q,!N63R\'C@;NYX[=:=<>(+6VO[BSD23S85C8<##AF ^4^V1GZBLR9M"@^T
M.U[-)\Y=D0;MN9E<@87G#D9ZXW?2K%U#H>J3S&2Z)E%Q&25.TK(CA %X_O':
M>O7% &G'K&GR2^6MRN[=M&5(!Z]"1@CY3R.,C%1G7M-5=QN"!L#@^6WS E0,
M<<G+J,#D;A6&\&C,VHV5W-<I! RVZF0XV#B4A,+G:.,DYX'IR9;FRT1+B[U9
MKF=_L[KY@B4,$(=&P"%R>8UXR<#/2@#4C\0V,F3F9%#.O[R)E8LKJF N,G)<
M 8'MUIUWK,5NMJT433BY5F0JRIP!DYW$>M9"KHUZ+II+N:)EDG4QNJG&9E#8
M!4ALNB\')^?'<5?^SZ.+2PDFG6:&V@=XFF(8,@ W,>.PQZ8H ?9>);"]$A!D
MCVJ'7>C?,NQ7XXQG#CY>M3'7]- _X^&Z D")R1ER@!&,@[@5P><BL^[@T6X:
M[#WLBMYC%]A_B8",A1@[ON@8YYR#Z4W3=/T4,;:UO&E=_+EX*@';(9QC:H7K
M)G [$=.M &G%KNG3(S1S.VW' A?<>=O QDG((('0C!HO-9M+.RMKLEI8;AE"
M-'S\I&XM] H+'V%8B)H=_9>8;J:(JQRA 9LM*SXVE2&&X-V/3U%2>5X=DM[.
MRN)A+#;Q?9H%=@RNI5/F.WV*C)Q][WH V$U027[6R6TK1K)Y+3 KM#[=W3.<
M<@9QU_.M"N;@LM*EN#)#?S2O:'SF4[3\X79OR5SSMYP=I(/'6M.#6M/?9%]K
M4R84'=U))4=1QG++T_O#UH T:*H-K6FHQ5KR(8#,23P ,D\].BL?H":C_M^P
M,Z0H[N[!2/D( S((\$G&#N/3K0!IT5G#7M+,;2"\0JN"2 3P<D$<<C"L<CC
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MGN)I[27,#6\:DA5B4YP3AODD'3DY.!Q0 ^*'0[:*ZADU42P36HA*/(N$A.<
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M?7-UO$&EK/#']M@*S!RL@D79E2@*YSU^<''I4[:MIR&4/?6RF$A9,RCY"3@
M_CQ]: ()-%CDEE8W-P(I)5F,(*[0X93GIGJHXSW/MBB/"%ELE5KFY;S5VECL
M!QLD3)(7DXE;DY)(%::ZUI;Q-*FHVK1IC<PE4@9SCOWP?R-+<ZG;V]KYZ9N
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M,WY#\4_MW30[AKN)(U1'\YG4(VXN  <]1L;/TJ4ZMIP>5#?6V^($R+YHRH!
M.?Q(_,>M %.[\.VUW%91-/.J6B*B ;3G:5()RIP?E'(QU-07?AB"6UCMXV8J
M1#$[.^"(XV8G&!R6#LIZ<-^>H-5T\LBB^MLR)YB#S1\R\\CGIP?R/I3+?6+&
MZAN9X[A/(MY/+>8L-A.U6X.>GS ?7- !<Z7'<W9G\^:/?&L<J)C$BJ20#D9'
MWFZ$=:H/X8ADCP;Z[\W9Y?F_)N\O85V_=QT8G.,Y[UJ1:C93R+'%=P.[1^:%
M60$E,D;OID$9]J@;7-+$(E&H6S*8VE7;*#N49R1Z_=;\CZ4 5W\.6K1;!-.I
M D 8$9!=D8GIV*#'XT-H2?;K&0',5M+-.2S?,S2,6VX QMW$-]57ZU+!X@TR
M:U6=[R"'*JS))*FY-PW '!(!(YZ]*DN=;TRT++-?0*RE0R[P2-Q ''_ A^8H
M BN=#AGFFF6XGAEF=F9X]O1D5"HR#QA%/KD?A3QHMLNE7&GHTB0S;N01E<^F
M1V]\U*VKZ:GF[K^V7RF"R9E'RDG !]\@CZT_^T+/R6F^UP>4D8E9_,& ASAB
M?0X//M0!G7'AFSNHE2625MK2,"=I^9Y5E)P1@_,HXQTIUUX>M[FPBM%GE@5(
MI(=T*HI97&&&-NT9Z\ 5;BUC3)VVPZA;.WHLJD_>"_S('U(]:BDUW3XKX6;S
MJ)&*JIR-K,3(-H/J#$P/X4 59_"]I<2S2232DRN)-NU-H8'.2-N&]/FR<5/9
MZ%;V-ZMS%+("L8CV*J(I& .=JC/3..@R<"G-K^G+ T@N8W=8Q(T*2*S@$ ]
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MS2)&BDY1UX 7;GYAVZ>]:Z.LB*Z,&1@"I'0BG4 8\7AVWMH$CMKBXA:-U=)
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M)!)<[RRK( % 8S$_^CB/PSST*0^$V5X'FOV81(BA-IP"OED]3C&8QT ZG.:
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M<1@QVWE-*@7S5CD:12N>N<GCKCM6C8:%'8WD\_FM*LGF;5?=E?,;>XZXQGT
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M4\>]7+/P[!9PWD2RLRW$;1@D?,BDL<9[_>_SR:V:*+ 8\NA0E7;F;]X9?*;
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M3N(QU/K3J&"04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Legend Biotech Corporation<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001801198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualProperty', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,348<span></span>
</td>
<td class="nump">$ 12,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185,615<span></span>
</td>
<td class="nump">78,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="nump">3,329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">195,053<span></span>
</td>
<td class="nump">93,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(69,497)<span></span>
</td>
<td class="num">(49,101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CostOfLicenseAndOtherRevenue', window );">Cost of license and other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,847)<span></span>
</td>
<td class="num">(5,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(101,924)<span></span>
</td>
<td class="num">(100,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdministrativeExpense', window );">Administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31,463)<span></span>
</td>
<td class="num">(31,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_SellingAndDistributionExpenses', window );">Selling and distribution expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,969)<span></span>
</td>
<td class="num">(24,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss', window );">Loss on asset impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(970)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,061)<span></span>
</td>
<td class="num">(5,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,056<span></span>
</td>
<td class="nump">13,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Other (expense)/income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(54,508)<span></span>
</td>
<td class="nump">49,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(99,130)<span></span>
</td>
<td class="num">(59,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,786)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100,916)<span></span>
</td>
<td class="num">(59,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Ordinary equity holders of the parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (100,916)<span></span>
</td>
<td class="num">$ (59,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExchangeDifferencesOnTranslationAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME/(LOSS)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 60,729<span></span>
</td>
<td class="num">$ (47,993)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Net other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,729<span></span>
</td>
<td class="num">(47,993)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,729<span></span>
</td>
<td class="num">(47,993)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,187)<span></span>
</td>
<td class="num">(107,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Attributable to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Ordinary equity holders of the parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (40,187)<span></span>
</td>
<td class="num">$ (107,786)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts have been reclassified to present finance income as a separate line item and to combine other income/(expense), net for comparative purposes</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity classifies as being administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExchangeDifferencesOnTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExchangeDifferencesOnTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 129<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_129_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CostOfLicenseAndOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost Of License And Other Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CostOfLicenseAndOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_RevenueFromLicensingOfIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from licensing of intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_RevenueFromLicensingOfIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_SellingAndDistributionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling and distribution expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_SellingAndDistributionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 98,810<span></span>
</td>
<td class="nump">$ 99,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdvancePaymentsForPropertyPlantAndEquipment', window );">Advance payments for property, plant and equipment</a></td>
<td class="nump">545<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">107,224<span></span>
</td>
<td class="nump">101,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_TimesDepositsNonCurrent', window );">Time deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">2,082<span></span>
</td>
<td class="nump">2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationPrepaidLeases', window );">Collaboration prepaid leases</a></td>
<td class="nump">182,613<span></span>
</td>
<td class="nump">172,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentNonfinancialAssets', window );">Other non-current assets</a></td>
<td class="nump">5,583<span></span>
</td>
<td class="nump">6,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">396,857<span></span>
</td>
<td class="nump">386,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Collaboration inventories, net</a></td>
<td class="nump">30,933<span></span>
</td>
<td class="nump">23,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">6,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepayments, other receivables and other assets</a></td>
<td class="nump">182,040<span></span>
</td>
<td class="nump">130,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_PledgedDeposits', window );">Pledged deposits</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_TimesDeposits', window );">Time deposits</a></td>
<td class="nump">563,678<span></span>
</td>
<td class="nump">835,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">441,702<span></span>
</td>
<td class="nump">286,749<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">1,218,792<span></span>
</td>
<td class="nump">1,283,918<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">1,615,649<span></span>
</td>
<td class="nump">1,670,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">58,143<span></span>
</td>
<td class="nump">38,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherPayablesAndAccrualsCurrent', window );">Other payables and accruals</a></td>
<td class="nump">116,810<span></span>
</td>
<td class="nump">166,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Government grants</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">5,341<span></span>
</td>
<td class="nump">4,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Tax payable</a></td>
<td class="nump">14,009<span></span>
</td>
<td class="nump">20,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">39,535<span></span>
</td>
<td class="nump">46,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">234,373<span></span>
</td>
<td class="nump">277,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Collaboration interest-bearing advanced funding</a></td>
<td class="nump">305,745<span></span>
</td>
<td class="nump">301,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities long term</a></td>
<td class="nump">51,724<span></span>
</td>
<td class="nump">44,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentGovernmentGrants', window );">Government grants</a></td>
<td class="nump">6,058<span></span>
</td>
<td class="nump">6,154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">363,527<span></span>
</td>
<td class="nump">351,963<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">597,900<span></span>
</td>
<td class="nump">629,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,017,712<span></span>
</td>
<td class="nump">1,040,509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total ordinary shareholders&#8217; equity</a></td>
<td class="nump">1,017,749<span></span>
</td>
<td class="nump">1,040,546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">1,017,749<span></span>
</td>
<td class="nump">1,040,546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,615,649<span></span>
</td>
<td class="nump">$ 1,670,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current government grants recognised on the statement of financial position as deferred income. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentNonfinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentNonfinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdvancePaymentsForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advance payments for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdvancePaymentsForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationPrepaidLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Prepaid Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationPrepaidLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherPayablesAndAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other payables and accruals, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherPayablesAndAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_PledgedDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pledged deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_PledgedDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_TimesDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Times deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_TimesDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_TimesDepositsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Times deposits, non-current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_TimesDepositsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Share premium</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Share-based compensation reserves</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Foreign currency translation reserve</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Retained accumulated losses</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,251,371<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td colspan="2" class="nump">$ 2,637,120<span></span>
</td>
<td colspan="2" class="nump">$ 54,621<span></span>
</td>
<td colspan="2" class="nump">$ 44,304<span></span>
</td>
<td colspan="2" class="num">$ (1,484,710)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_StatementOfChangesInEquityRollForward', window );"><strong>Statement of changes in equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(59,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(59,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="num">(47,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(47,993)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss) for the period</a></td>
<td class="num">(107,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(47,993)<span></span>
</td>
<td colspan="2" class="num">(59,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share options</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">2,668<span></span>
</td>
<td colspan="2" class="num">(897)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity', window );">Reclassification of vested restricted share units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">6,081<span></span>
</td>
<td colspan="2" class="num">(6,081)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based compensation expense</a></td>
<td class="nump">18,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">18,703<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">1,164,059<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td colspan="2" class="nump">2,645,869<span></span>
</td>
<td colspan="2" class="nump">66,346<span></span>
</td>
<td colspan="2" class="num">(3,689)<span></span>
</td>
<td colspan="2" class="num">(1,544,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">1,040,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">1,040,546<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td colspan="2" class="nump">2,695,976<span></span>
</td>
<td colspan="2" class="nump">74,427<span></span>
</td>
<td colspan="2" class="num">(68,158)<span></span>
</td>
<td colspan="2" class="num">(1,661,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_StatementOfChangesInEquityRollForward', window );"><strong>Statement of changes in equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(100,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="num">(100,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translation of foreign operations</a></td>
<td class="nump">60,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">60,729<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss) for the period</a></td>
<td class="num">(40,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">60,729<span></span>
</td>
<td colspan="2" class="num">(100,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share options</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">2,373<span></span>
</td>
<td colspan="2" class="num">(929)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity', window );">Reclassification of vested restricted share units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">14,495<span></span>
</td>
<td colspan="2" class="num">(14,495)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based compensation expense</a></td>
<td class="nump">15,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">15,946<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">1,017,749<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td colspan="2" class="nump">$ 2,712,844<span></span>
</td>
<td colspan="2" class="nump">$ 74,949<span></span>
</td>
<td colspan="2" class="num">$ (7,429)<span></span>
</td>
<td colspan="2" class="num">$ (1,762,652)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">$ 1,017,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These reserve accounts comprise the consolidated reserves of $1,017.7 million and $1,164.0 million in the consolidated statements of financial position as at March&#160;31, 2025 and, 2024, respectively</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through reclassification of vested restricted stock, equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_StatementOfChangesInEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statement of changes in equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_StatementOfChangesInEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS (USED IN)/PROVIDED BY OPERATING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (99,130)<span></span>
</td>
<td class="num">$ (59,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,056)<span></span>
</td>
<td class="num">(13,870)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,061<span></span>
</td>
<td class="nump">5,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForInventoryReserveProvision', window );">Provision for inventory reserve</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,798)<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Loss on asset impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">970<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">2,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForDepreciationOfRightOfUseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,787<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Fair value gains on financial assets measured at fair value through profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(449)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign currency exchange loss/(gain), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,192<span></span>
</td>
<td class="num">(49,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Equity-settled share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,946<span></span>
</td>
<td class="nump">18,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DeferredGovernmentGrant', window );">Deferred government grant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(134)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows provided by (used in) operations before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32,697)<span></span>
</td>
<td class="num">(91,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease in trade receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,918<span></span>
</td>
<td class="nump">96,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets', window );">Increase in prepayments, other receivables and other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48,586)<span></span>
</td>
<td class="num">(16,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets', window );">Decrease in other non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">473<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Increase in collaboration inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,232)<span></span>
</td>
<td class="num">(4,470)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase in trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">19,510<span></span>
</td>
<td class="nump">22,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">(Decrease)/increase in other payables and accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(38,635)<span></span>
</td>
<td class="nump">7,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities', window );">Increase/(decrease) in other non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent', window );">Decrease in contract liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,037)<span></span>
</td>
<td class="num">(12,181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash (used in)/provided by operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(106,286)<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Interest income received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,957<span></span>
</td>
<td class="nump">13,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income tax (paid)/received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,926)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities', window );">Interest on lease payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(499)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash (used in)/provided by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(103,754)<span></span>
</td>
<td class="nump">15,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS PROVIDED BY/(USED IN) INVESTING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,002)<span></span>
</td>
<td class="num">(6,243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets', window );">Prepayment to collaborator for collaboration assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,358)<span></span>
</td>
<td class="num">(16,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities', window );">Purchase of financial assets measured at fair value through profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities', window );">Cash receipts of investment income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets', window );">Proceeds from disposal of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AdditionInTimeDeposits', window );">Addition in time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(721,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DecreaseInTimeDeposits', window );">Decrease in time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">374,000<span></span>
</td>
<td class="nump">498,273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">256,640<span></span>
</td>
<td class="num">(396,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS PROVIDED BY FINANCING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of share options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">1,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal portion of lease payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(777)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">667<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">153,553<span></span>
</td>
<td class="num">(379,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of foreign exchange rate changes, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,400<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">286,749<span></span>
</td>
<td class="nump">1,277,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">441,702<span></span>
</td>
<td class="nump">897,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash and bank balances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,005,450<span></span>
</td>
<td class="nump">1,156,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Less: Pledged deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_TimesDepositsCurrentAndNoncurrent', window );">Time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">563,678<span></span>
</td>
<td class="nump">258,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition', window );">Cash and cash equivalents as stated in the statement of financial position</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">441,702<span></span>
</td>
<td class="nump">897,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows', window );">Cash and cash equivalents as stated in the statement of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 441,702<span></span>
</td>
<td class="nump">$ 897,571<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts have been reclassified between increase in trade payables and (decrease)/increase in other payables and accruals for comparative purposes</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial assets measured at fair value through profit or loss, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdditionInTimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition in time deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdditionInTimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Decrease (Increase) In Other Non-current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase in prepayments other receivable other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForDepreciationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForDepreciationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Contract Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other non current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AdjustmentsForInventoryReserveProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Inventory Reserve Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AdjustmentsForInventoryReserveProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents as stated in statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents as stated in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts of investment income classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DecreaseInTimeDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in time deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DecreaseInTimeDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DeferredGovernmentGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred government grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DeferredGovernmentGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest on lease payments classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment To Collaborator For Collaboration Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Disposals Of Property, Plant And Equipment, Intangible Assets Other Than Goodwill, Investment Property And Other Non-current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_TimesDepositsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Times deposits current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_TimesDepositsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract', window );"><strong>Disclosure of subsidiaries [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory', window );">CORPORATE INFORMATION</a></td>
<td class="text">CORPORATE INFORMATION <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legend Biotech Corporation, ("Legend"), was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Act (As Revised) of the Cayman Islands. The registered office address of Legend is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1002, Cayman Islands.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Legend is an investment holding company. Legend's subsidiaries are principally engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PREPARATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_BasisOfPreparationAbstract', window );"><strong>Basis of Preparation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">BASIS OF PREPARATION</a></td>
<td class="text">BASIS OF PREPARATION <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The unaudited interim condensed consolidated financial statements of Legend and its subsidiaries (collectively referred to as the &#8220;Company&#8221;) for the three months ended March&#160;31, 2025 have been prepared in accordance with International Accounting Standard (&#8220;IAS&#8221;) 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interim Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;IAS34&#8221;) issued by the International Accounting Standards Board (the &#8220;IASB&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies and basis of preparation adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's financial statements for the year ended December&#160;31, 2024. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company&#8217;s annual consolidated financial statements as at December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_BasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of Preparation [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_BasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</a></td>
<td class="text">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new International Financial Reporting Standards (&#8220;IFRS&#8221;), amendments or interpretations issued by the IASB that became effective in the three months ended March&#160;31, 2025 that had a material impact on the Company's unaudited interim condensed consolidated financial statements.</span></div>The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">REVENUE</a></td>
<td class="text">REVENUE<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Novartis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue - total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue and other revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the timing of transfer of goods or services is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue at a point in time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue over time*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the deferred revenue which is included in contract liabilities for the periods presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities (Current)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER (EXPENSE)/INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract', window );"><strong>Disclosure of Other Income and Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">OTHER (EXPENSE)/INCOME, NET</a></td>
<td class="text">OTHER (EXPENSE)/INCOME, NET <div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total other (expense)/income, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange (loss)/gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value gains on financial assets measured at fair value change through profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense)/income, net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(54,508)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:1pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign currency exchange (loss)/gain, net is comprised mainly of the unrealized foreign exchange (loss)/gain that was primarily related to changes in the intercompany loan balances and cash balances as a result of exchange rate changes between USD and EUR.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income or expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Income and Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME AND FINANCE COSTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_FinanceIncomeAndFinanceCostsAbstract', window );"><strong>Finance Income And Finance Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock', window );">FINANCE INCOME AND FINANCE COSTS</a></td>
<td class="text">FINANCE INCOME AND FINANCE COSTS<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Income</span></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance income of $12.1 million and $13.9 million for the three months ended March&#160;31, 2025 and 2024, respectively, is comprised mainly of interest income earned on various bank accounts and time deposits. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Costs </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration interest-bearing advanced funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of finance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_FinanceIncomeAndFinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_FinanceIncomeAndFinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</a></td>
<td class="text">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT <div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basic income or loss per share is calculated by dividing net income or loss attributable to ordinary equity holders of the parent by the weighted average ordinary shares outstanding. The diluted loss per share equals the basic loss per share amounts presented for the three months ended March&#160;31, 2025 and 2024, as the impact of the outstanding share options and RSUs had an anti-dilutive effect on the basic loss per share amounts presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted loss per share are based on: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100,916)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,793)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of shares<br/>Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367,525,855</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364,010,429</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeaseAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company as a lessee</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has leases for office, research laboratory and manufacturing facilities, equipment, vehicles, and land. The terms of the leases vary, although most generally have lease terms between 3 and 29 years. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of 50 years, and no ongoing payments will be made under the terms of these leasehold land. Leases with terms of 12 months or less are expensed as incurred. Collaboration assets represent the Company&#8217;s share of assets leased to the collaboration from Janssen Biotech, Inc., a Johnson &amp; Johnson company ("Janssen"), which purchased the assets on behalf of the collaboration, in connection with our collaboration and license agreement (the "Janssen Agreement"). Collaboration assets under construction that will be leased to the collaboration from Janssen when placed into service are classified as collaboration prepaid leases on the consolidated financial statements.</span></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Right-of-use assets</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s right-of-use assets and the movements for the three months ended March&#160;31, 2025 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000 </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at January 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Lease liabilities</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The balance of the Company&#8217;s lease liabilities and the movements for the three months ended March&#160;31, 2025 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at January 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accretion of interest recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analyzed into:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,065&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">COLLABORATION INVENTORIES, NET</a></td>
<td class="text">COLLABORATION INVENTORIES, NET<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration inventories, net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reserve for inventory was $17.9&#160;million and $21.7 million as of March&#160;31, 2025 and December&#160;31, 2024, respectively. The Company&#8217;s reserve for inventory was primarily related to certain batches or units of product that did not meet quality specifications, and expired materials. The inventory reserve was included in the collaboration cost of sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract', window );"><strong>Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock', window );">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</a></td>
<td class="text">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VAT recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default. The Company estimated that the expected credit loss for the above receivables as at March&#160;31, 2025 and December&#160;31, 2024 is insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS</a></td>
<td class="text">CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and bank balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,005,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,127,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pledged deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(563,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(840,296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">441,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">401,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in RMB</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">441,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and cash equivalents of the Company denominated in Renminbi (&#8220;RMB&#8221;) amounted to $15.1 million and $19.3 million in the consolidated statements of financial position as at March&#160;31, 2025 and December&#160;31, 2024, respectively. The RMB is not freely convertible into other currencies, however, under Greater China Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Company is permitted to exchange RMB for other currencies through banks authorized to conduct foreign exchange business. </span></div>Cash and cash equivalents earn interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default. The carrying amounts of the cash and cash equivalents approximate to their fair values.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUALS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherPayablesAndAccrualsAbstract', window );"><strong>Disclosure Of Other Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock', window );">OTHER PAYABLES AND ACCRUALS</a></td>
<td class="text">OTHER PAYABLES AND ACCRUALS<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payable for collaboration assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other tax payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other payables are non-interest-bearing and repayable on demand.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherPayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other payables and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherPayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other payables and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">COLLABORATION INTEREST-BEARING ADVANCED FUNDING</a></td>
<td class="text">COLLABORATION INTEREST-BEARING ADVANCED FUNDING <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective interest rate (%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Interest-bearing Advanced Funding</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.23&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No specific maturity date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the Janssen Agreement, the Company is entitled to receive funding advances from the collaborator when certain operational conditions are met. As a result, the Company took an initial funding advance with principal amounting to $17.3&#160;million on June 18, 2021, a second funding advance with principal amounting to $53.1&#160;million on September 17, 2021, a third funding advance with principal amounting to $49.3&#160;million on December 17, 2021, a forth funding advance with principal amounting to $5.3&#160;million on March 18, 2022, a fifth funding advance with principal amounting to $60.9&#160;million on June 17, 2022, a sixth funding advance with principal amounting to $60.5&#160;million on September 16, 2022, and a seventh funding advance with principal amounting to $3.6&#160;million on December 16, 2022, by reducing the same amount of other payables due to the collaborator, respectively (collectively, the &#8220;Funding Advances&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These Funding Advances are accounted for as interest-bearing borrowings funded by the collaborator, constituted by a principal amounting to $250.0&#160;million and applicable interests accrued amounting to $55.7&#160;million upon such principal. The respective interest rate of each borrowing has transitioned from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR) in accordance with the LIBOR ACT. Thus, outstanding advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of 2.5%.  For each of the seven batches of funding advances, interest started to accrue from June 18, 2021, September 17, 2021, December 17, 2021, March 18, 2022, June 17, 2022, September 16, 2022, and December 16, 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Pursuant to the terms of the Janssen Agreement, the collaborator may recoup the aggregate amount of Funding Advances, together with interest thereon, from Company&#8217;s share of pre-tax profits starting from the first calendar quarter </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">following the first profitable year of the collaboration program and, subject to some limitations, from milestone payments due to the Company under the Janssen Agreement. The Company&#8217;s management estimated the loan will not be recouped by the collaborator within one year, nor does the Company expect to repay the funding advances within one year, and thus the loan was classified as a long-term liability.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">SHARE CAPITAL AND SHARE PREMIUM</a></td>
<td class="text">SHARE CAPITAL AND SHARE PREMIUM <div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shares</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000,000,000 ordinary shares of $0.0001 each</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued and fully paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of movements in the Company&#8217;s share capital and share premium is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares in issue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>premium</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024 and January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367,298,315</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,695,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,696,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286,658</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification of vesting of restricted share units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">473,106</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,058,079</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,712,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,712,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Statement of financial position [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory', window );">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></td>
<td class="text">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The interim condensed consolidated financial statements were approved and authorized for issue by the Audit Committee of the Board of Directors on  May&#160;6, 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the authorisation of financial statements for issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of Analysis of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License revenue - Novartis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue - total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of Revenue by Geographic Area</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and other revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue and other revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,510&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States of America</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock', window );">Summary of Disclosure of Timing of transfer of Goods or Services</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the timing of transfer of goods or services is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue at a point in time</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue over time*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock', window );">Summary of Deferred Revenue from Contract Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the deferred revenue which is included in contract liabilities for the periods presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities (Current)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Deferred Revenue From Customer Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Timing Of Transfer Of Goods Or Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER (EXPENSE)/INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract', window );"><strong>Disclosure of Other Income and Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock', window );">Schedule Of Total Other Income And Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total other (expense)/income, net:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange (loss)/gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55,192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value gains on financial assets measured at fair value change through profit or loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense)/income, net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(54,508)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Detailed Information About Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Income and Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME AND FINANCE COSTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_FinanceIncomeAndFinanceCostsAbstract', window );"><strong>Finance Income And Finance Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">Summary of Finance Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration interest-bearing advanced funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,475&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_FinanceIncomeAndFinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_FinanceIncomeAndFinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Summary of Calculations of Basic and Diluted Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of basic and diluted loss per share are based on: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100,916)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,793)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of shares<br/>Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367,525,855</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">364,010,429</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeaseAbstract', window );"><strong>Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Summary of Carrying Amounts of The Right-of-use Assets and Movements</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s right-of-use assets and the movements for the three months ended March&#160;31, 2025 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000 </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at January 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,224&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeaseLiabilitiesTextBlock', window );">Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term</a></td>
<td class="text">The balance of the Company&#8217;s lease liabilities and the movements for the three months ended March&#160;31, 2025 are as follows:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at January 1, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accretion of interest recognized during the period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange realignment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analyzed into:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carrying amount at March 31, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,065&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LesseeLeaseLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee lease liabilities text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LesseeLeaseLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total collaboration inventories, net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,903&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract', window );"><strong>Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock', window );">Summary of Prepayments, Other Receivables and Other Assets</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other collaboration receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VAT recoverable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock', window );">Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and bank balances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,005,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,127,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pledged deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Time deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(563,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(840,296)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">441,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in USD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">401,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in RMB</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominated in EUR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">441,702&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about cash and cash equivalents, time deposits and pledged deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUALS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherPayablesAndAccrualsAbstract', window );"><strong>Disclosure Of Other Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock', window );">Summary of Other Payables and Accruals</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payable for collaboration assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other tax payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about other payables and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherPayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other payables and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherPayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Summary of Interest-Bearing Loans and Borrowings</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effective interest rate (%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Interest-bearing Advanced Funding</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.23&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No specific maturity date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">305,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Summary of Shares</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Shares</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Authorized:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000,000,000 ordinary shares of $0.0001 each</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued and fully paid:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock', window );">Summary of Movements in the Company's Share Capital and Share Premium</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of movements in the Company&#8217;s share capital and share premium is as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>shares in issue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share<br/>premium</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">US$&#8217;000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024 and January 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">367,298,315</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,695,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,696,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of share options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">286,658</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reclassification of vesting of restricted share units</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">473,106</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368,058,079</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,712,844&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,712,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements in the company's share capital and share premium explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Summary of Analysis of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualProperty', window );">License revenue</a></td>
<td class="nump">$ 9,348<span></span>
</td>
<td class="nump">$ 12,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="nump">185,615<span></span>
</td>
<td class="nump">78,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherRevenue', window );">Other revenue</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">3,329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">195,053<span></span>
</td>
<td class="nump">93,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=legn_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RevenueFromLicensingOfIntellectualProperty', window );">License revenue</a></td>
<td class="nump">$ 9,348<span></span>
</td>
<td class="nump">$ 12,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_RevenueFromLicensingOfIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from licensing of intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_RevenueFromLicensingOfIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=legn_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=legn_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Summary of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue and other revenue</a></td>
<td class="nump">$ 9,438<span></span>
</td>
<td class="nump">$ 15,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="nump">185,615<span></span>
</td>
<td class="nump">78,481<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">195,053<span></span>
</td>
<td class="nump">93,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue and other revenue</a></td>
<td class="nump">9,348<span></span>
</td>
<td class="nump">15,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="nump">158,942<span></span>
</td>
<td class="nump">70,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenue and other revenue</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationRevenue', window );">Collaboration revenue</a></td>
<td class="nump">$ 26,673<span></span>
</td>
<td class="nump">$ 8,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Analysis of Timing of Transfer of Goods or Services (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">$ 195,053<span></span>
</td>
<td class="nump">$ 93,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember', window );">Revenue at a point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">185,705<span></span>
</td>
<td class="nump">81,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember', window );">Revenue over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">$ 9,348<span></span>
</td>
<td class="nump">$ 12,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUE - Summary of Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>Disclosure of disaggregation of revenue from contracts with customers [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities (Current)</a></td>
<td class="nump">$ 39,535<span></span>
</td>
<td class="nump">$ 46,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Total</a></td>
<td class="nump">$ 39,535<span></span>
</td>
<td class="nump">$ 46,874<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>OTHER (EXPENSE)/INCOME, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract', window );"><strong>Disclosure of Other Income and Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign currency exchange (loss)/gain, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (55,192)<span></span>
</td>
<td class="nump">$ 49,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Fair value gains on financial assets measured at fair value change through profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherMiscellaneousIncomeExpense', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">684<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherGainsLosses', window );">Total other (expense)/income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (54,508)<span></span>
</td>
<td class="nump">$ 49,681<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts have been reclassified to present finance income as a separate line item and to combine other income/(expense), net for comparative purposes</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Other Income and Gains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherMiscellaneousIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherMiscellaneousIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME AND FINANCE COSTS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_FinanceIncomeAndFinanceCostsAbstract', window );"><strong>Finance Income And Finance Costs [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 12,056<span></span>
</td>
<td class="nump">$ 13,870<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain prior year amounts have been reclassified to present finance income as a separate line item and to combine other income/(expense), net for comparative purposes</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_FinanceIncomeAndFinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_FinanceIncomeAndFinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME AND FINANCE COSTS - Summary of Finance Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_FinanceIncomeAndFinanceCostsAbstract', window );"><strong>Finance Income And Finance Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Collaboration interest-bearing advanced funding</a></td>
<td class="nump">4,562<span></span>
</td>
<td class="nump">5,059<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total</a></td>
<td class="nump">$ 5,061<span></span>
</td>
<td class="nump">$ 5,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_FinanceIncomeAndFinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_FinanceIncomeAndFinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsPerShareAbstract', window );"><strong>Basic earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation</a></td>
<td class="num">$ (100,916)<span></span>
</td>
<td class="num">$ (59,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation (in shares)</a></td>
<td class="nump">367,525,855<span></span>
</td>
<td class="nump">364,010,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember', window );">Leasehold land</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeasingArrangementsLeasesTerm', window );">Lessee, lease terms</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OngoingLeasePaymentsUnderTheLandLease', window );">Ongoing lease payments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeasingArrangementsLeasesTerm', window );">Lessee, lease terms</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LesseeLeasingArrangementsLeasesTerm', window );">Lessee, lease terms</a></td>
<td class="text">29 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LesseeLeasingArrangementsLeasesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee leasing arrangements leases term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LesseeLeasingArrangementsLeasesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OngoingLeasePaymentsUnderTheLandLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ongoing lease payments under the land lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OngoingLeasePaymentsUnderTheLandLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_RightOfUseAssetsRollForward', window );"><strong>Right-of-Use Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Beginning balance</a></td>
<td class="nump">$ 101,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">6,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets', window );">Impairment</a></td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate', window );">Exchange realignment</a></td>
<td class="nump">2,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation of right-of-use assets</a></td>
<td class="num">(2,787)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Ending balance</a></td>
<td class="nump">$ 107,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for right-of-use assets. [Refer: Impairment loss recognised in profit or loss; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through effect of exchange realignment in foreign exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_RightOfUseAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_RightOfUseAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Analyzed into:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current portion</a></td>
<td class="nump">$ 5,341<span></span>
</td>
<td class="nump">$ 4,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current portion</a></td>
<td class="nump">51,724<span></span>
</td>
<td class="nump">44,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_LeasesRollForward', window );"><strong>Leases [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Beginning balance, carrying amount</a></td>
<td class="nump">49,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseInLeaseLiabilities', window );">Additions</a></td>
<td class="nump">6,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_IncreaseOfLeaseLiabilitiesBalance', window );">Accretion of interest recognized during the period</a></td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payments</a></td>
<td class="num">(1,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities', window );">Exchange realignment</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Ending balance, carrying amount</a></td>
<td class="nump">57,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Analyzed into:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current portion</a></td>
<td class="nump">5,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current portion</a></td>
<td class="nump">51,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Carrying amount at March 31, 2025</a></td>
<td class="nump">$ 57,065<span></span>
</td>
<td class="nump">$ 49,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_IncreaseOfLeaseLiabilitiesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase of lease liabilities balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_IncreaseOfLeaseLiabilitiesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_LeasesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_LeasesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET - Summary of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 23,176<span></span>
</td>
<td class="nump">$ 17,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WorkInProgress', window );">Work-in-process</a></td>
<td class="nump">4,933<span></span>
</td>
<td class="nump">4,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">2,824<span></span>
</td>
<td class="nump">2,009<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Total collaboration inventories, net</a></td>
<td class="nump">$ 30,933<span></span>
</td>
<td class="nump">$ 23,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WorkInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WorkInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COLLABORATION INVENTORIES, NET - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Classes of current inventories [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InventoryReserve', window );">Inventory reserve</a></td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="nump">$ 21.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details) - Prepayments Other Receivable and Other Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems', window );"><strong>Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherCollaborationReceivables', window );">Other collaboration receivables</a></td>
<td class="nump">$ 159,688<span></span>
</td>
<td class="nump">$ 112,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceLeaseReceivables', window );">Lease receivables</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ValueAddedTaxReceivables', window );">VAT recoverable</a></td>
<td class="nump">5,792<span></span>
</td>
<td class="nump">4,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">15,562<span></span>
</td>
<td class="nump">12,374<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_PrepaymentsOtherReceivablesAndOtherAssets', window );">Total</a></td>
<td class="nump">$ 182,040<span></span>
</td>
<td class="nump">$ 130,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceLeaseReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables related to finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceLeaseReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables related to a value added tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherCollaborationReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Collaboration Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherCollaborationReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_PrepaymentsOtherReceivablesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments, other receivables and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_PrepaymentsOtherReceivablesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=legn_PrepaymentsOtherReceivablesAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=legn_PrepaymentsOtherReceivablesAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndBankBalancesAtCentralBanks', window );">Cash and bank balances</a></td>
<td class="nump">$ 1,005,450<span></span>
</td>
<td class="nump">$ 1,127,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_PledgedShortTermDeposits', window );">Less: Pledged deposits</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DepositsFromBank', window );">Time deposits</a></td>
<td class="num">(563,678)<span></span>
</td>
<td class="num">(840,296)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">441,702<span></span>
</td>
<td class="nump">286,749<span></span>
</td>
<td class="nump">$ 897,571<span></span>
</td>
<td class="nump">$ 1,277,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">Denominated in USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">401,938<span></span>
</td>
<td class="nump">230,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">Denominated in RMB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">15,116<span></span>
</td>
<td class="nump">19,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Denominated in EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,648<span></span>
</td>
<td class="nump">$ 36,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndBankBalancesAtCentralBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and bank balances held at central banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndBankBalancesAtCentralBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DepositsFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposits from bank.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DepositsFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_PledgedShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pledged short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_PledgedShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 441,702<span></span>
</td>
<td class="nump">$ 286,749<span></span>
</td>
<td class="nump">$ 897,571<span></span>
</td>
<td class="nump">$ 1,277,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CNY', window );">Denominated in RMB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems', window );"><strong>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,116<span></span>
</td>
<td class="nump">$ 19,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CNY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CNY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER PAYABLES AND ACCRUALS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_DisclosureOfOtherPayablesAndAccrualsAbstract', window );"><strong>Disclosure Of Other Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AccruedPayroll', window );">Accrued payroll</a></td>
<td class="nump">$ 27,657<span></span>
</td>
<td class="nump">$ 43,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AccruedExpense', window );">Accrued expense</a></td>
<td class="nump">24,090<span></span>
</td>
<td class="nump">16,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_CollaborationPayable', window );">Collaboration payable</a></td>
<td class="nump">49,350<span></span>
</td>
<td class="nump">82,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_PayableForCollaborationAssets', window );">Payable for collaboration assets</a></td>
<td class="nump">6,735<span></span>
</td>
<td class="nump">14,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherTaxPayables', window );">Other tax payables</a></td>
<td class="nump">6,071<span></span>
</td>
<td class="nump">3,372<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_OtherPayablesAndAccrualsCurrent', window );">Total</a></td>
<td class="nump">$ 116,810<span></span>
</td>
<td class="nump">$ 166,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_CollaborationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_CollaborationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_DisclosureOfOtherPayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other payables and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_DisclosureOfOtherPayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherPayablesAndAccrualsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other payables and accruals, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherPayablesAndAccrualsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_OtherTaxPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other tax payables,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_OtherTaxPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_PayableForCollaborationAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payable For Collaboration Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_PayableForCollaborationAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details) - 11.0% Interest Bearing Loans<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure Of Detailed Information About Borrowings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Effective interest rate (%)</a></td>
<td class="nump">7.23%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived', window );">Collaboration Interest-bearing Advanced Funding</a></td>
<td class="nump">$ 305,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current loans received. [Refer: Loans received]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=legn_A110InterestBearingLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=legn_A110InterestBearingLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2022 </div>
<div>USD ($) </div>
<div>batch</div>
</th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract', window );"><strong>Disclosure of detailed information about borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Funding advances from collaborator principal amount</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 60.5<span></span>
</td>
<td class="nump">$ 60.9<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 49.3<span></span>
</td>
<td class="nump">$ 53.1<span></span>
</td>
<td class="nump">$ 17.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_InterestBearingBorrowingsFundedInterestsAccrued', window );">Interest accrued on funding advances</a></td>
<td class="nump">$ 55.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Interest rate margin percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_NumberOfBorrowingBatches', window );">Number of batches of funding advances | batch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAdjustmentToInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_InterestBearingBorrowingsFundedInterestsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest bearing borrowings funded interests accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_InterestBearingBorrowingsFundedInterestsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_NumberOfBorrowingBatches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Borrowing Batches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_NumberOfBorrowingBatches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Issued and fully paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AuthorisedAbstract', window );"><strong>Authorized:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Ordinary shares authorized (in shares)</a></td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Authorized, price per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_AuthorizedShareCapital', window );">2,000,000,000 ordinary shares of $0.0001 each</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAbstract', window );"><strong>Issued and fully paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Ordinary shares issued and fully paid (in shares)</a></td>
<td class="nump">368,058,079<span></span>
</td>
<td class="nump">367,298,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Price per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AuthorisedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AuthorisedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_AuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_AuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Beginning balance</a></td>
<td class="nump">$ 2,696,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOption', window );">Exercise of share options</a></td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium', window );">Reclassification of vesting of restricted share units</a></td>
<td class="nump">14,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Ending balance</a></td>
<td class="nump">$ 2,712,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Number of shares in issue</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">367,298,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOptionNumberOfSharesInIssue', window );">Exercise of share option (in shares) | shares</a></td>
<td class="nump">286,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue', window );">Reclassification of vesting of restricted share units (in shares) | shares</a></td>
<td class="nump">473,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">368,058,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=legn_ShareCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Beginning balance</a></td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOption', window );">Exercise of share options</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium', window );">Reclassification of vesting of restricted share units</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Ending balance</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Share premium</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalRollForward', window );"><strong>Share Capital [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Beginning balance</a></td>
<td class="nump">2,695,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ExerciseOfShareOption', window );">Exercise of share options</a></td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium', window );">Reclassification of vesting of restricted share units</a></td>
<td class="nump">14,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_legn_ShareCapitalAndSharePremium', window );">Ending balance</a></td>
<td class="nump">$ 2,712,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ExerciseOfShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of share option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ExerciseOfShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ExerciseOfShareOptionNumberOfSharesInIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of share option number of shares in issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ExerciseOfShareOptionNumberOfSharesInIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of vested restricted stock units, number of shares in issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of vested restricted stock units, share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ShareCapitalAndSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital and share premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ShareCapitalAndSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share capital and share premium, number of shares in issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_legn_ShareCapitalRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">legn_ShareCapitalRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>legn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=legn_ShareCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=legn_ShareCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !(XK5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !(XK5IBPN#>\0   "L"   1
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MG<HURV"U)KLP#LVZ"+(+0QQ;4AQI($?<D/M#;+C,2X:@N626Q$%,?@6T7?N
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M.5XPR77ULDKUH(#1FF"DQE1QVAPJ:\A)W>2\JZ.%9X>)0>SA*,+M @4T]+W
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MKLN/*Q$N1"89@+Y,T^+EBU2P_P\7KO\/4$L#!!0    ( !(XK5ID=^_690H
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MC5EU:+?Z4J3;\ACK8UH4Z::\7',8O$P(P._+-"U>OX@'U$>G+_\'4$L#!!0
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MT'3P\BP"TZEJMW&Z"4JVU8YT,2PK^A"A\0YD+S3-<K_Q 4Z?MMG_4$L#!!0
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M.KAZ>YV :_I<,_&VBKUE:SUWJC@LV 'HP@'>WUGKNTFXH/^S,?L+4$L#!!0
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MH4'KVX4'JIZ-M6)DZ>;11AJ:;D[,Z'>"RCK0>BJE.2@V0?.#&OP!4$L#!!0
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M.C%JW)!K<#9)/5#MLZ2=&+EU3X&5-'26N&%%+SE4UH"^;Z0T_<0&&-Z&B[\
M4$L#!!0    ( !(XK5H;<SJ\3 ,  $P'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;)U5ZV^;,!#_5TYLFEHI*H20-&V32'UD:C_TH3ZV2=,^.'"
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M\ KM&E%2SD_:#KR[WGFN3<*-"5>A+OP<=]XWTK;#KC_MKXK#=D+^%&_O&2K
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MTO=N/8AQ)XJ4UOKP@*=Z;AQ?I%-;_L.A\NVR<U18TMD)S!ED4E5/\7KZ#A>
MV^8[@. $",J\JT!EEA-!8M S^@#&>3.;$\I22S0G)Y5K2DB&WTK&T6"X6JV7
M3\-'6-[#YF$*L\5FNI[-8;Q<3*:+<#IQ4KA\G$V&&U;N9XOA8CQC_W##AOET
ML0E[/G$BCLZ/3D%'5=#@G:!MF&M%B86IBC'^'^]S 745P;F*47"5<"Y, ]JM
M+Q T@YLK?.WZJ[1+OO8[?"$)0AX] KV#G51"15*DD&LKRUGZ*;:6#$_4K[>*
MK[@[;W.[+;NSN8BP[_$:630OZ T^?VIUF]^N9-ZI,^]<8_^H?GYX4-@D"%(1
M&IE!I'DNE,7825:G,N9VQ!>-L.?^6#B@01!Y;O0+NPC%OX(2;>0?A] &I+4%
MPO8(Q!&&12P)QCK+)!&B:Z\SC[0PL5,FTO"YT,8"=QGFXE@UIEM-5N.M!OD7
MRY>AV9<GQG+FA:)J#VMK?<6&U?+^<Z].((_Q7BH+*>X8VFQ\O?' 5&>E4DCG
MY2IO-?%A*,6$+S$:Y\#O=UK367$!ZML^^ M02P,$%     @ $CBM6IM)([MM
M!   80P  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULM5=;D]HV%/XK
M9YQ.)LFXX L&3( 9EFS3SC1I!G;3ATX?A!&V)K;D2&+9[:_OD7P!M@ZEG?8%
M=#GZSG?.^73Q]"#D%Y51JN&QR+F:.9G6Y:3?5TE&"Z)ZHJ0<9W9"%D1C5Z9]
M54I*MG91D?<#SQOV"\*X,Y_:L4]R/A5[G3-./TE0^Z(@\NF&YN(P<WRG&5BQ
M---FH#^?EB2E:ZKORT\2>_T69<L*RA43'"3=S9R%/[D9&7MK\)G1@SII@XED
M(\07T_EI.W,\0XCF--$&@>#? UW2/#= 2.-KC>FT+LW"TW:#_H.-'6/9$$67
M(O^5;74V<\8.;.F.['.]$H<?:1U/9/ 2D2O["X?:UG,@V2LMBGHQ,B@8K_[)
M8YV':Q8$]8+ \JX<69;OB";SJ10'D,8:T4S#AFI7(SG&35'66N(LPW5ZOKK]
M?/OQ_A9>W9%-3M7K:5\CJIGK)S7"3840? ,AA ^"ZTS!+=_2[?GZ/K)I*04-
MI9O@(N '(GL0^BX$7A!=P O;$$.+%WX#[QU322[47E(0.]@R1=)4TI185>"(
MI ^4[RGLI"@@P5@D2D5A'7165X!*!;^1C;(SOW>EJ&(PZ&9@-M9$E22A,P=W
MCJ+R@3KSER_\H??V0GR#-K[!)?3YNMI/)I0%)_F38LJT5U5876POXG6S7> &
M.@%O<H8]HF G<MS<:@)WF:04BDH/U.@!L)I)UI;3_ S@?OW=RQ?CP!^]]3SO
M6:^F/8&?68)[G[:NGO>_AX_B@4B-%&(W'(S!#UQ_['?8::%)?FZ$FS@G&R$K
M$32F_CARAWX$H[$[0*-?=$9E.QE[$+IA$,.=A5LU:^+(]:(0XM"-8Q\NU#-J
MZQE=6\_&R>8)WE.12E)F+($%GKY=9;T(^X_*BO[2HS^"_LXKW<-*'S/,>'4Y
MF%2BF3DDMX!M3!_D(K$3%MX,M#NJ]U^HI2DVX>CQK%SWG&D$7&NBJ76^0*<L
M(8T.(C<<QK#,&">FM/[ KPO; /P5,G8'H5T9^=XS!:W^SJL?C=UX$,#(<WTO
MAMN]Q'L5@J$['(4P=L-14+M/KE'FOY7@L)7@\%H)GI^>=PSOH-364A*N=I@=
M;+\78HO12EBCJK BJDN=EST^$Z)1BN[TE3:^5.WK_SN#@&@@4 K&-6K<\*D*
M,?(B&/ONV#]:B@=D9PS>G)\S%POU9I$?Y8:7"R6%,IL-QQ*1<O8'4N^@0!\3
M6FH,6+;R;QR8L?94/.#>S4QV3N!:GKT+*AFU*AE=K1**Y9'H8'5ZF2[KRQ1Y
MD@W+F6;=TKCHIOO@,N=/57*C$6T>+Z R%("5SK:ATV2WS07C2;XWFL!L-G<]
MY$=Z-H4&HL1]:Y1F77+<U)-61AAM0HL-9A+;UREJV>7JU7*/)+E^#6'L1F$$
M@Z$['@UJT9R/=96K?_+LPV,FM8];A6'MN:Y>@.UH^WY>5,_&HWGU^,;04H:'
M=$YWN-3KC? ND=6#MNIH4=I'Y$9H/+YM,\-O "J- <[OA-!-QSAHORKF?P)0
M2P,$%     @ $CBM6G)?/=?^ @  6 8  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL?57;;MLX$/V5@5H$-F!$LBP[3F(;2%(7S4,NB)UV@<4^T-)(
M(DJ17I**T_WZ'5**XA:.7T0..7/F#.>BV4[IGZ9$M/!:"6GF06GM]B(,35IB
MQ<RIVJ*DFUSIBED2=1&:K4:6>:-*A'$43<**<1DL9O[L42]FJK:"2WS48.JJ
M8OK7-0JUFP?#X.W@B1>E=0?A8K9E!:[0/F\?-4EAAY+Q"J7A2H+&?!Y<#2^N
M$Z?O%;YSW)F]/;A(-DK]=,)M-@\B1P@%IM8A,%I>\ :%<$!$X]\6,^A<.L/]
M_1OZ5Q\[Q;)A!F^4^,$S6\Z#:0 9YJP6]DGMOF$;S]CAI4H8_X5=HSN. DAK
M8U75&A.#BLMF9:_M.^P93#\RB%N#V/-N''F67YAEBYE6.]!.F]#<QH?JK8D<
MERXI*ZOIEI.=73RLORV?H+?\ZW%YOUKVP]O[FX>[Y0#NEVOHK=E&H.G/0DN>
MG'Z8MJC7#6K\ >H([I2TI8&ES##[W3XDAAW-^(WF=7P4\([I4Q@-!Q!'\?@(
MWJ@+>^3Q1A_@?>$F%<K4&D'E\&!+U' K4U4A,)G!\I6*WB#\?;4Q5E/E_'/H
M#1H7R6$7KILNS):E. ^H70SJ%PP6)Y^&D^CR2 !)%T!R#'VQHN[,:H'PD,-:
M629^#^+J/8A#S(]B'V:^+A%R):B)N2S NLIH.YG_AP;(.5C/0WD>/6R\]T/N
M&0U HKV =:D1H6J* UUQ *4V+;O<ND\"SZO/)Y^F\?#L,HJB/R1J1FHU2<VA
M-<KT%^!K6C)9(/0HHZ8?%C2*O#OHC<>#X7G<A^1\$(TG\)5Q#2],U A.R0"-
MA9Q+)E-.Q)DQ: U4R%Q=9, LY.\&K0];:E47)6RURKD%I<$Y!<\OOH0D.6\3
ML1<V3*8)#,\F;:*./! Q3@;C:.H93Z9#.%0IX5ZW5Z@+/],,I*J6MFG\[K0;
MFU?-M'A7;V8NO7WAWD%@3J;1Z=DX -W,L4:P:NMGQT99FD1^6]+H1^T4Z#Y7
MRKX)SD'W,UG\#U!+ P04    "  2.*U:'Y R](T"  "&!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6Q]5%UOVC 4_2M7Z51M4M=\D- OB 2TU7@H
MK0K='J8].,D-L>K8S#;0_?O93LCH1'EQ?*_O.3[7SO%@*^2KJA UO-6,JZ%7
M:;VZ]GV55U@3=2Y6R,U**61-M GETE<KB:1PH)KY41#T_9I0[J4#EWN2Z4"L
M-:,<GR2H=5T3^6>,3&R'7NCM$L]T66F;\-/!BBQQCOIE]21-Y'<L!:V1*RHX
M2"R'WBB\'L>VWA5\I[A5>W.PG61"O-I@6@R]P I"AKFV#,1\-CA!QBR1D?&[
MY?2Z+2UP?[YCOW>]FUXRHG BV ]:Z&KH77I08$G63#^+[3=L^TDL7RZ8<B-L
MF]HX]B!?*RWJ%FP4U)0W7_+6GL,>X#+X !"U@,CI;C9R*F^))NE BBU(6VW8
M[,2UZM!&'.7V4N9:FE5J<#J]G\Y&L\D=3&>3QX<[&,UN89>:/,X7<_B\(!E#
M]67@:[.=!?EY2SUNJ*,/J'OP(+BN%-SQ HOW>-_([+1&.ZWCZ"CA Y'GT O/
M( JBY A?K^N]Y_AZ'_5..>$YPI3GHD88\0)VJ8E06L'/4::T-#_.KT/=-^3Q
M87)KIFNU(CD./>,6A7*#7GIZ$O:#FR/2XTYZ?(P]G3<> E&^EWQ(YU&FPSH7
ME42$NKD^M-<'YO#SJCM].\3P,O]T>G(9A1<W01#\%TVY1L.GP5B/H?$-,$HR
MRJBFJ""^NH(X[!O1C)%,2.(L2EO,UPR)I'P)I-C8W@HHU[RPB?@LZ4>0G 7)
M%2R$)LS.^Z$9XXL$#AVLO^>-&N72O0 *<K'FNK%)E^T>F5'CK7_ES0MECF!)
MN3+ME 8:G%\D'LC&]4V@Q<HY+1/:^-9-*_-0HK0%9KT40N\"NT'W]*9_ 5!+
M P04    "  2.*U:B.0')"$#  #1!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6RE55%OVC 0_BNG;*I:"34A0&D[0(*6J96ZPDBZ:9KV8)*#6$OL
MS';*]N]W=B!C'>5E#TE\]MUWWV>?+X.-5-]UAFC@9Y$+/?0R8\IKW]=)A@73
MY[)$02LKJ0IFR%1K7Y<*6>J"BMP/@^#"+Q@7WFC@YN9J-)"5R;G N0)=%053
MOR:8R\W0:WN[B05?9\9.^*-!R=88H7DJYXHLOT%)>8%"<RE X6KHC=O7DZ[U
M=PZ?.&[TWABLDJ64WZUQGPZ]P!+"'!-C$1A]GO$&\]P"$8T?6TRO26D#]\<[
M]/=..VE9,HTW,O_,4Y,-O4L/4ERQ*C<+N;G#K9Z>Q4MDKMT;-K5OGYR32AM9
M;(.)0<%%_64_M_NP%W 9O!(0;@-"Q[M.Y%C>,L-& R4WH*PWH=F!D^JBB1P7
M]E BHVB54YP9/<RB".;3!41WX\44QG&\N)\\Q>/)PQ3B&<P6M_>/X\47F'Y\
MNH^_P-WLX7:ZB&#V'N*[*<PIYC&&TY@M<]1G ]\0)0OL)]OTDSI]^$KZ#GR0
MPF0:IB+%].]XGZ0T>L*=GDEX%/ #4^?0:;<@#,+>$;Q.LS\=A]=Y!6_"-$\
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M2D]DX\4RU>X7]I5OX$%<:".S"DP,,B[*?_92U>$ T.F= '0K0/<8$)T ]"I
M[Q@0G@"$%2!TE2FEN#HLF&&SB9)[4-:;HMF!*Z9#DWPN[+(_&45?.>',[/[Y
MZ_(16LL_'Y9W3\NV?W,WO[]=7L#=\AE:"S2,I[H-G^';TP):G]KP";B YT06
MFHFUGOB&.-A(?ESEFY?YNB?R]>!6"I-H6(HUKM_C?>)>"^B^"9AWSP:\9>H2
M>IT+Z ;=J('/XK_#PS-T>G4]>RY>[T2\!==Q*G6A$.0&[DV""FY$+#,$*A@L
M7VB_:H3O5RMM%#7]7TTE+%.$S2GL03#6.8MQZM%.UZAVZ,U^_:73#WYKTO\_
M!7M7C;"N1G@N^HRV)FT\08VL%(KX%? E3IC8(K2H2+KM;^E@N@"!IJD,9>S(
MQ;;'UV[V.8HZH^[$WQT*_.@6CH*H7WN]8Q[5S*/SS!E7L&-I@6 Y:J S:L,%
M$S%G*3"MT6C(D-F57@,SL/D)J"2:1,EBFT"NY(8;D JLYB:A)97^@8+@2.-'
MCS <-2OLUPK[9Q66O<E=;YY<@OZ'O/UA>,3MHT]G<*+Z@YK;X"RW9VFHRM(Q
M;&&Y9]K^>:[7YT-^[S1NM4%#CX51,#S2^-$M'/6'G6:50^_(,*IEC_Z-XQP5
MG;F"FH93P[PB4\ R60CJMH3M$%:(]KJ-4VI!ON'4>T:"V[G"5 V*U:)2EP(#
MC3E3S"#89, -9NX@(A3YK*Q-'C2"7U?;E1GH76']7 BZGR$O5"XUZJ:SP3^X
MA3)46W>;:X(3^_+(J*WU@^':W9-']CD])#H-]JOA>#YLLH_&<_?P\'^F+5\M
M=+IO[>9-<4,4@LL!K: J7P+EQ,C<W8TK:>BF=<.$'D^HK -]WTAIWB8V0?T<
MF_T#4$L#!!0    ( !(XK5I)UW8!\P(  %D'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;*U544_;,!#^*Z<,32 QDB9M05U;J:2@\4!!%+8'M <W
MN386B9W9+H5_O[.39@6E; ][:>SS?9_O/O?NAANIGG2&:."ER(4>>9DQY<#W
M=9)AP?2)+%'0R5*J@AG:JI6O2X4L=: B]\,@Z/L%X\(;#YWM5HV'<FUR+O!6
M@5X7!5.OYYC+S<CK>%O#'5]EQAK\\;!D*YRC>2AO%>W\AB7E!0K-I0"%RY$W
MZ0RF?>OO'+YSW.B=-=A,%E(^V<U5.O("&Q#FF!C+P.CSC#'FN26B,'[5G%YS
MI07NKK?LERYWRF7!-,8R_\%3DXV\,P]27+)U;N[DYAO6^?0L7R)S[7YA4_L&
M'B1K;611@RF"@HOJRUYJ'78 G6@/(*P!X7M ;P\@J@'1>T!W#Z!; [I.F2H5
MI\.4&38>*KD!9;V)S2Z<F Y-Z7-AGWUN%)URPIGQY=5L,HLOX&H6WUQ?P&0V
MA:TIOIG?S^$+S)A2S+X.'$[1,)[K([(^S*=P>' $!\ %W&=RK9E(]= W%)2E
M]I,Z@+@*(-P30 374IA,PX5(,7V+]RF9)J-PFU$<?DAXS=0)1)UC"(.PUQ+/
M]-_AW0_"B1J!(\<7[1.8"R82A"N1R )A(E+8FF*IC8;'R4(;1?__GVWB5>3=
M=G+;$P:Z9 F./"IZC>H9O?'G3YU^\+4M\_]$]D:';J-#]R/V1@?N=&B)[OQC
M_&.G59\*U',@V^*>QYTPZ/6'_O-NXBU>T=EIT'B]R:CGO3/TFQ3[?PLQ1D45
M(J!47"IX1:: %7(MZ)TS1A6T0+3=,LF9UGS),04CP:DM#"S?2 1, P.-):/J
M0["7 3=8 -6919'/PMJDR5#5&/\07V@@:#PZ!D$S@\:"]7,4MH#+M2JE1MWV
MGOY.$RE0K5PSU@2GZ*MG;JQ-OS]W;>Z=/:8YT&FQ3_J#N-]F[PUBUY;]/]=6
M0X=J<<6%AAR7%$)P<DHOJ*I&7FV,+%UK6TA#C=(M,YI]J*P#G2^E--N-O:"9
MIN/?4$L#!!0    ( !(XK5J'&&MRT0(  "T'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;*U544_;,!#^*Z<,32 -DJ9-&*R-U ;0^D!!%+:':0]N
M<FTL'+NSW9;]^]E.FI42JCWL);'/]WW^[NP[]S="/JL"4<-+R;@:>(76RTO?
M5UF!)5%G8HG<K,R%+(DV4[GPU5(BR1VH9'X8!+%?$LJ]I.]L]S+IBY5FE..]
M!+4J2R)_CY")S<#K>%O# UT4VAK\I+\D"YRB?EK>2S/S&Y:<EL@5%1PDS@?>
ML'.9QM;?.7RCN%$[8["1S(1XMI-Q/O "*P@99MHR$/-;8XJ,62(CXU?-Z35;
M6N#N>,M^XV(WL<R(PE2P[S37Q<#[[$&.<[)B^D%LOF(=3V3Y,L&4^\*F]@T\
MR%9*B[(&&P4EY=6?O-1YV $8GG9 6 /"?4#O'4"W!G1=H)4R%]85T23I2[$!
M:;T-FQVXW#BTB89R>XI3+<TJ-3B=W(PGPTEZ#>-)>G=[#</)%6Q-Z=WT<0JG
M,*T.&,0<;B@G/$-(A=(*CJ]0$\K4B7%ZFE[!\=$)' 'E\%B(E2(\5WU?&XUV
M)S^K]8PJ/>$[>KIP*[@N%%SS'//7>-_$U@08;@,<A0<);XD\@V[G$X1!&+7H
M2?\=WCL@I]ODN^OXNN_EN\[@F&>B1!CR?"^I/X8SI:6YW3_;DE>1]]K);<5?
MJB7)<."9DE8HU^@E'S]TXN!+6^3_B>Q5'GI-'GJ'V),QUVA8-9A29FCJ$!@E
M,\JHIMAZ;2JZR-'9UK1.>A<7?7^]&U"+3R=N?%[IC!J=T4&=ICTP,A.2N*9#
M:]6G,R22\@60?&W/+H?YBN?&T*:\VB#>517%X9[TMTY1$%VT:X\;[?%![8]"
M$]:F*'Z3IRB(.WN*6IQZY]&>(G^G\Y0H%ZXA*\C$BNNJ1AMKU?-'IN>[WKAG
M-V_!T+5 _R]-]9"8"EQ0KLPMF1O*X.S<2))5<ZXF6BQ=?YL);;JE&Q;F/4-I
M'<SZ7 B]G=@-FA<R^0-02P,$%     @ $CBM6IA%F, Y P  J <  !D   !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&ULK57O;YM($/U71EQU2J0V8&R<)F<C
M^5>52&GM&N>JZG0?UC VJP)+=Q>[_>\[NQ#J1"2JU'Z!W67>8]YCF!D=A?RB
M4D0-W_*L4&,GU;J\=ET5IY@S=2%*+.C)3LB<:=K*O:M*B2RQH#QS?<\;NCGC
MA1..[-E*AB-1Z8P7N)*@JCQG\OL4,W$<.SWGX6#-]ZDV!VXX*MD>(]3WY4K2
MSFU9$IYCH;@H0.)N[$QZU[/ Q-N ?SD>U<D:C)*M$%_,YC89.YY)"#.,M6%@
M=#O@#+/,$%$:7QM.IWVE 9ZN']C?6>VD9<L4SD3VB2<Z'3MO'4APQZI,K\7Q
M!AL]-L%89,I>X=C$>@[$E=(B;\"40<Z+^LZ^-3Z< (BG&^ W /\I8/ ,H-\
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M47H7EY2=K.="O=&BM*UU*S0U:KM,:92B- 'T?">$?MB8%[3#.?P!4$L#!!0
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M    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;(55;6_:,!#^*U9639TTFN!
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M!^V8MA"O5452F'JFTA3('7C)^W?]*/C4H7C0*!YTH2=SR"GG]G[7A!&>0IO
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MZ1D2J+($EQTCLZ**S:3!FE@T5_AJ@;(!.+^0TKQU;&&LW\'X#U!+ P04
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MQFN\B 4Q9;N,@*]5L:8=Q6K5:MI5JW]N!1O,.4G8OUU5*0,QNP/)6]\UV^*
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MI@#R^8Q2\3)1G5C=VGO_ %!+ P04    "  2.*U:R.X!&04#  #:"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6RMEFMOFS 4AO^*Q:JID[9ROW4)
M$DTZ=5*W1DF[:9KVP2$G":K!S'8N_?>S@2(22-0/^P(VG/?U<PZ^,-A1]LS7
M  +M,Y+SH;86HKC6=9ZL(</\BA:0RS=+RC(L9)>M=%XPP(M2E!'=,@Q/SW":
M:]&@?#9AT8!N!$ESF##$-UF&V<L-$+H;:J;V^F":KM9"/="C08%7, /Q5$R8
M[.F-RR+-(.<IS1&#Y5"+S>M1J.++@!\I['BKC50F<TJ?5>?K8J@9"@@()$(Y
M8'G;P@@(4482XV_MJ35#*F&[_>K^I<Q=YC+''$:4_$P78CW4 @TM8(DW1$SI
M[@[J?%SEEU#"RRO:5;&>K:%DPP7-:K$DR-*\NN-]78>6P'1."*Q:8+U58-<"
MNTRT(BO3&F.!HP&C.\14M'13C;(VI5IFD^;J*\X$DV]3J1/1P^/=[11-XE_Q
MS?WM#,7?QR@>C:9/\?T,78Y!X)3P#^@3>IJ-T>7%!W2!TAP]KNF&XWS!![J0
M#,I)3^KQ;JKQK!/C?</L"MGF1V09EMLC'YV7CR%IY,ZA7)>9-^E;3?I6Z6>?
M\DMY0BC?,$ /2_0@UL#0!+_@.0&.XGR!XB1A&TPX^AW/N6!RUOWI2[H:Q>D?
M1:W$:U[@!(::7&H<V!:TZ/T[TS,^]Y7@/YD=%,1N"F*?<X_*?&&!"OS"*"%]
MN58&;FF@-HEM9/F>ZP_T;3N);I1CFT'01!W0.0V=\R8ZV,M=C$,?767@M>D<
M(S2.Z+I1IF<[?C^=V]"Y9^GD5D+PG#)<;E!%-8WZ&-W.Z$YHN\>,W:C ,FRW
MG]%K&+VSC-44K]EZUZ_7+6!H''_=;I!GM1(X0/,;-/\L6KWND#R:4')02LPY
MB%Y8O\OAMTI4P7:#3"<\-16#AC9X0R$%WI\M9M#E,WSSB*\;9-N^U8\7-GCA
M6;Q'*G#OZ@T[Z](TO< \GGP]89YG!L>?6&^=/.K4E]O[*LTY(K"40N/*EPZL
M.DFKCJ!%>1C-J9!'6]E<RY\/8"I OE]2*EX[ZGQK?F>B?U!+ P04    "  2
M.*U:]74VDI("  !-!0  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q]
M5.]OVC 0_5=.63NUTDI"@';K0J3PHQL2@PIH]V':!Y-<B-7$9K:![K_?.4DC
M.M%^2>RSW_-[YSL'!ZF>=(9HX+G(A>X[F3';6]?5<88%TRVY14$KJ50%,S15
M&U=O%;*D!!6YZWO>M5LP+IPP*&/W*@SDSN1<X+T"O2L*IOX.,)>'OM-V7@(+
MOLF,#;AAL&4;7*)YV-XKFKD-2\(+%)I+ 0K3OA.U;P==N[_<\,CQH(_&8)VL
MI7RRDTG2=SPK"'.,C65@]-OC$//<$I&,/S6GTQQI@<?C%_:[TCMY63.-0YG_
MY(G)^LYG!Q),V2XW"WGXCK6?GN6+9:[++QSJO9X#\4X;6=1@4E!P4?W9<YV'
M(X#OOP'P:X!?ZJX.*E6.F&%AH.0!E-U-;'906BW1)(X+>RE+HVB5$\Z$P_ET
M&@WFBV@UF<]@,EN-%^/EZFHPCA:3V3>(1H_1;#@>P=W#;&0#5["LK@]D"A-A
M4*$V5P-DBHL-3"43&IA(8" 5*:&8AHL1&L9S?4G@=KOEG3<X>(T[ RY@E<F=
M)@8=N(;\695N7'L95%[\-[S\8*H%G?8G\#V_!P_+$5R<7;ZF<4E4DR._R9%?
M\G;>X!UQ'>=2[Q3"/(7*#2;DHNH)6US1F@K^V/2O*9' Q&"A?Y]R4IW8/7VB
M[<1;O64Q]AUJ-8UJCT[X\4/[VOOZCI].XZ?S'GLX3E,LFX'R75^$8@;AXOSR
ME-2*[$M)9GM\'WHM[\;O!.[^A(AN(Z+[K@AJHYRMI:KRUU32NJZ(*-DS$5.6
M[W8BH< I8=4!O2-A':]WT^W])\P]Z@[[T%"9;#B56XXI ;W6#3&HJGFKB9';
MLF'6TE#[E<.,WCM4=@.MIU*:EXGMP>8%#?\!4$L#!!0    ( !(XK5HPS4AG
M%P0  +L3   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;*V8;:^B.!B&
M_TK#3C8SR8XHBB]GU40%E<T<SXF>,_MALQ\J5"4#E&VKSB;SX^<I(.,+<CA)
MORB4Y[Z>TMY]H?TC9=_XCA"!OH=!Q ?:3HCX0=>YNR,AYC4:DPB>;"@+L8!;
MMM5YS CV$E$8Z$:]WM9#[$?:L)^4/;-AG^Y%X$?DF2&^#T/,_A^3@!X'6D,[
M%2S][4[( GW8C_&6K(AXC9\9W.DYQ?-#$G&?1HB1S4 ;-1Z<CHQ/ K[ZY,C/
MKI%\DS6EW^2-XPVTNJP0"8@K) '#WX%,2!!($%3COXRIY2FE\/SZ1)\F[P[O
MLL:<3&CPM^^)W4#K:L@C&[P/Q)(>YR1['U/R7!KPY!<=L]BZAMP]%S3,Q%"#
MT(_2?_P]:X<S@6'<$1B9P+@6=.\(FIF@635#*Q.TJ@K,3&!6%;0S0;NJH),)
M.E4%W4S0K2KH98)>8H>T_Y+.M[# PSZC1\1D--#D1>*@1 U][D?2ZRO!X*D/
M.C&</'WY,AH_+4<OSM,".8L7>VFO7CZ/[='26<S0R/HZ6DQL"TU?%Y8L^(Q&
MGN=+G^( .5$ZV*1K/UI$8#_@G] 'Y$?HT0\"*.9]74 M92[=S6HT3FMDW*E1
M$SW22.PXLB./> 7Z2;F^T2T!Z- \>1L9IS8:&Z7$1\QJJ-GX QEUPT2O*PM]
M_/"IJ&+E&(NX-=1H)QCCA(&1*MQ= <PJAZU(? LKP-CEF+_V$6 Z;V*F%5JH
MT7T3,ZO20FEM&B68>96V>1OC5&F;;AGFPD[-?,@U$V[SWEOZW THWS."Z 8F
M9CELB >#YM=@PFM8EM":,D#[T9:C?_":"P8KP[]% RK-URK.)U?+!QYCEPPT
M6 XY80>B#7__K=&N_UED8I4P2R7,5@F;JH3-5,+F*F&.(MB%T5NYT5ME].%T
M'WG@7H2] XY<PM&&T1#!BA6 OQD6E*&8^9'KQ["6X)#N(U'D[C2)F2216[?#
MT##K??UP;MHTIGL6TZRU+V.LVYAVO69>!MF%0;W+H.EMD%EK7L;,;F-:O>N@
M>0&H66M<!CFW08W.&>FB:\R\:\S2KG$B0:##!6PV7;:'V0<FG<U5=Q7UA7E;
M8;/6N>J,TM3OG4%4PFR5L*E*V$PE;*X2YBB"7=BTG=NT7<VF,%L0V/:R+6PM
M8\)<$@GX$BMR: KLG3FT7H-MVY5%2].^UZ(J8;9*V%0E;*82-E<)<Q3!+BS:
MR2W:*;7H8A^N"9,[N60G#ZL<7%Y/I>C'W7W^N!3_WLU;"FN?N?]J<K94IK-5
MPJ8J83.5L+E*F*,(EII5/_OR#PG;)L=&'/98L)=*#P'RTOQD:I0<R.B_PM-C
MK<=D=N4H(!N0UFL=F/A9>E24W@@:)^<(:RH$#9/+'<$>83( GF\H%:<;F2 _
MKQO^!%!+ P04    "  2.*U:7A?"W5T#  "T#   &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6RU5VUOTS 0_BNG,*%-*LM;WVDCE1;$) ;5RN"SE[B+
M11('VUV!7\\Y3K-D9-E I5(;O]P]?AZ?+^?.]EQ\DS&E"GZD22;G5JQ4/K5M
M&<8T)?*<YS3#F2T7*5'8%;>VS 4E4>&4)K;G.$,[)2RS@EDQMA;!C.]4PC*Z
M%B!W:4K$SS<TX?NYY5J'@2MV&RL]8 >SG-S2#577^5I@SZY0(I;23#*>@:#;
MN;5PITO7TPZ%Q1=&][+6!BWEAO-ONG,1S2U',Z()#96&(/BXHTN:)!H)>7PO
M0:UJ3>U8;Q_0WQ7B4<P-D73)DZ\L4O'<&EL0T2W9)>J*[]_34M! XX4\D<4O
M[$M;QX)P)Q5/2V=DD++,/,F/<B-J#F[_$0>O=/">Z^"7#GXAU# K9*V((L%,
M\#T(;8UHNE'L3>&-:EBFP[A1 F<9^JE@\WYQ]1:6B_7%Y\4'6'Q<@1E97[V]
MO+B^A%>P,0$&OH5-3 25<+JBBK!$GN'L]68%IR=G< (V2#/-,KC.F)(]',3V
MYYCO),DB.;,5$M;+VF%)[HTAYSU"[I*(<_#='GB.-VAQ7W:[KVA8N?>;[C9N
M4[577K577H'G/X)W(>6.1H!:8+M+DI^0$Q9-VV09G'X[CL[,J<Q)2.<6IIZD
MXHY:P<L7[M!YW2;R2& -R7XEV>]"#_SAN.<,\#N:%+I/]59.P1^.>MYDW//=
MP1EP$;%,GY R_GA03IQSQW%<H"2,V_;'+#HH%M4OFKO '\WLN[KJ3I.&EGZE
MI=^IY=.!ISG&;;PZ ?XV;D<":V@=5%H'G4=UL5,Q%^P7;3^?@V/J/!)80^>P
MTCE\7DS+LT<JW7"*[QXS>M:V!09W6#M?6/G*SX.C^"S3!OU117_42?\^3#W(
M!0LIY%08U@7_B"<)$?)^M%6*6<-U:@1-_CW0\;1=0\2X$C'N%.'U$./P_9>W
MP?B/5/?^B$&W38/WI.(].=+K?'+,=#D26$.RZ]R7>^>O$H:U;<)3N5.N4<\(
M+!18)[!,/(A;J^D(:P>6CO;PN;6KB]NI9?W/&5,"/YTRSS!LDK^_2[B==?M_
M5=9RU<[2VFUC]-BU*Z6^S^-5[)9E$A*Z12?G?(3>PER134?QO+AEWG"%=]:B
M&>/?"BJT <YO.5>'CKZX5G]4@M]02P,$%     @ $CBM6A0^3I$>!   -1$
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MVH(F7D+"6Q+%+*+Q2[+W -E[7+* _4.2E 9+&B^3MT/W*LBT1TR(!OD!@/R
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MZB<:U;[+BETD2?<QO"1R9EW5=G\J"E>UA95?9_GYGQKG?YE\_A]02P,$%
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MO#_^NKR='+R7*\X!_I&_? -02P,$%     @ $CBM6C+A@>'' 0  $A\  !,
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M              "  >,!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ $CBM6L+-BS7  @  EP@  !@              ("!) @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !(XK5J_K"L*T@8  '0;   8
M              " @1H+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  2.*U:9%+56:H&   4'@  &               @($B$@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ $CBM6LXM#*T("@
M?$$  !@              ("! AD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( !(XK5ID=^_690H  $8M   8              " @4 C
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  2.*U:FVX-
M9TX#  #F!@  &               @(';+0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ $CBM6G4V<$5[ P  > @  !@
M ("!7S$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !(X
MK5J.T _F] (  *P&   8              " @1 U  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  2.*U:\_LSTP@$   G"@  &
M        @($Z.   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ $CBM6AMS.KQ, P  3 <  !D              ("!>#P  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  2.*U:/_NHGN<"  "1!@
M&0              @('[/P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( !(XK5HH,5<,BP,  -4(   9              " @1E#  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ $CBM6AH  'TH
M!0  < P  !D              ("!VT8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  2.*U:!MC00#(#  #[!@  &0
M@($Z3   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !(X
MK5I;RR/,40,  $0'   9              " @:-/  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ $CBM6M**]=@$!   "@D  !D
M         ("!*U,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  2.*U::IU&Q-L"   E!@  &0              @(%F5P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !(XK5H>O244\ 4  /$.
M   9              " @7A:  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ $CBM6B^V3"%0 P  ?0<  !D              ("!GV
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  2.*U:X/]'
M$Y("  #G!0  &0              @($F9   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( !(XK5J;22.[;00  &$,   9
M  " @>]F  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M$CBM6G)?/=?^ @  6 8  !D              ("!DVL  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  2.*U:'Y R](T"  "&!0  &0
M            @('(;@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( !(XK5J(Y <D(0,  -$&   9              " @8QQ  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ $CBM6K9>I>5_ P
MV@@  !D              ("!Y'0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  2.*U:VC[N^)D"  ""!0  &0              @(&:
M>   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !(XK5K3
M_&F,Q0(  /X%   9              " @6I[  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ $CBM6GS6XZS] @  H 8  !D
M     ("!9GX  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !(XK5K*+1ISI@,  "40   9              "
M@9*.  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ $CBM
M6NF7;*<G P  ?0L  !D              ("!;Y(  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    "  2.*U:?RTSXVX"  #C!0  &0
M        @('-E0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( !(XK5JZ#CU+GP,  )H)   9              " @7*8  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ $CBM6DG7=@'S @  60<
M !D              ("!2)P  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    "  2.*U:AQAK<M$"   M!P  &0              @(%RGP
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !(XK5J819C
M.0,  *@'   9              " @7JB  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ $CBM6KC@=]>Q @  < D  !D
M ("!ZJ4  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  2
M.*U:-YR?*-0"  !&!P  &0              @('2J   >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !(XK5H=MA$E#P0  '(0   9
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M970T-BYX;6Q02P$"% ,4    "  2.*U:)QZ[21(#  #F"P  &0
M    @(%"O0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M !(XK5K([@$9!0,  -H(   9              " @8O   !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ $CBM6O5U-I*2 @  304  !D
M             ("!Q\,  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    "  2.*U:,,U(9Q<$  "[$P  &0              @(&0Q@  >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !(XK5I>%\+=70,
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( !(XK5J3B($,@@0  .DB   /
M      "  037  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  2.*U:BC%V
M7\\!   S'P  &@              @ &SVP  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  2.*U:,N&!X<<!   2'P  $P
M    @ &ZW0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /  \ %L0  "R
%WP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>197</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>22</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Disclosure - CORPORATE INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/CORPORATEINFORMATION</Role>
      <ShortName>CORPORATE INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - BASIS OF PREPARATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/BASISOFPREPARATION</Role>
      <ShortName>BASIS OF PREPARATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY</Role>
      <ShortName>NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - OTHER (EXPENSE)/INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHEREXPENSEINCOMENET</Role>
      <ShortName>OTHER (EXPENSE)/INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - FINANCE INCOME AND FINANCE COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTS</Role>
      <ShortName>FINANCE INCOME AND FINANCE COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT</Role>
      <ShortName>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - COLLABORATION INVENTORIES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET</Role>
      <ShortName>COLLABORATION INVENTORIES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS</Role>
      <ShortName>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS</Role>
      <ShortName>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - OTHER PAYABLES AND ACCRUALS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS</Role>
      <ShortName>OTHER PAYABLES AND ACCRUALS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS</Role>
      <ShortName>APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/REVENUE</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables</Role>
      <ShortName>OTHER (EXPENSE)/INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/OTHEREXPENSEINCOMENET</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSTables</Role>
      <ShortName>FINANCE INCOME AND FINANCE COSTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables</Role>
      <ShortName>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/LEASES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - COLLABORATION INVENTORIES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables</Role>
      <ShortName>COLLABORATION INVENTORIES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables</Role>
      <ShortName>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables</Role>
      <ShortName>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - OTHER PAYABLES AND ACCRUALS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables</Role>
      <ShortName>OTHER PAYABLES AND ACCRUALS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - REVENUE - Summary of Analysis of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails</Role>
      <ShortName>REVENUE - Summary of Analysis of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - REVENUE - Summary of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUESummaryofRevenueDetails</Role>
      <ShortName>REVENUE - Summary of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails</Role>
      <ShortName>REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - REVENUE - Summary of Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails</Role>
      <ShortName>REVENUE - Summary of Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails</Role>
      <ShortName>OTHER (EXPENSE)/INCOME, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - FINANCE INCOME AND FINANCE COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSNarrativeDetails</Role>
      <ShortName>FINANCE INCOME AND FINANCE COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - FINANCE INCOME AND FINANCE COSTS - Summary of Finance Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails</Role>
      <ShortName>FINANCE INCOME AND FINANCE COSTS - Summary of Finance Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails</Role>
      <ShortName>LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - LEASES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESAdditionalInformationDetails</Role>
      <ShortName>LEASES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails</Role>
      <ShortName>LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails</Role>
      <ShortName>LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails</Role>
      <ShortName>COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - COLLABORATION INVENTORIES, NET - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails</Role>
      <ShortName>COLLABORATION INVENTORIES, NET - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails</Role>
      <ShortName>PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails</Role>
      <ShortName>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails</Role>
      <ShortName>CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - OTHER PAYABLES AND ACCRUALS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails</Role>
      <ShortName>OTHER PAYABLES AND ACCRUALS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails</Role>
      <ShortName>COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="legn-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails</Role>
      <ShortName>SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="legn-20250331.htm">legn-20250331.htm</File>
    <File>legn-20250331.xsd</File>
    <File>legn-20250331_cal.xml</File>
    <File>legn-20250331_def.xml</File>
    <File>legn-20250331_lab.xml</File>
    <File>legn-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="329">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "legn-20250331.htm": {
   "nsprefix": "legn",
   "nsuri": "http://legendbiotech.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "legn-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "legn-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "legn-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "legn-20250331_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "legn-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "legn-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 132,
   "keyCustom": 65,
   "axisStandard": 11,
   "axisCustom": 0,
   "memberStandard": 18,
   "memberCustom": 4,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 75,
   "entityCount": 1,
   "segmentCount": 22,
   "elementCount": 305,
   "unitCount": 5,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 329,
    "http://xbrl.sec.gov/dei/2024": 8
   },
   "report": {
    "R1": {
     "role": "http://legendbiotech.com/role/COVER",
     "longName": "0000001 - Document - COVER",
     "shortName": "COVER",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME",
     "longName": "9952151 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:RevenueFromLicensingOfIntellectualProperty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "longName": "9952152 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "longName": "9952153 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:Equity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952154 - Statement - UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForFinanceIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://legendbiotech.com/role/CORPORATEINFORMATION",
     "longName": "9952155 - Disclosure - CORPORATE INFORMATION",
     "shortName": "CORPORATE INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://legendbiotech.com/role/BASISOFPREPARATION",
     "longName": "9952156 - Disclosure - BASIS OF PREPARATION",
     "shortName": "BASIS OF PREPARATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY",
     "longName": "9952157 - Disclosure - NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY",
     "shortName": "NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://legendbiotech.com/role/REVENUE",
     "longName": "9952158 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://legendbiotech.com/role/OTHEREXPENSEINCOMENET",
     "longName": "9952159 - Disclosure - OTHER (EXPENSE)/INCOME, NET",
     "shortName": "OTHER (EXPENSE)/INCOME, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTS",
     "longName": "9952160 - Disclosure - FINANCE INCOME AND FINANCE COSTS",
     "shortName": "FINANCE INCOME AND FINANCE COSTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT",
     "longName": "9952161 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT",
     "shortName": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://legendbiotech.com/role/LEASES",
     "longName": "9952162 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET",
     "longName": "9952163 - Disclosure - COLLABORATION INVENTORIES, NET",
     "shortName": "COLLABORATION INVENTORIES, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS",
     "longName": "9952164 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS",
     "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS",
     "longName": "9952165 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS",
     "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS",
     "longName": "9952166 - Disclosure - OTHER PAYABLES AND ACCRUALS",
     "shortName": "OTHER PAYABLES AND ACCRUALS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING",
     "longName": "9952167 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM",
     "longName": "9952168 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS",
     "longName": "9952169 - Disclosure - APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
     "shortName": "APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://legendbiotech.com/role/REVENUETables",
     "longName": "9955511 - Disclosure - REVENUE (Tables)",
     "shortName": "REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables",
     "longName": "9955512 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Tables)",
     "shortName": "OTHER (EXPENSE)/INCOME, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSTables",
     "longName": "9955513 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Tables)",
     "shortName": "FINANCE INCOME AND FINANCE COSTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables",
     "longName": "9955514 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)",
     "shortName": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://legendbiotech.com/role/LEASESTables",
     "longName": "9955515 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables",
     "longName": "9955516 - Disclosure - COLLABORATION INVENTORIES, NET (Tables)",
     "shortName": "COLLABORATION INVENTORIES, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables",
     "longName": "9955517 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)",
     "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables",
     "longName": "9955518 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)",
     "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables",
     "longName": "9955519 - Disclosure - OTHER PAYABLES AND ACCRUALS (Tables)",
     "shortName": "OTHER PAYABLES AND ACCRUALS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables",
     "longName": "9955520 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables",
     "longName": "9955521 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM (Tables)",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
     "longName": "9955522 - Disclosure - REVENUE - Summary of Analysis of Revenue (Details)",
     "shortName": "REVENUE - Summary of Analysis of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "legn:RevenueFromLicensingOfIntellectualProperty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "legn:RevenueFromLicensingOfIntellectualProperty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails",
     "longName": "9955523 - Disclosure - REVENUE - Summary of Revenue (Details)",
     "shortName": "REVENUE - Summary of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails",
     "longName": "9955524 - Disclosure - REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)",
     "shortName": "REVENUE - Analysis of Timing of Transfer of Goods or Services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-43",
      "name": "ifrs-full:Revenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails",
     "longName": "9955525 - Disclosure - REVENUE - Summary of Deferred Revenue (Details)",
     "shortName": "REVENUE - Summary of Deferred Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentContractLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails",
     "longName": "9955526 - Disclosure - OTHER (EXPENSE)/INCOME, NET (Details)",
     "shortName": "OTHER (EXPENSE)/INCOME, NET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSNarrativeDetails",
     "longName": "9955527 - Disclosure - FINANCE INCOME AND FINANCE COSTS - Narrative (Details)",
     "shortName": "FINANCE INCOME AND FINANCE COSTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:FinanceIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails",
     "longName": "9955528 - Disclosure - FINANCE INCOME AND FINANCE COSTS - Summary of Finance Costs (Details)",
     "shortName": "FINANCE INCOME AND FINANCE COSTS - Summary of Finance Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:InterestExpenseOnLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails",
     "longName": "9955529 - Disclosure - LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details)",
     "shortName": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT - Summary of Calculations of Basic and Diluted Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:EarningsPerShareExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://legendbiotech.com/role/LEASESAdditionalInformationDetails",
     "longName": "9955530 - Disclosure - LEASES - Additional Information (Details)",
     "shortName": "LEASES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-49",
      "name": "legn:LesseeLeasingArrangementsLeasesTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-49",
      "name": "legn:LesseeLeasingArrangementsLeasesTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails",
     "longName": "9955531 - Disclosure - LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)",
     "shortName": "LEASES - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdditionsToRightofuseAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
     "longName": "9955532 - Disclosure - LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)",
     "shortName": "LEASES - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "legn:IncreaseInLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails",
     "longName": "9955533 - Disclosure - COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)",
     "shortName": "COLLABORATION INVENTORIES, NET - Summary of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:RawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails",
     "longName": "9955534 - Disclosure - COLLABORATION INVENTORIES, NET - Additional Information (Details)",
     "shortName": "COLLABORATION INVENTORIES, NET - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "legn:InventoryReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "legn:InventoryReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails",
     "longName": "9955535 - Disclosure - PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)",
     "shortName": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-53",
      "name": "legn:OtherCollaborationReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-53",
      "name": "legn:OtherCollaborationReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails",
     "longName": "9955536 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)",
     "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndBankBalancesAtCentralBanks",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndBankBalancesAtCentralBanks",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails",
     "longName": "9955537 - Disclosure - CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details)",
     "shortName": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails",
     "longName": "9955538 - Disclosure - OTHER PAYABLES AND ACCRUALS (Details)",
     "shortName": "OTHER PAYABLES AND ACCRUALS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "legn:AccruedPayroll",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "legn:AccruedPayroll",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails",
     "longName": "9955539 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Summary of Interest-Bearing Loans and Borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-61",
      "name": "ifrs-full:BorrowingsInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-61",
      "name": "ifrs-full:BorrowingsInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails",
     "longName": "9955540 - Disclosure - COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)",
     "shortName": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:Borrowings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails",
     "longName": "9955541 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-71",
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ifrs-full:NumberOfSharesAuthorised",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
     "longName": "9955542 - Disclosure - SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)",
     "shortName": "SHARE CAPITAL AND SHARE PREMIUM - Summary of Movements in the Company's Share Capital and Share Premium (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "legn:ShareCapitalAndSharePremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "legn:ShareCapitalAndSharePremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "legn-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "legn_A110InterestBearingLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "A110InterestBearingLoansMember",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "11.0% Interest Bearing Loans",
        "label": "11.0% Interest Bearing Loans [Member]",
        "documentation": "11.0% Interest Bearing Loans"
       }
      }
     },
     "auth_ref": []
    },
    "legn_AccruedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AccruedExpense",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": {
       "parentTag": "legn_OtherPayablesAndAccrualsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense",
        "label": "Accrued Expense",
        "documentation": "Accrued expense."
       }
      }
     },
     "auth_ref": []
    },
    "legn_AccruedPayroll": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AccruedPayroll",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": {
       "parentTag": "legn_OtherPayablesAndAccrualsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll",
        "label": "Accrued Payroll",
        "documentation": "Accrued payroll."
       }
      }
     },
     "auth_ref": []
    },
    "legn_AdditionInTimeDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdditionInTimeDeposits",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Addition in time deposits",
        "label": "Addition In Time Deposits",
        "documentation": "Addition in time deposits."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Adjustments for amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in collaboration inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "legn_AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in other non-current assets",
        "label": "Adjustments For Decrease (Increase) In Other Non-current Assets",
        "documentation": "Adjustments For Decrease (Increase) In Other Non-current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "legn_AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in prepayments, other receivables and other assets",
        "label": "Adjustments For Decrease Increase In Prepayments Other Receivable Other Assets",
        "documentation": "Adjustments for decrease increase in prepayments other receivable other assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in trade receivables",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of property, plant and equipment",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "legn_AdjustmentsForDepreciationOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdjustmentsForDepreciationOfRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of right-of-use assets",
        "label": "Adjustments For Depreciation Of Right Of Use Assets",
        "documentation": "Adjustments for depreciation of right-of-use assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFairValueGainsLosses",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value gains on financial assets measured at fair value through profit or loss",
        "label": "Adjustments for fair value losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance costs",
        "label": "Adjustments for finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Finance income",
        "label": "Adjustments for finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on asset impairment",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "legn_AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in contract liabilities, net",
        "label": "Adjustments For Increase (Decrease) In Contract Liabilities, Current",
        "documentation": "Adjustments For Increase (Decrease) In Contract Liabilities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "legn_AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in other non-current liabilities",
        "label": "Adjustments For Increase Decrease In Other Non Current Liabilities",
        "documentation": "Adjustments for increase (decrease) in other non current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease)/increase in other payables and accruals",
        "label": "Adjustments for increase (decrease) in other operating payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in trade payables",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "legn_AdjustmentsForInventoryReserveProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdjustmentsForInventoryReserveProvision",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for inventory reserve",
        "label": "Adjustments For Inventory Reserve Provision",
        "documentation": "Adjustments For Inventory Reserve Provision"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency exchange loss/(gain), net",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r158"
     ]
    },
    "ifrs-full_AdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Administrative expenses",
        "label": "Administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity classifies as being administrative."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r43",
      "r116"
     ]
    },
    "legn_AdvancePaymentsForPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AdvancePaymentsForPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance payments for property, plant and equipment",
        "label": "Advance Payments For Property Plant And Equipment",
        "documentation": "Advance payments for property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails",
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r78",
      "r106",
      "r109"
     ]
    },
    "legn_AuthorisedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AuthorisedAbstract",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized:",
        "label": "Authorised [Abstract]",
        "documentation": "Authorised."
       }
      }
     },
     "auth_ref": []
    },
    "legn_AuthorizedShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "AuthorizedShareCapital",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2,000,000,000 ordinary shares of $0.0001 each",
        "label": "Authorized Share Capital",
        "documentation": "Authorized share capital."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "ifrs-full_BasicEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share [abstract]",
        "label": "Basic earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_BasisOfPreparationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "BasisOfPreparationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Preparation [Abstract]",
        "documentation": "Basis of Preparation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding advances from collaborator principal amount",
        "label": "Borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsAdjustmentToInterestRateBasis",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate margin percentage",
        "label": "Borrowings, adjustment to interest rate basis"
       }
      },
      "en": {
       "role": {
        "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [axis]",
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_BorrowingsByNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsByNameDomain",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings by name [domain]",
        "label": "Borrowings by name [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate (%)",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of Range",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r79",
      "r94",
      "r95",
      "r135",
      "r136",
      "r163"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CNY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "CNY",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails",
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominated in RMB",
        "label": "China, Yuan Renminbi"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and bank balances",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_CashAndBankBalancesAtCentralBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndBankBalancesAtCentralBanks",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and bank balances",
        "label": "Cash and bank balances at central banks"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and bank balances held at central banks."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails",
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "totalLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r60",
      "r74"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS",
        "label": "Cash and cash equivalents [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_CashAndCashEquivalentsAsStatedInStatementOfCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "CashAndCashEquivalentsAsStatedInStatementOfCashFlows",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents as stated in the statement of cash flows",
        "label": "Cash And Cash Equivalents As Stated In Statement Of Cash Flows",
        "documentation": "Cash and cash equivalents as stated in statement of cash flows."
       }
      }
     },
     "auth_ref": []
    },
    "legn_CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents as stated in the statement of financial position",
        "label": "Cash And Cash Equivalents As Stated In Statement Of Financial Position",
        "documentation": "Cash and cash equivalents as stated in statement of financial position."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r61"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS PROVIDED BY FINANCING ACTIVITIES",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by/(used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r61"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS PROVIDED BY/(USED IN) INVESTING ACTIVITIES",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in)/provided by operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r53",
      "r61"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS (USED IN)/PROVIDED BY OPERATING ACTIVITIES",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash (used in)/provided by operations",
        "label": "Cash flows from (used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows provided by (used in) operations before changes in working capital",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r160"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "legn_CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash receipts of investment income",
        "label": "Cash Receipts Of Investment Income Classified As Investing Activities",
        "documentation": "Cash receipts of investment income classified as investing activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [axis]",
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial instruments [domain]",
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101"
     ]
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfInventoriesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of current inventories [abstract]",
        "label": "Classes of current inventories [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [domain]",
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "legn_CollaborationPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "CollaborationPayable",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": {
       "parentTag": "legn_OtherPayablesAndAccrualsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration payable",
        "label": "Collaboration Payable",
        "documentation": "Collaboration Payable"
       }
      }
     },
     "auth_ref": []
    },
    "legn_CollaborationPrepaidLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "CollaborationPrepaidLeases",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration prepaid leases",
        "label": "Collaboration Prepaid Leases",
        "documentation": "Collaboration Prepaid Leases"
       }
      }
     },
     "auth_ref": []
    },
    "legn_CollaborationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "CollaborationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Collaboration Revenue",
        "documentation": "Collaboration Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [domain]",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income/(loss) for the period",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r25",
      "r64",
      "r66",
      "r71",
      "r134"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to:",
        "label": "Comprehensive income attributable to [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Ordinary equity holders of the parent",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r27"
     ]
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83"
     ]
    },
    "legn_CostOfLicenseAndOtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "CostOfLicenseAndOtherRevenue",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cost of license and other revenue",
        "label": "Cost Of License And Other Revenue",
        "documentation": "Cost Of License And Other Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cost of collaboration revenue",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r33"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [axis]",
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparties [domain]",
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails",
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r134"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails": {
       "parentTag": "ifrs-full_ContractLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofDeferredRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "verboseLabel": "Contract liabilities (Current)",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_CurrentFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grants",
        "label": "Current government grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current portion",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r69",
      "r134"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments, other receivables and other assets",
        "label": "Current prepayments and other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax payable",
        "label": "Current tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119"
     ]
    },
    "legn_DecreaseInTimeDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DecreaseInTimeDeposits",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in time deposits",
        "label": "Decrease In Time Deposits",
        "documentation": "Decrease in time deposits."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DeferredGovernmentGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DeferredGovernmentGrant",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred government grant",
        "label": "Deferred Government Grant",
        "documentation": "Deferred government grant."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DepositsFromBank": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DepositsFromBank",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Deposits From Bank",
        "documentation": "Deposits from bank."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation of right-of-use assets",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://legendbiotech.com/role/NEWSTANDARDSINTERPRETATIONSANDAMENDMENTSADOPTEDBYTHECOMPANY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/APPROVALOFTHEINTERIMCONDENSEDCONSOLIDATEDFINANCIALSTATEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS",
        "label": "Disclosure of authorisation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the authorisation of financial statements for issue."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/BASISOFPREPARATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PREPARATION",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_DisclosureOfBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBorrowingsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COLLABORATION INTEREST-BEARING ADVANCED FUNDING",
        "label": "Disclosure of borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS",
        "label": "Disclosure of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]",
        "documentation": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsLineItems",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails",
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]",
        "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]",
        "documentation": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfCashAndCashEquivalentsTimeDepositsAndPledgedDepositsTable",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSAdditionalInformationDetails",
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]",
        "label": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]",
        "documentation": "Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUM"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE CAPITAL AND SHARE PREMIUM",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Classes Of Share Capital [Line Items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Classes Of Share Capital [Table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "legn_DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Revenue from Contract Liabilities",
        "label": "Disclosure Of Deferred Revenue From Customer Contract Liabilities [Table Text Block]",
        "documentation": "Disclosure Of Deferred Revenue From Customer Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Interest-Bearing Loans and Borrowings",
        "label": "Disclosure of detailed information about borrowings [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Borrowings [Line Items]",
        "label": "Disclosure of detailed information about borrowings [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Borrowings [Table]",
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "legn_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits",
        "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Time Deposits And Pledged Deposits Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about cash and cash equivalents, time deposits and pledged deposits."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Inventories",
        "label": "Disclosure Of Detailed Information About Inventories Explanatory [Table Text Block]",
        "documentation": "The disclosure of detailed information about inventories."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesLineItems",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]",
        "label": "Disclosure Of Detailed Information About Lease Liabilities [Line Items]",
        "documentation": "Disclosure of detailed information about lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDetailedInformationAboutLeaseLiabilitiesTable",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Detailed Information About Lease Liabilities [Table]",
        "label": "Disclosure Of Detailed Information About Lease Liabilities [Table]",
        "documentation": "Disclosure of detailed information about lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Total Other Income And Expense",
        "label": "Disclosure Of Detailed Information About Other Income (Expense) [Table Text Block]",
        "documentation": "Disclosure Of Detailed Information About Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Other Payables and Accruals",
        "label": "Disclosure Of Detailed Information About Other Payables And Accruals Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about other payables and accruals."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Prepayments, Other Receivables and Other Assets",
        "label": "Disclosure Of Detailed Information About Prepayments Other Receivables And Other Assets Explanatory [Table Text Block]",
        "documentation": "Disclosure of detailed information about prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [abstract]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Analysis of Revenue",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails",
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails",
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Table]",
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DisclosureOfFinanceCostExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinanceCostExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Finance Costs",
        "label": "Disclosure of finance cost [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of finance cost. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue by Geographic Area",
        "label": "Disclosure of geographical areas [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COLLABORATION INVENTORIES, NET",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93"
     ]
    },
    "legn_DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Movements in the Company's Share Capital and Share Premium",
        "label": "Disclosure Of Movements In Company Share Capital And Share Premium Explanatory [Table Text Block]",
        "documentation": "Disclosure of movements in the company's share capital and share premium explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/CORPORATEINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CORPORATE INFORMATION",
        "label": "Disclosure of notes and other explanatory information [text block]",
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "legn_DisclosureOfOtherIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfOtherIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Other Income and Expense [Abstract]",
        "documentation": "Disclosure of Other Income and Gains"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER (EXPENSE)/INCOME, NET",
        "label": "Disclosure of other operating income (expense) [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "legn_DisclosureOfOtherPayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfOtherPayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Other Payables And Accruals [Abstract]",
        "documentation": "Disclosure of other payables and accruals."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER PAYABLES AND ACCRUALS",
        "label": "Disclosure Of Other Payables And Accruals Explanatory [Text Block]",
        "documentation": "Disclosure of other payables and accruals."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS",
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets Explanatory [Text Block]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsLineItems",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]",
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsTable",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]",
        "label": "Disclosure Of Prepayments Other Receivables And Other Assets [Table]",
        "documentation": "Disclosure of prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Carrying Amounts of The Right-of-use Assets and Movements",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/REVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Shares",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Disclosure of Timing of transfer of Goods or Services",
        "label": "Disclosure Of Timing Of Transfer Of Goods Or Services [Table Text Block]",
        "documentation": "Disclosure Of Timing Of Transfer Of Goods Or Services"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "EUR",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominated in EUR",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Calculations of Basic and Diluted Loss per Share",
        "label": "Earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange rate changes, net",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "legn_EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCE INCOME AND FINANCE COSTS",
        "label": "Entire Disclosure Of Finance Income and Costs Explanatory [Text Block]",
        "documentation": "The entire disclosure of finance costs."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://legendbiotech.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r17",
      "r63",
      "r65",
      "r76",
      "r77",
      "r78"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total ordinary shareholders\u2019 equity",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExchangeDifferencesOnTranslationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExchangeDifferencesOnTranslationAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER COMPREHENSIVE INCOME/(LOSS)",
        "label": "Exchange differences on translation [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_ExerciseOfShareOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ExerciseOfShareOption",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share options",
        "label": "Exercise Of Share Option",
        "documentation": "Exercise of share option."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ExerciseOfShareOptionNumberOfSharesInIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ExerciseOfShareOptionNumberOfSharesInIssue",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share option (in shares)",
        "label": "Exercise Of Share Option Number Of Shares In Issue",
        "documentation": "Exercise of share option number of shares in issue."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-settled share-based compensation expense",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedNetLabel": "Finance costs",
        "totalLabel": "Total",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSNarrativeDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "legn_FinanceIncomeAndFinanceCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "FinanceIncomeAndFinanceCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income And Finance Costs [Abstract]",
        "label": "Finance Income And Finance Costs [Abstract]",
        "documentation": "Finance Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income received",
        "label": "Finance income received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_FinanceLeaseReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceLeaseReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease receivables",
        "label": "Finance lease receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables related to finance leases."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r154"
     ]
    },
    "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on disposal of property, plant and equipment",
        "label": "Gains (losses) on disposals of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency exchange (loss)/gain, net",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r41"
     ]
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value gains on financial assets measured at fair value change through profit or loss",
        "label": "Gains (losses) on financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue at a point in time",
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue over time",
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on asset impairment",
        "label": "Impairment loss recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossRightofuseAssets",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Impairment loss recognised in profit or loss, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for right-of-use assets. [Refer: Impairment loss recognised in profit or loss; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r34",
      "r35",
      "r36",
      "r44",
      "r75",
      "r105"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax (paid)/received",
        "label": "Income taxes paid (refund), classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r57",
      "r126"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "legn_IncreaseDecreaseInPledgedDepositsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "IncreaseDecreaseInPledgedDepositsNet",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange realignment",
        "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "legn_IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange realignment",
        "label": "Increase (Decrease) Through Effect Of Exchange Realignment In Foreign Exchange Rate",
        "documentation": "Increase (decrease) through effect of exchange realignment in foreign exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share options",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "legn_IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of vested restricted share units",
        "label": "Increase Decrease Through Reclassification Of Vested Restricted Stock Equity",
        "documentation": "Increase (decrease) through reclassification of vested restricted stock, equity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-settled share-based compensation expense",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "legn_IncreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "IncreaseInLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Increase In Lease Liabilities",
        "documentation": "Increase in lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "legn_IncreaseOfLeaseLiabilitiesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "IncreaseOfLeaseLiabilitiesBalance",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of interest recognized during the period",
        "label": "Increase Of Lease Liabilities Balance",
        "documentation": "Increase of lease liabilities balance."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r51"
     ]
    },
    "legn_InterestBearingBorrowingsFundedInterestsAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "InterestBearingBorrowingsFundedInterestsAccrued",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accrued on funding advances",
        "label": "Interest Bearing Borrowings Funded Interests Accrued",
        "documentation": "Interest bearing borrowings funded interests accrued."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration interest-bearing advanced funding",
        "label": "Interest expense on borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/FINANCEINCOMEANDFINANCECOSTSSummaryofFinanceCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "legn_InterestOnLeasePaymentsClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "InterestOnLeasePaymentsClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease payments",
        "label": "Interest On Lease Payments Classified As Operating Activities",
        "documentation": "Interest on lease payments classified as operating activities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration inventories, net",
        "totalLabel": "Total collaboration inventories, net",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r118"
     ]
    },
    "legn_InventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "InventoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Inventory reserve",
        "documentation": "Inventory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "verboseLabel": "368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "verboseLabel": "Number of shares in issue",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LandMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leasehold land",
        "label": "Land [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "legn_LeaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "LeaseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease [Abstract]",
        "documentation": "Lease abstract."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, carrying amount",
        "periodEndLabel": "Ending balance, carrying amount",
        "totalLabel": "Carrying amount at March 31, 2025",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analyzed into:",
        "label": "Lease liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r130",
      "r133"
     ]
    },
    "legn_LeasesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "LeasesLineItems",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Line Items]",
        "label": "Leases [Line Items]",
        "documentation": "Leases line items."
       }
      }
     },
     "auth_ref": []
    },
    "legn_LeasesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "LeasesRollForward",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Roll Forward]",
        "label": "Leases [Roll Forward]",
        "documentation": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "legn_LeasesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "LeasesTable",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Table]",
        "label": "Leases [Table]",
        "documentation": "Leases table."
       }
      }
     },
     "auth_ref": []
    },
    "legn_LesseeLeaseLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "LesseeLeaseLiabilitiesTextBlock",
     "presentation": [
      "http://legendbiotech.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term",
        "label": "Lessee Lease Liabilities [Text Block]",
        "documentation": "Lessee lease liabilities text block."
       }
      }
     },
     "auth_ref": []
    },
    "legn_LesseeLeasingArrangementsLeasesTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "LesseeLeasingArrangementsLeasesTerm",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, lease terms",
        "label": "Lessee Leasing Arrangements Leases Term",
        "documentation": "Lessee leasing arrangements leases term."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r76",
      "r77",
      "r78",
      "r106",
      "r110"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesAxis",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [axis]",
        "label": "Liabilities arising from financing activities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesArisingFromFinancingActivitiesDomain",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities arising from financing activities [domain]",
        "label": "Liabilities arising from financing activities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration interest-bearing advanced funding",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r68",
      "r134"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government grants",
        "label": "Non-current government grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current government grants recognised on the statement of financial position as deferred income. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails": {
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofLeaseLiabilitiesMeasuredatPresentValueofLeasePaymentstobeMadeOverLeaseTermDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities long term",
        "verboseLabel": "Non-current portion",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r70",
      "r134"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentPortionOfNoncurrentLoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentPortionOfNoncurrentLoansReceived",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGSummaryofInterestBearingLoansandBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Interest-bearing Advanced Funding",
        "label": "Non-current portion of non-current loans received"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current loans received. [Refer: Loans received]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "legn_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "NovartisMember",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis",
        "label": "Novartis [Member]",
        "documentation": "Novartis"
       }
      }
     },
     "auth_ref": []
    },
    "legn_NumberOfBorrowingBatches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "NumberOfBorrowingBatches",
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINTERESTBEARINGADVANCEDFUNDINGAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of batches of funding advances",
        "label": "Number Of Borrowing Batches",
        "documentation": "Number Of Borrowing Batches"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares authorized (in shares)",
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_NumberOfSharesIssuedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAbstract",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued and fully paid:",
        "label": "Number of shares issued [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssuedAndFullyPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssuedAndFullyPaid",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issued and fully paid (in shares)",
        "label": "Number of shares issued and fully paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity, for which full payment has been received."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "legn_OngoingLeasePaymentsUnderTheLandLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "OngoingLeasePaymentsUnderTheLandLease",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ongoing lease payments",
        "label": "Ongoing Lease Payments Under The Land Lease",
        "documentation": "Ongoing lease payments under the land lease."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "legn_OtherCollaborationReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "OtherCollaborationReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other collaboration receivables",
        "label": "Other Collaboration Receivables",
        "documentation": "Other Collaboration Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX",
        "label": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r24",
      "r31",
      "r73"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences on translation of foreign operations",
        "verboseLabel": "Exchange differences on translation of foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r31"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_OtherComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net other comprehensive income/(loss)",
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123"
     ]
    },
    "ifrs-full_OtherGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 9.0
      },
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense)/income, net",
        "totalLabel": "Total other (expense)/income, net",
        "label": "Other gains (losses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145"
     ]
    },
    "legn_OtherMiscellaneousIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "OtherMiscellaneousIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails": {
       "parentTag": "ifrs-full_OtherGainsLosses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHEREXPENSEINCOMENETDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Miscellaneous Income (Expense)",
        "documentation": "Other Miscellaneous Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_OtherNoncurrentNonfinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentNonfinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other non-current non-financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": {
       "parentTag": "legn_OtherPayablesAndAccrualsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "legn_OtherPayablesAndAccrualsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "OtherPayablesAndAccrualsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables and accruals",
        "totalLabel": "Total",
        "label": "Other Payables And Accruals Current",
        "documentation": "Other payables and accruals, current."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_OtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherRevenue",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenue",
        "label": "Other revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "legn_OtherTaxPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "OtherTaxPayables",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": {
       "parentTag": "legn_OtherPayablesAndAccrualsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other tax payables",
        "label": "Other Tax Payables",
        "documentation": "Other tax payables,"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Authorized, price per share (in dollars per share)",
        "verboseLabel": "Price per share (in dollars per share)",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "legn_PayableForCollaborationAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "PayableForCollaborationAssets",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails": {
       "parentTag": "legn_OtherPayablesAndAccrualsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/OTHERPAYABLESANDACCRUALSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable for collaboration assets",
        "label": "Payable For Collaboration Assets",
        "documentation": "Payable For Collaboration Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Principal portion of lease payments",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "legn_PledgedDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "PledgedDeposits",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pledged deposits",
        "label": "Pledged Deposits",
        "documentation": "Pledged deposits."
       }
      }
     },
     "auth_ref": []
    },
    "legn_PledgedShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "PledgedShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Pledged deposits",
        "label": "Pledged Short Term Deposits",
        "documentation": "Pledged short-term deposits."
       }
      }
     },
     "auth_ref": []
    },
    "legn_PrepaymentToCollaboratorForCollaborationRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "PrepaymentToCollaboratorForCollaborationRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepayment to collaborator for collaboration assets",
        "label": "Prepayment To Collaborator For Collaboration Right Of Use Assets",
        "documentation": "Prepayment To Collaborator For Collaboration Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Prepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Prepayments",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepayments",
        "label": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "legn_PrepaymentsOtherReceivablesAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "PrepaymentsOtherReceivablesAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Prepayments Other Receivables And Other Assets",
        "documentation": "Prepayments, other receivables and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "legn_PrepaymentsOtherReceivablesAndOtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "PrepaymentsOtherReceivablesAndOtherAssetsMember",
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments Other Receivable and Other Assets",
        "label": "Prepayments Other Receivables And Other Assets [Member]",
        "documentation": "Prepayments other receivables and other assets.,"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of share options",
        "label": "Proceeds from exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "legn_ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property, plant and equipment",
        "label": "Proceeds From (Payments For) Disposals Of Property, Plant And Equipment, Intangible Assets Other Than Goodwill, Investment Property And Other Non-current Assets",
        "documentation": "Proceeds From (Payments For) Disposals Of Property, Plant And Equipment, Intangible Assets Other Than Goodwill, Investment Property And Other Non-current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "legn_ProceedsFromPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ProceedsFromPurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FOR THE PERIOD",
        "terseLabel": "Loss for the period",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r23",
      "r54",
      "r64",
      "r66",
      "r106",
      "r108",
      "r134",
      "r139"
     ]
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Attributable to:",
        "label": "Profit (loss), attributable to [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Ordinary equity holders of the parent",
        "terseLabel": "Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before tax",
        "terseLabel": "Loss before tax",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r115",
      "r116",
      "r140",
      "r141"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment [member]",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r125",
      "r138"
     ]
    },
    "ifrs-full_PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of financial assets measured at fair value through profit or loss",
        "label": "Purchase of financial assets measured at fair value through profit or loss, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial assets measured at fair value through profit or loss, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r79",
      "r94",
      "r95",
      "r135",
      "r136",
      "r163"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [domain]",
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r79",
      "r94",
      "r95",
      "r135",
      "r136",
      "r163"
     ]
    },
    "ifrs-full_RawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Current raw materials"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r154"
     ]
    },
    "legn_ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of vesting of restricted share units (in shares)",
        "label": "Reclassification Of Vested Restricted Stock Units Number Of Shares In Issue",
        "documentation": "Reclassification of vested restricted stock units, number of shares in issue."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of vesting of restricted share units",
        "label": "Reclassification Of Vested Restricted Stock Units Share Capital And Share Premium",
        "documentation": "Reclassification of vested restricted stock units, share capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation reserve",
        "label": "Reserve of exchange differences on translation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r42",
      "r117"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation reserves",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained accumulated losses",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r117"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails",
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenue",
        "terseLabel": "Total Revenue",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r72",
      "r96",
      "r104",
      "r107",
      "r111",
      "r112",
      "r114",
      "r115",
      "r116",
      "r134"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue and other revenue",
        "label": "Revenue from contracts with customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "legn_RevenueFromLicensingOfIntellectualProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "RevenueFromLicensingOfIntellectualProperty",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofAnalysisofRevenueDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "Revenue From Licensing Of Intellectual Property",
        "documentation": "Revenue from licensing of intellectual property."
       }
      }
     },
     "auth_ref": []
    },
    "legn_RightOfUseAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "RightOfUseAssetsRollForward",
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-Use Assets [Roll Forward]",
        "label": "Right-of-Use Assets [Roll Forward]",
        "documentation": "Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/LEASESSummaryofCarryingAmountsofTheRightofuseAssetsandMovementsDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r90"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_SellingAndDistributionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "SellingAndDistributionExpenses",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFPROFITORLOSSANDOTHERCOMPREHENSIVEINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Selling and distribution expenses",
        "label": "Selling And Distribution Expenses",
        "documentation": "Selling and distribution expenses."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalAndSharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ShareCapitalAndSharePremium",
     "crdr": "credit",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Share Capital And Share Premium",
        "documentation": "Share capital and share premium."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalAndSharePremiumNumberOfSharesInIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ShareCapitalAndSharePremiumNumberOfSharesInIssue",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share Capital And Share Premium Number Of Shares In Issue",
        "documentation": "Share capital and share premium, number of shares in issue."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ShareCapitalMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Share Capital [Member]",
        "documentation": "Share capital."
       }
      }
     },
     "auth_ref": []
    },
    "legn_ShareCapitalRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "ShareCapitalRollForward",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital [Roll Forward]",
        "label": "Share Capital [Roll Forward]",
        "documentation": "Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://legendbiotech.com/role/SHARECAPITALANDSHAREPREMIUMSummaryofMovementsintheCompanysShareCapitalandSharePremiumDetails",
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Pledged deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "legn_StatementOfChangesInEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "StatementOfChangesInEquityRollForward",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [Roll Forward]",
        "label": "Statement of changes in equity [Roll Forward]",
        "documentation": "Statement of changes in equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "legn_TimesDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "TimesDeposits",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Times Deposits",
        "documentation": "Times deposits."
       }
      }
     },
     "auth_ref": []
    },
    "legn_TimesDepositsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "TimesDepositsCurrentAndNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Times Deposits Current And Noncurrent",
        "documentation": "Times deposits current and noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "legn_TimesDepositsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://legendbiotech.com/20250331",
     "localname": "TimesDepositsNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time deposits",
        "label": "Times Deposits Non Current",
        "documentation": "Times deposits, non-current."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [axis]",
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesDomain",
     "presentation": [
      "http://legendbiotech.com/role/REVENUEAnalysisofTimingofTransferofGoodsorServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of transfer of goods or services [domain]",
        "label": "Timing of transfer of goods or services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://legendbiotech.com/role/LEASESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of Range",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r79",
      "r94",
      "r95",
      "r135",
      "r136",
      "r163"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/UNAUDITEDINTERIMCONDENSEDCONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://legendbiotech.com/role/REVENUESummaryofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://legendbiotech.com/role/CASHANDCASHEQUIVALENTSTIMEDEPOSITSANDPLEDGEDDEPOSITSSummaryofCashandCashEquivalentsTimeDepositsandPledgedDepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominated in USD",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ValueAddedTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ValueAddedTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails": {
       "parentTag": "legn_PrepaymentsOtherReceivablesAndOtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/PREPAYMENTSOTHERRECEIVABLESANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "VAT recoverable",
        "label": "Value added tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of receivables related to a value added tax."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://legendbiotech.com/role/LOSSPERSHAREATTRIBUTABLETOORDINARYEQUITYHOLDERSOFTHEPARENTSummaryofCalculationsofBasicandDilutedLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_WorkInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WorkInProgress",
     "crdr": "debit",
     "calculation": {
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails": {
       "parentTag": "ifrs-full_Inventories",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://legendbiotech.com/role/COLLABORATIONINVENTORIESNETSummaryofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Current work in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets currently in production, which require further processes to be converted into finished goods or services. [Refer: Current finished goods; Inventories]"
       }
      }
     },
     "auth_ref": [
      "r120",
      "r154"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "129",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_129_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44D&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001801198-25-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001801198-25-000021-xbrl.zip
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M[3*0V#!QX1HE$)<+D&TX95\_DWJF)$[@#RT.A;DX%"OJ0CO8E*[J#)CZ1?G
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M. 8*E]PT6_76U185NW\ X"U"I7+YP+(4<<1):6),M92B@VA2I623%1]M-7H
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M[<6;Q8?.A1=0NO$>J(US86N]FW@D)O_6=\PI_#/RQ];'_P]02P,$%     @
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M!K@JC;'45E2?JKE1@5):DM"*1(N&CM0%J=*12?##*,IY@4+-0;O4>\V2H'3
M8Y($RB"34_,J4QUH<X0BK!LE_4>("%_EJLD:.N54Z@ X?W+"C&W=J?@YK3'1
MQ\Q16=D^"&/-.L9@E$LK.$'XXNG H6%4:J!53>URJ9*X9VW94LXC9*3(D(ID
MES([2G^R"5R!CJBA:#)4\SS*6/*:6VB:%YC'8]],UC%[/>3U6&9JJ;E)S1G2
M<LQL[ NO&C>)EP\*4;('15M,)\>-5SZZ_Q"G0!(KRDJGZ/(J8F ^/[D#;\&C
M!^[D$(+L$N*0Y6VK,@-3W06B.LC9,M-Y'GLD4584O01R$3JR*)0]%MDS1D]!
MG( Q%H4RR82I86D!$NVRJ<^]Q0/&/ZYA8DSF,8M"'5!./M 0LH2$AS;0L<0_
M_&Q<F51ROJB<0G;D5L.Z!W>8V=61!7CL*!@JOD*8KJTTNF\(W9B XS<$!S]P
M\60!-UWE4&]+PCDY2YX\MGYBCAG2) K*NT/E/ >TY/"BF/LA4/Z.S>>CVZ5X
M[.,5ED!JQ3:M4.%.J6-P-DV;XCO6E[H'G;J"+B$',_$?-+BS\282O?#(1WZF
M;H!!$>I((U"3G. K0Z>ZC\VZV%L:%R\,)HZ+8IU$]'2=P"(@;^I8@.0$K.R=
M 67DBR]4E^[XYC01;#W>A3UFE^D2?A%.0"N!QW37-6/XV:4(8]RG;N:>N*5>
MWD>+#XU&7$%DA"BL#3J+8XH7JSZ2'5]*,2I1YZ!FP<CN U$]CIWC/MTP/LKB
MG+_SMS^H'K9L&U7-7CWY/JBP 4B]W4Q39.%MB]1\-.7F.G"^C#,=&O0URJ:5
MO5?;_.&*4AO@N=6&DY\G72$%=MJLTW8O82.B'*]AXMLH?C$5'Z>=+U^<GF]>
MT^8!Q1NJO'&RZY3M.@O5XV=O7I^^V3S]>'-Z/CX[X[7=@R">P\ 3G@BO/ 3E
MVY,7)Z/CLKR%3AM,M4Z84?._JY[PRNRV&W'.TS\+?HX\FPP[X^ M7XW%_YO1
MY!X:8%V SF[7LD8F;V5[!^HZ^:+7@T_;\K\%RPQYB9.I4*T;*V+)LJ#64O7Y
M/0=?!1:I \L]P1\I^/G%9DDP%=]$R)[>K^5[B.E"+.$#0#->4G]Y#S #DJ4V
MF$'<_/)MUD$E87!,$&1Q,JKMA<2E'Y/R(B&>WX140""G"Q8T'):_&T.BZIWB
M)C*_*JHU 94XH#D5L:O[$8#>%5CNQ?F*7HA?_I%[@B]_]E_#PB.OTTF9*_?5
MWZ=_7IU<' G3_]'ZJZ'UYR#R6?P[CC/^^Y%_ U!+ P04    "  2.*U:+85V
M*VRN   L/ D $0   &QE9VXM,C R-3 S,S$N:'1M['U;=^)(EN[[_(HX3)_I
MS%ZRK1NZ.*LXB[1Q)C,VN %7=3WU$B@PF@*)EH0O_>O/CI $V( M(0$AB%Y=
M3AMTB8C]Q;['WK_\OY?)&#UA/W \]]>_2N?B7Q%V!Y[MN(^__K7>O6HV__K_
M:O_QR_\Y._O']\XMNO8&LPEV0W3E8RO$-GIVPA$*1QC][OE_.D\6NA];X=#S
M)V=GT6U7WO35=QY'(9)%N9I<EGSK7YI#:VC+_<&9,AC:9ZHM#\\L>VB<*::D
MZ;+<MZJ#H?!X:9JBI,B:>":KBG2F6I)Z9@Q%X\PV)6D@5?M5#6N"?=FW9,TV
M[*&JV(;:UT5+- >28>E#0]%$W=3H>T<AS!GF[0:7SLNOE5$83B\O+IZ?G\]?
M^O[XW/,?+V1XVX7CCAT7DWE7XLL#/YQ?/[2"/KT6/H3K936YZ"5PWCST68D?
M*4H7_[B[[0Y&>&*=.6X06NX )W?!J_[<-!91N2!?]ZU@?CGYUEZ\9_EB[2+Z
M,KETX,W<T']]>VV !^>/WM-%_.6;"3@OX?J1+!;D(O0M-R!TMD) #KE=/!/E
M,TF>/R3P5%G2/YA2?,5\1BLK$"^<9)KF!?UV>?+.1T]^M[;.T _.AK/Q.+HG
M2!:!?$[O"JT7S_4FT3*<B<J9K%_,;TJ>8F-G_1K"%^_7[PR^>S/ Y-J/EE"J
MG@&B%2E^SN:U( ">4W?F^[!C-Y$W_O;-^,;XT9U?#G]@U^X[7H@'H_.!-R&7
M5D4E'L;EV ).4,'NV4.W4OMEA"V[]LL$AQ8B]Y_A?\V<IU\K5YX; E<XZ[U.
M8=$'T5^_5D+\$E[0P5[4_N,__N.7T G'N$9>?Y:\Y)>+Z,-?+J)']SW[M?:+
M[3RA('P=XU\KMA-,Q];KI>NY& ;@O%R2"[$?_>K8-G;IK_!]"UB3[PRB][^$
M'3S\M3(X@WFXUH0\"3N7#1=>]WH%H_.M<=.U\<O_X-<*<NQ?*\,SI5(389,:
MHB29QB\7;QZ:X1T)C[R'"SV[X=K7P"DK**+TKQ5 QZ4-GYQ-X!&C,]MZ/7O%
MEI\,0JW4E M%HE3(/X8;)QA8XS_@^3?P29"\I%JI%?G\:*9OWJ!5:G^7MG_^
M%<7MTO!3+&/R:KU2D^0+)<?;ZS UFTYO;#V^?>70><'VV= :$U8<O<^HU&[J
MM]W&ROLNWB+4QT-,-B,.UFPLPMXN RH:8$2(LKO+$+;3KY7 F4S'A)?1ST8^
M&?";/73^$MBPP^C[%B^)WQEX,Y_^19GFY<QU0CKN&=R3?#C!5C#S<2WFR)</
MW>M?+MY^E?Q-[E_W+(! =V3Y>/Y,V,*.C9<OI>MBA9Z_Y6M7[B<?7F/@VXZ[
M[K'17P$95?#1<]\\XN+MZ#^:=?3DE45,^]J5Y[FS21_[&YXWA5\S/:UOA8/1
MRL,(;B[I5VD>%F\1^CRR19+/,>6BR5^P4/#WT,$^H@#&:P7?5?-_WK+7]S?/
M1_#VZ5/*6Y*_0*[[(6$$E'^=B1+\/[EO\=U\F/;2I<J9(BU>$7V3_)V\Y.+-
MO-<O@\S:,JCIET$M;AD4!I8ATO/"-01.OMEF9BI;,U-!J2YH9M5=SRQ&('XD
MPC/ZTX:7O4S'SL )[S!A<,AVX%MJ;U;F.O;EE3>9@H;GAD%[V "E,GRMOSC
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M+(V>E=%V&U</G6:OV>BB>NL:-?YQ];/>^M% 5^V[NV:WVVRW#C@%*=44?K>
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M1=M=]<BNH0/)(X.EF5+3&60$.;M/-!/+MQ/B+""_(+3_CI5D@*R/B6Q _5D
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M8([&T-YB*59\,MLNIA^-[!@7NN>$8_QFF1F 'CRA<AC5-<IHL/;[QA7N['K
MF!$8,\-?*Y9I2CAN914;?_^2B!ES/@H!-$1U_N7">N_F.N;]<F!TW%,[O!.1
M0D"1T;IBQY^O(0C?64SMK/],H=%I=(?)?(?M$R4/<U=1,W857<U=15?+KJ*%
MBZ6;PE4D;.$K$N;.(KZACV%#ZR;=T,I);NA# &2'/M-SKK:RNQ=!1ZV>)3&C
MJB0OZ:OJB6V^/=EW&[35F 1\K["[5W#D[##-:FC!LX<D[AF%/>=[IGJJ>^9@
M".DN1Z))T0++?44=$I&^H:396AV,G9[K5VX/>^X0BRF1$AC[<^5MN\3'CFD2
MAQ]ZXS$MR(DF%C&NK'% JPYLCJZLY-MD#+='8=PH\H_^\;USB[[@?X2D,@B)
M'WQ/D@RB%Y&!W5KNXPRTQJ^7Z(OSE;XJM4FX''@:HGO?&SHA23N_]> 51)6D
MM=SIAO;QB SB"<,S!]X$"_"VK5_W5GN]C_/SZ"/S3>&*'D,,:,H++9="GOF4
M[Y%6,$(W@((@,F^_P.-:0/4@RCS(\-QU!OC[W)L%:SS%;$A)*44Z)#MIVAL.
M/35_M.J]A\X'11[8R'5</@L=99##IO47>R_%,6/A?>KYR J0/1N_HH$U(UMP
M.0\27M/'*  "P1=>=*"PCT?6>$@B]R%-O +Q%5U G^SC&8GBTP=:LW#D^3 ]
M>TW0N]R!7U4[UW6CD'BM?FXH9B%/4N5ST5#R1'X_5(2TE<O8,E$W)$4W?C1:
MU^A[L]UK7/U$5^W.?;M3[RU70UG2KM_)#*GZ0<I^2JUQV\M2DHHM&FQRT[VB
ME:( [S5U+9V>7:9Y7P07Z ^B<_X$IOV8Q4F2<B,>AQ=IL40"NA^=7V=RO9::
M9:U?CZN1@X<@O).3RVUZ<ME'J\O"G,Y;O(:K%:'A&E)^#?= 24HHBA S<_#Q
M_2'VK%)W<PX@*V-_:-4?KFGAMV:KU^@T[V#XK>M&J]NXWDWZ;+JZ #O*W4VW
M)K "W?9M\[H^KX=WUVCUNJA]@^X[[9MF#[4[Z+;=C4K/M7L_&QU2=^Z^T_@)
M"]?\K0%K"7\W+KZ0B[ZB&[@<+H+_.HT&NFNW>C^["! #3[^K=ZY^OG/RD(>2
M,'D!]N5^S0M#.S<D(ZMU437/U6HQUD7UW# *RU UBQF3I'YJIY1\4-5TYX,/
M9%DL7R;):52D:/?L1TDRTF66;O .(^ 9A:F/J:PM]M:&>EM31$2RA3VR&1GL
MK<J'QF>6V9[,<JG%+E<Q.S$W?4Z+C _=O\3!-GB-@*A=AE\&&*9$?R>%10)2
M%Y^D&EN<:>Q]^;9P//:MP9^/OC=S[;-X&08#C(?#U!R*W[^G^S_+V5AYT)#^
MCQ'O73J[M-/XK=%Z:*21%5M,EWI@F)JO4L1,,R/L6._/O$/>;;48,HC\JS.^
M4VZ= <ER0#Y^PNX,;X6C?7 Z.=ORBZ@4^S:N)'SC6P.:^3USG:B.\"RP*ZN%
MA6T\<";6./BU0EJ;1&6&:1>A3D2]&]^;1 2%=6@/22K+>(P'X<P:W_L>Z 7A
M:R5.3OJUXKR$E^YL<F9[-$V3/!C6&!8&4VI%18K)X0%!48VD'G$RTEKD#'L/
MEVUVB)B61!Q1!2-*/@2B2,D 218D0SH23!6D3Y5"6EP17W0_*6661V;L0_9_
MM,/7$.$(=_A',N,-+>/MGG4O2["7C:J@2=6\F_F#3;&+S<SADU= % $?N5+3
M#4'-+PH80<\I&0Y15CDW&UC?PQM$P%)?:D+(^09>V:,*6 #BD:AJ'!DIN/LF
M9&1C[6JEI@B*;!X)<HI4\B6%<=;>\V@MVO)K]^D"/D>XM3]E^EONZBKH^V95
M$*M*01I;ZI <ZY; R4+M4RFR)=1('2)%,,VB; -VD5:0U<"T2+GR GK::U"8
M XE;#]O2XDNADH10MCWLPNX-LFYQO5+33$$U]94M_K5L^B%'33:AD ,U1J6F
MF@*MKU!VU)Q"*D;"^<=QH)D<O_=R^XX8,3".?1]_'#\@6SC.'ZB[=AYO@0EV
MA6"H>00!(RY@#J ,$83" "2+E5I5T)35/(72 >@4K($.#C ]&$&$@0T4'WM3
M6E(&OTP)&-(<%. 6 5LR8=G@CZ@+6_IZ0=M&1-JL&UNBI;0$DR3^EUW=XT#*
MZCDJ$$@R 9(HF-H1 .D4[(:Z/7'<N(/-$\XG&;BUP(9D>$O3+3>R4JDIDJ!J
MJR&(TNEZ'#_9!$(A^%$I?LPUH>G2X><4;(4N'H])+1YJ*A#:._T911*W%=C?
MT1_YCV+"$N5NB:SQIL[J%9:KE9I*M+L\NYH1[8YC*+4+J5@,:96:K JRG$>S
M8 1#IV AT +'I%U&0-ID.Y.IY?C$0.0F KN;^5,3H3DG(R%O!P^\1]#XL-UT
MH\K6;9]\OF;SZI6:J:\FJI9.ISM^P!1J$J3%R[(D&#HOV#[[-_:]-3@R*C5:
M74'^Q@\EE$841%79,<PO" LQ"$JQD5*5#N)JYXXD58PY$L7,K&F:)%PI:D>0
MPL)1DTU>Y4"-0H/<JKYZUK)TJ#D%\R2120YMM?*WDZE%LYU4XNIPD4(I:N^3
ME;](M#*#6-6.1//EV-E&-&V''1)>5P1CC05>3NR<@M44'>'^$@=2OEXX<5,P
M%X?;B:LR&E&I"HIR=;@@(XIT98+?-IPU_F$Y;D#\-9E]]XH"BH<J5,4\&:",
M*,?'CZ'B3ZGG0(Y*SY-HO!Y5B207[>KPO7'3[C10K_Z/,D=\CNK@\(Z$0^3*
M)]O[.X;-C7O62]9=7B5-I05)*2!"Q.Y)8@Z];87*+J&G@6IB"KI1P.$4=J%W
M"O929!FCT'I)DL]X[AF[>_SS5 -*3MC0<;[0%=SNN#-2Z'2*HPH%F95)G1QD
MU(U5#QJW0LJ-IL\3$5*A:04P!G68EQTL)V-S)#WB[AN=9ON:VQV,T&;G=D=6
M.6#&I\VD/)* >:6/0VZ']D9&R*EB9&:8!9R+8A=QIV!FU,,HDYTV!0V]2V:-
MC!3W+R%) ;C8WHQ,*E/KNF,86J'E0T7&\=OV8<R6_XKPOV9.^(I&WA@6.B!%
M@,(11E/+YTGZ3$NK;12D9:;5\]K/+E"\/;RGM,XJR:0"E:=#"RP.K=R*4)'0
MDHM3D@Z-K"*;#:R5*?1OQ[5AF2_/S-7.XH>WQL$*1]V?]4X#U7N]3O/[0Z_^
M_;:!>FW4[EPW6_7.'ZCQ]X=F[P_TLWU[W>C0WO#4?(=[6KV3R7'1#JE"<A7P
M9%QDWZW &7#-CAWQ>X_]+ND$_*&&)W\@A2E%&Y;OPJK0_)K%$V/9*LYEJU*I
MB><RK^%XK*"1=P$:E8#F&!3]4_!,73OC68AM9AU2*>*4*43^L>_CU,P_)G?*
MG5S-S?ZSD:@$07$.MO1"(QO8M-QB@WVPG8+%T 9KO(.NVG?WG<;/1JO;_*V!
MFBWXNW'QA9CX*_1DQII(<?\NS,L2#NVT'571(:N!-YGZ>$3Z:#\E1X(OOHR!
MR7U%X<@*T<1Z17V,?#P86T'@#!ULH]!#4^H%19Z/R+5P(PIF_0#_:T:J94]A
M1)X=E#I >'3WGP+7;KP,1I;[B)'M#(?8Q^X ;XE"1CCUT=U_VCQW'3Y)I;C0
MAX>.H]YCWI"$CN N^'6>H,DL)SW.#-SB^QA?+<O9*"6WA</VD.;E1J"X7F"B
M[?86B,@:2B3=RT1!/YH6M\</MQU%JO<-/-( 31?,7#%L1C"W\[PHIL44 "1N
MA?:!><"L6G5J";][$58]L 5_=\;C[[BS9 GVO.5BE@E?R<HWS*($5B;JEB"
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MURZAZSVA:MVU&PE-LSHR]4K-- 1#.I;NGQQ&2S!2]P8C@S;IDM=T2CH,C$Y
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M+^L7)TN<L9HV[64U>$B.P:VFM"1$.$!\E;5L&IZYM1<(:SO*W%(K-5G0%%V
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MT$=BH"  ::22E2'(>F['%[<']H:A>3&BI1)$%_/"1'$,I8!B1(Q8"N6HTG*
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MM_SA-#<%E?>N08UP'#XE\=8X*#KRG@,:AK7C59MOISGX'7<PGI'(%&R?0;R
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M6#P1DB=",IJCQA,A>2+D225"LK<ZO& !+UC 4QBW,$R:B1(,:N\86P%>KES
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M'"<.DM2[87(U'1,MFD:N'KQY($74?P/'@J>A[XX7XL%((*61SH%PZ+^]D1O
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M:& YR4PF&,(_,"8)_)WCG90?AG%53Q 1<E_;3JO-58L3M@?(@P]?4!8 ?Z.
M93!DZJ/0+Y8UR3S:)(^2HP<_#V?&67CK4"(/%\\P%5G_R9PXI:9>./AP4R+9
MC6/B[-53I+W7.2"(@/[.D9'WL!G1W'?SDHK5^[(+5^\>*P;_C.+ NT6B$&JQ
M1J9Z+.:.'^9)#$2GMT*73J,6,H]"=*65TIWFCAM'%4,6$Z0XS*U3&RE#DC(%
ME'_,C7U*9:><CU#E%Z<B3(P<H2D\@)>(X@^<',<U?"%H73) A>G5FNKQ"S_-
M\LQ(F17GPU#LJ\88Q9H0^9;-/_?CRB=7FF5=4((.QQ Y!PT36Q=83N7.\$Q=
M#LKXQ(@PH0K5U,3(#K116<*RJADF35UO>!XR=5PL,+CW%U8L+(T<-YEI#?_"
MS+:)$V(1&+EW Z:%:9!A7F%:.!?%Y6; !^7OT'D;NF"Z<SJV&R5R;/P-97)[
MEIMOP=1'; F.3D8AIS%B]IQ;\!477XX%>TDJ:8*"CZ7(,.;,^$:"C_7CRI8Q
M67H3!VII=1ITH&5=<.Y^L*2<*/H6TSHHX$KUFAZER:@\(W6Y8,T40S2/L)0F
MD],QOGW=8C[*K2.6'Z:\"!A!W?="5I\ZWR2;8\0LX3E/A$"JCMR_<,()Q406
MG"6*@3X95IO#6^!>4IZ0%$IZU0*O:> G,\S4C29P@:P$ENAROHS..J><7*SY
M%)ASB =7G)FL1.2D6LY9*II9L'O/X4I?<2866Y(R_$FEF8J%JJ(0>=TIVS')
M(W7?XVR^ */4#,X1"<H-=!5=ZH.B/'@U&FD2=&[."FW*?-B*="E278KI&!+Q
M0?P4\P75R'%=!178\KM:UC^B6YA ;-=.G*XYIA-F\L)P):K*.\.R43:MU?0I
MME^:!^:PJ50RCS('_YQAUF-1I!%%X4Z4LDK4R/!&J7VI#$'.9<YW?DKW5Z4Z
M_KBR+ISX9OE7ZJO;["=P"'.A_03LV>%0%SYR":]*D>+\E+@=4M0?6.#".2;R
M5U^B&P=3-JR+SU^U PA__CF*0=)9WP(LV;.-I^GX<=;P:[7[>)$(8T4FBTN.
M4%H\W-%8>+[FZ#)I&Z]N?CMIR1A&X[Q;==91EB:H>?!F'&U"VH'GEG5+IMH>
M.=='E0QL".0JM5.KEPCZ,N72-U/()\@3@*9!9 .[DA6_)/Q0PG/2;SYPGH++
MM^0F0LI1=Z(B4UQ]'&+Z-J:_2\%'&;GBFL@NKR@K%@!@Q2B6>5W/#(ZJ^*BZ
M^HFHU8^9L\X<;Q/NJB@;]ZFN4-GBM"AYOW/E0@Y:7*SD@2<D3WQB0?ZTK!;#
M<JY]XJZHG%O.-;(%5 \-::MXHKKTLF2QGGF\+M528+D/JG+E:BW\$-=X'45>
M@JA<GM).<\T/,Z(I3YZT B.[38[HL>&R@3:,?U#:+$%4)$GD<MR"I.X#+!7\
M4V7W6<X-V"S*3B$#"]B(IO=$Z;QX?#F5F\5):4P0++Q_MU%,B<:*IN$[U*4J
M:\HWM,C'G7VD"FP&'T:0)[#UG(KY?1;#AGZ&IV:)]9X*+RI\);3)5(.Q%137
M_OGG]P*B0<II:]D<)@N#)/4)['F.#>W/G/='W+D_OVWA^)&S4;*7P/-@7R@O
M[S?UCS<2%.0W/Z35T4-OY&!28%?X6FG[^>M<6K;:+#$EA+1\L_RZ!5_]NOKY
MX*S5Z7<KOVJW.I6?UPW5Z;;:9]6/U U5_WF_/7SFD^JO'4IB@9<4/D59VW>?
M'A]IF_B:ZXE%8SMHR!U'MRMPIP4,S,/LS[VA)/@G<$'$3*CJS;TSPEK]V5$0
MUH;0\]MU=#]HHMEX7_KWV9<[>A>LW<?.H+R1VV'V'^#5.R$;(LI@#"]Y774!
MGTF+L#H=U$!ZTKBS)=C$=T[J_+8!K=VOY<I+?/XE-!"YQ.+43-R+;C8!/G^)
MS^^()1'N]^C Z><3@5=BD'4]'3W/EDUCN]<_:_II'>;A=+IVYZS3G,YAGLY)
MUS[K]5X_]<'L2*8?!6^^0*?81(%./X1#'V][Y<[9P!YV!DWWZ\,\GM&9W=^:
M1S>G\U27ISVR.[W^4??^/@I._54"8[U(';K=J&B'>3(]N]<=-X=SF(=STK.[
MO?%1Z\^=WH&SY>\1)S@\6'%^5MW[.N.!W1[T'M03[]FT:WP>1SKNV>/Q/=7P
MYD0/\40[[8[='G8/[4@?*UIGYD_U*ZLI]ZK>ZY1#3(\,$Y$T@;IC#M35].63
M59A[\O5QVJJ[UN?'R=POP_-W,AS;_?%H<PVY<2L]U<GTQS;(I^9D#N]DNFV[
M-QX^^<F\3+5 \>Q QM!S%-^7Z0D\Z=AG_2T8=N-K>JJ#&=C#WEES, =W,#U[
MM+79?H".P$,/SUS6U7LI<^Z%!=5/T+LP[O:/6H-[F'UXD(?2ML?#U4-I=-[U
M^S8>MH]5X3T*[FFBM",8QT-XYO&*ZI->Q^X/GS[A;4^^N:,YDW%W-8C::)UK
MMZT_'#8ZYV-O\I4( E]V!?*0>_J33/> ?8DZ9Q^UFRT2'AJ5\PG<A7V[VUV5
M:8W&>8>F/K1'_>?C95T3)MM345+$<"6(0./'W'<L243Z@#C8\4KKD_%H"_OF
M +7.YWDL!%+=?=.D5Q[F\>SEUKR$@N,/!"XF&"KKI>FP [L]/.ZX][-380=V
M?S1H--@M/0"=XRX*.GP55K%)/W2C^4,2N(Y7!'>Z=GNP)T]3HR#=>3H]^VS4
ME&X=Z.E@*DUGB_CLD2JP>V//7+!Y(GVQKW]E-FUC]\67F6P[Z-N#]A8I0@>H
MVC[/D^F/[6%387^HIW/2:??MSMG3AS5>4@("N8,G8HJ=VE/GYT,2#YY5C=C)
M>&QW>MN[N?9?\;<CQ>YYG>9@;(_.ML_2;4[S($^SA]ARW0,ZS1>CVW\D71XE
MA<JU>+A*_[QHLP.,9OOP]?X9S8[TS.=UF*O.[^8@C_(@\59N'UPZ((%QT,C<
M:TP+U?P$.Q]%W@[,"PE\WX--]Z(,VY[0@3PS<L5RA<X68F2'>W0\VNR+( 6T
M7,;;I\8WE/#L**'?L3L5":6'2@DDXGZE)E/[;&!&(U9UKZ]N)U'&_#^<YHY;
M+D2!SS]D0?MIC5Z%G6_=.HGUR[C5L^!= :;Z;]=5#;L)8J\Z;EO]2Z?;ZMYO
MI'[+PD9PGI -,:.I]4NW-=:#X3SA$E&+RI0+$_B=:B&Q<*/K$';"LQ99G&34
ML#%2S6O?^E$J\)5GW<[H39+#'US#W"A9E[H?ZB:S:NY&X:UM-,@6MFQ^.)^+
M&'M*^O]E\!N8]J>WW4Z[:P K+"+JW>L$UL7YY>EW'#=V%MC\.1&!<&7CS13H
M11!>T[M/GTY[U@F^'N?;;;_1TU*G=ZZF33_HO'F-N^<G>C/HGWH_L#^YE0(5
M8;OBXH98V*0SH\;FUK<9;GS'<H%JN <P]>G$K> UE8Z(N_(9/8[Q';B B+J;
M6L R11PL_6(S<5!88<2Y\+BQ>1CB#N !X_YS3V9\[98]K9_D8FW)*2X*L$@E
M?K&/N[]19\A#8E875<!2S+(Z9X/6<#=,:W36&CR(:>DNOC@SV8>5>G;GS7W5
MW.'N(2R;NC2)$W!K>N ,__S7_WS_^"CD,204FKNVNZ(+-=+#::\2PP;6A0-@
M3GEGU'^S5[*N8"3<5=>D'N3'-5S_#WAY(D)FN:_47YK'OGK==/%^M"[>:QZM
M0;P[*&V0<W+J=,&MU[9'7EN @V<>VVYU=L-A>_?5+_M2KRFHA3U#QR2.&\-=
M"ZT):(;Y#[%[=V%%ACZD]179(QL&55W)J;FX5K<J& L^5J^.;;DZU07; ]L0
M6ZK#'+$5^G9]C1,?<W;Q =U:7:Z+=.9LDJ0.J9_8#1Q.)1 I*U^TOQNI!(=D
M2.:XIN]E4?+]U)J#8B,*E:U293PFM:W3O0L7E%G+<'Q?G:O,6_KC^W*I*NUM
M$?O8>!RNBM3C:NS'9 834(:.*]?+VEP%T]BW=@>G<HS:'1&3W%4R)FFW5_0S
M4NTH:N[Y:)L3#T<6&,6$E@6_QY. <\D->.0?KK-P7#]=WL_4/!3^4;AQGPQ4
MQX)J<DP\9#.<2FD&MLYVPT;N;4WVI2<(B"Q!P4I\+TD+#IBM]8C6<<LTHLD"
M@-T[ \#N87)[CS1Y)R2?=2M *OS2:7<,S^66ZES1GPHCM7?NFXCKUF&XZ9!D
M_2!U3ET12(J]C5!S#E/<F)*3$)$/KB-DJA[S5KYAT72:B+1.,\_'WV!"S^%&
ME$#)CO8>U("K2>KO=;90[:PZB['B!FU*]G73B\7<@;5XEM* 0,N;PK]LIN^2
MQPZLIND42/F4?BV\?!QYBV:P(T#%,^%X;I1A?" G]R""O; ^?E]YJ.@EE^:8
M#!R(GS!I_&811_\6Z).7FP>K ?M-_2R$0]2_,#<M<>8J'\2BWO4"U5D88PF7
MZ[B5G!5TJG<F.M7=%ZEF30?C=7H8*I>\>/U[RXKR[8-;)+NX[%KTJ,\\J20Y
M21*Y/MTONH1Y1*THC-P@\V0O$ZG.2]N+K0.8GBO4.Z[CZ!9_VSC7=T!\%7)W
MH[M3[>;=/Q-1->X?*VK<#U_R%BOTMU4MV6+JMCJ%NUT.X?=:XX??_8+#%HRT
MXH@E3XOVW\)]Q<N> CL#ZT\N$H17J)RV8"_Y4998$R?\"Q@$R=V$&".%MSU!
MURS96-@='%E>%!!JCHPJF:5O*WE8> UR+]Z*93YX&#T^9'I$6V3ETS1SHFTB
M@H\<$7QJ(E9J/BDID@-AV-B[(>*99B$J("IBX^=\ZG0"' KUC4D4L^:1T*]A
M+&!IREMYE_\2'4BIGU)6$SP&A!:Z_@+5(/C262R C6#&GWYK8F4+F!XES.@?
M;VXD'PSC8R\E2^-?3Z0F_[H"U. @+)8-(JB52]F>*:*H/AGT6X/7U6QQW<M0
MYO;'K=%N,O' E.2727E,$KW=+P5AJ\0Y)X'!* &'7:,8M@O-%G?FA-<"K.0D
M41>JF$S&/TB4&4M$3ZL/T;:&HYTX 5Y+EOVND\SR3Z05H-^"Z39ZP(E(;P7,
M[L?5.WKT_8_+HU(6R(]4* #Y5BP .9*[\F'+^X!DC>0B==AV.W</V>@F^:7=
MZH[0^<&1N>)=<?+'D7@'XSQHH![N#,V'M[POJYOO>__GE3]QND/OS)OV>]Y9
M?S)J.^VQVSES1M.SWK ]&@__W[C_:@]4URD=4%V:\W\RW_/3)5V3"V>!U&E=
MBB3*P-3>6$7=T^RO>)8<$I,+>9"OI[:4[:G"H%>4Y8%I;?B/14JT>RNLF7-#
MYF 6([$GP%_]*:@*H%5$.E$"*1\]Z'^R,]1-I2<&!BO_2''<$'0:"YCN'%.&
MX35*#6*GHM#>?V*_Z@_3<P\[CY/5GOU%'%W'SIP9-OR!2<? N$&I\H _\^0F
M(O!A"$[>0YZNF;N ,[QQ AAXGZ'HQ%XU-:6!*T'))HJK./1%!2NKFO_>B0L]
MX$$ ^V^1C@G4L<]M!NJX\3U0N<EN0U=@G(5@FA!;=H"1@UJ22BK]F5J=KN30
MJWSX2+R\M.H_5508%!>^W^H.3?T8UBOOC*V]F4IS0HG($0+,\ )3 ;:/C0@<
M[<.[<S1C/HA)G#GQTNJ>$1UVB7EX$:6=$?,(4WB:N DJ67H8^5J^MXK?X$-Y
M)C/^7@7E27M3UUO[9E4AA!P+3'+\F69D*&>C['I6YQ_@ETJ;*LJY%IA,AM[)
M01R<]T\?,^'@A'8<#Y"56Z=8$4S^%K-JZ]\9V&_394'!.GW<S+D[L;Z[PTK?
M\3[Y#?G"S7WLR [6O_2,B!]&GZ7* 8:QCG@D3%]_!UO'C?U%JJM8+J)XH?+,
M3E[I[U^]?M,<YEX.$ZZP$06&XX0I)GA;(U<(+S%2<(%'*$9W!1. >9VCAC$5
MP)) X2"-/'G^Q[C7TQK!:6'H\ #IZ]7OFH2R!:6?D"2"]X@DC4+01ITE*IR2
MI(KNM@VK0)X_=1TFD^@/S H#.&$TTXLL D_P1^NJI30<:Y%-X/PPU4+$*BCN
MH)O6([<Y_.*7CE&"BF,X*$.DCH/ZP@TZA!:!XQHE0%ID-+2P)^G?;AO9"[6T
ML'I\JM;N!OE!3/2@7/FW3ARC)>PG6 Y,85-0,9>H5W::<][3.7=[K?X&YURZ
MYJ AG+^[2D!E  /0#:*$LVK?":"""7#ZYDCW=Z3=0>GJ2F=1I4BNC("]J8];
M/9>CV^^E&XV,]/:'7KH_LH!X:+<YMD>^6+W^7;QR11Y2\8LKXM3Q<ZF8*,F'
MTO&/#+1F.+Y><WR/?.OZ)J[*EK>N?.FDWM)[_D)NOWZ+L1DWKSPS]M%BDBH'
MQZ=9$."A.5K?G(F _*]HGDK7AKZ);_ .-F?XJ&=8,"64UT#Z"?@,=>55KI2L
M*<9:[T8N',X6B>7UA[K'N/QY7=Q*^N&]HH?=^J7?[Q0O3%W@#H-GQ4<'PY[Q
M*.9SFX$UCK4YKIO-,S;G9(129I1:,M:V)N?I61U/>X15D5*P2ZZ"Q?V^YSOH
M-K6-+/ET%A$^TS66)&)<&(.XLPCC0S()YS2ZQ:1:@8DUH$,8D=]O(EH$XG\G
MUJ70DLFZF/FA(_%1OEU>O'H-IQ/C&^!X5?6)P(:W&+?3(;H.W,._R41]'TQS
MS#(\18AK((.ISZH*?\7!)"X$BV^HW#?U \YNTY_%PH$_!\5!C47*B$'+^D&7
M&N:)WR+Q8.C UDMG7EQ:_1SD*[ ("\@ UA!Z6-&&T!!9:BS ($9> FSZ%.-?
M%/#U! ;,J<((C2#7C6*/W [D8<+IR(QE*DY(@;R=V$NDQT+/LV6=TV]5NA-P
M) RW+7#H5"8HZBH0#M:I[>1-XQPINBI*18PPB)A@B!Y+@1*.ITTP#XI+EEK6
M-SE$+%*ND:I[%/=I(HP9X(2N!<7W:)WZ&PHEJZEIR:G\<,:@L.( *!8#@%4Q
M24EDM"XBB/R(M Z%&V9>!MPDC!>6HH6VE<![ @IDZF%SSV&29XT$.OU%7HMI
MQK!OBB1AC2Z'I'!'.&Z: W" !2QBN(("E#J7\DAQ(D$AIT8%N&*54].R,"MJ
MCAU#_! QTAS.\DB$!H+[F(JYU6^]/7V;)7!,26)]A1?=^,!=3JV_(\Y;2$+N
M4M,3?(Z;4_B T_GPXR\.+_V49O0- ^\4<3_]A*D<UB?GENDS?SR!Y\V_+BFS
M&7E.9+V3!U.HSDHD1!W5?<(FG(=A1IE$5)Z/H6E8*8B8TP\Z[0J)0J9;:0=/
MGIQXM*G76R2&C71BV('G:S^&]KE9BM<%JA<?@NBV/A>MICSB./"8, =W"B*;
M:]F8FP+WP@L)3&@^QV0.J0:0IC6%7]8G/*R>F1Q1W0%"JZ58V2(1OZE_O %N
MO@B<Y6]^2#.DA][(P>3%J2A@HRWDKW,";+69""4ZNWRS_!IDND0I+GP^ZK3&
MO>JOVJU.Y>=U0W6ZK?99]2-U0]5_WF\/=S>IWMJA[D"T7POT/%[Y604BLTMJ
MT-- ,I]M=+6_KRD6+Z T/V1O#!#M3:&:#WO7S.S"=2VE[USM9MLE;W]IC.>S
ME_V=4=KX891V5\.B"JN5-W0_6_?CZA>)D@6O*>EJFVSE\VFG_46D+)I/,G;B
MOOY5IK:R=U"G7N>5[B^RY_9)I]VS1X.G[QS<M'2^ZV@Z WO0.=M/P^T7T_M-
M\PF#._RJ>0:R"O98[8Q5'&_KVNY@: _[VW: ;SH+/UT#R:'=Z3]]2^Z7IU.8
MFH0LE&DTB>%PM!]9U6@2=QW-66_;?O"-&K$]:U#P6K^>J/+]UVMCLCMK,OL2
M&H5U!CU[,.C=3_DX]+YQN^UN^A+(X:0WPA:"X_MV/SV4QG&;A:0Z[?9=8 7[
MBP7E/0'.:Q2@^BG?E6&UQQ"05O:D+5CI,KH?"%R[9V)@Y$6T#H:7&(N%L48E
M;L9$8/8$]2?'_)NQ";I/T4C+\6CW8&XXH3 *3VGJ?BKF,I?' '4Q%I(D0E87
M![XS\0.)]GM.PW%&*\*V!DN9WP++(@P[,W%H6H#%,X%8?QD,#* :_&D5" V]
M_I?.P*A 13Q6D)/I$@XO30/$5L!*Q-.)!*^<(^".4X#A;%D7FZ^PM*@R^NPB
M%C)AS=:PYZX L8U\(L="EV,3X,]9GN)M5^(MPX#X>*(2J^*,@)NQHTKQ6?RZ
M\#S5X +)F0O(H8;&>;:=;-="@$"834<EZ08*='&1,*8G\FE18I?1%P+V4U.0
M0:)JQ\HX@;Q!C,".9[GII.3CE)<D<P1I! .!>)L,P#KF\;"<LT/@0G<YK[?%
MS6=.-,@/?'M&5,XH-)!]]L&6SHKYC%LR$)-M=7I%7E3D</**XJ;<=4V9EHVV
MG _C4H7W\?W-&1._;#S,=\'>X,IWNZ8H*OW^+LXUR@LD;,G%>T;A.?RDCDW<
M&[4)9.?A:D(?M:=X2TWH@.!$*QE.E0O\7JI/=S TA9ULW,&PZXKY4#9_+#PQ
MUT LJZ _O5'?E#%W2#ZKE):NT@[K\IZ),^;%/[D^@(EVQ;KVB%N&E0K=Z3X_
M?7+T(="-4I<?3C-22/6 IW7NIAD)CF4<E*ITK#L?YLY#@V.5ZMFK26\$/+-=
MY'OT[@SF+T&7<_ D^:8YL-2,<L%3:^KXL77C!)G0T#N<J(MH>!HGKS-HY_5+
M)MI0-8'?=5_ZX[-\N"K"W)3]#@^7_7[0GOCG:8C>%76X%T=NF_I"W=TJUF#I
M^BOLNL:MV!:<C\S5(8924$6LLC6&1-C%1&1)M0'I'1I2! =KY]K)QLT27]Y1
M]M51GFW&)HNV[C9'.WSBHWTV2>6=3K?)*K^3@3/,MW7)U2'SU2#)X6/K%F ^
MT2;T0]U\!11'W36FIFVVZN25LP)YT]PL<&(VS6^%,?!,U#?PBJ9V_LLH5JV,
M*OJ'35F/283X"ZS.^"_!BAOA$,+/@!O9$@%F%3OT8ZXPV6;2/.,?ZJ:=>C"C
M)XQ=7(O:)!-(->])X_^WZ/&S#-!X"7#*H(=VO@2[U'6RW,6'JW[$3P=;0=D,
MGR%U/YJ-4F%E^4QT"]JDXVHGG$)'I):_1*\2(W&UUZ4VZG$*?CB-'9A%AK\0
MR#DI9Y3?A)@ZJOHUD<"*UL7GKPR]Y<C?RA_F]5/TB_RY0N44+#.+T9C'^B::
M=AF*UABHNC>0Z:R ^<CJ1%DGUP*-"PONX.M@2>/C/$/!AQ--J&S2>(7$\Z_O
M'4\40?7XNGP,"&U*8+@QXIHKJ-3806FEJKFH'A F/!,AO1U/(Z9& BGY9K C
M&98))H0\[5>,Y[@S0L%U3/>,*C<4/U6-YSI@]6M8;*)T>:$QUN%5BR@5JADT
M=H5&,9D*=52)@'5[UG\RN.X(GS9%T3ZDW;RENKF)X%9+7(4(Q ];#7I_YM+E
M%@%V-L/Q"M"_99Z@H8#1<"7BJ+IB4WC1%IU<#H#Y<H\_5<J(V@\($1'*BD)N
MT.W&$>YQ-"?*#9D<"[6[UT$T8=C+*9!WJF]K(*L!N5P4_:+4#TL-EH42]"/%
M+M]X5K(&$0]:5B'>78)8KG;4.0.Q(0_I9DT#Y!QXUNS0C$*SMQUWY$VE+WV.
MI9O(BQ")A HHG436* ,G=+,$!Y@ ?=PR-]:EGY)%1"2UI"JYKKY\0W!F?1L4
MX#2A']?"#A.;6WL]\++C/<XO5.&>T87F;5FYTO>[T2WK:Y9?'GV*QAG1DF ?
ML!PS"@M'8%#;1@5C"$-10%H@%;!!H5B+0H'TXLRQVEN1I<1VT>V+M2M:MKS(
M.]^M-*Y;BYVU,8=LSO >9YBX<&-MEED"VY4P[Y6-1TA/8>\$*:7(SK *>VD7
M4/*3%&Z;:E925'PW.K[F!C[T]/PH!E'[WQP$-LRHK+S<IJ!.5VF.Z3&/B>Z1
M;2H/49:J9D,2&R.*"64>H0[DH:U:@LTI/=8IX7ZS ;FDYDH)II'Y4A/#(#'9
M5X40!R*H@,IQ W^29<-&#]I'(!*#H#FK1U4]V(A4V2P:+IMTR,AE%=ME>#(*
ML1M,3P(^@GRZON;@.W]Z5PL[5#%E9_=BJ,MP)0C#==!0P&-2@#2_X+)J<X><
MZ7!MKY7/"HR,^20#(Y&<$6BP4***^4WNQ2OH+5+U89*H.VZ%CM0<]*,+3U9"
MQ8(Z4=I@P^J.X2 EP6[-V.1TB"9D.TGI>E#<6]OMB#U$P2 &+DQ%$ BT]<E$
M!O,51 !E&B=26YH*Y4JK^.FI<I&Z@>,W>M33WWF78:[(]WZJ6A\4^O$8"A3;
MJL*=A;"2:[_1J)[HZN(-)=][*5: >*+74G9R#HEV$LC#@SN\'E*T.:<=GI/6
M>XD]QCKC4N67LN>&=6(5PBJ$7MCA+\,1AF6C0E.$7,?/UD6[CL@C+E,2"Q$M
MCJZ4R;@8CY-P>I,X<CR*X4^CP(_H )PX\$5\"N=P+:IC@;A>?[HD>:>\L'6L
M#OVYF2O=L1OY:Q"/T6$O,WKXLSG)6PX(^C><F:M]\9S:D"B%VOF+,FI!368L
M10K/8M@OE:YV';6Z$;%NL"8[W>$XB/D%DW>0])0?RL3@E'15$3[EQ%D.+*VV
M9Y-=I.\(K%;3(RMYLEV<S?./4OTRTZV9N;@(]ET;GTN/J,K_N..$<\A-U;,0
M5%#*^Z?'M>^TXL3I%'*(R3P .3'GB1[[&\</R&K%W<E/S#!?5^.--!T5<#0C
MRC'&8*)B]%$GW!@!/]S?B<)UC";_%A0MI*1S.&.DA,H1U(YC]T8];Q@V(P/<
M<;')GFF!<Q-%7,*Q<9+OD1'FSI'O5N&YU=E+RN)P, ZDST?ET^M!5!XD-@N:
M3S"*64CBU_#LL(&>F*3Y_B=VR>UAP[;@O;WV7=QE/^]3S=I76;"WK.^196IO
MDDHYKFQ&Q66<1TW5;)^F9DDBB2H \<1IIJQ;<+; + K@MB3*@T;='?0U\C$]
MR<O328E>9.@R$<8X1'*J)( CBG*[\DZ/JH&;O'4KP4C*&F$K0H$98[*7G&#+
M>E?89+YXBKIM.8&;*+@1IGN!7J4FAHYX>!P^QK!T*B6VAFZ5]HWAU$+^;"7
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M;XE/<EV>(-M2.U6,#6E9GX&\4>GEHH^UR\&Q/3&E(B%,(.)<=^S>[<.]TE6
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M](*(25-=$;]A\HU,3Y%/GWU#9DFC6%B^J09F8>(U.J[A.A]?\/%C-$^PH/M
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M?L6SY>Y]^J:I%,8GX/S:T,N84*?ZGXS_ZX<7.SP;D\':VOSZR_\!4$L#!!0
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M2F<I57MGH0N::@)_R646TF>O/7A7LK*:X!HS$\"8S!-3@>46B]%7J>N6(MP
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MO:9KQE++S\N/TD3V'W_[?U!+ P04    "  2.*U:@A7GRU@@   L3 $ %0
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M:"0I1%YZ1C!BN9#$^. TE\9D5FOH]OGE4^K6]CH2;4++):H<F34\"IR;3&E
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M 4 XH@%.")/2Z$33F8.A/3#' N[4C/+R@B^]!='Y0WG-G9Z8;+N5L=!Q3D_
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M@5/Q1N[8T3N$G1/V["G_N9+YG)&S3O1SI^2ZRWE-&]K)+YQ37Z8$(@@P)A3
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MI LN@^L;)^9&5DQ= #S48)U&Z^@BKWSQ^A]MP7Q3:E3W75H\B4OQO,X7&QU
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MJMJ6$QBC) %:L'6&C$![T)K3 QW&<2I_4_:MGJV*8K-U*>A3X4>I#-5>!4M
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MJ4S8&3^CR@*DQL0JF_N=EX.Z7KA\VVAB=R&J6G?NF5,,$C4F3 %.$@9@DD)
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MB'FCU.-TAE8/>UGKSR7E<@VW<>.UX&3@_.Q'>LM#F3W!*Z*EJ[,GP2U\E/T
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M+++-SQOU7#>3%=<I7<_:FSR/ ^K'01R#B"6Z0IJ:=$A7J\<^P@3S.$R(983
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M\XA%'/D!5OL='>(H$@)P% L@2"33A*4RA6&%U]7*N'%*=[1J8N:G$F71I\&
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MV#6]MJ)?\4_JMY\W9,'G$B&). D!2W31G9!3@'4[^B2,H"_2($7<* G:G.3
M"F.VEQ^W;<B^WZ+>WM:R@-1TG]<G4':JYUC7^GV0!N]<WR#K>;K7[S+R9^A@
MWP",81?[ICL=#(@B;?>&_-0!";I'RH2Q[(4L\RJ-=XZ(+V L?4!$FNC 9 EH
MC".00A)Q/\"Q^K^Q07&"V-#ZHD@R?Z[(%U. 5 Q8+,>G !.,(DJD!$&*N;+
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MGC.QFED64W*(\TK@\&3AK0"AN@^(0^39*4@LD;UD0IE L\Z>Q" Q@F+(A _
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MF6V#K1HDO%1%48%:VFXFU(O?RH.""_A12)]]G$Q?YXNQZ!(ZW(26/H0R>(P
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MU0&F*O31)6 MPHYEVO6NJ^HCL0V\E=903DDRO%2\92#.\D2LH%9%[;)BC9^
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M:0HJ0XAV*WM4%45M^]>5@6OG]&GE^NJLU=NZ7\O^-G#7)1IN1-/$?='N;4.
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M;7MAE:'EI6:N>RJ@$Z[]/R?3?RU>E-V@3F8#R;B5PG/"04@BM2U)28?!,N?
MM!&4J@8G!CRBK6TGJT8(':"$3H#HXW \G'U.\=?))*)O& S59<)EJ1(A$AP0
M4-:2K*!XAL;(9!O#T"/2VG:J:H30_BKH!(+6!#((C/%<QFD)RC3:4,L)<.F)
M-U$G%FA,IKE1LVN$M7,AU0AZ]A7_>_3(JYY:LN]2M?ODC<TWV1*B4OI@RXQ%
MLR@;9*79M,0_,F?@T$ERGK;0E+E"IWQ5/[#\O!^7J-/IMS1@N&<LRX+(:!/:
M8E#$,6J($RFDH'%;J?@6QE[\Y$[[U+LH^TG]Q0'RZVQOLHO+_D7OS]_+1+_S
MZ]_ZEY?]H_[)'V4&X%7O['CQK=[5%<;1!QBBG=>HQ@(=QEH5#Q[7+WDNINGK
MZM7E^?QSFEXB2(;?2MGRK#>.BV\M'_?>(Q64$(JJ3)+ N$TZC[Y2&<B5N&,B
ME6+ZIS'S%H7@.Y-1627\UBLO:[E!46ZHI!AF9/04'8H :*"$>>4P9 4FGC8L
MKY+[MI]4-H><5^O@:]17)SS[^U-B5<=1O!&4W^V"X\6+*L,5:"8="1"*PXG^
M*W@6"$CT-XUB'NEJWB]XC=SWAM8]8/-Z[_Q*=-A]6*Y>6"5*K75*D"0I[F^@
MD7@K4YFKPP4/3!G3PC"'UPGNC$-8#4QV@^$>.FN[>'OK/7PWYTDSPZV3!+UI
M73QA@9%Y\82C,-:$&+(66YW5.R[<:5SMH_=)0TIH&V!['1BG]^5/7+IHTK(X
M>3&2P! H'2><,+1$7Y&R[9ZL'49'1\K'&CAQFU9:V_A<,' T&>'W)]-E)Z\'
M!@=>0.(YH5,= K*CLB26!TDTUY+I4$8PTZW@MW&9]^;/[:GI22UB[X0K]U1>
M@VB3,X$GXJ6)N/_0WP >)<D!@S5.)0N\N0N$I]2]-VMV&-XJTE(G<+;T/A8S
M-](Z(VAN6"J42Z/P#QI*#P9(A"414N*"X;YI\K[S)2);?)O7*NJJT%DGP+=H
M*]>+,<5K^+[.B18I@@=)7"C-^K5FY35B)C8%HYPU D1S74A?H[+%MWRMPJ\2
MK76D?G9-> /&-<M.,*)5+&UB(J! LB=:T*"=Y4HU."!\C; 6']*UBK-]==/^
M_+>M136@&&9':P6ATELB$[/$28RJ,,JG$HR5G&\7#FR]9(O/X-H*#>I11W?+
M1'I7O_7.CLM?_?_Z=/)'[[1<8UZ?_-X_[E^<7YU<ERO,B]/^\:_]X[OOK$U6
MFGV&<2Q_E6&.WV!4Q'8]_)*.T]?);+B8JW0Q2O$FQ;OO'%)GTA:M%16J=$+4
M55\W%XIZ&PGK/2/LH6:+N:Q9F<H7?9G/QR/^%Z/$>Q9$,%K8IU7J6^37#J&H
MLF3C/D2LTF9>^T2=)3GY,HDN)#0KRA$.3#"PPOFGGD5-,NG2U71C*'LU$=F,
M0EN,M&;3^>I-9?BQN*IB/J;,'9YOF>$Y*K,F8$HQ+>/&&TJS>#J0])&+FV'F
M%T3B!R^\VU_2:#XK7Q6LR@5.GZ[YCM&VAZXG%0B^1<"$%<V#WFBTHO^A-V?F
M1E'N!8F>HO_EO2&V-"[0QG$EE70I;GJ6/TOA'S>3;[_<K;$$T-U7#P#:1$,[
M8#I,FY.*1=L%>'RZ.AY(*7+(E!$1RDANA3ZYUQI-,$I"^,2%D;%*..":[:B_
M.LT]A<*N8NR"ZH_._AQ8KU+PUA/02A'I')211YZ8,M0=$O"<-[5(V%GUN&8[
M-PSUJ7Y7,79!]?U/E\BT4C(D3S@K)0DI&#P-4R:"2<F<E=2:38]0=U8]KME.
MFK\^U>\JQK8OM ]UHQXR.,(RK;RBQ$I72M]+;ABT("Q)84.P@9KMLEV5D=21
MB\MFO=,6M=J):Z<5NQ]@_*]5^\M9;WZ$+$]A5+XY&SAO1&(HT,PPLI0!T$8K
M ")X9H*"I,PT=Q7P)KGO.,3:$T4O-J.L3J5M6]R5D*X^3Z;SY52MI;0&.E,-
M66L2')0YJ!*=Q7+7QI710M'H*)BM#.AK*[QC>W@8E*J3>]O@N2.ZM)DLT!](
M%;1,P CG#F-4+Q'Y3"K"8[;1E_"#OIFG?_&3.U)_T1)8#I)SE\[!)X(;J."]
M#Z7[*-=H*7EY9V\30\/I9'9*6S2531]^3VCL2.E%!TZ\0Y3WM[K!K/P%?-4T
MM'?CV-B;^6KO>#0$R3P7)("U"&6NB+52$!JI*I-OC3!;GEM_GYM$YGT,I>E)
MBMR3,@Z3>*]0,"JEH'2,;,O7,O__3>(>**OA)G$7A7;J)K%DJ1+7Q+L0RZ"V
M2'Q6FF2;(V<Y*1HVU0?_'WF3N).N7[U)W$'P74@:OY0^Y2%;FV@@T0=>^ODR
M8KDH_>6\TUP:DUFE]P<=ODG<19O;W"3N(MHNP*/<@P1F#0\"=X,I'<EEC,31
MS GE*!LG)1=\4V^UVJZ3FKU)W$ES+UTG[2+&UI,4E451#$)DG%&21%9$XK%-
MH!2)&BJ#Y(E3$W4C'M'?YTYAGW.J1:UV.9<"U%GM<#\K*'L2J,? W!OBE1:<
M\001&APFL'\NI9MNU9YXV3:7LHOR.MND:]&KZJ+WYUWOJM[1T>6GWNDA/;G>
M^LAJ,AT[$5YUXF+Q*. "?MP]$NB%,+V%T4/8F(2C,EI/6$!82 H(.%8Z-0@A
MK7)29;M[&X&W5CWHR%U\6(KX\2C>T<!%:YTV)5$HRF,M'XEEB'7/J&?::\AI
MN^S*X\_MB#6I5'^/SK@#Q-BVT[4BO?_]:QK/TB!'R:.WCGBP%/U%B?YBR3];
MHV.9316 ;M?#\?'G=L3]J1T!^XBQ;00\ZH^P$LX F::.4D5$2H)(PS#PT-00
MK5$*3&HMGK:V?@4'+WUZ1^X(ZT/#P2+MA/OZ2#X#X,&QX"BAFC,,  3%4#1:
M$D.6)D/*/#7<:^*.M(Y<_-4"IRJTT;:!61']<?*X%<OJ>67B@1G@0 P/I> 5
M,GKITI H@^+!)"_M=N^@-B[3D??2]9F<ZH3<-EP6,KJ&[_=8M\[I;+@B3GD\
M3(W :(M[23#48D%(IFA66R'DZ2=WY-ES?: X2)2=P,$+8ED-!!QX*QB76A(&
M"= $,H&8#HXX1YD4D+UCV\U[?V.AK5!BWCM**A)T=\M''H\/N.Y?]J^N/_1[
MER=GO_:._^B='?6//WXZ.\8OUT9\(933;/XAP70XOCF=P+@\O_XPF4XG?^$W
M*IQO5BT]M4Q<J%%DE8UEV&8*[@,M]ULG:R\L<XQ05:Y9?.GNH&C /[("X0P>
MG\U-4=N/A\/=_=W67=X*<*\XES:76ZF2Z9 ,CQ+%298IVFR9BJJY"4A[,-!V
MP]<&\/H\DJA;T9T(7A\8^/#C#+ZDQ<TZ> V<4T92,N@&2RC5E0%]81N2=IQ;
M:'!@UTL4OB\\[@&-9V \6$^=1-OJ^MX[[2!(04P0Y4D@#\0#RX1Q5C* %+1I
MKF'BRS2VC;C#]?\FI/901MNQ3X\Q^I(KM6K-30%"D. P?L?@37)MB+6"DBBH
M5$D%&?EV$?'F=;J&C7T4.:E'JIVP.KM9Z]/[BW$O>6 8QY'$2H.*+(  E>5V
M(H(7D2E%=4>]MM-V"VK:/"F;T'8G8/W Q-UFO81Y&AB:@XG4$@BQY*X2+:W^
M\$M0TCF) -/-74"\3&/;!K,1B&PX;_?65R=P=S89+VLGYQ>3:9'7>7[XUN*@
M6#:)3'%@= H>A"*4I3+T+^%1D:DB/H+D8- ]$:$Q+&Y/]_LRFE7ALR:]=K:Z
M:X>\7<TC8O=>NO$$9@LC9/?,_4BJN(RRE)9PA"CXDOMQZ =G[2VG/M.GOG]G
MG+?J<I4/GSFP6AIO!$8#FJ)MH!:(95D2 >!HH((+WEPU[0-=[\L5V M=FSR!
MG=32=K3])"9\X.+C;=GI=_\\6Q5Y#01GH!8O<G)I-$I3:<]F/3$Q9T GWG&]
M77'4C@N_K^/[($S5KI=.>)QKPHK_ZW8V+^W(KR?K7O0'F UQ,W%)<<,(PHS6
M1');&CI%3D(V!F-'X)XU%[!O270[17Z=,8#5*;1MZWAV6[)CY_F>MP\P#Y_3
M;) ]$UJCG\PRPP#/QF+B$Q!-19"*,RGB=EV]7UNAG<*^]NS=_]?=E?6V<0/A
M]_X7 KR/EP)&ZJ !FL:PF[X*/(:(T$0R)"5M^NL[E.Q8MHZN=KE'\B(? I;#
MF6]GOB&'G"J:GFQ:<O?KU>WUJZN;-W]<_7;U^R_;/V]NK]^^>?_V6_G W0<T
M39>RBLL'J9-J=)Q<+TG%MVZBVX%?^?OYQG_\AE+ET.-$9TM5CR(2'">.24V,
MLA*QQD'+X9;3&HM==]'\Z%"[M5I+I4E.<:)R+GVS/"O55$ ,4HE,E4PN#W?;
M7S.9IY1RU,/>^87P2A:<!!L\KK.R'QHH&(5C$NIM.3I 2P=!KTE@3BL;@3HU
MW#[R23$GC[\6N#C=FKN3D::+MX<]UK*)*ERI(XT*.8Q(D02%V;Q+H*W(8'CR
MXR)N&N4+E>#0#&8M;#,)H+U;I?D"*=". #WLMC,>F>8V$PUE,S3S0+R5& BB
MEA8G)E(>[D;!8Q).$EIM('!XE*BK/2:!JO]U]T_[1^ ,3;ZTGM2);3MR$.>\
M*P=R753:*#9@%\?F<D]IO:^W@-J3&<=>-;GZO/FP7,W7D)[6!2*.P@0C$+,A
M,N&;:P%),,>WCK-D\4?#T_4'SQ[;5_5EQ&4]C4["9SVN\.P\[].,9@X2#4*C
M&\_,E=(@U(K&=R@*B^D0!4?E<"<03DDYXCT.78U_6!10PQ*3P-2-7VV[+]_
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M96%S97$Q,C R-2YH=&U02P$"% ,4    "  2.*U:LZ??G$D*  !&(@  '@
M            @ %]+0  97AH:6)I=#DY-71A<FEF9G)I<VMF86-T;W(N:'1M
M4$L! A0#%     @ $CBM6BV%=BMLK@  +#P) !$              ( ! C@
M &QE9VXM,C R-3 S,S$N:'1M4$L! A0#%     @ $CBM6AZ<=NI#$@  >L@
M !$              ( !G>8  &QE9VXM,C R-3 S,S$N>'-D4$L! A0#%
M  @ $CBM6G]8ZK1V(0  0D,! !4              ( !#_D  &QE9VXM,C R
M-3 S,S%?8V%L+GAM;%!+ 0(4 Q0    ( !(XK5J"%>?+6"   "Q, 0 5
M          "  ;@: 0!L96=N+3(P,C4P,S,Q7V1E9BYX;6Q02P$"% ,4
M"  2.*U:B6^'P7.,   F904 %0              @ %#.P$ ;&5G;BTR,#(U
M,#,S,5]L86(N>&UL4$L! A0#%     @ $CBM6OD[O7D]50  <Z@# !4
M         ( !Z<<! &QE9VXM,C R-3 S,S%?<')E+GAM;%!+ 0(4 Q0    (
M !(XK5JPCMSW/@4  )8)   6              "  5D= @!Q,3(U+7!I<&5L
B:6YE-3$R,C4N:'1M4$L%!@     )  D 90(  ,LB @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>legn-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:legn="http://legendbiotech.com/20250331"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="legn-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">legn:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">legn:PrepaymentsOtherReceivablesAndOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CNY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">legn:A110InterestBearingLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2021-06-18</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2021-09-17</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2021-12-17</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2022-03-18</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <instant>2022-12-16</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2022-12-16</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001801198</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">legn:ShareCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="batch">
        <measure>legn:batch</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-3">0001801198</dei:EntityCentralIndexKey>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-5">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-6">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-7">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="c-1" id="f-8">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">6-K</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c-1" id="f-2">Legend Biotech Corporation</dei:EntityRegistrantName>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-1" decimals="-3" id="f-9" unitRef="usd">9348000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-2" decimals="-3" id="f-10" unitRef="usd">12181000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:CollaborationRevenue contextRef="c-1" decimals="-3" id="f-11" unitRef="usd">185615000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-2" decimals="-3" id="f-12" unitRef="usd">78481000</legn:CollaborationRevenue>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-3" id="f-13" unitRef="usd">90000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2" decimals="-3" id="f-14" unitRef="usd">3329000</ifrs-full:OtherRevenue>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-15" unitRef="usd">195053000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-2" decimals="-3" id="f-16" unitRef="usd">93991000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c-1" decimals="-3" id="f-17" unitRef="usd">69497000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c-2" decimals="-3" id="f-18" unitRef="usd">49101000</ifrs-full:CostOfSales>
    <legn:CostOfLicenseAndOtherRevenue contextRef="c-1" decimals="-3" id="f-19" unitRef="usd">1847000</legn:CostOfLicenseAndOtherRevenue>
    <legn:CostOfLicenseAndOtherRevenue contextRef="c-2" decimals="-3" id="f-20" unitRef="usd">5638000</legn:CostOfLicenseAndOtherRevenue>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-21" unitRef="usd">101924000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-2" decimals="-3" id="f-22" unitRef="usd">100964000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:AdministrativeExpense contextRef="c-1" decimals="-3" id="f-23" unitRef="usd">31463000</ifrs-full:AdministrativeExpense>
    <ifrs-full:AdministrativeExpense contextRef="c-2" decimals="-3" id="f-24" unitRef="usd">31929000</ifrs-full:AdministrativeExpense>
    <legn:SellingAndDistributionExpenses contextRef="c-1" decimals="-3" id="f-25" unitRef="usd">40969000</legn:SellingAndDistributionExpenses>
    <legn:SellingAndDistributionExpenses contextRef="c-2" decimals="-3" id="f-26" unitRef="usd">24223000</legn:SellingAndDistributionExpenses>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-27" unitRef="usd">970000</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLoss contextRef="c-2" decimals="-3" id="f-28" unitRef="usd">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-29" unitRef="usd">5061000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-2" decimals="-3" id="f-30" unitRef="usd">5475000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-3" id="f-31" unitRef="usd">12056000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-2" decimals="-3" id="f-32" unitRef="usd">13870000</ifrs-full:FinanceIncome>
    <ifrs-full:OtherGainsLosses contextRef="c-1" decimals="-3" id="f-33" unitRef="usd">-54508000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c-2" decimals="-3" id="f-34" unitRef="usd">49681000</ifrs-full:OtherGainsLosses>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-35" unitRef="usd">-99130000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-2" decimals="-3" id="f-36" unitRef="usd">-59788000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-37" unitRef="usd">1786000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-2" decimals="-3" id="f-38" unitRef="usd">5000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-39" unitRef="usd">-100916000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-2" decimals="-3" id="f-40" unitRef="usd">-59793000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-41" unitRef="usd">-100916000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-2" decimals="-3" id="f-42" unitRef="usd">-59793000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-43"
      unitRef="usdPerShare">-0.27</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-2"
      decimals="2"
      id="f-44"
      unitRef="usdPerShare">-0.16</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-45"
      unitRef="usdPerShare">-0.27</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-2"
      decimals="2"
      id="f-46"
      unitRef="usdPerShare">-0.16</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-47" unitRef="usd">60729000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-2" decimals="-3" id="f-48" unitRef="usd">-47993000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-1" decimals="-3" id="f-49" unitRef="usd">60729000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax contextRef="c-2" decimals="-3" id="f-50" unitRef="usd">-47993000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-1" decimals="-3" id="f-51" unitRef="usd">60729000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome contextRef="c-2" decimals="-3" id="f-52" unitRef="usd">-47993000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-53" unitRef="usd">-40187000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-2" decimals="-3" id="f-54" unitRef="usd">-107786000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-55" unitRef="usd">-40187000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent contextRef="c-2" decimals="-3" id="f-56" unitRef="usd">-107786000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">98810000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">99288000</ifrs-full:PropertyPlantAndEquipment>
    <legn:AdvancePaymentsForPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">545000</legn:AdvancePaymentsForPropertyPlantAndEquipment>
    <legn:AdvancePaymentsForPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">374000</legn:AdvancePaymentsForPropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">107224000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">101932000</ifrs-full:RightofuseAssets>
    <legn:TimesDepositsNonCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">0</legn:TimesDepositsNonCurrent>
    <legn:TimesDepositsNonCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">4362000</legn:TimesDepositsNonCurrent>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">2082000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">2160000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <legn:CollaborationPrepaidLeases contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">182613000</legn:CollaborationPrepaidLeases>
    <legn:CollaborationPrepaidLeases contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">172064000</legn:CollaborationPrepaidLeases>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">5583000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:OtherNoncurrentNonfinancialAssets contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">6056000</ifrs-full:OtherNoncurrentNonfinancialAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">396857000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">386236000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c-3" decimals="-3" id="f-73" unitRef="usd">30933000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">23903000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables contextRef="c-3" decimals="-3" id="f-75" unitRef="usd">369000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">6287000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">182040000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">130975000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <legn:PledgedDeposits contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">70000</legn:PledgedDeposits>
    <legn:PledgedDeposits contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">70000</legn:PledgedDeposits>
    <legn:TimesDeposits contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">563678000</legn:TimesDeposits>
    <legn:TimesDeposits contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">835934000</legn:TimesDeposits>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">441702000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">286749000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">1218792000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">1283918000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">1615649000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">1670154000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">58143000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">38594000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <legn:OtherPayablesAndAccrualsCurrent contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">116810000</legn:OtherPayablesAndAccrualsCurrent>
    <legn:OtherPayablesAndAccrualsCurrent contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">166180000</legn:OtherPayablesAndAccrualsCurrent>
    <ifrs-full:CurrentGovernmentGrants contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">535000</ifrs-full:CurrentGovernmentGrants>
    <ifrs-full:CurrentGovernmentGrants contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">532000</ifrs-full:CurrentGovernmentGrants>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-95" unitRef="usd">5341000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">4794000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentTaxLiabilities contextRef="c-3" decimals="-3" id="f-97" unitRef="usd">14009000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">20671000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-99" unitRef="usd">39535000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">46874000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-3" id="f-101" unitRef="usd">234373000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">277645000</ifrs-full:CurrentLiabilities>
    <ifrs-full:LongtermBorrowings contextRef="c-3" decimals="-3" id="f-103" unitRef="usd">305745000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings contextRef="c-4" decimals="-3" id="f-104" unitRef="usd">301196000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-105" unitRef="usd">51724000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-106" unitRef="usd">44613000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentGovernmentGrants contextRef="c-3" decimals="-3" id="f-107" unitRef="usd">6058000</ifrs-full:NoncurrentGovernmentGrants>
    <ifrs-full:NoncurrentGovernmentGrants contextRef="c-4" decimals="-3" id="f-108" unitRef="usd">6154000</ifrs-full:NoncurrentGovernmentGrants>
    <ifrs-full:NoncurrentLiabilities contextRef="c-3" decimals="-3" id="f-109" unitRef="usd">363527000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">351963000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c-3" decimals="-3" id="f-111" unitRef="usd">597900000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">629608000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-113" unitRef="usd">37000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">37000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves contextRef="c-3" decimals="-3" id="f-115" unitRef="usd">1017712000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">1040509000</ifrs-full:OtherReserves>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-3" decimals="-3" id="f-117" unitRef="usd">1017749000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c-4" decimals="-3" id="f-118" unitRef="usd">1040546000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-119" unitRef="usd">1017749000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">1040546000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-3" id="f-121" unitRef="usd">1615649000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-4" decimals="-3" id="f-122" unitRef="usd">1670154000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">36000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-124" unitRef="usd">2637120000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-3" id="f-125" unitRef="usd">54621000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-3" id="f-126" unitRef="usd">44304000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-127" unitRef="usd">-1484710000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-128" unitRef="usd">1251371000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-11" decimals="-3" id="f-129" unitRef="usd">-59793000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-2" decimals="-3" id="f-130" unitRef="usd">-59793000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-12" decimals="-3" id="f-131" unitRef="usd">-47993000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-2" decimals="-3" id="f-132" unitRef="usd">-47993000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-12" decimals="-3" id="f-133" unitRef="usd">-47993000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-11" decimals="-3" id="f-134" unitRef="usd">-59793000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-2" decimals="-3" id="f-135" unitRef="usd">-107786000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-13" decimals="-3" id="f-136" unitRef="usd">2668000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-14" decimals="-3" id="f-137" unitRef="usd">-897000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-2" decimals="-3" id="f-138" unitRef="usd">1771000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-13" decimals="-3" id="f-139" unitRef="usd">6081000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-14" decimals="-3" id="f-140" unitRef="usd">-6081000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-2" decimals="-3" id="f-141" unitRef="usd">0</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-14" decimals="-3" id="f-142" unitRef="usd">18703000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-2" decimals="-3" id="f-143" unitRef="usd">18703000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-15" decimals="-3" id="f-144" unitRef="usd">36000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-16" decimals="-3" id="f-145" unitRef="usd">2645869000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-17" decimals="-3" id="f-146" unitRef="usd">66346000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-18" decimals="-3" id="f-147" unitRef="usd">-3689000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-19" decimals="-3" id="f-148" unitRef="usd">-1544503000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-149" unitRef="usd">1164059000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-150" unitRef="usd">37000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-151" unitRef="usd">2695976000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-152" unitRef="usd">74427000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-153" unitRef="usd">-68158000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-3" id="f-154" unitRef="usd">-1661736000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-155" unitRef="usd">1040546000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-26" decimals="-3" id="f-156" unitRef="usd">-100916000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">-100916000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-27" decimals="-3" id="f-158" unitRef="usd">60729000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">60729000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-27" decimals="-3" id="f-160" unitRef="usd">60729000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-26" decimals="-3" id="f-161" unitRef="usd">-100916000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">-40187000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-28" decimals="-3" id="f-163" unitRef="usd">2373000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-29" decimals="-3" id="f-164" unitRef="usd">-929000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">1444000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-28" decimals="-3" id="f-166" unitRef="usd">14495000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-29" decimals="-3" id="f-167" unitRef="usd">-14495000</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">0</legn:IncreaseDecreaseThroughReclassificationOfVestedRestrictedStockEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-29" decimals="-3" id="f-169" unitRef="usd">15946000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">15946000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-30" decimals="-3" id="f-171" unitRef="usd">37000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-3" id="f-172" unitRef="usd">2712844000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-32" decimals="-3" id="f-173" unitRef="usd">74949000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-33" decimals="-3" id="f-174" unitRef="usd">-7429000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-3" id="f-175" unitRef="usd">-1762652000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-176" unitRef="usd">1017749000</ifrs-full:Equity>
    <ifrs-full:OtherReserves contextRef="c-3" decimals="-5" id="f-177" unitRef="usd">1017700000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c-20" decimals="-5" id="f-178" unitRef="usd">1164000000</ifrs-full:OtherReserves>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">-99130000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-2" decimals="-3" id="f-180" unitRef="usd">-59788000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">12056000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome contextRef="c-2" decimals="-3" id="f-182" unitRef="usd">13870000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">5061000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts contextRef="c-2" decimals="-3" id="f-184" unitRef="usd">5475000</ifrs-full:AdjustmentsForFinanceCosts>
    <legn:AdjustmentsForInventoryReserveProvision contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-3798000</legn:AdjustmentsForInventoryReserveProvision>
    <legn:AdjustmentsForInventoryReserveProvision contextRef="c-2" decimals="-3" id="f-186" unitRef="usd">1757000</legn:AdjustmentsForInventoryReserveProvision>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">970000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c-2" decimals="-3" id="f-188" unitRef="usd">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">2284000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c-2" decimals="-3" id="f-190" unitRef="usd">2796000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">-53000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-2" decimals="-3" id="f-192" unitRef="usd">-2000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForAmortisationExpense contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">128000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense contextRef="c-2" decimals="-3" id="f-194" unitRef="usd">885000</ifrs-full:AdjustmentsForAmortisationExpense>
    <legn:AdjustmentsForDepreciationOfRightOfUseAssets contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">2787000</legn:AdjustmentsForDepreciationOfRightOfUseAssets>
    <legn:AdjustmentsForDepreciationOfRightOfUseAssets contextRef="c-2" decimals="-3" id="f-196" unitRef="usd">2041000</legn:AdjustmentsForDepreciationOfRightOfUseAssets>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">0</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses contextRef="c-2" decimals="-3" id="f-198" unitRef="usd">-449000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">55192000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-2" decimals="-3" id="f-200" unitRef="usd">-49056000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">15946000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-2" decimals="-3" id="f-202" unitRef="usd">18703000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <legn:DeferredGovernmentGrant contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-134000</legn:DeferredGovernmentGrant>
    <legn:DeferredGovernmentGrant contextRef="c-2" decimals="-3" id="f-204" unitRef="usd">-157000</legn:DeferredGovernmentGrant>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">-32697000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-2" decimals="-3" id="f-206" unitRef="usd">-91661000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">5918000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-2" decimals="-3" id="f-208" unitRef="usd">96734000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-48586000</legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets>
    <legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets contextRef="c-2" decimals="-3" id="f-210" unitRef="usd">-16266000</legn:AdjustmentsForDecreaseIncreaseInPrepaymentsOtherReceivableOtherAssets>
    <legn:AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">473000</legn:AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets>
    <legn:AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets contextRef="c-2" decimals="-3" id="f-212" unitRef="usd">77000</legn:AdjustmentsForDecreaseIncreaseInOtherNonCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-3232000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c-2" decimals="-3" id="f-214" unitRef="usd">-4470000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">19510000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-2" decimals="-3" id="f-216" unitRef="usd">22796000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">-38635000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-2" decimals="-3" id="f-218" unitRef="usd">7380000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <legn:AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">0</legn:AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities>
    <legn:AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities contextRef="c-2" decimals="-3" id="f-220" unitRef="usd">-25000</legn:AdjustmentsForIncreaseDecreaseInOtherNonCurrentLiabilities>
    <legn:AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">-9037000</legn:AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent>
    <legn:AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent contextRef="c-2" decimals="-3" id="f-222" unitRef="usd">-12181000</legn:AdjustmentsForIncreaseDecreaseInContractLiabilitiesCurrent>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">-106286000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-2" decimals="-3" id="f-224" unitRef="usd">2384000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">14957000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities contextRef="c-2" decimals="-3" id="f-226" unitRef="usd">13479000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">11926000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="c-2" decimals="-3" id="f-228" unitRef="usd">-71000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <legn:InterestOnLeasePaymentsClassifiedAsOperatingActivities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">-499000</legn:InterestOnLeasePaymentsClassifiedAsOperatingActivities>
    <legn:InterestOnLeasePaymentsClassifiedAsOperatingActivities contextRef="c-2" decimals="-3" id="f-230" unitRef="usd">-416000</legn:InterestOnLeasePaymentsClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">-103754000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-2" decimals="-3" id="f-232" unitRef="usd">15518000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">2002000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-2" decimals="-3" id="f-234" unitRef="usd">6243000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">15358000</legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets>
    <legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets contextRef="c-2" decimals="-3" id="f-236" unitRef="usd">16541000</legn:PrepaymentToCollaboratorForCollaborationRightOfUseAssets>
    <ifrs-full:PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">0</ifrs-full:PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities contextRef="c-2" decimals="-3" id="f-238" unitRef="usd">150308000</ifrs-full:PurchaseOfFinancialAssetsMeasuredAtFairValueThroughProfitOrLossClassifiedAsInvestingActivities>
    <legn:CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">0</legn:CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities>
    <legn:CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities contextRef="c-2" decimals="-3" id="f-240" unitRef="usd">663000</legn:CashReceiptsOfInvestmentIncomeClassifiedAsInvestingActivities>
    <legn:ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">0</legn:ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets>
    <legn:ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets contextRef="c-2" decimals="-3" id="f-242" unitRef="usd">-2000</legn:ProceedsFromPaymentsForDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNonCurrentAssets>
    <legn:AdditionInTimeDeposits contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">100000000</legn:AdditionInTimeDeposits>
    <legn:AdditionInTimeDeposits contextRef="c-2" decimals="-3" id="f-244" unitRef="usd">721990000</legn:AdditionInTimeDeposits>
    <legn:DecreaseInTimeDeposits contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">374000000</legn:DecreaseInTimeDeposits>
    <legn:DecreaseInTimeDeposits contextRef="c-2" decimals="-3" id="f-246" unitRef="usd">498273000</legn:DecreaseInTimeDeposits>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">256640000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-2" decimals="-3" id="f-248" unitRef="usd">-396148000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">1444000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-2" decimals="-3" id="f-250" unitRef="usd">1589000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">777000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-2" decimals="-3" id="f-252" unitRef="usd">758000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">667000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-2" decimals="-3" id="f-254" unitRef="usd">831000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">153553000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="c-2" decimals="-3" id="f-256" unitRef="usd">-379799000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">1400000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-258" unitRef="usd">-343000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-259" unitRef="usd">286749000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-10" decimals="-3" id="f-260" unitRef="usd">1277713000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-261" unitRef="usd">441702000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-20" decimals="-3" id="f-262" unitRef="usd">897571000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Cash contextRef="c-3" decimals="-3" id="f-263" unitRef="usd">1005450000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-20" decimals="-3" id="f-264" unitRef="usd">1156674000</ifrs-full:Cash>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-3" decimals="-3" id="f-265" unitRef="usd">70000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c-20" decimals="-3" id="f-266" unitRef="usd">359000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <legn:TimesDepositsCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-267" unitRef="usd">563678000</legn:TimesDepositsCurrentAndNoncurrent>
    <legn:TimesDepositsCurrentAndNoncurrent contextRef="c-20" decimals="-3" id="f-268" unitRef="usd">258744000</legn:TimesDepositsCurrentAndNoncurrent>
    <legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition contextRef="c-3" decimals="-3" id="f-269" unitRef="usd">441702000</legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition>
    <legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition contextRef="c-20" decimals="-3" id="f-270" unitRef="usd">897571000</legn:CashAndCashEquivalentsAsStatedInStatementOfFinancialPosition>
    <legn:CashAndCashEquivalentsAsStatedInStatementOfCashFlows contextRef="c-3" decimals="-3" id="f-271" unitRef="usd">441702000</legn:CashAndCashEquivalentsAsStatedInStatementOfCashFlows>
    <legn:CashAndCashEquivalentsAsStatedInStatementOfCashFlows contextRef="c-20" decimals="-3" id="f-272" unitRef="usd">897571000</legn:CashAndCashEquivalentsAsStatedInStatementOfCashFlows>
    <legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory contextRef="c-1" id="f-273">CORPORATE INFORMATION &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legend Biotech Corporation, ("Legend"), was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Act (As Revised) of the Cayman Islands. The registered office address of Legend is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1002, Cayman Islands.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Legend is an investment holding company. Legend's subsidiaries are principally engaged in the discovery, development, manufacturing and commercialization of novel cell therapies for oncology and other indications.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-274">BASIS OF PREPARATION &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The unaudited interim condensed consolidated financial statements of Legend and its subsidiaries (collectively referred to as the &#x201c;Company&#x201d;) for the three months ended March&#160;31, 2025 have been prepared in accordance with International Accounting Standard (&#x201c;IAS&#x201d;) 34 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Interim Financial Reporting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(&#x201c;IAS34&#x201d;) issued by the International Accounting Standards Board (the &#x201c;IASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies and basis of preparation adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's financial statements for the year ended December&#160;31, 2024. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company&#x2019;s annual consolidated financial statements as at December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-275">NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE COMPANY&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new International Financial Reporting Standards (&#x201c;IFRS&#x201d;), amendments or interpretations issued by the IASB that became effective in the three months ended March&#160;31, 2025 that had a material impact on the Company's unaudited interim condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c-1" id="f-276">REVENUE&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License revenue - Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue - total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the timing of transfer of goods or services is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue over time*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the deferred revenue which is included in contract liabilities for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities (Current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-277">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License revenue - Novartis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License revenue - total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-35" decimals="-3" id="f-278" unitRef="usd">9348000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-36" decimals="-3" id="f-279" unitRef="usd">12181000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">9348000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:RevenueFromLicensingOfIntellectualProperty contextRef="c-2" decimals="-3" id="f-281" unitRef="usd">12181000</legn:RevenueFromLicensingOfIntellectualProperty>
    <legn:CollaborationRevenue contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">185615000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-2" decimals="-3" id="f-283" unitRef="usd">78481000</legn:CollaborationRevenue>
    <ifrs-full:OtherRevenue contextRef="c-1" decimals="-3" id="f-284" unitRef="usd">90000</ifrs-full:OtherRevenue>
    <ifrs-full:OtherRevenue contextRef="c-2" decimals="-3" id="f-285" unitRef="usd">3329000</ifrs-full:OtherRevenue>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">195053000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-2" decimals="-3" id="f-287" unitRef="usd">93991000</ifrs-full:Revenue>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c-1" id="f-288">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of revenue by geographic area is as follows. The revenue information is based on the locations of the customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States of America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;158,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-37" decimals="-3" id="f-289" unitRef="usd">9348000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-38" decimals="-3" id="f-290" unitRef="usd">15369000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-39" decimals="-3" id="f-291" unitRef="usd">90000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-40" decimals="-3" id="f-292" unitRef="usd">141000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">9438000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers contextRef="c-2" decimals="-3" id="f-294" unitRef="usd">15510000</ifrs-full:RevenueFromContractsWithCustomers>
    <legn:CollaborationRevenue contextRef="c-37" decimals="-3" id="f-295" unitRef="usd">158942000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-38" decimals="-3" id="f-296" unitRef="usd">70109000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-41" decimals="-3" id="f-297" unitRef="usd">26673000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-42" decimals="-3" id="f-298" unitRef="usd">8372000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">185615000</legn:CollaborationRevenue>
    <legn:CollaborationRevenue contextRef="c-2" decimals="-3" id="f-300" unitRef="usd">78481000</legn:CollaborationRevenue>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">195053000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-2" decimals="-3" id="f-302" unitRef="usd">93991000</ifrs-full:Revenue>
    <legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock contextRef="c-1" id="f-303">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the timing of transfer of goods or services is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;185,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue over time*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;195,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;*All revenue streams are recognized at a point in time except for License Revenue for Novartis which is recognized over time.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfTimingOfTransferOfGoodsOrServicesTableTextBlock>
    <ifrs-full:Revenue contextRef="c-43" decimals="-3" id="f-304" unitRef="usd">185705000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-44" decimals="-3" id="f-305" unitRef="usd">81810000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-45" decimals="-3" id="f-306" unitRef="usd">9348000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-46" decimals="-3" id="f-307" unitRef="usd">12181000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">195053000</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c-2" decimals="-3" id="f-309" unitRef="usd">93991000</ifrs-full:Revenue>
    <legn:DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock contextRef="c-1" id="f-310">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the deferred revenue which is included in contract liabilities for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities (Current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDeferredRevenueFromCustomerContractLiabilitiesTableTextBlock>
    <ifrs-full:CurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-311" unitRef="usd">39535000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities contextRef="c-4" decimals="-3" id="f-312" unitRef="usd">46874000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-3" decimals="-3" id="f-313" unitRef="usd">39535000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-4" decimals="-3" id="f-314" unitRef="usd">46874000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="c-1" id="f-315">OTHER (EXPENSE)/INCOME, NET &lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total other (expense)/income, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange (loss)/gain, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value gains on financial assets measured at fair value change through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other (expense)/income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The foreign currency exchange (loss)/gain, net is comprised mainly of the unrealized foreign exchange (loss)/gain that was primarily related to changes in the intercompany loan balances and cash balances as a result of exchange rate changes between USD and EUR.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock contextRef="c-1" id="f-316">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total other (expense)/income, net:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange (loss)/gain, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value gains on financial assets measured at fair value change through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total other (expense)/income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutOtherIncomeExpenseTableTextBlock>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">-55192000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-2" decimals="-3" id="f-318" unitRef="usd">49056000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">0</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c-2" decimals="-3" id="f-320" unitRef="usd">449000</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <legn:OtherMiscellaneousIncomeExpense contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">684000</legn:OtherMiscellaneousIncomeExpense>
    <legn:OtherMiscellaneousIncomeExpense contextRef="c-2" decimals="-3" id="f-322" unitRef="usd">176000</legn:OtherMiscellaneousIncomeExpense>
    <ifrs-full:OtherGainsLosses contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-54508000</ifrs-full:OtherGainsLosses>
    <ifrs-full:OtherGainsLosses contextRef="c-2" decimals="-3" id="f-324" unitRef="usd">49681000</ifrs-full:OtherGainsLosses>
    <legn:EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock contextRef="c-1" id="f-325">FINANCE INCOME AND FINANCE COSTS&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance income of $12.1 million and $13.9 million for the three months ended March&#160;31, 2025 and 2024, respectively, is comprised mainly of interest income earned on various bank accounts and time deposits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration interest-bearing advanced funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:EntireDisclosureOfFinanceIncomeAndCostsExplanatoryTextBlock>
    <ifrs-full:FinanceIncome contextRef="c-1" decimals="-5" id="f-326" unitRef="usd">12100000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c-2" decimals="-5" id="f-327" unitRef="usd">13900000</ifrs-full:FinanceIncome>
    <ifrs-full:DisclosureOfFinanceCostExplanatory contextRef="c-1" id="f-328">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration interest-bearing advanced funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceCostExplanatory>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">499000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-2" decimals="-3" id="f-330" unitRef="usd">416000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">4562000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings contextRef="c-2" decimals="-3" id="f-332" unitRef="usd">5059000</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:FinanceCosts contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">5061000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c-2" decimals="-3" id="f-334" unitRef="usd">5475000</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-335">LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT &lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The basic income or loss per share is calculated by dividing net income or loss attributable to ordinary equity holders of the parent by the weighted average ordinary shares outstanding. The diluted loss per share equals the basic loss per share amounts presented for the three months ended March&#160;31, 2025 and 2024, as the impact of the outstanding share options and RSUs had an anti-dilutive effect on the basic loss per share amounts presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of basic and diluted loss per share are based on: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(100,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;br/&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367,525,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364,010,429&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="c-1" id="f-336">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculations of basic and diluted loss per share are based on: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(100,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of shares&lt;br/&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average number of ordinary shares outstanding during the period used in the basic and diluted earnings per share calculation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367,525,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;364,010,429&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">-100916000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent contextRef="c-2" decimals="-3" id="f-338" unitRef="usd">-59793000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-339" unitRef="shares">367525855</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-2" decimals="0" id="f-340" unitRef="shares">364010429</ifrs-full:WeightedAverageShares>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c-1" id="f-341">LEASES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company as a lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has leases for office, research laboratory and manufacturing facilities, equipment, vehicles, and land. The terms of the leases vary, although most generally have lease terms between 3 and 29 years. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of 50 years, and no ongoing payments will be made under the terms of these leasehold land. Leases with terms of 12 months or less are expensed as incurred. Collaboration assets represent the Company&#x2019;s share of assets leased to the collaboration from Janssen Biotech, Inc., a Johnson &amp;amp; Johnson company ("Janssen"), which purchased the assets on behalf of the collaboration, in connection with our collaboration and license agreement (the "Janssen Agreement"). Collaboration assets under construction that will be leased to the collaboration from Janssen when placed into service are classified as collaboration prepaid leases on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s right-of-use assets and the movements for the three months ended March&#160;31, 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:45pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The balance of the Company&#x2019;s lease liabilities and the movements for the three months ended March&#160;31, 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accretion of interest recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Analyzed into:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <legn:LesseeLeasingArrangementsLeasesTerm contextRef="c-47" id="f-342">P3Y</legn:LesseeLeasingArrangementsLeasesTerm>
    <legn:LesseeLeasingArrangementsLeasesTerm contextRef="c-48" id="f-343">P29Y</legn:LesseeLeasingArrangementsLeasesTerm>
    <legn:LesseeLeasingArrangementsLeasesTerm contextRef="c-49" id="f-344">P50Y</legn:LesseeLeasingArrangementsLeasesTerm>
    <legn:OngoingLeasePaymentsUnderTheLandLease contextRef="c-49" decimals="INF" id="f-345" unitRef="usd">0</legn:OngoingLeasePaymentsUnderTheLandLease>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-346">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s right-of-use assets and the movements for the three months ended March&#160;31, 2025 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000 &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;107,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-347" unitRef="usd">101932000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">6703000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossRightofuseAssets contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">970000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossRightofuseAssets>
    <legn:IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">2346000</legn:IncreaseDecreaseThroughEffectOfExchangeRealignmentInForeignExchangeRate>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">2787000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-352" unitRef="usd">107224000</ifrs-full:RightofuseAssets>
    <legn:LesseeLeaseLiabilitiesTextBlock contextRef="c-1" id="f-353">The balance of the Company&#x2019;s lease liabilities and the movements for the three months ended March&#160;31, 2025 are as follows:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accretion of interest recognized during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exchange realignment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Analyzed into:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Carrying amount at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:LesseeLeaseLiabilitiesTextBlock>
    <ifrs-full:LeaseLiabilities contextRef="c-50" decimals="-3" id="f-354" unitRef="usd">49407000</ifrs-full:LeaseLiabilities>
    <legn:IncreaseInLeaseLiabilities contextRef="c-51" decimals="-3" id="f-355" unitRef="usd">6435000</legn:IncreaseInLeaseLiabilities>
    <legn:IncreaseOfLeaseLiabilitiesBalance contextRef="c-51" decimals="-3" id="f-356" unitRef="usd">499000</legn:IncreaseOfLeaseLiabilitiesBalance>
    <ifrs-full:CashOutflowForLeases contextRef="c-51" decimals="-3" id="f-357" unitRef="usd">1276000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities contextRef="c-51" decimals="-3" id="f-358" unitRef="usd">2000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LeaseLiabilities contextRef="c-52" decimals="-3" id="f-359" unitRef="usd">57065000</ifrs-full:LeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-52" decimals="-3" id="f-360" unitRef="usd">5341000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-52" decimals="-3" id="f-361" unitRef="usd">51724000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-52" decimals="-3" id="f-362" unitRef="usd">57065000</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c-1" id="f-363">COLLABORATION INVENTORIES, NET&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's reserve for inventory was $17.9&#160;million and $21.7 million as of March&#160;31, 2025 and December&#160;31, 2024, respectively. The Company&#x2019;s reserve for inventory was primarily related to certain batches or units of product that did not meet quality specifications, and expired materials. The inventory reserve was included in the collaboration cost of sales.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock contextRef="c-1" id="f-364">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total collaboration inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutInventoriesExplanatoryTableTextBlock>
    <ifrs-full:RawMaterials contextRef="c-3" decimals="-3" id="f-365" unitRef="usd">23176000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials contextRef="c-4" decimals="-3" id="f-366" unitRef="usd">17454000</ifrs-full:RawMaterials>
    <ifrs-full:WorkInProgress contextRef="c-3" decimals="-3" id="f-367" unitRef="usd">4933000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress contextRef="c-4" decimals="-3" id="f-368" unitRef="usd">4440000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods contextRef="c-3" decimals="-3" id="f-369" unitRef="usd">2824000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c-4" decimals="-3" id="f-370" unitRef="usd">2009000</ifrs-full:FinishedGoods>
    <ifrs-full:Inventories contextRef="c-3" decimals="-3" id="f-371" unitRef="usd">30933000</ifrs-full:Inventories>
    <ifrs-full:Inventories contextRef="c-4" decimals="-3" id="f-372" unitRef="usd">23903000</ifrs-full:Inventories>
    <legn:InventoryReserve contextRef="c-3" decimals="-5" id="f-373" unitRef="usd">17900000</legn:InventoryReserve>
    <legn:InventoryReserve contextRef="c-4" decimals="-5" id="f-374" unitRef="usd">21700000</legn:InventoryReserve>
    <legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock contextRef="c-1" id="f-375">PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other collaboration receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default. The Company estimated that the expected credit loss for the above receivables as at March&#160;31, 2025 and December&#160;31, 2024 is insignificant.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTextBlock>
    <legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other collaboration receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VAT recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;182,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;130,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutPrepaymentsOtherReceivablesAndOtherAssetsExplanatoryTableTextBlock>
    <legn:OtherCollaborationReceivables contextRef="c-53" decimals="-3" id="f-377" unitRef="usd">159688000</legn:OtherCollaborationReceivables>
    <legn:OtherCollaborationReceivables contextRef="c-54" decimals="-3" id="f-378" unitRef="usd">112656000</legn:OtherCollaborationReceivables>
    <ifrs-full:OtherReceivables contextRef="c-53" decimals="-3" id="f-379" unitRef="usd">954000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c-54" decimals="-3" id="f-380" unitRef="usd">780000</ifrs-full:OtherReceivables>
    <ifrs-full:FinanceLeaseReceivables contextRef="c-53" decimals="-3" id="f-381" unitRef="usd">44000</ifrs-full:FinanceLeaseReceivables>
    <ifrs-full:FinanceLeaseReceivables contextRef="c-54" decimals="-3" id="f-382" unitRef="usd">568000</ifrs-full:FinanceLeaseReceivables>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c-53" decimals="-3" id="f-383" unitRef="usd">5792000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:ValueAddedTaxReceivables contextRef="c-54" decimals="-3" id="f-384" unitRef="usd">4597000</ifrs-full:ValueAddedTaxReceivables>
    <ifrs-full:Prepayments contextRef="c-53" decimals="-3" id="f-385" unitRef="usd">15562000</ifrs-full:Prepayments>
    <ifrs-full:Prepayments contextRef="c-54" decimals="-3" id="f-386" unitRef="usd">12374000</ifrs-full:Prepayments>
    <legn:PrepaymentsOtherReceivablesAndOtherAssets contextRef="c-53" decimals="-3" id="f-387" unitRef="usd">182040000</legn:PrepaymentsOtherReceivablesAndOtherAssets>
    <legn:PrepaymentsOtherReceivablesAndOtherAssets contextRef="c-54" decimals="-3" id="f-388" unitRef="usd">130975000</legn:PrepaymentsOtherReceivablesAndOtherAssets>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c-1" id="f-389">CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and bank balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,005,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,127,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Pledged deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(563,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(840,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;441,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominated in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;401,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;230,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominated in RMB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominated in EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;441,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash and cash equivalents of the Company denominated in Renminbi (&#x201c;RMB&#x201d;) amounted to $15.1 million and $19.3 million in the consolidated statements of financial position as at March&#160;31, 2025 and December&#160;31, 2024, respectively. The RMB is not freely convertible into other currencies, however, under Greater China Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Company is permitted to exchange RMB for other currencies through banks authorized to conduct foreign exchange business. &lt;/span&gt;&lt;/div&gt;Cash and cash equivalents earn interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default. The carrying amounts of the cash and cash equivalents approximate to their fair values.</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock contextRef="c-1" id="f-390">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and bank balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,005,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,127,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Pledged deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(563,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(840,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;441,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominated in USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;401,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;230,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominated in RMB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominated in EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;441,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTimeDepositsAndPledgedDepositsExplanatoryTableTextBlock>
    <ifrs-full:CashAndBankBalancesAtCentralBanks contextRef="c-3" decimals="-3" id="f-391" unitRef="usd">1005450000</ifrs-full:CashAndBankBalancesAtCentralBanks>
    <ifrs-full:CashAndBankBalancesAtCentralBanks contextRef="c-4" decimals="-3" id="f-392" unitRef="usd">1127115000</ifrs-full:CashAndBankBalancesAtCentralBanks>
    <legn:PledgedShortTermDeposits contextRef="c-3" decimals="-3" id="f-393" unitRef="usd">-70000</legn:PledgedShortTermDeposits>
    <legn:PledgedShortTermDeposits contextRef="c-4" decimals="-3" id="f-394" unitRef="usd">-70000</legn:PledgedShortTermDeposits>
    <legn:DepositsFromBank contextRef="c-3" decimals="-3" id="f-395" unitRef="usd">-563678000</legn:DepositsFromBank>
    <legn:DepositsFromBank contextRef="c-4" decimals="-3" id="f-396" unitRef="usd">-840296000</legn:DepositsFromBank>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-397" unitRef="usd">441702000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-398" unitRef="usd">286749000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-55" decimals="-3" id="f-399" unitRef="usd">401938000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-56" decimals="-3" id="f-400" unitRef="usd">230833000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-57" decimals="-3" id="f-401" unitRef="usd">15116000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-58" decimals="-3" id="f-402" unitRef="usd">19334000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-59" decimals="-3" id="f-403" unitRef="usd">24648000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-60" decimals="-3" id="f-404" unitRef="usd">36582000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-405" unitRef="usd">441702000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-406" unitRef="usd">286749000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-57" decimals="-5" id="f-407" unitRef="usd">15100000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-58" decimals="-5" id="f-408" unitRef="usd">19300000</ifrs-full:CashAndCashEquivalents>
    <legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock contextRef="c-1" id="f-409">OTHER PAYABLES AND ACCRUALS&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payable for collaboration assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other tax payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;166,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other payables are non-interest-bearing and repayable on demand.&lt;/span&gt;&lt;/div&gt;</legn:DisclosureOfOtherPayablesAndAccrualsExplanatoryTextBlock>
    <legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock contextRef="c-1" id="f-410">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payable for collaboration assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other tax payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;116,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;166,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfDetailedInformationAboutOtherPayablesAndAccrualsExplanatoryTableTextBlock>
    <legn:AccruedPayroll contextRef="c-3" decimals="-3" id="f-411" unitRef="usd">27657000</legn:AccruedPayroll>
    <legn:AccruedPayroll contextRef="c-4" decimals="-3" id="f-412" unitRef="usd">43188000</legn:AccruedPayroll>
    <legn:AccruedExpense contextRef="c-3" decimals="-3" id="f-413" unitRef="usd">24090000</legn:AccruedExpense>
    <legn:AccruedExpense contextRef="c-4" decimals="-3" id="f-414" unitRef="usd">16347000</legn:AccruedExpense>
    <legn:CollaborationPayable contextRef="c-3" decimals="-3" id="f-415" unitRef="usd">49350000</legn:CollaborationPayable>
    <legn:CollaborationPayable contextRef="c-4" decimals="-3" id="f-416" unitRef="usd">82035000</legn:CollaborationPayable>
    <ifrs-full:OtherPayables contextRef="c-3" decimals="-3" id="f-417" unitRef="usd">2907000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c-4" decimals="-3" id="f-418" unitRef="usd">6250000</ifrs-full:OtherPayables>
    <legn:PayableForCollaborationAssets contextRef="c-3" decimals="-3" id="f-419" unitRef="usd">6735000</legn:PayableForCollaborationAssets>
    <legn:PayableForCollaborationAssets contextRef="c-4" decimals="-3" id="f-420" unitRef="usd">14988000</legn:PayableForCollaborationAssets>
    <legn:OtherTaxPayables contextRef="c-3" decimals="-3" id="f-421" unitRef="usd">6071000</legn:OtherTaxPayables>
    <legn:OtherTaxPayables contextRef="c-4" decimals="-3" id="f-422" unitRef="usd">3372000</legn:OtherTaxPayables>
    <legn:OtherPayablesAndAccrualsCurrent contextRef="c-3" decimals="-3" id="f-423" unitRef="usd">116810000</legn:OtherPayablesAndAccrualsCurrent>
    <legn:OtherPayablesAndAccrualsCurrent contextRef="c-4" decimals="-3" id="f-424" unitRef="usd">166180000</legn:OtherPayablesAndAccrualsCurrent>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="c-1" id="f-425">COLLABORATION INTEREST-BEARING ADVANCED FUNDING &lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Interest-bearing Advanced Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No specific maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Pursuant to the Janssen Agreement, the Company is entitled to receive funding advances from the collaborator when certain operational conditions are met. As a result, the Company took an initial funding advance with principal amounting to $17.3&#160;million on June 18, 2021, a second funding advance with principal amounting to $53.1&#160;million on September 17, 2021, a third funding advance with principal amounting to $49.3&#160;million on December 17, 2021, a forth funding advance with principal amounting to $5.3&#160;million on March 18, 2022, a fifth funding advance with principal amounting to $60.9&#160;million on June 17, 2022, a sixth funding advance with principal amounting to $60.5&#160;million on September 16, 2022, and a seventh funding advance with principal amounting to $3.6&#160;million on December 16, 2022, by reducing the same amount of other payables due to the collaborator, respectively (collectively, the &#x201c;Funding Advances&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;These Funding Advances are accounted for as interest-bearing borrowings funded by the collaborator, constituted by a principal amounting to $250.0&#160;million and applicable interests accrued amounting to $55.7&#160;million upon such principal. The respective interest rate of each borrowing has transitioned from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR) in accordance with the LIBOR ACT. Thus, outstanding advances accrue interest at 12 month CME term SOFR plus LIBOR/SOFR adjustment (12 month) plus a margin of 2.5%.  For each of the seven batches of funding advances, interest started to accrue from June 18, 2021, September 17, 2021, December 17, 2021, March 18, 2022, June 17, 2022, September 16, 2022, and December 16, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Pursuant to the terms of the Janssen Agreement, the collaborator may recoup the aggregate amount of Funding Advances, together with interest thereon, from Company&#x2019;s share of pre-tax profits starting from the first calendar quarter &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;following the first profitable year of the collaboration program and, subject to some limitations, from milestone payments due to the Company under the Janssen Agreement. The Company&#x2019;s management estimated the loan will not be recouped by the collaborator within one year, nor does the Company expect to repay the funding advances within one year, and thus the loan was classified as a long-term liability.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="c-1" id="f-426">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effective interest rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Interest-bearing Advanced Funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No specific maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;305,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:BorrowingsInterestRate contextRef="c-61" decimals="4" id="f-427" unitRef="number">0.0723</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived contextRef="c-61" decimals="-3" id="f-428" unitRef="usd">305745000</ifrs-full:NoncurrentPortionOfNoncurrentLoansReceived>
    <ifrs-full:Borrowings contextRef="c-62" decimals="-5" id="f-429" unitRef="usd">17300000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-63" decimals="-5" id="f-430" unitRef="usd">53100000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-64" decimals="-5" id="f-431" unitRef="usd">49300000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-65" decimals="-5" id="f-432" unitRef="usd">5300000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-66" decimals="-5" id="f-433" unitRef="usd">60900000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-67" decimals="-5" id="f-434" unitRef="usd">60500000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-68" decimals="-5" id="f-435" unitRef="usd">3600000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings contextRef="c-3" decimals="-5" id="f-436" unitRef="usd">250000000</ifrs-full:Borrowings>
    <legn:InterestBearingBorrowingsFundedInterestsAccrued contextRef="c-1" decimals="-5" id="f-437" unitRef="usd">55700000</legn:InterestBearingBorrowingsFundedInterestsAccrued>
    <ifrs-full:BorrowingsAdjustmentToInterestRateBasis contextRef="c-3" decimals="3" id="f-438" unitRef="number">0.025</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
    <legn:NumberOfBorrowingBatches contextRef="c-69" decimals="INF" id="f-439" unitRef="batch">7</legn:NumberOfBorrowingBatches>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-440">SHARE CAPITAL AND SHARE PREMIUM &lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000,000,000 ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued and fully paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of movements in the Company&#x2019;s share capital and share premium is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares in issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2024 and January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367,298,315&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,695,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,696,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286,658&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassification of vesting of restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;473,106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368,058,079&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,712,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,712,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-441">&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,000,000,000 ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Issued and fully paid:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368,058,079 and (2024: 367,298,315) ordinary shares of $0.0001 each&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c-70"
      decimals="INF"
      id="f-442"
      unitRef="shares">2000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="c-71"
      decimals="INF"
      id="f-443"
      unitRef="shares">2000000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="c-71"
      decimals="INF"
      id="f-444"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-70"
      decimals="INF"
      id="f-445"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <legn:AuthorizedShareCapital contextRef="c-71" decimals="-3" id="f-446" unitRef="usd">200000</legn:AuthorizedShareCapital>
    <legn:AuthorizedShareCapital contextRef="c-70" decimals="-3" id="f-447" unitRef="usd">200000</legn:AuthorizedShareCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-71"
      decimals="INF"
      id="f-448"
      unitRef="shares">368058079</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="c-70"
      decimals="INF"
      id="f-449"
      unitRef="shares">367298315</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:ParValuePerShare
      contextRef="c-70"
      decimals="INF"
      id="f-450"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c-71"
      decimals="INF"
      id="f-451"
      unitRef="usdPerShare">0.0001</ifrs-full:ParValuePerShare>
    <ifrs-full:IssuedCapital contextRef="c-71" decimals="-3" id="f-452" unitRef="usd">37000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-70" decimals="-3" id="f-453" unitRef="usd">37000</ifrs-full:IssuedCapital>
    <legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock contextRef="c-1" id="f-454">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of movements in the Company&#x2019;s share capital and share premium is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;shares in issue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Share&lt;br/&gt;premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;US$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2024 and January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;367,298,315&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,695,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,696,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise of share options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;286,658&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reclassification of vesting of restricted share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;473,106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368,058,079&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,712,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,712,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</legn:DisclosureOfMovementsInCompanyShareCapitalAndSharePremiumExplanatoryTableTextBlock>
    <legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue
      contextRef="c-21"
      decimals="INF"
      id="f-455"
      unitRef="shares">367298315</legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue>
    <legn:ShareCapitalAndSharePremium contextRef="c-72" decimals="-3" id="f-456" unitRef="usd">37000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-22" decimals="-3" id="f-457" unitRef="usd">2695976000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-4" decimals="-3" id="f-458" unitRef="usd">2696013000</legn:ShareCapitalAndSharePremium>
    <legn:ExerciseOfShareOptionNumberOfSharesInIssue
      contextRef="c-73"
      decimals="INF"
      id="f-459"
      unitRef="shares">286658</legn:ExerciseOfShareOptionNumberOfSharesInIssue>
    <legn:ExerciseOfShareOption contextRef="c-74" decimals="-3" id="f-460" unitRef="usd">0</legn:ExerciseOfShareOption>
    <legn:ExerciseOfShareOption contextRef="c-28" decimals="-3" id="f-461" unitRef="usd">2373000</legn:ExerciseOfShareOption>
    <legn:ExerciseOfShareOption contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">2373000</legn:ExerciseOfShareOption>
    <legn:ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue
      contextRef="c-73"
      decimals="INF"
      id="f-463"
      unitRef="shares">473106</legn:ReclassificationOfVestedRestrictedStockUnitsNumberOfSharesInIssue>
    <legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium contextRef="c-74" decimals="-3" id="f-464" unitRef="usd">0</legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium>
    <legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium contextRef="c-28" decimals="-3" id="f-465" unitRef="usd">14495000</legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium>
    <legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium contextRef="c-1" decimals="-3" id="f-466" unitRef="usd">14495000</legn:ReclassificationOfVestedRestrictedStockUnitsShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue
      contextRef="c-30"
      decimals="INF"
      id="f-467"
      unitRef="shares">368058079</legn:ShareCapitalAndSharePremiumNumberOfSharesInIssue>
    <legn:ShareCapitalAndSharePremium contextRef="c-75" decimals="-3" id="f-468" unitRef="usd">37000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-31" decimals="-3" id="f-469" unitRef="usd">2712844000</legn:ShareCapitalAndSharePremium>
    <legn:ShareCapitalAndSharePremium contextRef="c-3" decimals="-3" id="f-470" unitRef="usd">2712881000</legn:ShareCapitalAndSharePremium>
    <ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory contextRef="c-1" id="f-471">APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The interim condensed consolidated financial statements were approved and authorized for issue by the Audit Committee of the Board of Directors on  May&#160;6, 2025.</ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#f-31" xlink:label="f-31" xlink:type="locator"/>
        <link:loc xlink:href="#f-34" xlink:label="f-34" xlink:type="locator"/>
        <link:loc xlink:href="#f-32" xlink:label="f-32" xlink:type="locator"/>
        <link:loc xlink:href="#f-33" xlink:label="f-33" xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts have been reclassified to present finance income as a separate line item and to combine other income/(expense), net for comparative purposes</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-31"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-34"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-32"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-33"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-166"
          xlink:label="f-166"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-129"
          xlink:label="f-129"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-154"
          xlink:label="f-154"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-140"
          xlink:label="f-140"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-133"
          xlink:label="f-133"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-156"
          xlink:label="f-156"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-175"
          xlink:label="f-175"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-134"
          xlink:label="f-134"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-151"
          xlink:label="f-151"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-169"
          xlink:label="f-169"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-131"
          xlink:label="f-131"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-152"
          xlink:label="f-152"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-158"
          xlink:label="f-158"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-124"
          xlink:label="f-124"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-160"
          xlink:label="f-160"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-125"
          xlink:label="f-125"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-161"
          xlink:label="f-161"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-142"
          xlink:label="f-142"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-153"
          xlink:label="f-153"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-137"
          xlink:label="f-137"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-136"
          xlink:label="f-136"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-145"
          xlink:label="f-145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-139"
          xlink:label="f-139"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-126"
          xlink:label="f-126"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-147"
          xlink:label="f-147"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-148"
          xlink:label="f-148"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-164"
          xlink:label="f-164"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-174"
          xlink:label="f-174"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-172"
          xlink:label="f-172"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-167"
          xlink:label="f-167"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-163"
          xlink:label="f-163"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-173"
          xlink:label="f-173"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-146"
          xlink:label="f-146"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-127"
          xlink:label="f-127"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These reserve accounts comprise the consolidated reserves of $1,017.7 million and $1,164.0 million in the consolidated statements of financial position as at March&#160;31, 2025 and, 2024, respectively</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-166"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-129"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-154"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-140"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-133"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-156"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-175"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-134"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-151"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-169"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-131"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-152"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-158"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-124"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-160"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-125"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-161"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-142"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-153"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-137"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-136"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-145"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-139"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-126"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-147"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-148"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-164"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-174"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-172"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-167"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-163"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-173"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-146"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-127"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-217"
          xlink:label="f-217"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-215"
          xlink:label="f-215"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-218"
          xlink:label="f-218"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-216"
          xlink:label="f-216"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain prior year amounts have been reclassified between increase in trade payables and (decrease)/increase in other payables and accruals for comparative purposes</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-217"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-215"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-218"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-216"
          xlink:to="fn-3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
